<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE PATDOC SYSTEM "ST32-US-Grant-025xml.dtd" [
<!ENTITY US06485872-20021126-M00001.NB SYSTEM "US06485872-20021126-M00001.NB" NDATA NB>
<!ENTITY US06485872-20021126-M00001.TIF SYSTEM "US06485872-20021126-M00001.TIF" NDATA TIF>
<!ENTITY US06485872-20021126-D00001.TIF SYSTEM "US06485872-20021126-D00001.TIF" NDATA TIF>
<!ENTITY US06485872-20021126-D00002.TIF SYSTEM "US06485872-20021126-D00002.TIF" NDATA TIF>
<!ENTITY US06485872-20021126-D00003.TIF SYSTEM "US06485872-20021126-D00003.TIF" NDATA TIF>
<!ENTITY US06485872-20021126-D00004.TIF SYSTEM "US06485872-20021126-D00004.TIF" NDATA TIF>
<!ENTITY US06485872-20021126-D00005.TIF SYSTEM "US06485872-20021126-D00005.TIF" NDATA TIF>
<!ENTITY US06485872-20021126-D00006.TIF SYSTEM "US06485872-20021126-D00006.TIF" NDATA TIF>
<!ENTITY US06485872-20021126-D00007.TIF SYSTEM "US06485872-20021126-D00007.TIF" NDATA TIF>
<!ENTITY US06485872-20021126-D00008.TIF SYSTEM "US06485872-20021126-D00008.TIF" NDATA TIF>
<!ENTITY US06485872-20021126-D00009.TIF SYSTEM "US06485872-20021126-D00009.TIF" NDATA TIF>
<!ENTITY US06485872-20021126-D00010.TIF SYSTEM "US06485872-20021126-D00010.TIF" NDATA TIF>
<!ENTITY US06485872-20021126-D00011.TIF SYSTEM "US06485872-20021126-D00011.TIF" NDATA TIF>
<!ENTITY US06485872-20021126-D00012.TIF SYSTEM "US06485872-20021126-D00012.TIF" NDATA TIF>
]>
<PATDOC DTD="2.5" STATUS="Build 20020918">
<SDOBI>
<B100>
<B110><DNUM><PDAT>06485872</PDAT></DNUM></B110>
<B130><PDAT>B1</PDAT></B130>
<B140><DATE><PDAT>20021126</PDAT></DATE></B140>
<B190><PDAT>US</PDAT></B190>
</B100>
<B200>
<B210><DNUM><PDAT>09718602</PDAT></DNUM></B210>
<B211US><PDAT>09</PDAT></B211US>
<B220><DATE><PDAT>20001122</PDAT></DATE></B220>
</B200>
<B400>
<B472>
<B474US><PDAT>65</PDAT></B474US>
</B472>
</B400>
<B500>
<B510>
<B511><PDAT>G03C  500</PDAT></B511>
<B516><PDAT>7</PDAT></B516>
</B510>
<B520>
<B521><PDAT>430 30</PDAT></B521>
<B522><PDAT>430944</PDAT></B522>
<B522><PDAT>2504721</PDAT></B522>
<B522><PDAT>2504731</PDAT></B522>
<B522><PDAT>2504741</PDAT></B522>
</B520>
<B540><STEXT><PDAT>Method and apparatus for measuring the composition and other properties of thin films utilizing infrared radiation</PDAT></STEXT></B540>
<B560>
<B561>
<PCIT>
<DOC><DNUM><PDAT>4905170</PDAT></DNUM>
<DATE><PDAT>19900200</PDAT></DATE>
<KIND><PDAT>A</PDAT></KIND>
</DOC>
<PARTY-US>
<NAM><SNM><STEXT><PDAT>Forouhi et al.</PDAT></STEXT></SNM></NAM>
</PARTY-US>
<PNC><PDAT>364556</PDAT></PNC></PCIT><CITED-BY-OTHER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>5403433</PDAT></DNUM>
<DATE><PDAT>19950400</PDAT></DATE>
<KIND><PDAT>A</PDAT></KIND>
</DOC>
<PARTY-US>
<NAM><SNM><STEXT><PDAT>Morrison et al.</PDAT></STEXT></SNM></NAM>
</PARTY-US>
<PNC><PDAT>156626</PDAT></PNC></PCIT><CITED-BY-OTHER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>5595916</PDAT></DNUM>
<DATE><PDAT>19970100</PDAT></DATE>
<KIND><PDAT>A</PDAT></KIND>
</DOC>
<PARTY-US>
<NAM><SNM><STEXT><PDAT>Fujimura et al.</PDAT></STEXT></SNM></NAM>
</PARTY-US>
<PNC><PDAT>437  8</PDAT></PNC></PCIT><CITED-BY-OTHER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>5604581</PDAT></DNUM>
<DATE><PDAT>19970200</PDAT></DATE>
<KIND><PDAT>A</PDAT></KIND>
</DOC>
<PARTY-US>
<NAM><SNM><STEXT><PDAT>Liu et al.</PDAT></STEXT></SNM></NAM>
</PARTY-US>
<PNC><PDAT>356 73</PDAT></PNC></PCIT><CITED-BY-OTHER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>5666200</PDAT></DNUM>
<DATE><PDAT>19970900</PDAT></DATE>
<KIND><PDAT>A</PDAT></KIND>
</DOC>
<PARTY-US>
<NAM><SNM><STEXT><PDAT>Drevillon et al.</PDAT></STEXT></SNM></NAM>
</PARTY-US>
<PNC><PDAT>356368</PDAT></PNC></PCIT><CITED-BY-OTHER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>5706212</PDAT></DNUM>
<DATE><PDAT>19980100</PDAT></DATE>
<KIND><PDAT>A</PDAT></KIND>
</DOC>
<PARTY-US>
<NAM><SNM><STEXT><PDAT>Thompson et al.</PDAT></STEXT></SNM></NAM>
</PARTY-US>
<PNC><PDAT>364525</PDAT></PNC></PCIT><CITED-BY-OTHER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>5900633</PDAT></DNUM>
<DATE><PDAT>19990500</PDAT></DATE>
<KIND><PDAT>A</PDAT></KIND>
</DOC>
<PARTY-US>
<NAM><SNM><STEXT><PDAT>Solomon et al.</PDAT></STEXT></SNM></NAM>
</PARTY-US>
<PNC><PDAT>25033908</PDAT></PNC></PCIT><CITED-BY-OTHER/>
</B561>
</B560>
<B570>
<B577><PDAT>32</PDAT></B577>
<B578US><PDAT>1</PDAT></B578US>
</B570>
<B580>
<B582><PDAT>430 30</PDAT></B582>
<B582><PDAT>430944</PDAT></B582>
<B582><PDAT>2504721</PDAT></B582>
<B582><PDAT>2504731</PDAT></B582>
<B582><PDAT>2504741</PDAT></B582>
</B580>
<B590><B595><PDAT>12</PDAT></B595><B596><PDAT>21</PDAT></B596></B590>
</B500>
<B600>
<B680US><DOC><DNUM><PDAT>60/168974</PDAT></DNUM><DATE><PDAT>19991203</PDAT></DATE><KIND><PDAT>00</PDAT></KIND></DOC></B680US>
</B600>
<B700>
<B720>
<B721>
<PARTY-US>
<NAM><FNM><PDAT>Peter A.</PDAT></FNM><SNM><STEXT><PDAT>Rosenthal</PDAT></STEXT></SNM></NAM>
<ADR>
<CITY><PDAT>West Simsbury</PDAT></CITY>
<STATE><PDAT>CT</PDAT></STATE>
</ADR>
</PARTY-US>
</B721>
<B721>
<PARTY-US>
<NAM><FNM><PDAT>Sylvie</PDAT></FNM><SNM><STEXT><PDAT>Charpenay</PDAT></STEXT></SNM></NAM>
<ADR>
<CITY><PDAT>Vernon</PDAT></CITY>
<STATE><PDAT>CT</PDAT></STATE>
</ADR>
</PARTY-US>
</B721>
<B721>
<PARTY-US>
<NAM><FNM><PDAT>Victor A.</PDAT></FNM><SNM><STEXT><PDAT>Yakovlev</PDAT></STEXT></SNM></NAM>
<ADR>
<CITY><PDAT>West Hartford</PDAT></CITY>
<STATE><PDAT>CT</PDAT></STATE>
</ADR>
</PARTY-US>
</B721>
</B720>
<B730>
<B731>
<PARTY-US>
<NAM><ONM><STEXT><PDAT>MKS Instruments, Inc.</PDAT></STEXT></ONM></NAM>
<ADR><CITY><PDAT>Andover</PDAT></CITY><STATE><PDAT>MA</PDAT></STATE></ADR>
</PARTY-US>
</B731>
<B732US>
<PDAT>02</PDAT>
</B732US>
</B730>
<B740>
<B741>
<PARTY-US>
<NAM><FNM><PDAT>Ira S.</PDAT></FNM><SNM><STEXT><PDAT>Dorman</PDAT></STEXT></SNM></NAM>
</PARTY-US>
</B741>
</B740>
<B745>
<B746>
<PARTY-US>
<NAM><FNM><PDAT>Christopher G.</PDAT></FNM><SNM><STEXT><PDAT>Young</PDAT></STEXT></SNM></NAM>
</PARTY-US>
</B746>
<B748US><PDAT>1756</PDAT></B748US>
</B745>
</B700>
</SDOBI>
<SDOAB>
<BTEXT>
<PARA ID="P-00001" LVL="0"><PTEXT><PDAT>The composition, free carrier concentrations, and other properties of thin films and graded layers embedded in film stack structures are measured by the method of the invention, which is based upon the application of two novel algorithms to extract the composition of a measured layer independently of the confounding effects of additional layers, and which can be effected even when calibration samples are not available with the same layered structure as the samples to be measured. The method uses sample model-based analysis algorithms to extract the dielectric function of the layer to be measured, combined with model-based analysis to relate the composition of the layer to its dielectric function. Because the dielectric function of a layer is a bulk spectral property of the material, and is inherently independent of the thickness of the layer, the composition of the material can be determined more easily and unambiguously from its dielectric function than from raw spectral quantities such as reflectance, ellipsometry, and transmittance, which spectral data are influenced strongly by the optical properties of the overlayers, the underlayers, and the substrate material. The method enables the measurement of layer composition with significantly fewer calibration samples, it allows product wafer analysis with structures that are significantly more complicated than the calibration samples, and it is intrinsically more reliable for transferring calibrations between tools even when the measurement geometry varies from tool-to-tool.</PDAT></PTEXT></PARA>
</BTEXT>
</SDOAB>
<SDODE>
<RELAPP>
<BTEXT>
<H LVL="1"><STEXT><PDAT>CROSS-REFERENCE TO RELATED APPLICATIONN</PDAT></STEXT></H>
<PARA ID="P-00002" LVL="0"><PTEXT><PDAT>The present application claims the benefit of U.S. Provisional Application No. 60/168,974 filed Dec. 3, 1999 in the names of the present inventors.</PDAT></PTEXT></PARA>
</BTEXT>
</RELAPP>
<GOVINT>
<BTEXT>
<H LVL="1"><STEXT><PDAT>STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT</PDAT></STEXT></H>
<PARA ID="P-00003" LVL="0"><PTEXT><PDAT>The United States Government has rights in this invention pursuant to National Science Foundation Contract No. DMI-9860798.</PDAT></PTEXT></PARA>
</BTEXT>
</GOVINT>
<BRFSUM>
<BTEXT>
<H LVL="1"><STEXT><PDAT>BACKGROUND OF THE INVENTION</PDAT></STEXT></H>
<PARA ID="P-00004" LVL="0"><PTEXT><PDAT>Many current processes for manufacturing microelectronic devices, and the like, entail the fabrication of stacks of thin films having compositions that must be controlled to satisfy exacting standards and extremely tight tolerances. For example, fluorinated silica glass (FSG) films are used as dielectric layers in semiconductor integrated circuits (IC&apos;s); because the fluorine constituent serves to reduce the dielectric constant of the layer, and thereby to improve circuit speed and reduce cross-talk between wires, it is important to control its concentration so as to optimize the electrical, chemical, and other properties of the layer. Similarly, the dopant concentrations in boron- and phosphorus-doped silica glass (BPSG) films, which are used as intermetal dielectrics, are quite critical and must be monitored and controlled carefully to maintain high yields in production, and the same is true of many of the newer materials that are now being employed as thin films, which materials tend to be compounds with complex chemical compositions and interfaces that must be monitored and controlled.</PDAT></PTEXT></PARA>
<PARA ID="P-00005" LVL="0"><PTEXT><PDAT>It is now also common for integrated circuits to include complex submicron geometric structures. For example, dynamic random access memory (DRAM) devices are typically formed with deep, tapered trenches etched into the silicon to thereby provide larger area capacitors without increasing the chip surface area utilized. The sidewall taper angle and depth of such trenches must be controlled carefully to maintain yield; moreover, the formed trenches may themselves be filled subsequently with materials such as dielectrics and polysilicon, giving rise to the need for yet further process monitoring and control capability.</PDAT></PTEXT></PARA>
<PARA ID="P-00006" LVL="0"><PTEXT><PDAT>In addition to the foregoing, compositionally graded structures are often employed in thin film manufacturing; dopants are typically diffused or implanted into semiconductor devices to provide diffuse composition profiles; and silicon on insulator (SOI) wafers are commonly fabricated by forming a buried oxide layer with a graded composition profile, which must be sharpened by thermal annealing. Controlling the depth profiles of such structures is of critical importance.</PDAT></PTEXT></PARA>
<PARA ID="P-00007" LVL="0"><PTEXT><PDAT>In all of the processes referred to, as well as in others that will be evident to those skilled in the art, it is necessary to measure the properties and characteristics of at least one layer of interest. Typically, and for any of a number of reasons, such measurements cannot presently be performed directly on the product wafers: i.e., product wafers with patterns, and multilayered film stacks, are often too complex for practical data analysis; measurements are often either destructive to the sample or are such that they pose a significant risk of contamination or defect introduction; and current techniques, carried out in the visible and ultraviolet wavelength ranges, are not sufficiently sensitive to enable accurate measurement of crucial layer properties, such as composition and carrier concentration. In any event, nondestructive measurement techniques will usually be preferred, largely because they enable the use of in-line process control methodologies without undue consumption of expensive, non-product test wafers.</PDAT></PTEXT></PARA>
<H LVL="1"><STEXT><PDAT>SUMMARY OF THE INVENTION</PDAT></STEXT></H>
<PARA ID="P-00008" LVL="0"><PTEXT><PDAT>Accordingly, broad objects of the present invention are to provide a novel method and apparatus for measuring and controlling the composition and other properties of thin films, in accordance with which at least certain of the limitations and deficiencies of current techniques and procedures, as described herein, are minimized, avoided and/or overcome.</PDAT></PTEXT></PARA>
<PARA ID="P-00009" LVL="0"><PTEXT><PDAT>It has now been found that certain of the foregoing and related objects of the invention are attained by the provision of a method for estimating at least one parameter of a sample, determined from the dielectric function of a material of which at least one layer of the sample consists. The method comprises the steps:</PDAT></PTEXT></PARA>
<PARA ID="P-00010" LVL="2"><PTEXT><PDAT>(a) providing a sample comprised of at least one layer and having a substantially specular surface;</PDAT></PTEXT></PARA>
<PARA ID="P-00011" LVL="2"><PTEXT><PDAT>(b) defining an optical model of the sample along a direction perpendicular to its surface and based upon reflectance values, the &ldquo;at least one layer&rdquo; being defmed in the model by a thickness value and, for each of a multiplicity of wavelengths in the infrared spectral region, by a dielectric function value;</PDAT></PTEXT></PARA>
<PARA ID="P-00012" LVL="2"><PTEXT><PDAT>(c) providing a training set consisting of measured values of the &ldquo;at least one parameter&rdquo; and an associated dielectric function, the measured values being obtained from a multiplicity of samples selected to represent a range of values of the at least one parameter;</PDAT></PTEXT></PARA>
<PARA ID="P-00013" LVL="2"><PTEXT><PDAT>(d) determining from the training set a predictive mathematical relationship between the at least one parameter and the associated dielectric function, so as to enable prediction of the at least one parameter from input values of dielectric function;</PDAT></PTEXT></PARA>
<PARA ID="P-00014" LVL="2"><PTEXT><PDAT>(e) irradiating the specular surface of the sample with infrared radiation, including the multiplicity of wavelengths referred to in step (b), and obtaining a measured reflectance spectrum composed of values obtained over the multiplicity of wavelengths;</PDAT></PTEXT></PARA>
<PARA ID="P-00015" LVL="2"><PTEXT><PDAT>(f) simulating a reflectance spectrum from the optical model at the multiplicity of wavelengths using various values of the dielectric function calculated from assumed dielectric function descriptors and a value of the thickness of the at least one layer, and computing the various values of the dielectric function descriptors so as to minimize the difference between the simulated reflectance spectrum and the measured reflectance spectrum, thereby determining an optimized dielectric function value for the at least one layer at the multiplicity of wavelengths; and</PDAT></PTEXT></PARA>
<PARA ID="P-00016" LVL="2"><PTEXT><PDAT>(g) calculating the value of the at least one parameter using the optimized dielectric function value and the predictive mathematical relationship.</PDAT></PTEXT></PARA>
<PARA ID="P-00017" LVL="0"><PTEXT><PDAT>In certain preferred embodiments a pattern of variation derived from the training set is utilized so as to constrain the number of the descriptors required to describe the dielectric function. The values of dielectric function used may be parametrized as weighted linear superpositions of vectors determined to span the space of dielectric functions derived from the training set, with the descriptors being the coefficients of the vectors. At least one of the vectors will desirably be determined through a multivariate statistical regression of the set of dielectric functions measured in creating the training set. The predictive mathematical relationship may for example be determined through a multivariate statistical regression of the training set; it may be determined employing a neural network algorithm calibrated with the training set; or it may be determined by establishing a library of dielectric function values with associated values of the at least one parameter, organized in the form of a look-up table which is accessed to determine the parameter from the optimized values, and access may include the additional step of interpolating between elements thereof. The predictive mathematical relationship may be established between the at least one parameter and spectral features derived from the dielectric function of the training set. The spectral feature may be at least one characteristic of at least one peak observed in the training set dielectric function, such a characteristic typically being the intensity, position, height or width of the at least one peak. In certain instances the thickness value will be varied in step (f) as well as using the computed values of the dielectric function descriptors.</PDAT></PTEXT></PARA>
<PARA ID="P-00018" LVL="0"><PTEXT><PDAT>The at least one parameter calculated by the present method may represent the species and/or the concentration of at least one chemical constituent of the material of the at least one layer. In particular, the parameter may be the concentration of fluorine atoms within the material, the concentration of hydroxyl groups within a dielectric matrix, the concentration of water molecules within a dielectric matrix, the concentration of hydrogen atoms within a dielectric matrix, or the concentrations of at least one of boron, phosphorus, and germanium in the at least one layer. When the at least one layer contains barium, strontium and/or titanium atoms, the parameter may be the concentration thereof. Additionally, the parameter value calculated may represent the stress in the at least one layer, the density of crystal defects therein, or a porosity characteristic thereof, which characteristic may describe the pore size distribution or the total fractional pore volume within the layer. Furthermore, the value determined may be characteristic of a lithography process, in instances in which the layer of interest comprises a lithographic resist layer, with the parameter representing the exposure dose of the lithographic resist layer, a critical dimension obtained after completing a lithography process step on the sample, or a measure of the sidewall profile obtained following such a process step. In instances in which the one layer is a compound semiconductor composed of at least three chemical elements, the parameter may be representative of the relative ratios of the elements, such elements generally being selected from the group consisting of Si, Ge, Al, Ga, As, N, P, In, C, Sb, Zn, Hg, Cd, B, and Te. Finally, the at least one parameter may be representative of the electrical dielectric constant of the. analyzed layer.</PDAT></PTEXT></PARA>
<PARA ID="P-00019" LVL="0"><PTEXT><PDAT>Other objects of the invention are attained by the provision of apparatus for estimating at least one parameter of a sample, determined from the dielectric function of a material of which at least one layer of the sample consists. The apparatus comprises means for irradiating a surface of a sample with infrared radiation, including each of multiplicity of wavelengths in the infrared spectral region, and for obtaining a measured reflectance spectrum composed of values obtained over the multiplicity of wavelengths; and electronic data processing means. The data processing means of the apparatus is programmed to:</PDAT></PTEXT></PARA>
<PARA ID="P-00020" LVL="2"><PTEXT><PDAT>(a) define an optical model of the sample along a direction perpendicular to a surface thereof and based upon reflectance values, the at least one layer of the sample being defined in the model by a thickness value and, for each of a multiplicity of wavelengths in the infrared spectral region, by a dielectric function value;</PDAT></PTEXT></PARA>
<PARA ID="P-00021" LVL="2"><PTEXT><PDAT>(b) provide a training set consisting of measured values of the at least one parameter and an associated dielectric function, the measured values being obtained from a multiplicity of samples selected to represent a range of values of the at least one parameter;</PDAT></PTEXT></PARA>
<PARA ID="P-00022" LVL="2"><PTEXT><PDAT>(c) determine from the training set a predictive mathematical relationship between the at least one parameter and the associated dielectric function, so as to enable prediction of the at least one parameter from input values of dielectric function;</PDAT></PTEXT></PARA>
<PARA ID="P-00023" LVL="2"><PTEXT><PDAT>(d) simulate a reflectance spectrum from the optical model at the multiplicity of wavelengths using values of the dielectric function calculated from various dielectric function descriptors and a value of the thickness of the at least one layer, and to compute the values of the dielectric function descriptors so as to minimize the difference between the simulated reflectance spectrum and the measured reflectance spectrum, thereby determining an optimized dielectric function value for the at least one layer at the multiplicity of wave-lengths; and</PDAT></PTEXT></PARA>
<PARA ID="P-00024" LVL="2"><PTEXT><PDAT>(e) calculate the value of the at least one parameter using the optimized dielectric function value and the predictive mathematical relationship.</PDAT></PTEXT></PARA>
<PARA ID="P-00025" LVL="0"><PTEXT><PDAT>As a practical matter, the invention relates to the measurement and control of layer and interface properties of thin films fabricated during the manufacture of microelectronic devices, solar conversion devices, magnetic storage devices, and the like, enabling the control of such properties and of such manufacturing operations. It provides a new approach for measuring layers deposited in thin-film structures of both present and also anticipated constructions, and it enables measurements of layers in relatively complex structures, such as multilayered film stacks. The method does not require calibration to be performed on the same measurement system as that which is present in a tool by which the method is to be implemented, and calibration samples can be relatively simple; for example, they may comprise a set of films covering a range of composition, all deposited on inexpensive, unpatterned silicon substrates. As will be appreciated, once the calibration has been performed using the calibration samples, actual measurements can be carried out on metallic substrates, multilayered configurations, or other more complicated structures.</PDAT></PTEXT></PARA>
<PARA ID="P-00026" LVL="0"><PTEXT><PDAT>The method and apparatus of the invention exploit a number of unique capabilities associated with infrared measurement techniques. In particular, the optical constants of most materials encode a great deal of chemical composition information that is unavailable in the UV and visible ranges. The longer wavelengths of infrared light also allow specular measurements on many patterned samples, whereas the scattering and diffraction of UV and visible probing beams, caused by patterns and layer roughness, often preclude accurate specular measurements. In addition, the infrared dielectric function is a complex spectral quantity which encodes information about the absorption and index of refraction of a material, as a function of optical frequency, and most materials have characteristic dielectric function signatures, in the infrared, that are related to their composition. The present invention enables the extraction of information indicative of the composition of a given layer, by computing its dielectric function from optical measurements, and at the same time eliminates confounding effects of other layers and substrate materials present in the structure; chemometric compositional analysis of the dielectric function can then be performed effectively.</PDAT></PTEXT></PARA>
<PARA ID="P-00027" LVL="0"><PTEXT><PDAT>One advantage of the instant approach resides in the correlation that it provides between the composition of a material and its dielectric function, which correlation does not depend upon details of the measurement geometry employed, e.g., the angle of incidence or the polarization of the probe beam. Optical properties, such as reflectance and transmit-tance, do on the other hand depend strongly upon the characteristics of the probe beam.</PDAT></PTEXT></PARA>
<PARA ID="P-00028" LVL="0"><PTEXT><PDAT>It is know that infrared reflectometry can be employed to extract layer composition (see J. E. Franke, T. M. Niemczyk, and D. M. Haaland, &ldquo;Infrared spectroscopic techniques for quantitative characterization of dielectric thin films on silicon wafers&rdquo; Spectrochimica Acta. Wol. 50A, No. 10. Pp 1687-1723, 1994 Elsevier Science Ltd. U.K.). However, in the methodology described the chemometric compositional analysis algorithm is applied directly to the reflectance, which not only limits the range of allowable sample thicknesses to that which is provided in the calibration sample set, but also requires the training set to constitute a relatively large number of sample thicknesses (as well as compositions) to accommodate measurements over widely varying thicknesses. Thus, the method of Haaland (and other current methods) permits measurements to be made only on samples comprised of a substrate and film stack structure that is essentially identical to that which constitutes the calibration training set. By applying chemometric analysis to the dielectric function (DF), on the other hand, which can be extracted from the reflectance in accordance with the present invention, the foregoing shortcomings are eliminated and calibration of the analysis system is enabled using much simpler, and much smaller, training sets.</PDAT></PTEXT></PARA>
<PARA ID="P-00029" LVL="0"><PTEXT><PDAT>More specifically, because the DF deconvolution removes from the chemometric model the influences of other variables, such as are attributable to the substrate and to the thickness of the layers, the training set need not span a wide range of film thicknesses and it can constitute relatively few members. Also, because the deconvolution process eliminates the effects of other layers that may be present thin films deposited in more complicated structures, such as on metal or dielectric underlayers, can be analyzed using an established calibration model; i.e., no new set of training samples is required. And finally, because the DF deconvolution eliminates any influence that the angle of probe beam incidence might have upon the spectral data obtained, measurements can be performed using a measurement geometry that is radically different from that which is employed to generate the calibration data.</PDAT></PTEXT></PARA>
</BTEXT>
</BRFSUM>
<DRWDESC>
<BTEXT>
<H LVL="1"><STEXT><PDAT>BRIEF DESCRIPTION OF THE DRAWINGS</PDAT></STEXT></H>
<PARA ID="P-00030" LVL="0"><PTEXT><FGREF ID="DRAWINGS"><PDAT>FIG. 1</PDAT></FGREF><PDAT> is a plot of curves showing measured reflectance spectra for two films of fluorine-doped glass of different thickness, namely, 0.78 &mgr;m and 1 &mgr;m;</PDAT></PTEXT></PARA>
<PARA ID="P-00031" LVL="0"><PTEXT><FGREF ID="DRAWINGS"><PDAT>FIG. 2</PDAT></FGREF><PDAT> comprises plots of curves showing the extracted dielectric functions for the two films of </PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 1</PDAT></FGREF><PDAT>, wherein plot (a) shows the refractive indices n and plot (b) shows the extinction coefficients k.</PDAT></PTEXT></PARA>
<PARA ID="P-00032" LVL="0"><PTEXT><FGREF ID="DRAWINGS"><PDAT>FIG. 3</PDAT></FGREF><PDAT> is a plot of curves showing detailed regions of the extinction coefficients k around the Si&mdash;F chemical absorption at 930 cm</PDAT><HIL><SP><PDAT>&minus;1</PDAT></SP></HIL><PDAT>;</PDAT></PTEXT></PARA>
<PARA ID="P-00033" LVL="0"><PTEXT><FGREF ID="DRAWINGS"><PDAT>FIG. 4</PDAT></FGREF><PDAT> is a plot of curves showing oscillator amplitudes for the two films;</PDAT></PTEXT></PARA>
<PARA ID="P-00034" LVL="0"><PTEXT><FGREF ID="DRAWINGS"><PDAT>FIG. 5</PDAT></FGREF><PDAT> is a plot of curves showing detailed regions around 930 cm</PDAT><HIL><SP><PDAT>&minus;1 </PDAT></SP></HIL><PDAT>for the oscillator amplitudes shown in </PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 4</PDAT></FGREF><PDAT>;</PDAT></PTEXT></PARA>
<PARA ID="P-00035" LVL="0"><PTEXT><FGREF ID="DRAWINGS"><PDAT>FIG. 6</PDAT></FGREF><PDAT> is a plot of curves showing reflectance of four silicon dioxide layers, deposited on metal, ranging in thickness from 0.17 &mgr;m to 2.13 &mgr;m;</PDAT></PTEXT></PARA>
<PARA ID="P-00036" LVL="0"><PTEXT><FGREF ID="DRAWINGS"><PDAT>FIG. 7</PDAT></FGREF><PDAT> is a plot of curves showing extinction coefficients k in the &mdash;OH absorption region, from which it can be seen that the 2.13 &mgr;m film has a smaller hydroxyl group absorption band than the two other films;</PDAT></PTEXT></PARA>
<PARA ID="P-00037" LVL="0"><PTEXT><FGREF ID="DRAWINGS"><PDAT>FIG. 8</PDAT></FGREF><PDAT> comprises plots of curves showing dielectric functions extracted for the same silicon dioxide film on two different systems, namely, a large spot (5 mm), 10&deg; angle of incidence system and a small spot (28 &mgr;m), 23&deg; angle of incidence system, wherein plot (a) shows the refractive indices n and plot (b) shows the extinction coefficients k;</PDAT></PTEXT></PARA>
<PARA ID="P-00038" LVL="0"><PTEXT><FGREF ID="DRAWINGS"><PDAT>FIG. 9</PDAT></FGREF><PDAT> comprises plots of curves showing (a) the extracted indices of refraction and (b) extinction coefficients for a UV5 resist, determined as a function of exposure level;</PDAT></PTEXT></PARA>
<PARA ID="P-00039" LVL="0"><PTEXT><FGREF ID="DRAWINGS"><PDAT>FIG. 10</PDAT></FGREF><PDAT> comprises plots of curves showing an expanded view of the spectral regions over which the photoresist DF varied with exposure after the post-exposure bake.;</PDAT></PTEXT></PARA>
<PARA ID="P-00040" LVL="0"><PTEXT><FGREF ID="DRAWINGS"><PDAT>FIGS. 11 and 12</PDAT></FGREF><PDAT> are cross-validation scatter plots for phosphorous and boron measurements, respectively; in each instance the vertical axis shows the concentration of the element in a training set, as predicted by a multivariate model, and the horizontal axis shows the nominal concentration of the element provided with the training set;</PDAT></PTEXT></PARA>
<PARA ID="P-00041" LVL="0"><PTEXT><FGREF ID="DRAWINGS"><PDAT>FIG. 13</PDAT></FGREF><PDAT> is a plot of curves showing measurements of dielectric functions of fluorine-doped silica glass films used in training data set to generate loading vectors and a predictive model for fluorine concentrations; the data range from 600 nm to 1000 nm in thickness, and from zero to 8 weight percent fluorine;</PDAT></PTEXT></PARA>
<PARA ID="P-00042" LVL="0"><PTEXT><FGREF ID="DRAWINGS"><PDAT>FIG. 14</PDAT></FGREF><PDAT> is a cross-validation plot of fluorine concentration precision; the vertical axis represents the fluorine concentrations predicted via fitting of loading vectors to the dielectric functions of samples, extracted from infrared data, and the horizontal axis represents nominal concentrations measured independently and used to calibrate the predictive model; and</PDAT></PTEXT></PARA>
<PARA ID="P-00043" LVL="0"><PTEXT><FGREF ID="DRAWINGS"><PDAT>FIG. 15</PDAT></FGREF><PDAT> is a diagrammatic representation of apparatus embodying the invention.</PDAT></PTEXT></PARA>
</BTEXT>
</DRWDESC>
<DETDESC>
<BTEXT>
<H LVL="1"><STEXT><PDAT>DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS</PDAT></STEXT></H>
<PARA ID="P-00044" LVL="0"><PTEXT><PDAT>The apparatus of the invention is diagrammatically illustrated in </PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 15</PDAT></FGREF><PDAT>, and consists fundamentally of a detector and electronic data processing means, generally designated by the numeral </PDAT><HIL><BOLD><PDAT>10</PDAT></BOLD></HIL><PDAT>, and an infrared radiation source, generally designated by the numeral </PDAT><HIL><BOLD><PDAT>12</PDAT></BOLD></HIL><PDAT>. The incident beam I from the source </PDAT><HIL><BOLD><PDAT>12</PDAT></BOLD></HIL><PDAT> is directed toward the surface of a sample S, supported on a stage </PDAT><HIL><BOLD><PDAT>14</PDAT></BOLD></HIL><PDAT>, and reflected radiation R is detected and processed, in accordance with the description herein set forth, by the detector/data processing means </PDAT><HIL><BOLD><PDAT>10</PDAT></BOLD></HIL><PDAT>. Specific features of such apparatus will be apparent to those skilled in the art from the information provided, and need not therefore be explained in further detail.</PDAT></PTEXT></PARA>
<PARA ID="P-00045" LVL="0"><PTEXT><PDAT>In accordance with the present invention, the training set will preferably include a sufficient number of samples to adequately characterize the variation of the layer properties as a function of input parameters, which parameters will typically be indicative of the concentration of one or more components of the composition. More generally, however, the parameters may be indicative of variables such as crystallinity, mobility, strain, defect density, etc. In those instances in which the subject layer is a patterned test structure, the parameters that are varied in the training set may most appropriately be linewidth, thickness, sidewall taper angle, and/or other microstructural properties.</PDAT></PTEXT></PARA>
<PARA ID="P-00046" LVL="0"><PTEXT><PDAT>Any of numerous approaches can be employed for determining the dielectric function of a layer. If optical methods are utilized however, as is preferred, a reflectance, transmission, or ellipsometry measurement will typically be performed on the sample, with the measured data being analyzed mathematically to extract the dielectric function using algorithms such as a Kramers Kronig inversion, the so-called sum-of-Lorentzian method taught in Morrison et al. U.S. Pat. No. 5,403,433, and other similar parametric model-based analysis techniques. Such algorithms allow extraction of the wavelength-dependent dielectric functions from optical measurements, such as reflectance, transmittance, or ellipsometry. The DF deconvolution explicitly eliminates from the data the effects of layer thickness, substrate properties, and of other layers present in the structure, effectively isolating the properties of the subject layer from such confounding influences.</PDAT></PTEXT></PARA>
<PARA ID="P-00047" LVL="0"><PTEXT><PDAT>The DF deconvolution procedure described in the above-identified Morrison et al. patent provides another useful parametrization of the DF that can also be analyzed according to the present invention. In accordance with the Morrison et al. approach, the dielectric function &egr;(&ngr;) is decomposed into a basis set of narrow, equally spaced Lorentzians of equal width, as shown in Equation 1, which follows: </PDAT>
<CWU>
<MATH-US ID="MATH-US-00001">
<MATHEMATICA ID="MATHEMATICA-00001" ALT="mathematica file" FILE="US06485872-20021126-M00001.NB"/>
<MATHML>
<math>
<mrow>
  <mrow>
    <mi>&varepsilon;</mi>
    <mo>&af;</mo>
    <mrow>
      <mo>(</mo>
      <mi>v</mi>
      <mo>)</mo>
    </mrow>
  </mrow>
  <mo>=</mo>
  <mrow>
    <msub>
      <mi>&varepsilon;</mi>
      <mi>&infin;</mi>
    </msub>
    <mo>+</mo>
    <mrow>
      <mo>&Sum;</mo>
      <mstyle>
        <mtext>&emsp;</mtext>
      </mstyle>
      <mo>&it;</mo>
      <mfrac>
        <msub>
          <mi>A</mi>
          <mi>k</mi>
        </msub>
        <mrow>
          <msubsup>
            <mi>v</mi>
            <mi>k</mi>
            <mn>2</mn>
          </msubsup>
          <mo>-</mo>
          <msup>
            <mi>v</mi>
            <mn>2</mn>
          </msup>
          <mo>-</mo>
          <mrow>
            <mi>iv</mi>
            <mo>&it;</mo>
            <mstyle>
              <mtext>&emsp;</mtext>
            </mstyle>
            <mo>&it;</mo>
            <mi>&gamma;</mi>
          </mrow>
        </mrow>
      </mfrac>
    </mrow>
  </mrow>
</mrow>
</math>
</MATHML>
<EMI ID="EMI-M00001" ALT="embedded image" FILE="US06485872-20021126-M00001.TIF"/>
</MATH-US>
</CWU>
</PTEXT></PARA>
<PARA ID="P-00048" LVL="7"><PTEXT><PDAT>in which the values &ngr;</PDAT><HIL><SB><PDAT>k </PDAT></SB></HIL><PDAT>are defined to be equally spaced by some small increment, i.e. &ngr;</PDAT><HIL><SB><PDAT>k</PDAT></SB></HIL><PDAT>&equals;&ngr; &plus;k&dgr;&ngr;, and wherein the values A</PDAT><HIL><SB><PDAT>k </PDAT></SB></HIL><PDAT>can be related directly to the density of chemical bonds with resonant absorptions at the frequency &ngr;</PDAT><HIL><SB><PDAT>k</PDAT></SB></HIL><PDAT>. Other approaches to extraction of the dielectric function include Kramers Kronig analysis, ellipsometric analysis, multiangle reflectometry, etc.</PDAT></PTEXT></PARA>
<PARA ID="P-00049" LVL="0"><PTEXT><PDAT>After the DF has been extracted, the next step is to relate the spectral features of the DF to the composition of the layer, for which step there are also several alternative approaches. For example, a multivariate model that relates the sample parameters to measured spectra can be constructed using a suitable chemometric algorithm such as classical least squares, inverse least squares, partial least squares, or principal component or factor analysis. All of these methods are based upon the construction of an analysis model using a regression analysis of a training set.</PDAT></PTEXT></PARA>
<PARA ID="P-00050" LVL="0"><PTEXT><PDAT>One approach to relating the DF to the sample parameters, in accordance with step (d), is to employ knowledge of the optical properties of the material in question to identify the spectral regions of the DF that encode particular compositional information. For example, it is known that hydroxyl groups have a strong absorption band lying between about 3000 and 3500 cm</PDAT><HIL><SP><PDAT>&minus;1</PDAT></SP></HIL><PDAT>. The amplitude of the dielectric function within that range may therefore be related to the &mdash;OH concentration in a film through correlation with independent knowledge of the &mdash;OH concentration obtained either by independent measurements or through knowledge of the fabrication process. This approach allows heuristic knowledge of the layer chemistry to be used in the construction of the model.</PDAT></PTEXT></PARA>
<PARA ID="P-00051" LVL="0"><PTEXT><PDAT>A second, more general approach for relating the DF to the sample parameters applies a statistical discipline, such as principal component analysis, to characterize the variation of the DF spectra, extracted from the training set in terms of so-called scores and loading vectors. This approach enables the rigorous construction of a vector space that spans the observed variation of the training set using relatively few degrees of freedom, and enables a dielectric function to be represented as a linear combination of independent vectors, weighted by a particular set of scores. The approach provides the considerable advantage of allowing prediction of the dielectric function using a statistically optimized minimal number of parameters and without requiring first-principles models to construct the model for DF prediction.</PDAT></PTEXT></PARA>
<PARA ID="P-00052" LVL="0"><PTEXT><PDAT>After calibration of the DF-prediction model, using the training samples, an unknown sample to be analyzed is measured in accordance with step (e). Preferred methods for measurement are infrared reflectometry, ellipsometry, and variations of those basic techniques; the basic techniques and the variants thereof are referred to herein and in the appended claims by the general terms &ldquo;reflectance,&rdquo;&ldquo;reflectometry, &rdquo; and the like. The layer stack structure of the sample must be known, but it need not have the same layer sequence as that which is provided in the training set.</PDAT></PTEXT></PARA>
<PARA ID="P-00053" LVL="0"><PTEXT><PDAT>In step (f) a predictive model is constructed that can predict the measured data of a structure of the type supplied in step (e), using the model developed in step (b) and employing assumed values of the unknown layer parameters in order to compute the DF of the unknown layer. Any additional layers present in the structure can be treated in the same way, using different DF models previously computed from other training sets, or they can be treated using other physical models, such as those that are described in Liu et al. U.S. Pat. No. 5,604,581, to predict the DF of each additional layer. Similar procedures are applied to predict the DF of the substrate as well.</PDAT></PTEXT></PARA>
<PARA ID="P-00054" LVL="0"><PTEXT><PDAT>In addition to determining the DF of every layer in the structure, other parameters (e.g. layer thicknesses) that are needed to predict the measured data are defined in step (f). Once the thicknesses and DF parameters of each layer are defined in the model, multilayered optical calculations, based on Maxwell&apos;s equations, can be used to predict reflectance, ellipsometry parameters, and other measured properties of the layer stack. The transfer matrix method described by Liu et al. to calculate the reflectance from the dielectric functions and thicknesses of the layer stack is an example of this approach. Other parameters of the model that relate to the measurement configuration can also be defined, such as the angle of incidence and/or the polarization of the probing beam, etc.</PDAT></PTEXT></PARA>
<PARA ID="P-00055" LVL="0"><PTEXT><PDAT>The reflectance analysis of a fluorinated silica glass film on a silicon substrate provides an example of the implementation of step (d). Inputs to the model are the fluorine concentration, the film thickness, and the substrate carrier concentration. The DF model, previously constructed from the analysis of a training set of FSG films of different fluorine concentrations, would be employed to compute the DF of the layer based upon its assumed fluorine concentration. The reflectance of the sample would thus be predicted from assumed values of the layer thickness, substrate doping, and fluorine concentration, using a transfer matrix method analogous to that described in the above-identified Morrison et al. and Liu et al. patents.</PDAT></PTEXT></PARA>
<PARA ID="P-00056" LVL="0"><PTEXT><PDAT>Step (f) may be carried out using an iterative regression analysis, in accordance with which a set of assumed input parameters for the model of step (b) are varied in order to best fit to the measured data to the data predicted by the model. A subset of the parameters defined in step (b) may be held fixed, at assumed values, during the fit.</PDAT></PTEXT></PARA>
<PARA ID="P-00057" LVL="0"><PTEXT><PDAT>Finally, in accordance with step (g) the predicted parameters are reported as the measurement results. A &ldquo;goodness-of-fit parameter, &rdquo; quantifying the degree of agreement between the predicted and measured data, may also be reported to characterize the quality of the measurement.</PDAT></PTEXT></PARA>
<PARA ID="P-00058" LVL="0"><PTEXT><PDAT>Illustrative of the efficacy of the method of the invention are the following examples:</PDAT></PTEXT></PARA>
<H LVL="1"><STEXT><PDAT>EXAMPLE ONE</PDAT></STEXT></H>
<H LVL="1"><STEXT><PDAT>Compositional Analysis of a Single Layer of BPSG on a Silicon Substrate</PDAT></STEXT></H>
<PARA ID="P-00059" LVL="0"><PTEXT><PDAT>In this Example the method of the invention is applied for the determination of the composition of a thin film; specifically, a boro-phospho-silica glass (BPSG) film, deposited on a silicon substrate, is analyzed using the seven-step methodology described above.</PDAT></PTEXT></PARA>
<PARA ID="P-00060" LVL="0"><PTEXT><PDAT>First, a training set of BPSG films, ranging up to approximately one micron thick, were deposited on silicon substrates (step (c)); the concentrations of boron and phosphorus in the training set spanned a range from pure SiO</PDAT><HIL><SB><PDAT>2 </PDAT></SB></HIL><PDAT>(i.e., no boron or phosphorus) to levels of about 8 percent by weight of the elements.</PDAT></PTEXT></PARA>
<PARA ID="P-00061" LVL="0"><PTEXT><PDAT>The mid-infrared reflectance spectrum of each sample in the training set was measured and a DF deconvolution was performed, using the method of Morrison et al., to determine the dielectric function of each layer. It will be appreciated that ellipsometry, or combined reflectance and transmittance measurements followed by appropriate numerical analysis, may alternatively be employed to extract the DF of the film for each sample constituting the training set.</PDAT></PTEXT></PARA>
<PARA ID="P-00062" LVL="0"><PTEXT><PDAT>These dielectric functions, together with the independently provided nominal boron and phosphorous concentrations of the training set samples, comprised a training data set. A principal component analysis was then performed, using the training data set dielectric functions as inputs. This procedure generates a set of loading vectors and scores constructed such that the dielectric function of each sample in the training set can be well approximated by a weighted linear sum of loading vectors. Each sample is distinguished by its weighting coefficient, while the loading vectors are common to the samples in the training set. The boron and phosphorous concentrations of the samples are in turn represented as a function of the scores, with this function also common to the training set and the particular details of the principal component.</PDAT></PTEXT></PARA>
<PARA ID="P-00063" LVL="0"><PTEXT><PDAT>Given an unknown sample, the measurement process then reduces to determining its dielectric function, fitting the dielectric function as a linear sum of loading vectors, and then taking the appropriate function of the scores to compute the boron or phosphorous composition. One approach to determining the dielectric function of the unknown sample is to perform a &ldquo;sum of Lorentzian&rdquo; (Morrison et al,) or Kramers-Kronig decomposition of the reflectance data. Another approach is to perform an iterative fit of the reflectance in which the dielectric function of the BPSG layer is represented as an unknown linear sum of loading vectors derived from the training set. The unknown scores are adjusted during the fit to best match the modeled reflectance data to the measured data. Of course it should be appreciated that other parameters such as layer thicknesses and dielectric function parameters of other layers in the structure may be fitted following this procedure as well.</PDAT></PTEXT></PARA>
<PARA ID="P-00064" LVL="0"><PTEXT><PDAT>Following this procedure, a set of fourteen samples was employed to generate loading vectors and to cross-validate the predictive model. The fourteen samples were separated into an &ldquo;unknown sample&rdquo; and a training set of thirteen samples. The training set was analyzed to determine a set of five loading vectors. The reflectance of the fourteenth &ldquo;unknown sample&rdquo; was then fitted for its dielectric function. The dielectric function was then fitted as a linear sum of the five loading vectors and the boron and phosphorous concentrations were computed from the scores obtained. This process was repeated systematically with each sample in the set getting treated in turn as an unknown sample, using the model derived from the other thirteen samples to predict the unknown&apos;s composition.</PDAT></PTEXT></PARA>
<PARA ID="P-00065" LVL="0"><PTEXT><PDAT>The results of this cross-validation procedure can be presented in the form of scatter plots in which the vertical axis represents the predicted value of the boron or phosphorous concentration, and the horizontal axis represents the nominal values of the boron or phosphorous concentrations provided with the training data set. The results of this cross-validation of the model are summarized in the scatter plots of </PDAT><FGREF ID="DRAWINGS"><PDAT>FIGS. 11 and 12</PDAT></FGREF><PDAT>. As can be seen, the model predicted excellently the boron and phosphorous concentrations of the samples in the training set.</PDAT></PTEXT></PARA>
<H LVL="1"><STEXT><PDAT>EXAMPLE TWO</PDAT></STEXT></H>
<H LVL="1"><STEXT><PDAT>Analysis of Composition of a BPSG Layer Deposited on a Doped Silicon Substrate</PDAT></STEXT></H>
<PARA ID="P-00066" LVL="0"><PTEXT><PDAT>This Example illustrates a layer analysis in which the fitting model employs fitting parameters that relate to structures other than the BPSG in question. The approach is similar to that of Example One; however, a sample of unknown boron and phosphorus composition, unknown thickness, and unknown substrate carrier concentration is measured using an infrared reflectometer.</PDAT></PTEXT></PARA>
<PARA ID="P-00067" LVL="0"><PTEXT><PDAT>In step (f) a fitting model is was employed in which the unknown parameters were boron concentration, phosphorus concentration, BPSG layer thickness, and substrate carrier concentration. The substrate dielectric function was modeled as a function of carrier concentration using a Drude model, as in the Liu et al. patent referred to above. The DF of the BPSG layer was modeled as a sum of loading vectors or Lorentzians, using the same method employed in the previous Example, and the reflectance was modeled using the transfer matrix formalism described in the referenced Morrison et al. patent.</PDAT></PTEXT></PARA>
<PARA ID="P-00068" LVL="0"><PTEXT><PDAT>The modeled reflectance was iteratively fit to the measured data by varying the model-fitting parameters. As will be appreciated, if parameters such as the film thickness are known independently, through means such as visible wavelength reflectometry analysis, they may of course be held fixed at their nominal values. One again, the final values of boron and phosphorus concentrations, and any other fitting parameters and goodness-of-fit numbers determined, are reported in step (7) as the measurement results. In this Example, the optical effects of the substrate doping upon the reflectance do not interfere with the determination of the BPSG properties, because the fitting model explicitly accounts for the substrate doping effects.</PDAT></PTEXT></PARA>
<H LVL="1"><STEXT><PDAT>EXAMPLE THREE</PDAT></STEXT></H>
<H LVL="1"><STEXT><PDAT>Analysis of Fluorine Doped Silica Glass</PDAT></STEXT></H>
<PARA ID="P-00069" LVL="0"><PTEXT><PDAT>Reference to </PDAT><FGREF ID="DRAWINGS"><PDAT>FIGS. 1 through 5</PDAT></FGREF><PDAT> provides graphic illustration of step (2) of the present method. As noted, </PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 1</PDAT></FGREF><PDAT> shows the measured reflectance of two films of fluorine-doped silica glass (FSG) having similar compositions but different nominal thicknesses, it being seen that the reflectance spectra vary from one another due to the thickness-related effects of the interference fringe and absorption bands. </PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 2</PDAT></FGREF><PDAT> shows the dielectric function spectra for the same two films, extracted using the method of Morrison et al., and </PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 3</PDAT></FGREF><PDAT> provides greater detail as to the region of the spectrum around 930 wavenumbers where the Si&mdash;F chemical absorption is observed; it is noted that the dielectric functions of the two films are nearly identical, even though the layer thickness and reflectance spectra are significantly different. </PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 4</PDAT></FGREF><PDAT> shows the oscillator amplitudes A</PDAT><HIL><SB><PDAT>k</PDAT></SB></HIL><PDAT>, as defined in Equation 1 and expressed as a function of frequency rather than index k, and </PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 5</PDAT></FGREF><PDAT> shows the detailed region around 930 wavenumbers. Just as in </PDAT><FGREF ID="DRAWINGS"><PDAT>FIGS. 2 and 3</PDAT></FGREF><PDAT>, because the oscillator amplitude spectra are representative of the bulk properties of the layer material, and are independent of the layer thickness or substrate, the spectra in </PDAT><FGREF ID="DRAWINGS"><PDAT>FIGS. 4 and 5</PDAT></FGREF><PDAT> are nearly identical for the two layers.</PDAT></PTEXT></PARA>
<PARA ID="P-00070" LVL="0"><PTEXT><PDAT>The fluorine concentration was determined using one of several methods, such as a chemometric calibration of the dielectric functions or A</PDAT><HIL><SB><PDAT>k </PDAT></SB></HIL><PDAT>spectra in the vicinity of the 930 wavenumber absorption, or a simple peak height or peak area analysis of the 930 wavenumber feature. To perform the detailed quantitative measurement of the fluorine concentration, a statistical empirical model was created using a calibration sample set of independently analyzed composition. A set of dielectric function data, expressed as absorption coefficients for a training set of FSG films, is shown in </PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 13. A</PDAT></FGREF><PDAT> cross-validation plot for this sample set (</PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 14</PDAT></FGREF><PDAT>) demonstrates the efficacy of the method to correctly predict the fluorine concentrations of the samples in the training set. In this Example, four loading vectors we needed to span the training set.</PDAT></PTEXT></PARA>
<H LVL="1"><STEXT><PDAT>EXAMPLE FOUR</PDAT></STEXT></H>
<H LVL="1"><STEXT><PDAT>Analysis of Moisture and Bonded Hydroxyl Groups in Deposited Silicon Oxide Layers</PDAT></STEXT></H>
<PARA ID="P-00071" LVL="0"><PTEXT><PDAT>This Example illustrates the application of the present method for monitoring the hydroxyl group impurity levels in a dielectric film. </PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 6</PDAT></FGREF><PDAT> shows the measured infrared reflectance of four silicon dioxide layers deposited on metallized substrates, the thicknesses of the layers being 0.17 &mgr;m, 0.68 &mgr;m, 1.01 &mgr;m and 2.13 &mgr;m. Although features associated with the &mdash;OH and moisture absorption bands at about 3500 cm</PDAT><HIL><SP><PDAT>&minus;1 </PDAT></SP></HIL><PDAT>are visible in the reflectance curves, confounding effects of the thin film interference fringe make it difficult to estimate the moisture level from these spectra. </PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 7</PDAT></FGREF><PDAT> shows the extinction spectra k of the three thickest films in the region where &mdash;OH groups absorb strongly, extracted using the method of Morrison et al. The data clearly show the 2.13 micron film to have the smallest absorption band, and therefore the lowest concentration of &mdash;OH groups dispersed in the layer. To provide a quantitative analysis of the hydroxyl group and water concentrations, a statistical empirical chemometric model would be constructed (using step (c)) from a sample set covering the approximate range of moisture and &mdash;OH concentrations expected in the measurements. An unknown sample measurement would then be fit to the empirical model to provide the &mdash;OH concentration of the layer.</PDAT></PTEXT></PARA>
<PARA ID="P-00072" LVL="0"><PTEXT><PDAT>Because the algorithms relate the composition to the DF (a bulk layer property), rather than to the reflectance directly, the chemometric calibrations can be transferred readily from one system to another, even when gross differences exist in the measurement geometry. </PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 8</PDAT></FGREF><PDAT> shows dielectric function data extracted from the same sample using measurements from two very different systems, and illustrates this feature. The first system is a near normal (10&deg;) incidence system with a 5 mm measurement, and the second is a small (28 micron) spot system with an average angle of incidence of 23&deg;. The similarity of the two superimposed dielectric function spectra illustrates the ability of the present method to eliminate effects of machine-related structure from the reflectance data. This machine-independent characteristic of the method allows the use of reflection, emission, or ellipsometric data to compute layer properties, independently of the method used to generate the calibration model.</PDAT></PTEXT></PARA>
<H LVL="1"><STEXT><PDAT>EXAMPLE FIVE</PDAT></STEXT></H>
<H LVL="1"><STEXT><PDAT>Analysis of Photoresist Chemistry</PDAT></STEXT></H>
<PARA ID="P-00073" LVL="0"><PTEXT><PDAT>Organic photoresist thin films are commonly used in the semiconductor and related industries for the lithographic transfer, to substrates and thin films, of patterns having microscopic features. As the industry moves to incorporate into semiconductor devices features having dimensions of 0.25 micron and smaller, new classes of photoresists, which are sensitive to shorter wavelengths of light, are being employed. These so-called &ldquo;chemically amplified photoresists,&rdquo; or &ldquo;CARs,&rdquo; in which an annealing step (post exposure bake, or PEB) is performed after exposure, have relatively complex chemistries. During the PEB, the thickness of such a photoresist film is seen to decrease and subtle changes in the DF of the layer can also be observed, the latter being relatable to the chemical reactions that occur in the process. A method to monitor such chemical changes, which discriminates them from changes caused by film shrinkage, is therefore needed.</PDAT></PTEXT></PARA>
<PARA ID="P-00074" LVL="0"><PTEXT><PDAT>Infrared spectroscopy is an ideal technique for probing such a process because much of the relevent chemical information is encoded in the infrared absorption bands. Using a combination of sample model-based analysis and DF analysis, the chemical information can be decoded and differentiated from film thickness-related interference fringes. In the present Example a novel model-based synthetic differencing technique is used to accentuate features that are attributable to chemical reactions.</PDAT></PTEXT></PARA>
<PARA ID="P-00075" LVL="0"><PTEXT><PDAT>The IR reflectance of photoresist films, subjected to various levels of exposure, was measured in the range 800-5000 cm</PDAT><HIL><SP><PDAT>&minus;1 </PDAT></SP></HIL><PDAT>(12.5-2 &mgr;m), at an average angle of incidence of 23&deg; from the surface normal. The sensitivity of the IR dielectric function to thin-film chemistry is well illustrated for the case of photoresist analysis. Chemically amplified resists are known to undergo key catalytic reactions during a post-exposure bake, which reactions depend not only upon the bake conditions but also upon the exposure dose and the chemical composition of the photoresist resin.</PDAT></PTEXT></PARA>
<PARA ID="P-00076" LVL="0"><PTEXT><FGREF ID="DRAWINGS"><PDAT>FIG. 9</PDAT></FGREF><PDAT> shows the extracted dielectric function for a CAR layer (UV5) subjected to a range of exposure doses ranging from unexposed through doses significantly higher than those employed for the nominal exposure process, and being represented as the index of refraction n and the absorption index k and expressed as functions of wavenumber; </PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 10</PDAT></FGREF><PDAT> shows, in greater detail, specific regions that changed as a function of exposure dose, and in both </PDAT><FGREF ID="DRAWINGS"><PDAT>FIGS. 9 and 10</PDAT></FGREF><PDAT> the exposure dose decreased as the curve labels increased. The data show a great deal of structure that can be related to the various carbon-based and &mdash;OH functional groups. At various levels of exposure the sample resist shows, very clearly, systematic variations in chemistry as well as changes in indices. The Figures also show that only limited regions of the spectral range change with exposure. In particular, the reduction of the band around 1150 cm</PDAT><HIL><SP><PDAT>&minus;1 </PDAT></SP></HIL><PDAT>corresponds to &mdash;CO groups reacting to produce &mdash;OH groups, the increase of which is visible in the 3100-3500 cm</PDAT><HIL><SP><PDAT>&minus;1 </PDAT></SP></HIL><PDAT>region. Changes in the 1700 cm</PDAT><HIL><SP><PDAT>&minus;1 </PDAT></SP></HIL><PDAT>region have been attributed to the deprotection reaction involving ester bonds reacting with the photo-generated acid, to yield carboxylic acids. Finally, it is noted that a method such as PCA, which is capable of isolating the minimum degrees of freedom needed to span the sample variation, could greatly reduce the computational complexity involved in modeling the reflectance of these materials.</PDAT></PTEXT></PARA>
<PARA ID="P-00077" LVL="0"><PTEXT><PDAT>Thus, it can be seen that the foregoing and related objects of the invention are readily attained by the practice of the method of the instant invention, and by the provision of apparatus for implementing the method.</PDAT></PTEXT></PARA>
</BTEXT>
</DETDESC>
</SDODE>
<SDOCL>
<H LVL="1"><STEXT><PDAT>Having thus described the invention, what is claimed is: </PDAT></STEXT></H>
<CL>
<CLM ID="CLM-00001">
<PARA ID="P-00078" LVL="0"><PTEXT><PDAT>1. A method for estimating at least one parameter of a sample, determined from the dielectric function of a material of which at least one layer of the sample consists, comprising the steps:</PDAT></PTEXT></PARA>
<CLMSTEP LVL="2"><PTEXT><PDAT>(a) providing a sample comprised of at least one layer and having a substantially specular surface; </PDAT></PTEXT></CLMSTEP>
<CLMSTEP LVL="2"><PTEXT><PDAT>(b) defining an optical model of said sample along a direction perpendicular to said surface and based upon reflectance values, said at least one layer being defined in said model by a thickness value and, for each of a multiplicity of wavelengths in the infrared spectral region, by a dielectric function value; </PDAT></PTEXT></CLMSTEP>
<CLMSTEP LVL="2"><PTEXT><PDAT>(c) providing a traing set consisting of measured values of said at least one parameter and an associated dielectric function, said measured values being obtained from a multiplicity of samples selected to represent a range of values of said at least one parameter; </PDAT></PTEXT></CLMSTEP>
<CLMSTEP LVL="2"><PTEXT><PDAT>(d) determining from said traing set a predictive mathematical relationship between said at least one parameter and said associated dielectric function, so as to enable prediction of said at least one parameter from input values of dielectric function; </PDAT></PTEXT></CLMSTEP>
<CLMSTEP LVL="2"><PTEXT><PDAT>(e) irradiating said specular surface of said sample with infrared radiation, including said multiplicity of wavelengths, and obtaining a measured reflectance spectrum composed of values obtained over said multiplicity of wavelengths; </PDAT></PTEXT></CLMSTEP>
<CLMSTEP LVL="2"><PTEXT><PDAT>(f) simulating a reflectance spectrum from said optical model at said multiplicity of wavelengths using values of said dielectric function calculated from assumed dielectric function descriptors and a value of said thickness of said at least one layer, and computing said various values of said dielectric function descriptors so as to minimize the difference between said simulated reflectance spectrum and said measured reflectance spectrum, thereby determining an optimized dielectric function value for said at least one layer at said multiplicity of wavelengths; and </PDAT></PTEXT></CLMSTEP>
<CLMSTEP LVL="2"><PTEXT><PDAT>(g) calculating the value of said at least one parameter using said optimized dielectric function value and said predictive mathematical relationship. </PDAT></PTEXT></CLMSTEP>
</CLM>
<CLM ID="CLM-00002">
<PARA ID="P-00079" LVL="0"><PTEXT><PDAT>2. The method of </PDAT><CLREF ID="CLM-00001"><PDAT>claim 1</PDAT></CLREF><PDAT> wherein a pattern of variation derived from said training set is utilized so as to constrain the number of said descriptors required to describe said dielectric function.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00003">
<PARA ID="P-00080" LVL="0"><PTEXT><PDAT>3. The method of </PDAT><CLREF ID="CLM-00002"><PDAT>claim 2</PDAT></CLREF><PDAT> wherein said values of dielectric function used are parametrized as weighted linear superpositions of vectors determined to span the space of dielectric functions derived from said training set, and wherein said descriptors are the coefficients of said vectors.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00004">
<PARA ID="P-00081" LVL="0"><PTEXT><PDAT>4. The method of </PDAT><CLREF ID="CLM-00003"><PDAT>claim 3</PDAT></CLREF><PDAT> in which at least one of said vectors is determined through a multivariate statistical regression of the set of dielectric functions measured in creating said training set.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00005">
<PARA ID="P-00082" LVL="0"><PTEXT><PDAT>5. The method of </PDAT><CLREF ID="CLM-00001"><PDAT>claim 1</PDAT></CLREF><PDAT> wherein said predictive mathematical relationship is determined through a multivariate statistical regression of said training set.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00006">
<PARA ID="P-00083" LVL="0"><PTEXT><PDAT>6. The method of </PDAT><CLREF ID="CLM-00001"><PDAT>claim 1</PDAT></CLREF><PDAT> wherein said predictive mathematical relationship is determined employing a neural network algorithm calibrated with said training set.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00007">
<PARA ID="P-00084" LVL="0"><PTEXT><PDAT>7. The method of </PDAT><CLREF ID="CLM-00001"><PDAT>claim 1</PDAT></CLREF><PDAT> wherein said predictive mathematical relationship is determined by establishing a library of dielectric function values with associated values of said at least one parameter, organized in the form of a look-up table, and wherein said look-up table is accessed to determined said parameter from said optimized values.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00008">
<PARA ID="P-00085" LVL="0"><PTEXT><PDAT>8. The method of </PDAT><CLREF ID="CLM-00007"><PDAT>claim 7</PDAT></CLREF><PDAT> wherein said look-up table access includes the additional step of interpolating between elements of said look-up table.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00009">
<PARA ID="P-00086" LVL="0"><PTEXT><PDAT>9. The method of </PDAT><CLREF ID="CLM-00001"><PDAT>claim 1</PDAT></CLREF><PDAT> wherein said predictive mathematical relationship is established between said at least one parameter and spectral features derived from the dielectric function of said training set.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00010">
<PARA ID="P-00087" LVL="0"><PTEXT><PDAT>10. The method of </PDAT><CLREF ID="CLM-00009"><PDAT>claim 9</PDAT></CLREF><PDAT> wherein said spectral feature is at least one characteristic of at least one peak observed in said training set dielectric function.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00011">
<PARA ID="P-00088" LVL="0"><PTEXT><PDAT>11. The method of </PDAT><CLREF ID="CLM-00010"><PDAT>claim 10</PDAT></CLREF><PDAT> wherein said at least one characteristic is the intensity, position, height or width of said at least one peak.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00012">
<PARA ID="P-00089" LVL="0"><PTEXT><PDAT>12. The method of </PDAT><CLREF ID="CLM-00001"><PDAT>claim 1</PDAT></CLREF><PDAT> wherein said thickness value is varied in said step (f).</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00013">
<PARA ID="P-00090" LVL="0"><PTEXT><PDAT>13. The method of </PDAT><CLREF ID="CLM-00001"><PDAT>claim 1</PDAT></CLREF><PDAT> wherein said at least one parameter represents at least one of the species and the concentration of at least one chemical constituent of said material of said at least one layer.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00014">
<PARA ID="P-00091" LVL="0"><PTEXT><PDAT>14. The method of </PDAT><CLREF ID="CLM-00013"><PDAT>claim 13</PDAT></CLREF><PDAT> in which said at least one parameter is the concentration of fluorine atoms within said material of said at least one layer.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00015">
<PARA ID="P-00092" LVL="0"><PTEXT><PDAT>15. The method of </PDAT><CLREF ID="CLM-00013"><PDAT>claim 13</PDAT></CLREF><PDAT>, wherein said at least one parameter is the concentration of hydroxyl groups within a dielectric matrix.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00016">
<PARA ID="P-00093" LVL="0"><PTEXT><PDAT>16. The method of </PDAT><CLREF ID="CLM-00013"><PDAT>claim 13</PDAT></CLREF><PDAT> wherein said at least one parameter is the concentration of water molecules within a dielectric matrix.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00017">
<PARA ID="P-00094" LVL="0"><PTEXT><PDAT>17. The method of </PDAT><CLREF ID="CLM-00013"><PDAT>claim 13</PDAT></CLREF><PDAT> wherein said at least one parameter is the concentration of hydrogen atoms within a dielectric matrix.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00018">
<PARA ID="P-00095" LVL="0"><PTEXT><PDAT>18. The method of </PDAT><CLREF ID="CLM-00013"><PDAT>claim 13</PDAT></CLREF><PDAT> wherein said at least one parameter is the concentrations of at least one of boron, phosphorus, and germanium in said at least one layer.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00019">
<PARA ID="P-00096" LVL="0"><PTEXT><PDAT>19. The method of </PDAT><CLREF ID="CLM-00013"><PDAT>claim 13</PDAT></CLREF><PDAT> wherein said at least one layer contains at least one of the species barium, strontium and titanium atoms, and wherein said at least one parameter is the concentration of said at least one species atom therein.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00020">
<PARA ID="P-00097" LVL="0"><PTEXT><PDAT>20. The method of </PDAT><CLREF ID="CLM-00001"><PDAT>claim 1</PDAT></CLREF><PDAT> wherein said at least one parameter represents the stress in said at least one layer.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00021">
<PARA ID="P-00098" LVL="0"><PTEXT><PDAT>21. The method of </PDAT><CLREF ID="CLM-00001"><PDAT>claim 1</PDAT></CLREF><PDAT> wherein said at least one parameter represents the density of crystal defects in said at least one layer.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00022">
<PARA ID="P-00099" LVL="0"><PTEXT><PDAT>22. The method of </PDAT><CLREF ID="CLM-00001"><PDAT>claim 1</PDAT></CLREF><PDAT> wherein said at least one parameter represents a porosity characteristic of said at least one layer.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00023">
<PARA ID="P-00100" LVL="0"><PTEXT><PDAT>23. The method of </PDAT><CLREF ID="CLM-00022"><PDAT>claim 22</PDAT></CLREF><PDAT> wherein said porosity characteristic describes the pore size distribution within said at least one layer.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00024">
<PARA ID="P-00101" LVL="0"><PTEXT><PDAT>24. The method of </PDAT><CLREF ID="CLM-00022"><PDAT>claim 22</PDAT></CLREF><PDAT> wherein said porosity characteristic describes the total fractional pore volume within said at least one layer.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00025">
<PARA ID="P-00102" LVL="0"><PTEXT><PDAT>25. The method of </PDAT><CLREF ID="CLM-00001"><PDAT>claim 1</PDAT></CLREF><PDAT> wherein said at least one parameter is characteristic of a lithography process, and wherein said at least one layer comprises a lithographic resist layer.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00026">
<PARA ID="P-00103" LVL="0"><PTEXT><PDAT>26. The method of </PDAT><CLREF ID="CLM-00025"><PDAT>claim 25</PDAT></CLREF><PDAT> wherein said at least one parameter represents the exposure dose of said lithographic resist layer.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00027">
<PARA ID="P-00104" LVL="0"><PTEXT><PDAT>27. The method of </PDAT><CLREF ID="CLM-00025"><PDAT>claim 25</PDAT></CLREF><PDAT> wherein said at least one parameter represents the critical dimension obtained after completing a lithography process step on said sample.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00028">
<PARA ID="P-00105" LVL="0"><PTEXT><PDAT>28. The method of </PDAT><CLREF ID="CLM-00013"><PDAT>claim 13</PDAT></CLREF><PDAT> wherein said at least one parameter is a measure of the sidewall profile obtained after completing a lithography process step on said sample.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00029">
<PARA ID="P-00106" LVL="0"><PTEXT><PDAT>29. The method of </PDAT><CLREF ID="CLM-00013"><PDAT>claim 13</PDAT></CLREF><PDAT> wherein said at least one layer is a compound semi-conductor composed of at least three chemical elements, and wherein said at least one parameter is representative of the relative ratios of said at least three chemical elements.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00030">
<PARA ID="P-00107" LVL="0"><PTEXT><PDAT>30. The method of </PDAT><CLREF ID="CLM-00029"><PDAT>claim 29</PDAT></CLREF><PDAT> wherein said elements are selected from the group consisting of Si, Ge, Al, Ga, As, N, P, In, C, Sb, Zn, Hg, Cd, B, and Te.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00031">
<PARA ID="P-00108" LVL="0"><PTEXT><PDAT>31. The method of </PDAT><CLREF ID="CLM-00001"><PDAT>claim 1</PDAT></CLREF><PDAT> wherein said at least one parameter is representative of the electrical dielectric constant of said at least one layer.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00032">
<PARA ID="P-00109" LVL="0"><PTEXT><PDAT>32. Apparatus for estimating at least one parameter of a sample, determined from the dielectric function of a material of which at least one layer of the sample consists, comprising: means for irradiating a surface of a sample with infrared radiation, including each of multiplicity of wavelengths in the infrared spectral region, and for obtaining a measured reflectance spectrum composed of values obtained over said multiplicity of wavelengths; and electronic data processing means, said data processing means being programmed to:</PDAT></PTEXT></PARA>
<CLMSTEP LVL="2"><PTEXT><PDAT>(a) define an optical model of the sample along a direction perpendicular to a surface thereof and based upon reflectance values, the at least one layer of the sample being defined in said model by a thickness value and, for each of a multiplicity of wavelengths in said infrared spectral region, by a dielectric function value; </PDAT></PTEXT></CLMSTEP>
<CLMSTEP LVL="2"><PTEXT><PDAT>(b) provide a training set consisting of measured values of said at least one parameter and an associated dielectric function, said measured values being obtained from a multiplicity of samples selected to represent a range of values of said at least one parameter; </PDAT></PTEXT></CLMSTEP>
<CLMSTEP LVL="2"><PTEXT><PDAT>(c) determine from said training set a predictive mathematical relationship between said at least one parameter and said associated dielectric function, so as to enable prediction of said at least one parameter from input values of dielectric function; </PDAT></PTEXT></CLMSTEP>
<CLMSTEP LVL="2"><PTEXT><PDAT>(d) simulate a reflectance spectrum from said optical model at said multiplicity of wavelengths using values of said dielectric function calculated from assumed dielectric function descriptors and a value of said thickness of said at least one layer, and to compute the values of said dielectric function descriptors so as to minimize the difference between said simulated reflectance spectrum and said measured reflectance spectrum, thereby determining an optimized dielectric function value for said at least one layer at said multiplicity of wavelengths; and </PDAT></PTEXT></CLMSTEP>
<CLMSTEP LVL="2"><PTEXT><PDAT>(e) calculate the value of said at least one parameter using said optimized dielectric function value and said predictive mathematical relationship.</PDAT></PTEXT></CLMSTEP>
</CLM>
</CL>
</SDOCL>
<SDODR ID="DRAWINGS">
<EMI ID="EMI-D00001" ALT="embedded image" FILE="US06485872-20021126-D00001.TIF"/>
<EMI ID="EMI-D00002" ALT="embedded image" FILE="US06485872-20021126-D00002.TIF"/>
<EMI ID="EMI-D00003" ALT="embedded image" FILE="US06485872-20021126-D00003.TIF"/>
<EMI ID="EMI-D00004" ALT="embedded image" FILE="US06485872-20021126-D00004.TIF"/>
<EMI ID="EMI-D00005" ALT="embedded image" FILE="US06485872-20021126-D00005.TIF"/>
<EMI ID="EMI-D00006" ALT="embedded image" FILE="US06485872-20021126-D00006.TIF"/>
<EMI ID="EMI-D00007" ALT="embedded image" FILE="US06485872-20021126-D00007.TIF"/>
<EMI ID="EMI-D00008" ALT="embedded image" FILE="US06485872-20021126-D00008.TIF"/>
<EMI ID="EMI-D00009" ALT="embedded image" FILE="US06485872-20021126-D00009.TIF"/>
<EMI ID="EMI-D00010" ALT="embedded image" FILE="US06485872-20021126-D00010.TIF"/>
<EMI ID="EMI-D00011" ALT="embedded image" FILE="US06485872-20021126-D00011.TIF"/>
<EMI ID="EMI-D00012" ALT="embedded image" FILE="US06485872-20021126-D00012.TIF"/>
</SDODR>
</PATDOC>

<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE PATDOC SYSTEM "ST32-US-Grant-025xml.dtd" [
<!ENTITY US06485912-20021126-C00001.CDX SYSTEM "US06485912-20021126-C00001.CDX" NDATA CDX>
<!ENTITY US06485912-20021126-C00001.MOL SYSTEM "US06485912-20021126-C00001.MOL" NDATA MOL>
<!ENTITY US06485912-20021126-C00001.TIF SYSTEM "US06485912-20021126-C00001.TIF" NDATA TIF>
<!ENTITY US06485912-20021126-C00002.CDX SYSTEM "US06485912-20021126-C00002.CDX" NDATA CDX>
<!ENTITY US06485912-20021126-C00002.MOL SYSTEM "US06485912-20021126-C00002.MOL" NDATA MOL>
<!ENTITY US06485912-20021126-C00002.TIF SYSTEM "US06485912-20021126-C00002.TIF" NDATA TIF>
<!ENTITY US06485912-20021126-C00003.CDX SYSTEM "US06485912-20021126-C00003.CDX" NDATA CDX>
<!ENTITY US06485912-20021126-C00003.MOL SYSTEM "US06485912-20021126-C00003.MOL" NDATA MOL>
<!ENTITY US06485912-20021126-C00003.TIF SYSTEM "US06485912-20021126-C00003.TIF" NDATA TIF>
<!ENTITY US06485912-20021126-C00004.CDX SYSTEM "US06485912-20021126-C00004.CDX" NDATA CDX>
<!ENTITY US06485912-20021126-C00004.MOL SYSTEM "US06485912-20021126-C00004.MOL" NDATA MOL>
<!ENTITY US06485912-20021126-C00004.TIF SYSTEM "US06485912-20021126-C00004.TIF" NDATA TIF>
<!ENTITY US06485912-20021126-D00001.TIF SYSTEM "US06485912-20021126-D00001.TIF" NDATA TIF>
<!ENTITY US06485912-20021126-D00002.TIF SYSTEM "US06485912-20021126-D00002.TIF" NDATA TIF>
<!ENTITY US06485912-20021126-D00003.TIF SYSTEM "US06485912-20021126-D00003.TIF" NDATA TIF>
]>
<PATDOC DTD="2.5" STATUS="Build 20020918">
<SDOBI>
<B100>
<B110><DNUM><PDAT>06485912</PDAT></DNUM></B110>
<B130><PDAT>B1</PDAT></B130>
<B140><DATE><PDAT>20021126</PDAT></DATE></B140>
<B190><PDAT>US</PDAT></B190>
</B100>
<B200>
<B210><DNUM><PDAT>09648933</PDAT></DNUM></B210>
<B211US><PDAT>09</PDAT></B211US>
<B220><DATE><PDAT>20000824</PDAT></DATE></B220>
</B200>
<B500>
<B510>
<B511><PDAT>C12Q  168</PDAT></B511>
<B516><PDAT>7</PDAT></B516>
</B510>
<B520>
<B521><PDAT>435  6</PDAT></B521>
<B522><PDAT>435455</PDAT></B522>
<B522><PDAT>435462</PDAT></B522>
<B522><PDAT>435463</PDAT></B522>
<B522><PDAT>435466</PDAT></B522>
<B522><PDAT>435471</PDAT></B522>
<B522><PDAT>435473</PDAT></B522>
<B522><PDAT>435476</PDAT></B522>
<B522><PDAT>435440</PDAT></B522>
<B522><PDAT>4353201</PDAT></B522>
</B520>
<B540><STEXT><PDAT>Methods of performing gene trapping in bacterial and bacteriophage-derived artificial chromosomes and use thereof</PDAT></STEXT></B540>
<B560>
<B561>
<PCIT>
<DOC><DNUM><PDAT>5851808</PDAT></DNUM>
<DATE><PDAT>19981200</PDAT></DATE>
<KIND><PDAT>A</PDAT></KIND>
</DOC>
<PARTY-US>
<NAM><SNM><STEXT><PDAT>Elledge et al.</PDAT></STEXT></SNM></NAM>
</PARTY-US>
</PCIT><CITED-BY-OTHER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>6069101</PDAT></DNUM>
<DATE><PDAT>20000500</PDAT></DATE>
<KIND><PDAT>A</PDAT></KIND>
</DOC>
<PARTY-US>
<NAM><SNM><STEXT><PDAT>Choi</PDAT></STEXT></SNM></NAM>
</PARTY-US>
</PCIT><CITED-BY-OTHER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>0 485 701</PDAT></DNUM>
<DATE><PDAT>19920500</PDAT></DATE>
<CTRY><PDAT>EP</PDAT></CTRY>
</DOC>
</PCIT>
<CITED-BY-OTHER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>0742285</PDAT></DNUM>
<DATE><PDAT>19961100</PDAT></DATE>
<CTRY><PDAT>EP</PDAT></CTRY>
</DOC>
</PCIT>
<CITED-BY-OTHER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>WO 97/10343</PDAT></DNUM>
<DATE><PDAT>19970300</PDAT></DATE>
<CTRY><PDAT>WO</PDAT></CTRY>
</DOC>
</PCIT>
<CITED-BY-OTHER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>WO 97/29202</PDAT></DNUM>
<DATE><PDAT>19970800</PDAT></DATE>
<CTRY><PDAT>WO</PDAT></CTRY>
</DOC>
</PCIT>
<CITED-BY-OTHER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>WO 98/59060</PDAT></DNUM>
<DATE><PDAT>19981200</PDAT></DATE>
<CTRY><PDAT>WO</PDAT></CTRY>
</DOC>
</PCIT>
<CITED-BY-OTHER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>WO 99/29837</PDAT></DNUM>
<DATE><PDAT>19990600</PDAT></DATE>
<CTRY><PDAT>WO</PDAT></CTRY>
</DOC>
</PCIT>
<CITED-BY-OTHER/>
</B561>
<B562><NCIT><STEXT><PDAT>Zhang et al., Nature Genetics, 20(2):123-8, 1998. </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Yoon et al., Genetic Analysis: Biomolec. Engineering, 14: 89-95, 1998. </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Yang et al., Nature Biotech., 15: 859-65, 1997. </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Metcalf et al., Plasmid, 35: 1-13, 1996. </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Balasubramanian et al., </PDAT><HIL><ITALIC><PDAT>J. of Bacteriology</PDAT></ITALIC></HIL><PDAT> 178:273-279 (1996). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Birnboim et al., </PDAT><HIL><ITALIC><PDAT>Nucleic Acids Res. </PDAT></ITALIC></HIL><PDAT>7:1513-1523 (1979. </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Bochner et al., </PDAT><HIL><ITALIC><PDAT>J. Bacteriol. </PDAT></ITALIC></HIL><PDAT>143:926-33 (1980). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Boyseu et al., </PDAT><HIL><ITALIC><PDAT>Genome Research</PDAT></ITALIC></HIL><PDAT>, 7:330-338 (1997). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Bradley et al., </PDAT><HIL><ITALIC><PDAT>Nature Genet</PDAT></ITALIC></HIL><PDAT>. 14:121-3 (1997). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Brinster et al. (1989) </PDAT><HIL><ITALIC><PDAT>Proc.Natl.Acad.Sci. </PDAT></ITALIC></HIL><PDAT>86:7087-91. </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Brinster et al., </PDAT><HIL><ITALIC><PDAT>Proc.Natl.Acad.Sci. </PDAT></ITALIC></HIL><PDAT>85:836-840 (1988). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Burke et al., </PDAT><HIL><ITALIC><PDAT>Science </PDAT></ITALIC></HIL><PDAT>236:806-12. </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Clark et al., </PDAT><HIL><ITALIC><PDAT>Critical Reviews in Microbiology </PDAT></ITALIC></HIL><PDAT>20:125-142 (1994). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Deng and Capecchi (</PDAT><HIL><ITALIC><PDAT>MCB</PDAT></ITALIC></HIL><PDAT>, 12:3365-3371). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Dillon et al., </PDAT><HIL><ITALIC><PDAT>Trends Genet. </PDAT></ITALIC></HIL><PDAT>9:134-7 (1993). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Fujitani et al. (1995) Genetics 140:797-809. </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Gnirke et al. (1993) Genomics 15:659-67. </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Hamilton et al., </PDAT><HIL><ITALIC><PDAT>J. Bacteriol. </PDAT></ITALIC></HIL><PDAT>171:4617-22 (1989). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Harrington et al. </PDAT><HIL><ITALIC><PDAT>Nature Genetics</PDAT></ITALIC></HIL><PDAT>, 15:345-355 (1997). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Hashimoto-Gotoh et al. (1977) J. Bacteriol. 131:405-12. </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Hosoda et al., </PDAT><HIL><ITALIC><PDAT>Nucleic Acids Res. </PDAT></ITALIC></HIL><PDAT>18:3863-9 (1990). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Ioannou et al., </PDAT><HIL><ITALIC><PDAT>Nat. Gener.</PDAT></ITALIC></HIL><PDAT>, 6:84-89 (1994). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Jaenisch et al., </PDAT><HIL><ITALIC><PDAT>Science </PDAT></ITALIC></HIL><PDAT>240:1468-74 (1985). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Joyner, A., Ed. </PDAT><HIL><ITALIC><PDAT>Gene Targeting, a practical approach</PDAT></ITALIC></HIL><PDAT>, IRL Press: Oxford, New York, Tokyo. </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Kennison, </PDAT><HIL><ITALIC><PDAT>Trends Genet. </PDAT></ITALIC></HIL><PDAT>9:75-9 (1993). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Kim et al. </PDAT><HIL><ITALIC><PDAT>MCB</PDAT></ITALIC></HIL><PDAT>, 12:3636-3643 (1992). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Kim et al., </PDAT><HIL><ITALIC><PDAT>Proc.Natl.Acad.Sci. </PDAT></ITALIC></HIL><PDAT>93:6297-6301 (1996). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Kuhn et al., </PDAT><HIL><ITALIC><PDAT>Science </PDAT></ITALIC></HIL><PDAT>269:1427-9 (1995). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Maloy et al., </PDAT><HIL><ITALIC><PDAT>Bacteriol. </PDAT></ITALIC></HIL><PDAT>145:1110 (1981). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>McKee et al., </PDAT><HIL><ITALIC><PDAT>Chromosoma </PDAT></ITALIC></HIL><PDAT>7:479-488 (1996). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Mejia et al., </PDAT><HIL><ITALIC><PDAT>Genome Res. </PDAT></ITALIC></HIL><PDAT>7:179-186 (1997). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Monaco et al., </PDAT><HIL><ITALIC><PDAT>Trends Biotechnol </PDAT></ITALIC></HIL><PDAT>12:280-286 (1994). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>O&apos;Connor et al. </PDAT><HIL><ITALIC><PDAT>Science</PDAT></ITALIC></HIL><PDAT>, 244:1307-1312 (1989). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Palmiter et al., </PDAT><HIL><ITALIC><PDAT>Cell </PDAT></ITALIC></HIL><PDAT>41:343-5 (1985). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Peakman et al., </PDAT><HIL><ITALIC><PDAT>Proc.Natl.Acad.Sci. </PDAT></ITALIC></HIL><PDAT>93:10222-10227 (1996). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Peterson et al., </PDAT><HIL><ITALIC><PDAT>TIG </PDAT></ITALIC></HIL><PDAT>(</PDAT><HIL><ITALIC><PDAT>Trends Genet.</PDAT></ITALIC></HIL><PDAT>) 13:61-66 (1997). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Reiss et al.,</PDAT><HIL><ITALIC><PDAT>Proc.Natl.Acad.Sci. </PDAT></ITALIC></HIL><PDAT>93:3094-3098 (1996). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Shizuya et al., </PDAT><HIL><ITALIC><PDAT>Proc. Natl. Acad. Sci. </PDAT></ITALIC></HIL><PDAT>89:8794-8797 (1992). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Spencer et al. (1993) Meth.: Comp. Meth. Enzymol. 5:161-75. </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Tsien et al., </PDAT><HIL><ITALIC><PDAT>Cell </PDAT></ITALIC></HIL><PDAT>87:1317-26 (1996). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Wang et al., </PDAT><HIL><ITALIC><PDAT>Genomics </PDAT></ITALIC></HIL><PDAT>24:527-34 (1994). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Wilson et al., </PDAT><HIL><ITALIC><PDAT>Annu.Rev.Cell.Biol. </PDAT></ITALIC></HIL><PDAT>6:679-714 (1990). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Woo et al., </PDAT><HIL><ITALIC><PDAT>Nucleic Acids Res.</PDAT></ITALIC></HIL><PDAT>, 22:4922-31 (1994). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Wooster et al., </PDAT><HIL><ITALIC><PDAT>Nature </PDAT></ITALIC></HIL><PDAT>378:789-92 (1995). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Yang et al., </PDAT><HIL><ITALIC><PDAT>Development </PDAT></ITALIC></HIL><PDAT>122:555-66 (1996). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Baker &amp; Cotton, Nucleic Acids Research 25:1950-56 (1997). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Chatterjee &amp; Cohen, Nucleic Acids Research 25:2205-2212 (1997). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Eggleston &amp; West, Trends Genet. 12:20-25 (1996). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Kim et al., Genomics 34:213-18 (1996). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Larionov et al., Nucleic Acids Research 22:4154-4161 (1994). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Simon, Nature Biotech 15:839 (1997). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Yang et al., Nature Biotech. 15:859-65 (1997). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Boren et al., Genome Research, 6:1123-30 (1996). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Chatterjee et al., Elsevier Science 13:33-42 (1996).</PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
</B560>
<B570>
<B577><PDAT>12</PDAT></B577>
<B578US><PDAT>1</PDAT></B578US>
</B570>
<B580>
<B582><PDAT>435  6</PDAT></B582>
<B582><PDAT>435455</PDAT></B582>
<B582><PDAT>435462</PDAT></B582>
<B582><PDAT>435463</PDAT></B582>
<B582><PDAT>435466</PDAT></B582>
<B582><PDAT>435473</PDAT></B582>
<B582><PDAT>435471</PDAT></B582>
<B582><PDAT>435476</PDAT></B582>
<B582><PDAT>435440</PDAT></B582>
<B582><PDAT>4353201</PDAT></B582>
</B580>
<B590><B595><PDAT>3</PDAT></B595><B596><PDAT>6</PDAT></B596></B590>
</B500>
<B600>
<B630><B631><PARENT-US><CDOC><DOC><DNUM><PDAT>09/648933</PDAT></DNUM></DOC></CDOC><PDOC><DOC><DNUM><PDAT>09/102488</PDAT></DNUM><DATE><PDAT>19980622</PDAT></DATE><CTRY><PDAT>US</PDAT></CTRY><KIND><PDAT>00</PDAT></KIND></DOC></PDOC><PSTA><PDAT>01</PDAT></PSTA><PPUB><DOC><DNUM><PDAT>6156574</PDAT></DNUM><CTRY><PDAT>US</PDAT></CTRY><KIND><PDAT>A </PDAT></KIND></DOC></PPUB></PARENT-US></B631></B630>
<B630><B632><PARENT-US><CDOC><DOC><DNUM><PDAT>09/102488</PDAT></DNUM></DOC></CDOC><PDOC><DOC><DNUM><PDAT>09/007206</PDAT></DNUM><DATE><PDAT>19980114</PDAT></DATE><CTRY><PDAT>US</PDAT></CTRY><KIND><PDAT>00</PDAT></KIND></DOC></PDOC><PSTA><PDAT>01</PDAT></PSTA><PPUB><DOC><DNUM><PDAT>6130090</PDAT></DNUM><CTRY><PDAT>US</PDAT></CTRY><KIND><PDAT>A </PDAT></KIND></DOC></PPUB></PARENT-US></B632></B630>
<B630><B632><PARENT-US><CDOC><DOC><DNUM><PDAT>09/007206</PDAT></DNUM></DOC></CDOC><PDOC><DOC><DNUM><PDAT>08/880966</PDAT></DNUM><DATE><PDAT>19970623</PDAT></DATE><CTRY><PDAT>US</PDAT></CTRY><KIND><PDAT>00</PDAT></KIND></DOC></PDOC><PSTA><PDAT>01</PDAT></PSTA><PPUB><DOC><DNUM><PDAT>6143566</PDAT></DNUM><CTRY><PDAT>US</PDAT></CTRY><KIND><PDAT>A </PDAT></KIND></DOC></PPUB></PARENT-US></B632></B630>
</B600>
<B700>
<B720>
<B721>
<PARTY-US>
<NAM><FNM><PDAT>Nathaniel</PDAT></FNM><SNM><STEXT><PDAT>Heintz</PDAT></STEXT></SNM></NAM>
<ADR>
<CITY><PDAT>Pelham Manor</PDAT></CITY>
<STATE><PDAT>NY</PDAT></STATE>
</ADR>
</PARTY-US>
</B721>
<B721>
<PARTY-US>
<NAM><FNM><PDAT>Weining</PDAT></FNM><SNM><STEXT><PDAT>Jiang</PDAT></STEXT></SNM></NAM>
<ADR>
<CITY><PDAT>New York</PDAT></CITY>
<STATE><PDAT>NY</PDAT></STATE>
</ADR>
</PARTY-US>
</B721>
<B721>
<PARTY-US>
<NAM><FNM><PDAT>Xiangdong W.</PDAT></FNM><SNM><STEXT><PDAT>Yang</PDAT></STEXT></SNM></NAM>
<ADR>
<CITY><PDAT>New York</PDAT></CITY>
<STATE><PDAT>NY</PDAT></STATE>
</ADR>
</PARTY-US>
</B721>
</B720>
<B730>
<B731>
<PARTY-US>
<NAM><ONM><STEXT><PDAT>The Rockefeller University</PDAT></STEXT></ONM></NAM>
<ADR><CITY><PDAT>New York</PDAT></CITY><STATE><PDAT>NY</PDAT></STATE></ADR>
</PARTY-US>
</B731>
<B732US>
<PDAT>02</PDAT>
</B732US>
</B730>
<B740>
<B741>
<PARTY-US>
<NAM><ONM><STEXT><PDAT>Klauber &amp; Jackson</PDAT></STEXT></ONM></NAM>
</PARTY-US>
</B741>
</B740>
<B745>
<B746>
<PARTY-US>
<NAM><FNM><PDAT>James</PDAT></FNM><SNM><STEXT><PDAT>Ketter</PDAT></STEXT></SNM></NAM>
</PARTY-US>
</B746>
<B748US><PDAT>1636</PDAT></B748US>
</B745>
</B700>
</SDOBI>
<SDOAB>
<BTEXT>
<PARA ID="P-00001" LVL="0"><PTEXT><PDAT>A method of efficiently sequencing multiple exons from complex genomic DNAs is disclosed. The methodology includes the use of bacterial and bacteriophage-derived artificial chromosomes (BBPACS) in novel gene trapping protocols. Targeted gene trapping by homologous recombination, and random gene trapping with the use of a transposon system are exemplified. Included in the invention are methods of preparing a gene map from BBPAC contigs, the resulting gene maps, methods of constructing a cDNA library from BBPAC contigs, and the resulting cDNA libraries.</PDAT></PTEXT></PARA>
</BTEXT>
</SDOAB>
<SDODE>
<RELAPP>
<BTEXT>
<H LVL="1"><STEXT><PDAT>CROSS-REFERENCE TO RELATED APPLICATIONS</PDAT></STEXT></H>
<PARA ID="P-00002" LVL="0"><PTEXT><PDAT>The present Application is a Continuation of U.S. Ser. No. 09/102,488, filed Jun. 22, 1998, now U.S. Pat. No. 6,156,574 which is a Continuation-In-Part of U.S. Ser. No. 09/007,206, filed Jan. 14, 1998 now U.S. Pat. No. 6,130,090, which is a Continuation-In-Part of U.S. Ser. No. 08/880,966, filed Jun. 23, 1997 now U.S. Pat. No. 6,143,566, the disclosures of which are hereby incorporated by reference in their entireties. Applicants claim the benefits of these Application under 35 U.S.C. &sect;120.</PDAT></PTEXT></PARA>
</BTEXT>
</RELAPP>
<GOVINT>
<BTEXT>
<H LVL="1"><STEXT><PDAT>GOVERNMENTAL SUPPORT</PDAT></STEXT></H>
<PARA ID="P-00003" LVL="0"><PTEXT><PDAT>The research leading to the present invention was supported, at least in part, by a grant from the National Science Foundation Grant No. MCB-9316625. Accordingly, the Government may have certain rights in the invention.</PDAT></PTEXT></PARA>
</BTEXT>
</GOVINT>
<BRFSUM>
<BTEXT>
<H LVL="1"><STEXT><PDAT>FIELD OF THE INVENTION</PDAT></STEXT></H>
<PARA ID="P-00004" LVL="0"><PTEXT><PDAT>This invention relates generally to methods of efficiently isolating coding sequences from complex genomic DNAs. More particularly, the present invention relates to a novel methodology for gene trapping in bacterial and bacteriophage-derived artificial chromosomes. The procedures are exemplified by either targeted gene trapping using homologous recombination methodology or random gene trapping employing a transposon system. Included in the invention are methods of preparing a gene map from a bacterial or bacteriophage-derived artificial chromosome contig, the resulting gene maps, methods of constructing a cDNA library from bacterial or bacteriophage-derived artificial chromosomes contigs, and the resulting cDNA libraries.</PDAT></PTEXT></PARA>
<H LVL="1"><STEXT><PDAT>BACKGROUND OF THE INVENTION</PDAT></STEXT></H>
<PARA ID="P-00005" LVL="0"><PTEXT><PDAT>In recent years, the sequencing of the genomes of individual species, including humans, has become a major goal of biomedical research. The most prevalent procedure for sequencing the coding regions of a gene relies on RNA based methods, such as direct screening of a cDNA library. However, such methods are inherently biased towards the identification of nucleic acids which are prevalent in the tissue sample being studied. Therefore, genes which are expressed solely in tissues that are difficult to obtain, and/or expressed under relatively rare circumstances, have a good chance of being missed. Particularly in the latter case, these genes are likely to play a unique role during a specific cellular challenge, and thus could be important in a specific diseased state.</PDAT></PTEXT></PARA>
<PARA ID="P-00006" LVL="0"><PTEXT><PDAT>Exon trapping is one method of potentially overcoming the inherent bias of the mRNA based procedures of genomic sequencing. Exon trapping was originally developed to efficiently isolate coding sequences from complex genomic sequences &lsqb;Duyk et al., </PDAT><HIL><ITALIC><PDAT>PNAS </PDAT></ITALIC></HIL><PDAT>87, 8995-8999 (1990); Buckler et al., </PDAT><HIL><ITALIC><PDAT>PNAS </PDAT></ITALIC></HIL><PDAT>88:40054009 (1991)&rsqb;. This method is based on the selection of exons which are flanked by functional 5&prime; and 3&prime; splice sites. Conventional exon trapping vectors contain a driving promoter (i.e. SV40 promoter, metallothionein-1 promoter) which controls the expression of an exon having a 5&prime; splice site; an intron with multiple cloning sites; and a 3&prime; exon having a 3&prime; splice site and a poly-adenylation (poly A) signal sequence. Genomic fragments containing potential exons are first subcloned into the intron. The resulting plasmid DNA is then transfected into COS-7 cells, which transcribe and then process the RNA products. The mature RNAs containing the trapped exons can be amplified by reverse transcriptase PCR and subcloned. The trapped exons can be identified by sequencing the cloned cDNA products. In addition to its simplicity and efficiency, exon trapping is also independent, of the amount, location, and timing of the expression of a given gene, and therefore is preferable to mRNA based methods. Consequently, exon trapping has become widely employed in transcription map construction for positional cloning and in general genomic sequencing.</PDAT></PTEXT></PARA>
<PARA ID="P-00007" LVL="0"><PTEXT><PDAT>Unfortunately, current exon trapping systems have a number of limitations. First, the size of the genomic insert in the exon-trapping vector is limited to 1-2 kilobases (kb), so the resulting trapped exon is usually a single small exon (80-150 basepairs (bp)). Such small exons are usually difficult to use in subsequent biological procedures, such as library screening, Northern blot analysis, or in in situ hybridizations. Second, different exons from a single gene will be dispersed in different trapping vectors. Therefore, reconstruction of the gene from the small pieces of the gene requires considerable additional work. Third, subcloning of small genomic fragments may disrupt the elements necessary for proper splicing, thereby increasing the chance of missing. certain exons. Fourth, current exon trapping systems can only be used in combination with specific cell lines (i.e. COS cells). However since specific cellular factors are required to support the SV40 origin of replication, exons that are spliced in a tissue specific manner could be missed in the COS cells.</PDAT></PTEXT></PARA>
<PARA ID="P-00008" LVL="0"><PTEXT><PDAT>One recent advance towards solving some of these problems uses cosmid-based exon trapping vectors &lsqb;Datson et al., </PDAT><HIL><ITALIC><PDAT>NAR </PDAT></ITALIC></HIL><PDAT>24, 1105-1111 (1996)&rsqb;. A specially designed cosmid vector is used, with a promoter and 5&prime; splice site on one end, and 3&prime; splice site and poly-adenylation signal sequence on the other end. The genomic insert now can be as large as 40 kb. In this case, multiple exons can be trapped together. Such a trapped gene segment can be greater than 800 bp. The major disadvantage of this system is that it is necessary to use a specialized genomic cosmid library. Furthermore, cosmid clones are inherently unstable.</PDAT></PTEXT></PARA>
<PARA ID="P-00009" LVL="0"><PTEXT><PDAT>An alternative to using a cosmid based system is to use one or more of the </PDAT><HIL><ITALIC><PDAT>E. coli </PDAT></ITALIC></HIL><PDAT>based cloning systems based on the </PDAT><HIL><ITALIC><PDAT>E. coli </PDAT></ITALIC></HIL><PDAT>fertility factor which have been developed to construct large genomic DNA insert libraries. These are bacterial artificial chromosomes (BACs) and P-1 derived artificial chromosomes (PACs) &lsqb;Mejia et al., </PDAT><HIL><ITALIC><PDAT>Genome Res</PDAT></ITALIC></HIL><PDAT>. 7:179-186 (1997); Shizuya et al., Proc. Natl. Acad. Sci. 89:8794-8797 (1992);Ioannou et al., </PDAT><HIL><ITALIC><PDAT>Nat. Genet</PDAT></ITALIC></HIL><PDAT>., 6:84-89 (1994); Hosoda et al., </PDAT><HIL><ITALIC><PDAT>Nucleic Acids Res</PDAT></ITALIC></HIL><PDAT>. 18:3863 (1990)&rsqb;. BACs are based on the </PDAT><HIL><ITALIC><PDAT>E. coli </PDAT></ITALIC></HIL><PDAT>fertility plasmid (F factor); and PACs are based on the bacteriophage P1. The size of DNA fragments from eukaryotic genomes that can be stably cloned in </PDAT><HIL><ITALIC><PDAT>Escherichia coli </PDAT></ITALIC></HIL><PDAT>as plasmid molecules has been expanded by the advent of PACs and BACs. These vectors propagate at a very low copy number (1-2 per cell) enabling genomic inserts up to 700 kb in size to be stably maintained in recombination deficient hosts. The host cell is required to be recombination deficient to ensure that non-specific and potentially deleterious recombination events are kept to a very minimum. As a result, libraries of PACs and BACs are relatively free of the high proportion of chimeric or rearranged clones typical in Yeast artificial chromosomes (YACs). &lsqb;Burke et al., </PDAT><HIL><ITALIC><PDAT>Science </PDAT></ITALIC></HIL><PDAT>236:806; Peterson et al., </PDAT><HIL><ITALIC><PDAT>Trends Genet</PDAT></ITALIC></HIL><PDAT>. 13:61 (1997); Choi, et al., </PDAT><HIL><ITALIC><PDAT>Nat. Genet</PDAT></ITALIC></HIL><PDAT>., 4:117-223 (1993), Davies, et al., </PDAT><HIL><ITALIC><PDAT>Biotechnology </PDAT></ITALIC></HIL><PDAT>11:911-914 (1993), Matsuura, et al., </PDAT><HIL><ITALIC><PDAT>Hum. Mol. Genet</PDAT></ITALIC></HIL><PDAT>., 5:451-459 (1996), Peterson et al., </PDAT><HIL><ITALIC><PDAT>Proc. Natl. Acad. Sci</PDAT></ITALIC></HIL><PDAT>., 93:6605-6609 (1996); Schedl, et al., </PDAT><HIL><ITALIC><PDAT>Cell</PDAT></ITALIC></HIL><PDAT>, 6:71-82 (1996); Monaco et al., </PDAT><HIL><ITALIC><PDAT>Trends Biotechnol </PDAT></ITALIC></HIL><PDAT>12:280-286 (1994); Boyseu et al., </PDAT><HIL><ITALIC><PDAT>Genome Research</PDAT></ITALIC></HIL><PDAT>, 7:330-338 (1997)&rsqb;. In addition, isolating and sequencing DNA from PACs or BACs involves simpler procedures than for YACs, and PACs and BACs have a higher cloning efficiency than YACs &lsqb;Shizuya et al., Proc. Natl. Acad. Sci. 89:8794-8797 (1992);Ioannou et al., </PDAT><HIL><ITALIC><PDAT>Nat. Genet</PDAT></ITALIC></HIL><PDAT>., 6:84-89 (1994); Hosoda et al., </PDAT><HIL><ITALIC><PDAT>Nucleic Acids Res</PDAT></ITALIC></HIL><PDAT>. 18:3863 (1990)&rsqb;. Such advantages have made BACs and PACs important tools for physical mapping in many genomes &lsqb;Woo et al., </PDAT><HIL><ITALIC><PDAT>Nucleic Acids Res</PDAT></ITALIC></HIL><PDAT>., 22:4922 (1994); Kim et al., </PDAT><HIL><ITALIC><PDAT>Proc. Natl. Acad. Sci</PDAT></ITALIC></HIL><PDAT>. 93:6297-6301 (1996); Wang et al., </PDAT><HIL><ITALIC><PDAT>Genomics </PDAT><HIL><BOLD><PDAT>24</PDAT></BOLD></HIL><PDAT>:</PDAT><HIL><BOLD><PDAT>527</PDAT></BOLD></HIL></ITALIC></HIL><PDAT>(1994); Wooster et al., </PDAT><HIL><ITALIC><PDAT>Nature </PDAT></ITALIC></HIL><PDAT>378:789 (1995)&rsqb;. Furthermore, the PACs and BACs are circular DNA molecules that are readily isolated from the host genomic background by classical alkaline lysis &lsqb;Birnboim et al., </PDAT><HIL><ITALIC><PDAT>Nucleic Acids Res</PDAT></ITALIC></HIL><PDAT>. 7:1513-1523 (1979&rsqb;. In addition, BACs have been found to be an important source of genomic DNA for the direct sequencing of the human genome &lsqb;Rowen et al., </PDAT><HIL><ITALIC><PDAT>Sequence </PDAT></ITALIC></HIL><PDAT>278: 605-607 (1997)&rsqb;. On the other hand, their use in gene identification is still extremely limited. Indeed, heretofore, BACs and PACs have not been shown to be useful in methods that directly isolate genes, such as exon trapping.</PDAT></PTEXT></PARA>
<PARA ID="P-00010" LVL="0"><PTEXT><PDAT>Therefore, there is a need to efficiently sequence coding regions of eukaryotic genes, and in particular human genes, which are expressed relatively rarely and/or only at specific times (such as the genes involved in circadian rhythms or those involved in body weight homeostasis); and/or are predominantly expressed in tissues that are difficult to obtain, such as the human organ of Corti. In addition there is a need to produce new and improved gene maps for BAC or PAC contigs. Furthermore, there is a need to compile new cDNA libraries that are not biased by the expression pattern of the tissue that serve as the source for the mRNAs used to construct the cDNA library.</PDAT></PTEXT></PARA>
<PARA ID="P-00011" LVL="0"><PTEXT><PDAT>The citation of any reference herein should not be construed as an admission that such reference is available as &ldquo;Prior Art&rdquo; to the instant application.</PDAT></PTEXT></PARA>
<H LVL="1"><STEXT><PDAT>SUMMARY OF THE INVENTION</PDAT></STEXT></H>
<PARA ID="P-00012" LVL="0"><PTEXT><PDAT>The present invention provides a novel and efficient method of determining the nucleotide sequence of a portion of a eukaryotic gene that minimally contains one exon which has a 3&prime; splice acceptor, i.e., any exon other than the first exon. Preferably the portion of the eukaryotic gene contains two or more exons that have 3&prime; splice acceptors. In a more preferred embodiment, the portion of the eukaryotic gene contains three or more exons that have 3&prime; splice acceptors. In the most preferred embodiment, the portion of the eukaryotic gene contains all of the exons of the gene except the first exon.</PDAT></PTEXT></PARA>
<PARA ID="P-00013" LVL="0"><PTEXT><PDAT>The present invention includes methods of including a eukaryotic promoter exonlintron unit (PEU) in a Bacterial or Bacteriophage-Derived Artificial Chromosome (BBPAC) with a trappable eukaryotic gene. In one aspect of the present invention,r the PEU is placed into existing BBPACs. Preferably the PEU is inserted operatively upstream to one or more exons of the trappable eukaryotic gene. More preferably, the PEU is inserted operatively upstream to all, or all but the first exon of the trappable eukaryotic gene.</PDAT></PTEXT></PARA>
<PARA ID="P-00014" LVL="0"><PTEXT><PDAT>In an alternative aspect of the present invention, BBPACs are constructed using vectors containing one or more PEUs, and genomic DNA containing trappable eukaryotic genes is inserted into the vectors to form a BBPAC containing one or more PEUs and trappable eukaryotic genes. Preferably a PEU is operatively upstream to one or more exoris of the inserted trappable eukaryotic gene. More preferably, the PEU is operatively upstream to all but the first exon of the inserted trappable eukaryotic gene.</PDAT></PTEXT></PARA>
<PARA ID="P-00015" LVL="0"><PTEXT><PDAT>In one embodiment the trappable eukaryotic gene(s) are vertebrate genes. In a preferred embodiment of this type the vertebrate genes are mammalian genes. In a more preferred embodiment of this type the mammalian genes are human genes. In another embodiment the trappable eukaryotic gene(s) are invertebrate genes. In a preferred embodiment of this type the invertebrate genes are insect genes. In still another embodiment the trappable eukaryotic genes are plant genes.</PDAT></PTEXT></PARA>
<PARA ID="P-00016" LVL="0"><PTEXT><PDAT>In a related aspect, the present invention provides methods of obtaining a cell that contains a BBPAC containing a PEU and a trappable eukaryotic gene. Preferably the PEU is operatively upstream to one or more exons of the trappable eukaryotic gene. More preferably, the PEU is operatively upstream to all but the first exon of the trappable eukaryotic gene.</PDAT></PTEXT></PARA>
<PARA ID="P-00017" LVL="0"><PTEXT><PDAT>The present invention also includes methods of transcribing a trappable eukaryotic gene contained in a BBPAC in a eukaryotic cell. In one such embodiment the eukaryotic cell is a vertebrate cell. In a preferred embodiment of this type the vertebrate cell is a mammalian cell. In a more preferred embodiment the mammalian cell is. a human cell. In another embodiment the eukaryotic cell is an invertebrate cell. In a preferred embodiment of this type the invertebrate cell is an insect cell. In still another embodiment the eukaryotic cell is a plant cell.</PDAT></PTEXT></PARA>
<PARA ID="P-00018" LVL="0"><PTEXT><PDAT>The present invention further provides methods of determining the nucleotide sequence of a trappable eukaryotic gene contained in a BBPAC. In another aspect, the present invention provides methods of preparing a gene map for a BBPAC contig. Still another aspect of the present invention includes methods of constructing a cDNA library from genoric DNA contained in a BBPAC genomic library. In a preferred embodiment the BBPAC either contains all of the exons of the eukaryotic gene, or alternatively, all of the exons of the gene except the first exon. In another preferred embodiment the BBPAC is a BAC.</PDAT></PTEXT></PARA>
<PARA ID="P-00019" LVL="0"><PTEXT><PDAT>The PEU of the present invention is specifically constructed to contain at least one 5&prime; vector-derived exon and at least part of one intron (e.g., a fragment of an intron). In one such embodiment, the PEU does not contain a 3&prime; polyadenylation sequence. In a preferred embodiment the PEU is a bi-directional eukaryotic promoter-exon/intron unit (BPEU).</PDAT></PTEXT></PARA>
<PARA ID="P-00020" LVL="0"><PTEXT><PDAT>The PEU of the present invention can be introduced into a host cell containing the BBPAC via a shuttle vector. In a preferred embodiment the shuttle vector is a conditional replication shuttle vector. The conditional replication shuttle vector is preferably a temperature sensitive shuttle vector (TSSV) having a temperature-sensitive origin of replication, such that the TSSV replicates at a permissive temperature, but does not replicate at a non-permissive temperature. In a particular embodiment, the permissive temperature is 30&deg; C., and the non-permissive temperature is 43&deg; C. The TSSV is diluted out when the host cell containing the TSSV is grown at the non-permissive temperature.</PDAT></PTEXT></PARA>
<PARA ID="P-00021" LVL="0"><PTEXT><PDAT>One aspect of the present invention relates to a method for placing a PEU operatively upstream to an exon of a trappable eukaryotic gene of a BBPAC. One such embodiment comprises introducing a conditional replication shuttle vector into a host cell under conditions in which the conditional replication shuttle vector can replicate and transform the host cell. The host cell comprises a BBPAC that contains a trappable eukaryotic gene, BBPAC vector DNA, and a second marker gene. The conditional ,replication shuttle vector comprises a first marker gene and the PEU. The PEU comprises a eukaryotic promoter, at least one 5&prime; vector-derived exon, and at least one intron or fragment thereof. A 5&prime; vector-derived exon is adjacent to the intron or fragment thereof and is operatively downstream from the eukaryotic promoter. The PEU and the first marker gene are configured on the conditional replication shuttle vector such that when the PEU is transferred from the conditional replication shuttle vector to the BBPAC, the first marker gene remains with the conditional replication shuttle vector. In a related embodiment of this type the PEU further comprises a third marker gene and/or the first marker gene can be counter-selected against. In a preferred embodiment, the first marker gene is a tetracycline resistance gene that can be counter-selected against by growing the cell in the presence of fusaric acid.</PDAT></PTEXT></PARA>
<PARA ID="P-00022" LVL="0"><PTEXT><PDAT>The transformed host cell is then grown under conditions in which the conditional replication shuttle vector can replicate, and under conditions that select for a cell that contains the first and second marker gene. The PEU is then transferred from the conditional replication shuttle vector to the BBPAC of the selected cell, while the first marker gene remains with the conditional replication shuttle vector. When the BBPAC contains a trappable eukaryotic gene, the PEU can integrate into the BBPAC and place one or more exons of the trappable eukaryotic gene operatively downstream of the PEU. (Of course, the presence of the trappable eukaryotic gene in the BBPAC is not required for the insertion of the PEU into the BBPAC, since the PEU can integrate into a BBPAC which does not contain a trappable gene.)</PDAT></PTEXT></PARA>
<PARA ID="P-00023" LVL="0"><PTEXT><PDAT>In a preferred embodiment of this type the PEU is transferred from the conditional replication shuttle vector to the BBPAC through homologous recombination between the conditional replication shuttle vector and the BBPAC.</PDAT></PTEXT></PARA>
<PARA ID="P-00024" LVL="0"><PTEXT><PDAT>In an alternative embodiment, the PEU is transferred from the conditional replication shuttle vector to the BBPAC by the addition of transposase to the host cell. In this case the PEU is positioned in between a pair of inverted transposon ends on the conditional replication shuttle vector. In one embodiment of this type, the host cell contains a nucleic acid encoding transposase; in another embodiment the BBPAC contains a nucleic acid encoding transposase; in still a third such embodiment the conditional replication shuttle vector contains a nucleic acid encoding transposase. In this case, the transposase remains with the conditional replication shuttle vector when the PEU is transferred. In all of these alternative embodiments, the transcription of the nucleic acid encoding transposase can be placed under the control of an inducible promoter and in such cases, the addition of transposase to the host cell is achieved by adding an inducer of the inducible promoter to the host cell. This facilitates the transcription of an mRNA encoding transposase which can then be translated by the host cell, resulting in the expression of transposase.</PDAT></PTEXT></PARA>
<PARA ID="P-00025" LVL="0"><PTEXT><PDAT>The present invention also includes methods of isolating a cell that contains a BBPAC with a trappable eukaryotic gene and a PEU. Preferably the PEU is operatively upstream of one or more exons of the trappable eukaryotic gene. One such embodiment comprises growing the cell under conditions in which the conditional replication shuttle vector cannot replicate, and in which a cell that contains the second and third marker genes is selected for, while a cell that contains the first marker gene is selected against. A cell containing a BBPAC having a PEU is then isolated. In this manner cells containing a PEU operatively upstream of one or more exons of a trappable eukaryotic gene can be obtained. In such an embodiment the PEU can further comprise the third marker gene and the first marker gene can be counter-selected against.</PDAT></PTEXT></PARA>
<PARA ID="P-00026" LVL="0"><PTEXT><PDAT>The present invention also includes a method of transcribing one or more exons of a trappable eukaryotic gene contained in a BBPAC in a eukaryotic cell. One such embodiment comprises isolating a BBPAC containing the trappable eukaryotic gene operably downstream of the PEU from an isolated cell that comprises the BBPAC. The isolated BBPAC is transfected into a eukaryotic cell and the eukaryotic cell is cultured. In this case the eukaryotic promoter of the PEU facilitates the transcription of the trappable eukaryotic gene into an mRNA. In a related embodiment the mRNA is used as a template for preparing a cognate cDNA in order to determine the nucleotide sequence of the trappable eukaryotic gene contained in the BBPAC by determining the nucleotide sequence of the cognate cDNA.</PDAT></PTEXT></PARA>
<PARA ID="P-00027" LVL="0"><PTEXT><PDAT>The present invention further provides additional methods of placing a PEU operatively upstream to a trappable eukaryotic gene contained in a BBPAC. One such embodiment comprises introducing a conditional replication shuttle vector into a host cell that contains the BBPAC under conditions in which the conditional replication shuttle vector can replicate and transform the host cell. The BBPAC contains a trappable eukaryotic gene, BBPAC vector DNA, and a second marker gene. The conditional replication shuttle vector contains a first marker gene, and a recombination cassette. The recombination cassette comprises a PEU flanked on both its 5&prime; and 3&prime; ends by nucleotide sequences that are homologous to BBPAC vector DNA and the recombination cassette, and the first marker gene are linked together on the conditional replication shuttle vector such that when the PEU integrates into the BBPAC, the first marker gene does not remain linked to the integrated PEU. The PEU comprises a eukaryotic promoter, at least one 5&prime; vector-derived exon, and at least one intron or fragment thereof. In a preferred embodiment the PEU does not contain an exon encoding a 3&prime; polyadenylation sequence. The 5&prime; vector-derived exon is adjacent to the intron or fragment thereof and operatively downstream from the eukaryotic promoter. Thus when the BBPAC contains a trappable eukaryotic gene, the PEU can integrate into the BBPAC placing the exon of the trappable eukaryotic gene operatively downstream of the PEU. In a related embodiment of this type the PEU further comprises a third marker gene and/or the first marker gene can be counter-selected against. In a preferred embodiment of this type the first marker gene is a tetracycline resistance gene that can be counter-selected against by growing the cell in the presence of fusaric acid.</PDAT></PTEXT></PARA>
<PARA ID="P-00028" LVL="0"><PTEXT><PDAT>The transformed host cell is grown under conditions in which the conditional replication shuttle vector can replicate, and a cell that contains the first and second marker genes can be selected for. In this case a first homologous recombination event is allowed to occur between the recombination cassette and the BBPAC to form a co-integrate. The cell is then grown under conditions in which the conditional replication shuttle vector cannot replicate and in which a cell that contains the first and second markers is selected for. A cell containing the co-integrate between the recombination cassette and the BBPAC is thus selected for. This cell is then grown under conditions in which the conditional replication shuttle vector cannot replicate and in which a cell that contains the second marker gene is selected for. A second homologous recombination event is then allowed to occur between the conditional replication shuttle vector and the BBPAC. The PEU is thus allowed to integrate into the BBPAC and place the exon of the trappable eukaryotic gene operatively downstream of the PEU. In one such embodiment the eukaryotic promoter is a mammalian promoter and/or the eukaryotic gene is a mammalian gene. In another such embodiment the eukaryotic promoter is a plant promoter, and the eukaryotic gene is a plant gene.</PDAT></PTEXT></PARA>
<PARA ID="P-00029" LVL="0"><PTEXT><PDAT>A cell containing BBPAC having the integrated PEU can be isolated in a related embodiment. Such an embodiment comprises growing the cell under conditions in which a cell that contains the second and third marker genes is selected for, while a cell that contains the first marker gene is selected against. The cell containing the BBPAC having the PEU is then isolated. In this embodiment the PEU further comprises the third marker gene, and the first marker gene can be counter-selected against.</PDAT></PTEXT></PARA>
<PARA ID="P-00030" LVL="0"><PTEXT><PDAT>A particular embodiment of the present invention further includes a method of transcribing one or more exons of the trappable eukaryotic gene contained in a BBPAC in a eukaryotic cell. This embodiment comprises isolating the BBPACs containing the PEU from the isolated cell, and then transfecting the isolated BBPACs into eukaryotic cells. The eukaryotic cell are then cultured. When the PEU is operatively upstream of an exon (or more than one exon) of the trappable eukaryotic gene, the eukaryotic promoter of the PEU facilitates the transcription of the exon(s) of the trappable eukaryotic gene into an mRNA.</PDAT></PTEXT></PARA>
<PARA ID="P-00031" LVL="0"><PTEXT><PDAT>A related aspect of the present invention includes a method of determining the nucleotide sequence of the exon(s) of the trappable eukaryotic gene contained in the BBPAC. One such embodiment comprises preparing cognate cDNA by using the mRNA as a template, and determining the nucleotide sequence of the cognate cDNA. The nucleotide sequence of the exons of the trappable eukaryotic gene contained in the BBPAC is thus determined.</PDAT></PTEXT></PARA>
<PARA ID="P-00032" LVL="0"><PTEXT><PDAT>A preferred embodiment for a method for placing a PEU into a BBPAC containing a trappable eukaryotic gene comprises introducing a conditional replication shuttle vector into a host cell containing the BBPAC under conditions in which the conditional replication shuttle vector can replicate and transform the host cell. The BBPAC contains a trappable eukaryotic gene, BBPAC vector DNA, and a second marker gene; the conditional replication shuttle vector contains a RecA-like protein gene, a first marker gene, and a recombination cassette. The recombination cassette comprises a PEU flanked on both its 5&prime; and 3&prime; ends by nucleotide sequences that are homologous to BBPAC vector DNA. The recombination cassette, the RecA-like protein gene, and the first marker gene are linked together on the conditional replication vector such that when the PEU integrates into the BBPAC, the RecA-like protein gene and the first marker gene remain linked together, but neither the RecA-like protein gene nor the first marker gene remain linked to the integrated PEU. The PEU comprises a eukaryotic promoter, at least one 5&prime; vector-derived exon, and at least one intron or fragment thereof. In a more preferred embodiment of this type the PEU does not contain an exon encoding a 3&prime; polyadenylation sequence. The 5&prime; vector-derived exon is adjacent to the intron or fragment thereof, and operatively downstream from the eukaryotic promoter. When the trappable eukaryotic gene comprises an exon with a 3&prime; splice acceptor, the PEU can integrate into the BBPAC and place the exon of the trappable eukaryotic gene operatively downstream of the PEU. In a preferred embodiment of this type neither the host cell nor the BBPAC independently or in conjunction can support homologous recombination, without the conditional replication shuttle vector. The transformed host cell can be grown under conditions in which the conditional replication shuttle vector can replicate, the RecA-like gene can be expressed, and in which a cell that contains the first and second marker genes is selected for, and in which a first homologous recombination event is allowed to occur between the recombination cassette and the BBPAC to form a co-integrate. This cell is then grown under conditions in which the conditional replication shuttle vector cannot replicate and in which a cell that contains the first and second marker is selected for. In this way, a cell containing the co-integrate between the recombination cassette and the BBPAC is selected for. This cell is then grown under conditions in which the conditional replication shuttle vector cannot replicate and in which a cell that contains the second marker gene is selected for and wherein a second homologous recombination event is allowed to occur between the conditional replication shuttle vector and the BBPAC. The PEU can thus integrate into the BBPAC placing the exon of the trappable eukaryotic gene operatively downstream of the PEU.</PDAT></PTEXT></PARA>
<PARA ID="P-00033" LVL="0"><PTEXT><PDAT>In an alternative embodiment of this type, the PEU further comprises a third marker gene and/or the first marker gene can be counter-selected against. In a preferred embodiment of this type the first marker gene is a tetracycline resistance gene that can be counter-selected against by growing the cell in the presence of fusaric acid.</PDAT></PTEXT></PARA>
<PARA ID="P-00034" LVL="0"><PTEXT><PDAT>A related aspect of the invention further comprises a method of isolating such a cell which contains a BBPAC having a PEU. One such embodiment comprises growing the cell under conditions in which a cell that contains the second and third, marker genes is selected for, while a cell that contains the first marker gene is selected against. A cell containing a BBPAC having a eukaryotic promoter exon/intron unit (PEU) is obtained. In one such embodiment the PEU further comprises the third marker gene, and the first marker gene can be counter-selected against.</PDAT></PTEXT></PARA>
<PARA ID="P-00035" LVL="0"><PTEXT><PDAT>A further related aspect of the present invention comprises a method of transcribing a trappable eukaryotic gene contained in a BBPAC in a eukaryotic cell. One such embodiment comprises isolating the BBPAC containing the PEU from the isolated cell and transfecting the isolated BBPAC into the eukaryotic cell. The eukaryotic cell is then cultured. When the PEU is operatively upstream of an exon (or more than one exon) of the trappable eukaryotic gene, the eukaryotic promoter of the PEU facilitates the transcription of the exon(s) of the trappable eukaryotic gene into an mRNA.</PDAT></PTEXT></PARA>
<PARA ID="P-00036" LVL="0"><PTEXT><PDAT>A related embodiment further includes a method of determining the nucleotide sequence of the exon(s) of the trappable eukaryotic gene contained in the BBPAC comprising preparing a cognate cDNA using the mRNA as a template and then determining the nucleotide sequence of the cognate cDNA. The nucleotide sequence of the trappable eukaryotic gene contained in the BBPAC is thus determined. In a preferred embodiment of this type preparation of the cognate cDNA is performed by PCR.</PDAT></PTEXT></PARA>
<PARA ID="P-00037" LVL="0"><PTEXT><PDAT>As is true for the entire invention, in this aspect of the invention, preferably the PEU is a bi-directional eukaryotic promoter-exon/intron unit (BPEU). Similarly it is preferred that the conditional replication shuttle vector is a temperature sensitive shuttle vector (TSSV) having a temperature-sensitive origin of replication, such that the TSSV replicates at a permissive temperature, but does not replicate at a non-permissive temperature. In another preferred embodiment the BBPAC is a BAC. In one particular embodiment the PEU comprises two 5&prime; vector-derived exons and one intron or fragment thereof. In a preferred embodiment the two 5&prime; vector-derived exons consist of the first exon of beta-globin and a fusion exon containing the second exon of beta-globin fused to the HIV-tat exon, and the intron is the HIV-tat intron or fragment thereof. In this embodiment the fusion exon is adjacent to the HIV-tat intron.</PDAT></PTEXT></PARA>
<PARA ID="P-00038" LVL="0"><PTEXT><PDAT>Another variation of the present invention includes a method of placing a eukaryotic promoter exon/intron unit (PEU) into a BBPAC by introducing a conditional replication shuttle vector into a host cell containing the BBPAC under conditions in which the conditional replication shuttle vector can replicate and transform the host cell. The BBPAC contains a trappable eukaryotic gene, BBPAC vector DNA, and a second marker gene, whereas the conditional replication shuttle vector comprises a first marker gene, the PEU, a mini-transposon containing a pair of inverted transposon ends, a nucleic acid encoding transposase, and an inducible promoter. The expression of transposase is maintained under the control of the inducible promoter. The PEU is positioned in between the pair of inverted transposon ends and the nucleic acid encoding transposase, the inducible promoter, and the first marker gene are positioned outside of the pair of inverted transposon ends. The PEU comprises a eukaryotic promoter, at least one 5&prime; vector-derived exon, and at least onc intron or fragment thereof. Preferably the PEU does not contain an exon encoding a 3&prime; polyadenylation sequence. A 5&prime; vector-derived exon is adjacent to the intron or fragment thereof and operatively downstream from the eukaryotic promoter. When the trappable eukaryotic gene comprises an exon with a 3&prime; splice acceptor, the PEU can integrate into the BBPAC and place the exon of the trappable eukaryotic gene operatively downstream of the PEU. The transformed host cell is grown under conditions in which the conditional replication shuttle vector can replicate, and in which a cell that contains the first and second marker gene are selected for. The inducible promoter of this cell is induced and transposase is expressed. The PEU can then integrate into the BBPAC and place the exon of the trappable eukaryotic gene operatively downstream of the PEU. A cell that contains the first and second marker gene is then selected for. In a related embodiment of this type the PEU further comprises a third marker gene and/or the first marker gene can be counter-selected against. In a preferred embodiment of this type, the first marker gene is a tetracycline resistance gene that can be counter-selected against by growing the cell in the presence of fusaric acid.</PDAT></PTEXT></PARA>
<PARA ID="P-00039" LVL="0"><PTEXT><PDAT>A related embodiment further includes a method of isolating the cell containing the BBPAC having the PEU which comprises growing the cell under conditions in which the conditional replication shuttle vector cannot replicate, and in which a cell that contains the second and third marker genes are selected for, while a cell that contains the first marker gene is selected against. In a preferred embodiment of this type, the selection for the second and third marker genes are performed in one step, and the counterselection for the first marker gene is performed in a subsequent step. In either case a cell containing a BBPAC having a eukaryotic promoter exon/intron unit PEU is isolated. In this embodiment the PEU further comprises the third marker gene, and the first marker gene can be counter-selected against.</PDAT></PTEXT></PARA>
<PARA ID="P-00040" LVL="0"><PTEXT><PDAT>In a particular embodiment of this type the inducible promoter is the &bgr;-galactosidase promoter and the bacterial host expresses lacI</PDAT><HIL><SP><PDAT>q</PDAT></SP></HIL><PDAT>. In a related embodiment the conditional replication shuttle vector encodes lacI</PDAT><HIL><SP><PDAT>q</PDAT></SP></HIL><PDAT>. In either case the inducing of the inducible promoter comprises contacting the bacterial host cell with IPTG. In a preferred embodiment the amount of IPTG used to contact the bacterial host is controlled so that the BBPAC receives only a single transposon or none at all.</PDAT></PTEXT></PARA>
<PARA ID="P-00041" LVL="0"><PTEXT><PDAT>The conditional replication shuttle vector is preferably a temperature sensitive shuttle vector (TSSV) having a temperature-sensitive origin of replication, such that the TSSV replicates at a permissive temperature, but does not replicate at a non-permissive temperature. The BBPAC is preferably a BAC. The first marker gene is preferably a tetracycline resistance gene that can be counter-selected against by growing the cell in the presence of fusaric acid. In a more preferred embodiment the PEU is a bi-directional eukaryotic promoter-exon/intron unit (BPEU).</PDAT></PTEXT></PARA>
<PARA ID="P-00042" LVL="0"><PTEXT><PDAT>This aspect of the invention also provides for isolating a BBPAC which has a PEU from a cell containing the BBPAC. As any person having skill in. the art would readily recognize once a PEU is introduced into a BBPAC, the subsequent isolation and manipulation of the BBPAC is independent of the method for placing the PEU into the BBPAC.</PDAT></PTEXT></PARA>
<PARA ID="P-00043" LVL="0"><PTEXT><PDAT>One specific embodiment comprises performing an alkaline lysis of the isolated cell therein isolating the BBPAC DNA. The isolated BBPAC DNA is next electroporated into competent bacterial cells, and then the bacterial cells are grown under conditions in which the conditional replication shuttle vector cannot replicate and in which cells that contain the second and third marker genes are selected for. Alkaline lysis of these bacterial cells is then performed to isolate the purified BBPAC DNA.</PDAT></PTEXT></PARA>
<PARA ID="P-00044" LVL="0"><PTEXT><PDAT>In addition the present invention also provides an embodiment that further includes a method of transcribing one or more exons of the trappable eukaryotic gene contained in a BBPAC in a eukaryotic cell which comprises transfecting the purified BBPAC into a eukaryotic cell and then culturing the eukaryotic cell. When the BBPAC contains a PEU operatively upstream to one or more exons of the trappable eukaryotic gene, the eukaryotic promoter facilitates the transcription of the trappable eukaryotic gene into an mRNA.</PDAT></PTEXT></PARA>
<PARA ID="P-00045" LVL="0"><PTEXT><PDAT>A particular embodiment further includes a method of determining the nucleotide sequence of one or more exons of the trappable eukaryotic gene contained in the BBPAC which comprises preparing a cognate cDNA by using the mRNA as a template, and then determining the nucleotide sequence of the cognate cDNA. The nucleotide sequence of one or more exons of the trappable eukaryotic gene contained in the BBPAC is thus determined. In a preferred embodiment of this type, preparing the cognate cDNA is performed by PCR.</PDAT></PTEXT></PARA>
<PARA ID="P-00046" LVL="0"><PTEXT><PDAT>The present invention further provides a method of mapping the insertion site of the PEU. In a preferred embodiment of this type, the mapping is performed by pulse field gel electrophoresis. In a related embodiment the mapping is performed by Southern blot.</PDAT></PTEXT></PARA>
<PARA ID="P-00047" LVL="0"><PTEXT><PDAT>Still another aspect of the present invention includes methods of preparing a gene map for a BBPAC contig that contains trappable eukaryotic genes. This aspect of the invention comprises introducing a eukaryotic promoter exon/intron units (PEU) in each BBPAC of a BBPAC contig. In one embodiment of this aspect of the invention, the PEU is placed into an existing BBPAC contig. Preferably the PEU is inserted operatively upstream to one or more exons of the trappable eukaryotic gene. More preferably, the PEU is inserted operatively upstream to either all, or all but the first exon of the trappable eukaryotic gene.</PDAT></PTEXT></PARA>
<PARA ID="P-00048" LVL="0"><PTEXT><PDAT>In an alternative aspect of the present invention, a BBPAC contig is constructed using vectors containing one or more PEUs, and genomic DNA containing trappable eukaryotic genes is inserted into the vectors to form a BBPAC contig with BBPACs having one or more PEUs and trappable eukaryotic genes. Preferably a PEU is operatively upstream to one or more exons of the inserted trappable eukaryotic gene. More preferably, the PEU is operatively upstream to all, or all but the first exon of the inserted trappable eukaryotic gene.</PDAT></PTEXT></PARA>
<PARA ID="P-00049" LVL="0"><PTEXT><PDAT>The trappable eukaryotic gene(s) for this aspect of the invention can be any eukaryotic gene including vertebrate genes, preferably mammalian genes, and more preferably human genes; invertebrate genes, preferably insect genes; or plant genes.</PDAT></PTEXT></PARA>
<PARA ID="P-00050" LVL="0"><PTEXT><PDAT>The insertion of the PEU into the BBPAC is preferably performed by one of the methods of placing a PEU operatively upstream to a trappable eukaryotic gene contained in a BBPAC described herein. The BBPACs are then isolated and transfected into eukaryotic cells, which are cultured. When the BBPAC contains a PEU operatively upstream to a trappable eukaryotic gene, the eukaryotic promoter facilitates the transcription of the trappable eukaryotic gene into an mRNA. Preferably, cognate cDNAs are prepared using the mRNAs as a template and the physical location of each gene is assigned within the BBPAC by hybridization of the cognate cDNAs to the BBPACs of the BBPAC contig. Alternatively the mRNAs can be used in the hybridization. In one such embodiment, RNA probes are generated e.g., from the cDNA, and are used in in situ hybridization determinations. In any case, preferably the BBPAC contig is a BAC contig.</PDAT></PTEXT></PARA>
<PARA ID="P-00051" LVL="0"><PTEXT><PDAT>Still another aspect of the present invention provides methods of constructing a cDNA library from genoric DNA, comprising trappable eukaryotic genes, contained in a BBPAC genoric library. Prior to, or alternatively as part of one such embodiment, a BBPAC genomic DNA library is subdivided into individual BBPAC genomic sub-libraries, wherein the BBPACs of the BBPAC sub-library contain trappable eukaryotic genes. Thus in one embodiment the BBPAC genomic library is subdivided into a sub-library that comprises 20 to 1000 BBPACs. In an alternative embodiment the BBPAC genomic library is subdivided into a sub-library comprising 40 to 500 BBPACs. In still another embodiment the BBPAC genomic library is subdivided into a sub-library comprising 80 to 250 BBPACs. In a preferred embodiment the BBPAC genomic library is subdivided into a sub-library comprising 100 to 200 BBPACs. In another preferred embodiment the BBPAC genomic library is subdivided into a sub-library comprising 20 to 80 BBPACs. In preferred embodiments the BBPAC genomic library is a BAC library.</PDAT></PTEXT></PARA>
<PARA ID="P-00052" LVL="0"><PTEXT><PDAT>The genomic libraries for this aspect of this aspect of the invention can derived from any eukaryotic genome including a vertebrate genome, preferably a mammalian genome, and more preferably the human genome; an invertebrate genome, preferably an insect genome; or a plant genome.</PDAT></PTEXT></PARA>
<PARA ID="P-00053" LVL="0"><PTEXT><PDAT>PEUs are placed into the BBPACs of a BBPAC sub-library. The insertion of the PEU into the BBPAC is preferably performed by one of the methods of placing a PEU in a BBPAC described herein. The BBPACs are then isolated, transfected into eukaryotic cells, and the eukaaryotic cells are cultured. When the BBPAC contains a PEU operatively upstream to one or more exons of a trappable eukaryotic gene, the eukaryotic promoter facilitates the transcription of the exon(s) of the trappable eukaryotic gene into an mRNA. Cognate cDNAs are prepared using the mRNAs as a template. A related embodiment further comprises determining the nucleotide sequence of the cognate cDNA. The nucleotide sequences of the exons of the trappable eukaryotic genes contained in the BBPAC genomic library are thus determined.</PDAT></PTEXT></PARA>
<PARA ID="P-00054" LVL="0"><PTEXT><PDAT>Accordingly, it is a principal object of the present invention to provide a method for sequencing trappable eukaryotic genes contained in BBPAC genomic libraries.</PDAT></PTEXT></PARA>
<PARA ID="P-00055" LVL="0"><PTEXT><PDAT>It is a further object of the present invention to provide a method of introducing a PEU (preferably a BPEU) operatively upstream to a trappable eukaryotic gene contained in a BBPAC.</PDAT></PTEXT></PARA>
<PARA ID="P-00056" LVL="0"><PTEXT><PDAT>It is a further object of the present invention to provide a method of obtaining bacterial cells that contain a BBPAC comprising a PEU operatively upstream to a trappable eukaryotic gene.</PDAT></PTEXT></PARA>
<PARA ID="P-00057" LVL="0"><PTEXT><PDAT>It is a further object of the present invention to provide a method of procuring isolated BBPACs containing a PEU and a trappable eukaryotic gene.</PDAT></PTEXT></PARA>
<PARA ID="P-00058" LVL="0"><PTEXT><PDAT>It is a further object of the present invention to provide a method of transcribing a trappable eukaryotic gene.</PDAT></PTEXT></PARA>
<PARA ID="P-00059" LVL="0"><PTEXT><PDAT>It is a further object of the present invention to provide a method of determining the sequence of the transcribed trappable eukaryotic gene.</PDAT></PTEXT></PARA>
<PARA ID="P-00060" LVL="0"><PTEXT><PDAT>It is a further object of the present invention to provide a method of providing a gene map for a BBPAC contig.</PDAT></PTEXT></PARA>
<PARA ID="P-00061" LVL="0"><PTEXT><PDAT>It is a further object of the present invention to provide a map of the insertion sites of a PEU placed into a BBPAC.</PDAT></PTEXT></PARA>
<PARA ID="P-00062" LVL="0"><PTEXT><PDAT>It is a further object of the present invention to provide a cDNA library from a BBPAC eukaryotic genomic library.</PDAT></PTEXT></PARA>
<PARA ID="P-00063" LVL="0"><PTEXT><PDAT>It is a further object of the present invention to provide a method of sequencing a cDNA library prepared from a BBPAC eukaryotic genomic library.</PDAT></PTEXT></PARA>
<PARA ID="P-00064" LVL="0"><PTEXT><PDAT>These and other aspects of the present invention will be better appreciated by reference to the following drawings and Detailed Description.</PDAT></PTEXT></PARA>
</BTEXT>
</BRFSUM>
<DRWDESC>
<BTEXT>
<H LVL="1"><STEXT><PDAT>BRIEF DESCRIPTION OF THE DRAWINGS</PDAT></STEXT></H>
<PARA ID="P-00065" LVL="0"><PTEXT><FGREF ID="DRAWINGS"><PDAT>FIG. 1A</PDAT></FGREF><PDAT> shows a schematic representation of a Promoter Exon/Intron Unit (PEU) with an antibiotic resistance gene. The PEU comprises a ubiquitous mammalian promoter as a driving promoter, a 5&prime; vector-derived exon, and an intron, wherein the 5&prime; vector-derived exon is adjacent to the intron and under the control of the driving promoter. SD, stands for the vector derived splice donor.</PDAT></PTEXT></PARA>
<PARA ID="P-00066" LVL="0"><PTEXT><FGREF ID="DRAWINGS"><PDAT>FIG. 1B</PDAT></FGREF><PDAT> shows a schematic representation of a Bi-Directional Promoter Exon/Intron Unit (BPEU) with an antibiotic resistance gene.</PDAT></PTEXT></PARA>
<PARA ID="P-00067" LVL="0"><PTEXT><FGREF ID="DRAWINGS"><PDAT>FIG. 2A</PDAT></FGREF><PDAT> shows a schematic representation of targeting the BPEU to a BAC/PAC (BBPAC) vector backbone. The eukaryotic genomic genes (depicted as Genes </PDAT><HIL><BOLD><PDAT>1</PDAT></BOLD></HIL><PDAT>, </PDAT><HIL><BOLD><PDAT>2</PDAT></BOLD></HIL><PDAT>, and </PDAT><HIL><BOLD><PDAT>3</PDAT></BOLD></HIL><PDAT>) are placed in between two Notl sites. Most genes contain a poly-adenylation (PolyA) signal sequence. The BPEU is inserted outside of the region included in between the two NotI sites.</PDAT></PTEXT></PARA>
<PARA ID="P-00068" LVL="0"><PTEXT><FGREF ID="DRAWINGS"><PDAT>FIG. 2B</PDAT></FGREF><PDAT> shows a schematic representation of the targeted gene trap. In the schematic two BPEUs are inserted into the BBPAC backbone, outside of the region included in between the two NotI site. The BPEU on the left has trapped Gene </PDAT><HIL><BOLD><PDAT>1</PDAT></BOLD></HIL><PDAT> (i.e., Gene </PDAT><HIL><BOLD><PDAT>1</PDAT></BOLD></HIL><PDAT> is under the control the bi-directional promoter of the BPEU) whereas the BPEU on the right has trapped Gene </PDAT><HIL><BOLD><PDAT>1</PDAT></BOLD></HIL><PDAT>. The bi-directionality of the promoters is demonstrated in the schematic. Note, the first exon of the Genes is not trapped, because the first exon of a gene does not contain a 3&prime; splice acceptor.</PDAT></PTEXT></PARA>
<PARA ID="P-00069" LVL="0"><PTEXT><FGREF ID="DRAWINGS"><PDAT>FIG. 3A</PDAT></FGREF><PDAT> shows a schematic representation of the structure of the pSV. Tn10-RGT vector. The Randomized Gene Trapping (RGT) shuttle vector contains a tetracycline (Tet) resistance gene, a gene encoding transposase under the control of an inducible promoter (not shown), a temperature sensitive origin of replication, a bi-directional promoter exon/intron unit (BPEU) and a pair of inverted transposon ends. The BPEU is positioned in between the pair of inverted transposon ends.</PDAT></PTEXT></PARA>
<PARA ID="P-00070" LVL="0"><PTEXT><FGREF ID="DRAWINGS"><PDAT>FIG. 3B</PDAT></FGREF><PDAT> shows a schematic representation of random integration of multiple BPEUs into a BBPAC.</PDAT></PTEXT></PARA>
</BTEXT>
</DRWDESC>
<DETDESC>
<BTEXT>
<H LVL="1"><STEXT><PDAT>DETAILED DESCRIPTION OF THE INVENTION</PDAT></STEXT></H>
<PARA ID="P-00071" LVL="0"><PTEXT><PDAT>The present invention provides a novel procedure for determining the nucleotide sequence of all but the first exon of a eukaryotic gene. Furthermore, the methodology allows the determination of essentially all of the exons of any selected eukaryotic genome. The present invention thus provides a facile method for identifying genes in a eukaryotic genome, including the human genome.</PDAT></PTEXT></PARA>
<PARA ID="P-00072" LVL="0"><PTEXT><PDAT>Heretofore, sequencing the exons in a particular genome relied on procuring the mRNAs that had been transcribed, or alternatively required the sequencing of genomic DNA. In the former case, genes that are solely transcribed in obscure tissues and/or are rarely transcribed, are likely to be missed. In the latter case, exon-trapping represents the most unbiased methodology to date. However even this technique is limited due to its lack of ability to process more than about a single exon of a gene at one time. The present invention therefore provides an alternative genomic sequencing methodology which instead of being limited to lone exon trapping, essentially allows full gene trapping.</PDAT></PTEXT></PARA>
<PARA ID="P-00073" LVL="0"><PTEXT><PDAT>The present invention further exploits the stability of BBPACs to ensure that the trapped eukaryotic gene is an endogenous gene, not an artifactural chimeric gene. In addition, unlike the smaller plasmids used heretofore, recent evidence indicates that BBPACs are large enough to contain the necessary elements for DNA replication and nuclear retention in eukaryotic cells. Thus BBPACs are maintained as stable episomal plasmids when introduced into eukaryotic cells, allowing gene trapping to be performed in a variety of cell lines.</PDAT></PTEXT></PARA>
<PARA ID="P-00074" LVL="0"><PTEXT><PDAT>The new methodology of the present invention can also be directly applied to BBPAC contigs. The use of BBPAC contigs can increase the efficiency of gene trapping, since many BBPACs contain multiple genes and the insertion of a single PEU into a BBPAC can maximally trap only one gene, and even the use of a BPEU can only allow the trapping of two genes (assuming the genes are in the proper orientation). Thus any additional genes contained by the BBPAC will be missed. Therefore, the present invention further provides a method of targeted gene trapping employing BBPAC contigs, which contain sets of BBPACs having multiple overlapping genomic DNAs. Performing targeted gene trapping on such a set of BBPACs can result in obtaining essentially all of the genes in the region.</PDAT></PTEXT></PARA>
<PARA ID="P-00075" LVL="0"><PTEXT><PDAT>In addition a mini-gene trap cDNA library can be generated through the gene trapping methodology of the present invention. Each gene then can be readily assigned to a physical location within a BBPAC contig by hybridization to the BBPAC library. In this manner essentially all of the genes of a given genomic DNA can be mapped. In addition the resulting cDNAs can be directly used for further biological experimentation. Furthermore, multiple BBPACs in the contig can be pooled to perform the gene trap technology of the present invention at once. Thus the gene trap methodology of the present invention is not only useful for making transcriptional maps for positional cloning projects, but is also valuable for building gene maps from a BBPAC physical map. Such a gene map can be used in genome projects, including the human genome project.</PDAT></PTEXT></PARA>
<PARA ID="P-00076" LVL="0"><PTEXT><PDAT>Furthermore, the gene trap methodology of the present invention can also be used to generate a cDNA library from genomic DNA. The present invention provides a method of constructing a cDNA library from the genomic DNA from any eukaryotic source, irrespective of the in vivo gene expression patterns and levels. Therefore, a gene trap cDNA library can be constructed to contain an essentially complete set of exons from any selected genome.</PDAT></PTEXT></PARA>
<PARA ID="P-00077" LVL="0"><PTEXT><PDAT>In accordance with the present invention there may be employed conventional molecular biology, microbiology, and recombinant DNA techniques within the skill of the art. Such techniques are explained fully in the literature. See, e.g., Sambrook, Fritsch &amp; Maniatis, </PDAT><HIL><ITALIC><PDAT>Molecular Cloning: A Laboratory Manual</PDAT></ITALIC></HIL><PDAT>, Second Edition (1989) Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (herein &ldquo;Sambrook et al., 1989&rdquo;); </PDAT><HIL><ITALIC><PDAT>DNA Cloning: A Practical Approach</PDAT></ITALIC></HIL><PDAT>, Volumes I and II (D. N. Glover ed. 1985); </PDAT><HIL><ITALIC><PDAT>Oligonucleotide Synthesis </PDAT></ITALIC></HIL><PDAT>(M. J. Gait ed. 1984); </PDAT><HIL><ITALIC><PDAT>Nucleic Acid Hybridization </PDAT></ITALIC></HIL><PDAT>&lsqb;B. D. Hames &amp; S. J. Higgins eds. (1985)&rsqb;; </PDAT><HIL><ITALIC><PDAT>Transcription And Translation </PDAT></ITALIC></HIL><PDAT>&lsqb;B. D. Hames &amp; S. J. Higgins, eds. (1984)&rsqb;; </PDAT><HIL><ITALIC><PDAT>Animal Cell Culture </PDAT></ITALIC></HIL><PDAT>&lsqb;R. I. Freshney, ed. (1986)&rsqb;; </PDAT><HIL><ITALIC><PDAT>Immobilized Cells And Enzymes </PDAT></ITALIC></HIL><PDAT>&lsqb;IRL Press, (1986)&rsqb;; B. Perbal, </PDAT><HIL><ITALIC><PDAT>A Practical Guide To Molecular Cloning </PDAT></ITALIC></HIL><PDAT>(1984); F. M. Ausubel et al. (eds.), </PDAT><HIL><ITALIC><PDAT>Current Protocols in Molecular Biology</PDAT></ITALIC></HIL><PDAT>, John Wiley &amp; Sons, Inc. (1994).</PDAT></PTEXT></PARA>
<PARA ID="P-00078" LVL="0"><PTEXT><PDAT>As used herein an &ldquo;IOBCV&rdquo; is an independent origin based cloning vector. One example of such a cloning vector is a BBPAC defined below. An IOBCV generally comprises a nucleic acid insert which either is or contains one or more eukaryotic genes. The present invention includes methodology for inserting a eukaryotic promoter exon intron unit (PEU) operatively upstream of the eukaryotic gene. This facilitates the transcription of all but the first exon of the eukaryotic gene, when the IOBCV is placed into a eukaryotic cell. A &ldquo;vector&rdquo; is a replicon, such as a plasmid, phage or cosmid, to which another DNA segment may be attached so as to bring about the replication of the attached segment. A &ldquo;replicon&rdquo; is any genetic element (e.g., plasmid, chromosome, virus) that functions as an autonomous unit of DNA replication in vivo, i.e., capable of replication under its own control.</PDAT></PTEXT></PARA>
<PARA ID="P-00079" LVL="0"><PTEXT><PDAT>As used herein, a &ldquo;Bacterial or Bacteriophage-Derived Artificial Chromosome&rdquo; or &ldquo;BBPAC&rdquo; denotes a vector that is derived from a bacterium or bacteriophage such as a Bacterial Artificial Chromosome (BAC) which is an </PDAT><HIL><ITALIC><PDAT>E. coli </PDAT></ITALIC></HIL><PDAT>F element based cloning system, a P1-Derived Artificial Chromosome (PAC) or a bacteriophage-based gnomic vector. In one embodiment, the BBPAC encodes up to 700 kilobases of genomic sequences. In a preferred embodiment, the BBPAC encodes between 120 to 180 kilobases of genomic sequences. In one particular embodiment the BBPAC encodes 130 kilobases of genomic sequence.</PDAT></PTEXT></PARA>
<PARA ID="P-00080" LVL="0"><PTEXT><PDAT>A &ldquo;promoter sequence&rdquo; is a DNA regulatory region capable of binding RNA polymerase in a cell and initiating transcription of a downstream (3&prime; direction) coding sequence. For purposes of defining the present invention, the promoter sequence is bounded at its 3&prime; terminus by the transcription initiation site and extends upstream (5&prime; direction) to include the minimum number of bases or elements necessary to initiate transcription at levels detectable above background. Within the promoter sequence will be found a transcription initiation site (conveniently defined for example, by mapping with nuclease S</PDAT><HIL><BOLD><PDAT>1</PDAT></BOLD></HIL><PDAT>), as well as protein binding domains (consensus sequences) responsible for the binding of RNA polymerase.</PDAT></PTEXT></PARA>
<PARA ID="P-00081" LVL="0"><PTEXT><PDAT>A coding sequence is &ldquo;under the control&rdquo; of transcriptional and translational control sequences in a cell when RNA polymerase transcribes the coding sequence into mRNA. The mRNA may then be spliced and translated into the protein encoded by the coding sequence.</PDAT></PTEXT></PARA>
<PARA ID="P-00082" LVL="0"><PTEXT><PDAT>As used herein a &ldquo;trappable eukaryotic gene&rdquo; is a portion of a eukaryotic gene that minimally contains one exon of the gene which has a 3&prime; splice acceptor. Preferably it also contains (or encodes) a 3&prime; polyadenylation sequence. Since neither the first exon of a gene, nor the sole exon of a gene that has only one exon contains a 3&prime; splice acceptor, neither can be included in a trappable eukaryotic gene. A trappable elukaryotic gene can contain all of the exons of the gene that have 3&prime; splice acceptors, i.e., all of the exons other than the first exon. A BBPAC contains a trappable eukaryotic gene when it comprises an entire eukaryotic gene which has at least one exon with a 3&prime; splice acceptor; or a fragment of the gene which minimally contains one exon of the gene that has a 3&prime; splice acceptor, i.e., other than the first exon, and preferably a 3&prime; polyadenylation sequence.</PDAT></PTEXT></PARA>
<PARA ID="P-00083" LVL="0"><PTEXT><PDAT>A eukaryotic promoter (or a eukaryotic promoter exon/intron unit (PEU)) is operatively upstream of an exon (and conversely the exon is therefore operatively downstream of the eukaryotic promoter or PEU) if the exon is under the control of the eukaryotic promoter when the promoter and exon are placed into a eukaryotic cell e.g., when the transcription of the exon can be initiated in a eukaryotic (e.g., a mammalian, or a plant) cell by the binding of RNA polymerase to the eukaryotic promoter. The eukaryotic promoter thereby facilitates the transcription of the exon in a eukaryotic cell.</PDAT></PTEXT></PARA>
<PARA ID="P-00084" LVL="0"><PTEXT><PDAT>A PEU that is operatively upstream of an exon of the trappable eukaryotic gene (and the exon of the trappable eukaryotic gene is therefore operatively downstream of the PEU) if the exon of the trappable eukaryotic gene is under the control of the PEU when the trappable eukaryotic gene and the PEU are placed into a eukaryotic cell e.g., when the transcription of the trappable eukaryotic gene can be initiated in a eukaryotic cell by the binding of RNA polymerase to the eukaryotic promoter. The eukaryotic promoter thereby facilitates the transcription of the trappable eukaryotic gene in a eukaryotic cell. Depending on the position of the PEU relative to the exons of the trappable eukaryotic gene, the transcription of more than one exon of the trappable eukaryotic gene can be facilitated. In a preferred embodiment, the PEU is operatively upstream from all, or all but the first exon of the trappable eukaryotic gene, thereby facilitating the transcription of all but the first exon.</PDAT></PTEXT></PARA>
<PARA ID="P-00085" LVL="0"><PTEXT><PDAT>A &ldquo;PEU&rdquo; is a eukaryotic promoter-5&prime; Exon/Intron Unit comprising a eukaryotic promoter, one or more 5&prime; exons (also termed herein a &ldquo;vector-derived exon&rdquo;), and an intron. A 5&prime; vector-derived exon is adjacent to an intron and downstream to the eukaryotic promoter. In addition, a PEU can further contain a marker gene. In a preferred embodiment the eukaryotic promoter of the PEU is a bi-directional eukaryotic promoter and the PEU is termed a &ldquo;BPEU&rdquo;. The bidirectional eukaryotic promoter can be either a single promoter which functions bi-directionally, or preferably one constructed by placing two unidirectional promoters in the BPEU in opposite orientations. Generally these two promoters are identical, except for their orientation. In any case, the BPEU is constructed to contain two sets of vector-derived exons with their corresponding introns, as described above, with each set being downstream and in the operable orientation relative to their corresponding eukaryotic promoter. The term PEU is meant to include both single-directional, and bi-directional eukaryotic promoter-5&prime; Exon/Intron Units. Therefore as used herein, a BPEU is one type of PEU.</PDAT></PTEXT></PARA>
<PARA ID="P-00086" LVL="0"><PTEXT><PDAT>A &ldquo;BBPAC contig&rdquo; contains BBPACs comprising overlapping genomic fragments, e.g., a &ldquo;BAC contig&rdquo; contains BACs comprising overlapping genomic fragments.</PDAT></PTEXT></PARA>
<PARA ID="P-00087" LVL="0"><PTEXT><PDAT>As used herein a &ldquo;gene of interest&rdquo; is a gene contained by a host cell genome or more preferably an independent origin based cloning vector that has been selected to undergo homologous recombination with a specific nucleic acid contained in a recombination cassette. A gene of interest can be either specifically placed into the host cell or independent origin based cloning vector for this purpose, or can already contained by the host cell or independent origin based cloning vector.</PDAT></PTEXT></PARA>
<PARA ID="P-00088" LVL="0"><PTEXT><PDAT>As used herein a &ldquo;marker&rdquo; is an indicator, whose presence or absence can be used to distinguish the presence or absence of a particular nucleic acid and preferably the corresponding presence or absence of a larger DNA which contains and/or is linked to the specific nucleic acid. In a preferred embodiment the marker is a protein or a gene encoding the protein, and thus can be more specifically termed a &ldquo;marker protein&rdquo; or a &ldquo;marker gene&rdquo;. The term &ldquo;marker&rdquo; (and thus marker protein or marker gene) is meant to be used extremely broadly and includes fluorescent proteins such as, green fluorescent protein, enzymes such as luciferase, and further includes drug resistant proteins, whose presence or absence may not solely be regarded as a means to detect cells that contain the drug resistance protein; and/or the genes that encode such proteins. However, drug resistance proteins and/or their corresponding genes can allow the preferential growth of cells that contain the drug resistant gene (or alternatively allow the counter-selection of cells that do not contain the drug resistant gene) and therefore bestow a type of selectable distinction which is meant to fall within the present definition of a marker.</PDAT></PTEXT></PARA>
<PARA ID="P-00089" LVL="0"><PTEXT><PDAT>The term &ldquo;a gene which encodes a marker protein&rdquo; is used herein interchangeably with the term &ldquo;marker protein gene&rdquo; and denotes a nucleic acid which encodes a marker protein.</PDAT></PTEXT></PARA>
<PARA ID="P-00090" LVL="0"><PTEXT><PDAT>A &ldquo;cassette&rdquo; refers to a segment of DNA that can be inserted into a vector at specific restriction sites. The segment of DNA can encode a particular polypeptide and/or contain a PEU. The cassette and restriction sites are designed to ensure insertion of the cassette in the proper reading frame for transcription and translation, when required. The present invention provides a &ldquo;recombination cassette&rdquo; that includes two homology fragments interrupted by a PEU and/or a PEU with a nucleic acid which encodes one or more marker protems.</PDAT></PTEXT></PARA>
<PARA ID="P-00091" LVL="0"><PTEXT><PDAT>As used herein a recombinant deficient host cell is &ldquo;RecA</PDAT><HIL><SP><PDAT>&minus;</PDAT></SP></HIL><PDAT>&rdquo; when the host cell is unable to express a RecA-like protein, including recA itself, which can support homologous recombination. In the simplest case, the gene encoding the RecA-like protein has been deleted in a RecA</PDAT><HIL><SP><PDAT>&minus;</PDAT></SP></HIL><PDAT> host cell. Alternatively the RecA-host cell contains a mutation in the recA gene that impairs its function.</PDAT></PTEXT></PARA>
<PARA ID="P-00092" LVL="0"><PTEXT><PDAT>A &ldquo;RecA-like protein&rdquo; is defined herein to have the meaning generally accepted in the art except as used herein the recA protein itself is included as being a specific RecA-like protein. RecA-like proteins are proteins involved in homologous recombination and are homologs to recA &lsqb;Clark et al., </PDAT><HIL><ITALIC><PDAT>Critical Reviews in Microbiology </PDAT></ITALIC></HIL><PDAT>20:125-142 (1994)&rsqb;. The recA protein is the central enzyme in prokaryotic homologous recombination. It catalyzes pairing and strand exchange between homologous DNA molecules, and functions in both DNA repair and genetic recombination &lsqb;McKee et al., </PDAT><HIL><ITALIC><PDAT>Chromosomn </PDAT></ITALIC></HIL><PDAT>7:479488 (1996)&rsqb;. A number of RecA-like proteins have been found in eukaryotic organisms and yeast &lsqb;Reiss et al., </PDAT><HIL><ITALIC><PDAT>Proc. Natl. Acad. Sci</PDAT></ITALIC></HIL><PDAT>. 93:3094-3098 (1996)&rsqb;. Two RecA-like proteins in yeast are Rad51 and Dmc1 &lsqb;McKee et al. (1996) supra&rsqb;. Rad51 is a highly conserved RecA-like protein in eukaryotes &lsqb;Peakman et al., </PDAT><HIL><ITALIC><PDAT>Proc. Natl. Acad. Sci</PDAT></ITALIC></HIL><PDAT>. 93:10222-10227 (1996)&rsqb;.</PDAT></PTEXT></PARA>
<PARA ID="P-00093" LVL="0"><PTEXT><PDAT>&ldquo;Heterologous&rdquo; DNA refers to DNA not naturally located in the cell, or in a chromosomal site of the cell. Preferably, the heterologous DNA includes a gene foreign to the cell.</PDAT></PTEXT></PARA>
<PARA ID="P-00094" LVL="0"><PTEXT><PDAT>A &ldquo;nucleic acid molecule&rdquo; refers to the phosphate ester polymeric form of ribonucleosides (adenosine, guanosine, uridine or cytidine; &ldquo;RNA molecules&rdquo;) or deoxyribonucleosides (deoxyadenosine, deoxyguanosine, deoxythymidine, or deoxycytidine; &ldquo;DNA molecules&rdquo;), or any phosphoester analogues thereof, such as phosphorothioates and thioesters, in either single stranded form, or a double-stranded helix. Double stranded DNA-DNA, DNA-RNA and RNA-RNA helices are possible. The term nucleic acid molecule, and in particular DNA or RNA molecule, refers only to the primary and secondary structure of the molecule, and does not limit it to any particular tertiary forms. Thus, this term includes double-stranded DNA found, inter alia, in linear or circular DNA molecules (e.g., restriction fragments), plasmids, and chromosomes. In discussing the structure of particular double-stranded DNA molecules, sequences may be described herein according to the normal convention of giving only the sequence in the 5&prime; to 3&prime; direction along the nontranscribed strand of DNA (i.e., the strand having a sequence homologous to the mRNA). A &ldquo;recombinant DNA molecule&rdquo; is a DNA molecule that has undergone a molecular biological manipulation.</PDAT></PTEXT></PARA>
<PARA ID="P-00095" LVL="0"><PTEXT><PDAT>&ldquo;Homologous recombination&rdquo; refers to the insertion of a modified or foreign DNA sequence contained by a first vector into another DNA sequence contained in second vector, or a chromosome of a cell. The first vector targets a specific chromosomal site for homologous recombination. For specific homologous recombination, the first vector will contain sufficiently long regions of homology to sequences of the second vector or chromosome to allow complementary binding and incorporation of DNA from the first vector into the DNA of the second vector, or the chromosome. Longer regions of homology, and greater degrees of sequence similarity, may increase the efficiency of homologous recombination.</PDAT></PTEXT></PARA>
<PARA ID="P-00096" LVL="0"><PTEXT><PDAT>A DNA &ldquo;coding sequence&rdquo; is a double-stranded DNA sequence which is transcribed and translated into a polypeptide in a cell in vitro or in vivo when placed under the control of appropriate regulatory sequences. The boundaries of the coding sequence are determined by a start codon at the 5&prime; (amino) terminus and a translation stop codon at the 3&prime; (carboxyl) terminus. A coding sequence can include, but is not limited to, prokaryotic sequences, cDNA from eukaryotic mRNA, genomic DNA sequences from eukaryotic (e.g., mammalian) DNA, and even synthetic DNA sequences. If the coding sequence is intended for expression in a eukaryotic cell, a polyadenylation signal sequence is usually required.</PDAT></PTEXT></PARA>
<PARA ID="P-00097" LVL="0"><PTEXT><PDAT>Transcriptional and translational control sequences are DNA regulatory sequences, such as promoters, enhancers, terminators, and the like, that provide for the expression of a coding sequence in a host cell. In eukaryotic cells, polyadenylation signal sequences are control sequences.</PDAT></PTEXT></PARA>
<PARA ID="P-00098" LVL="0"><PTEXT><PDAT>A &ldquo;translocation signal sequence&rdquo; as used herein refers to a signal sequence that is included at the beginning of the coding sequence for a protein to be expressed on the surface of a cell. This sequence encodes a signal peptide, N-terminal to the mature polypeptide, that directs the host cell to translocate the polypeptide. Translocation signal sequences can be found associated with a variety of proteins native to eukaryotes and prokaryotes, and are often functional in both types of organisms.</PDAT></PTEXT></PARA>
<PARA ID="P-00099" LVL="0"><PTEXT><PDAT>Any eukaryotic cell potentially can serve as the source for the genomic DNA to be used in the present invention. The genomic DNA can contain regulatory and intron DNA regions in addition to coding regions; clones derived from cDNA will not contain intron sequences. Sources envisioned by the present invention include all types of eukaryotic cells in the animal and plant kingdom. Particular sources include but are not limited to mammals including humans, chimpanzees, gorillas, orangutans, whales, porpoises, cattle, horses, goats, sheep, dogs, cats, mice, rats, and rabbit; avians including chickens, pigeons, turkeys, parrots, parakeets, and canaries; amphibians such as frogs; fish such as salmon and zebrafish; invertebrates such as insects including bees, beetles, ants, and flies; and plants including trees, grasses, and agricultural crops including corn, wheat, soybeans, peas, carrots, potatoes, and rice.</PDAT></PTEXT></PARA>
<PARA ID="P-00100" LVL="0"><PTEXT><PDAT>The present invention provides methods for determining the nucleotide sequence of one or more exons, and preferably all but the first exon, of a eukaryotic gene contained in a BBPAC genomic library. A key aspect of the present invention provides a method of including a promoter-5&prime; Exon/Intron Unit (PEU) (preferably a BPEU) and eukaryotic genomic DNA in a BBPAC. In one aspect of the invention the BBPAC is constructed with a vector that contains a PEU. In another aspect of the invention the PEU is places into a BBPAC that contains eukaryotic genomic DNA. In one embodiment of this aspect of the present invention, the insertion of the PEU into the BBPAC is performed by homologous recombination. In a preferred embodiment of this type is performed as described in U.S. patent application Ser. No. 08/880,966, filed Jun. 23, 1997, which is specifically incorporated herein by reference in its entirety. In another embodiment of the present invention the insertion of the PEU into the BBPAC is performed using a transposon system.</PDAT></PTEXT></PARA>
<PARA ID="P-00101" LVL="0"><PTEXT><PDAT>The gene trapping system of the present invention relies on the insertion of an exon/intron unit that comprises a strong promoter, a 5&prime; exon that is adjacent to an intron element, and in preferred embodiments a marker such as a bacterial antibiotic resistance gene. The 5&prime; vector-derived exon can be any initial exon of any eukaryotic gene. Preferably the eukaryotic gene is a mammalian gene. For example, the conventional 5&prime; exonlintron region used in the pSPL3 vector &lsqb;Buckler et al., </PDAT><HIL><ITALIC><PDAT>PNAS </PDAT></ITALIC></HIL><PDAT>88:4005-4009 (1991)&rsqb; can be used.</PDAT></PTEXT></PARA>
<PARA ID="P-00102" LVL="0"><PTEXT><PDAT>In a preferred embodiment the first exon is the beta-globin first exon, the second exon is a fusion of the second beta-globin exon and the HIV tat exon. These exons are then followed by HIV-tat intron or a fragment thereof. The gene trap system is designed to also trap the polyA signal sequence and therefore a 3&prime; polyA containing exon is specifically not included in the gene trapping system.</PDAT></PTEXT></PARA>
<PARA ID="P-00103" LVL="0"><PTEXT><PDAT>The promoter should stimulate strong and ubiquitous expression in most eukaryotic cell types. Preferably the eukaryotic promoter of the PEU will be a strong promoter such as the SV40 promoter, metallothionein-1 promoter, the cytomegalovirus (CMV) promoter, the actin promoter, the cauliflower mosaic virus promoter, and the nopaline synthase promoter. &lsqb;Broido et al., </PDAT><HIL><ITALIC><PDAT>Nucl. Acids Res</PDAT></ITALIC></HIL><PDAT>. 17:7891-7903 (1989)&rsqb;.</PDAT></PTEXT></PARA>
<PARA ID="P-00104" LVL="0"><PTEXT><PDAT>More preferably the PEU contains a bi-directional promoter (i.e., the PEU is a BPEU). In this case a single insertion enables trapping of genes that lie in opposite orientations on both sides of the BPEU elements. In addition, a marker such as an antibiotic resistance gene, or a gene encoding green fluorescent protein can also be included in the PEU.</PDAT></PTEXT></PARA>
<PARA ID="P-00105" LVL="0"><PTEXT><PDAT>In the case when the insertion of the PEU into the BBPAC is performed by homologous recombination, a particular nucleotide sequence in the BBPAC is selected for PEU insertion. Preferably, the particular nucleotide sequence is in the BBPAC vector backbone, i.e., it is not part of the eukaryotic genomic fragment contained by the BBPAC.</PDAT></PTEXT></PARA>
<PARA ID="P-00106" LVL="0"><PTEXT><PDAT>The BBPACs that can be employed in the methods of the present invention are obtainable from a number of sources. For example, </PDAT><HIL><ITALIC><PDAT>E. coli</PDAT></ITALIC></HIL><PDAT>-based artificial chromosomes for human libraries have been described &lsqb;Shizuya et al., Proc. Natl. Acad. Sci. 89:8794-8797 (1992); loannou et al., In </PDAT><HIL><ITALIC><PDAT>Current Protocols in Human Genetics </PDAT></ITALIC></HIL><PDAT>(ed. Dracopoli et al.) 5.15.1-5.15.24 John Wiley &amp; Sons, New York (1996); Kim et al., Genomics 34:213-218 (1996)&rsqb;. Libraries of PACs and BACs have been constructed &lsqb;reviewed in Monaco et al., </PDAT><HIL><ITALIC><PDAT>Trends Biotechol</PDAT></ITALIC></HIL><PDAT>., 12:280-286 (1994)&rsqb;, that are readily isolated from the host genomic background for example by classical alkaline lysis plasmid preparation. protocols &lsqb;Bimboim et al., </PDAT><HIL><ITALIC><PDAT>Nucleic Acids Res</PDAT></ITALIC></HIL><PDAT>. 7:1513-1523 (1979)&rsqb;, or alternatively, with the use of a nucleobond kit, a boiling Prep, or by cesium gradient (Maniatis, supra). BAC, PAC, and P1 libraries are also available for a variety of species (e.g. Research Genetics, Inc., Genome Research, Inc., Texas A&amp;M has a BAC center to make a BAC library for livestock and important crops). BACs also can be used as a component of mammalian artificial chromosomes.</PDAT></PTEXT></PARA>
<PARA ID="P-00107" LVL="0"><PTEXT><PDAT>In addition, the BBPACs can be constructed from vectors containing PEUs. &lsqb;See Shizuya et al., </PDAT><HIL><ITALIC><PDAT>Proc. Natl. Acad. Sci</PDAT></ITALIC></HIL><PDAT>. 18:8794-8797 (1992); and Kim et al., Genomics 34:213-218 (1996), the contents of which are hereby incorporated by reference in their entireties&rsqb;. The PEUs can be inserted into the vectors by known methodology including homologous recombination e.g., by means described in U.S. Ser. No. 08/880,966, filed Jun. 23, 1997.</PDAT></PTEXT></PARA>
<PARA ID="P-00108" LVL="0"><PTEXT><PDAT>BBPAC contigs are available from various Genome projects, including the Human Genome Project.</PDAT></PTEXT></PARA>
<PARA ID="P-00109" LVL="0"><PTEXT><PDAT>Bacterial cells that can be used to manipulate the BBPACs include any bacterial cell that can support the BBPAC and the shuttle vector, preferably the original BBPAC host cell.</PDAT></PTEXT></PARA>
<PARA ID="P-00110" LVL="0"><PTEXT><PDAT>Most mammalian cells can be used to transcribe trappable eukaryotic genes contained in the BBPACs including COS cells and 3TC cells. Plant cells include tobacco plant cells such as </PDAT><HIL><ITALIC><PDAT>Nicotiana plumbaginifolia</PDAT></ITALIC></HIL><PDAT>, and </PDAT><HIL><ITALIC><PDAT>Nicotiana benthamiana. </PDAT></ITALIC></HIL></PTEXT></PARA>
<PARA ID="P-00111" LVL="0"><PTEXT><PDAT>In particular instances, when a PEU is inserted into a selected locus of the BBPAC, the region of insertion can be mapped for restriction enzyme sites. Whereas subcloning is necessary for detailed mapping, it is generally unnecessary since rough mapping is usually sufficient.</PDAT></PTEXT></PARA>
<PARA ID="P-00112" LVL="0"><PTEXT><PDAT>Maxiprep DNA from BBPACs with PEU insertions can be prepared by a number of methods including by cesium gradient, or with commercially available columns (e.g., Nucleobond, etc.) as described in U.S. patent application Ser. No. 08/880,966, filed Jun. 23, 1997 hereby incorporated by reference in its entirety. If a pool of modified BBPACs are to be used for gene trapping, the maxiprep DNA can be prepared from the culture containing the pool of bacteria.</PDAT></PTEXT></PARA>
<PARA ID="P-00113" LVL="0"><PTEXT><PDAT>The conditional replication shuttle vectors of the present invention are constructed so as to contain a recombination cassette that can selectively integrate into the nucleotide sequence of the particular nucleotide sequence contained by the BBPAC. Such conditional replication shuttle vectors can be constructed which either contain a marker e.g.,a specific drug resistant gene, or can be subsequently modified to contain one. In a preferred embodiment the drug resistant gene can also be counter-selected against, such as the combination of a tetracycline resistant gene which can be counter-selected with fusaric acid. Alternatively, in addition to the drug resistant gene the conditional replication shuttle vector can also contain a counter-selection gene such as a gene that confers sensitivity to galactose, for example. More preferably the conditional replication shuttle vector is a temperature sensitive shuttle vector (TSSV) that replicates at a permissive temperature, but does not replicate at a non-permissive temperature. In a particular embodiment, the permissive terrp-rature is 30&deg; C., and the non-permissive temperature is 43&deg; C. The TSSV is diluted out when the host cell is grown at the non-permissive temperature.</PDAT></PTEXT></PARA>
<PARA ID="P-00114" LVL="0"><PTEXT><PDAT>The conditional replication shuttle vectors of this aspect of the present invention should also contain at least one unique cloning site. When a building vector is used for the construction of the recombination cassette as described below, one unique site is reserved for transferring the recombination cassette containing the specific nucleic acid from the building vector to the conditional replication shuttle vector. For example a polylinker can be inserted between two specific restriction sites to create additional restriction sites that allow cloning of the recombination cassette into the conditional replication shuttle vector. In any case the conditional replication shuttle vector created should minimally contain a recombination cassette comprising the PEU flanked at both the 5&prime; and 3&prime; ends by genomic fragments, preferably containing 250 basepairs or more of the particular nucleotide sequence of the BBPAC.</PDAT></PTEXT></PARA>
<PARA ID="P-00115" LVL="0"><PTEXT><PDAT>In certain cases a building vector is used to construct the recombination cassette. Two small genomic fragments, each containing about 350 basepairs (250 basepairs to 600 basepairs is sufficient) of the particular nucleotide sequence are cloned into the building vector (e.g., pBV1) in appropriate order and orientation to generate the flanking regions of the recombination cassette. The PEU (and if desired, DNA containing a promoter sequence 5&prime; to a particular nucleotide sequence encoding a marker protein, and/or recA etc.), is inserted between the two genomic fragments in the properlorientation. The recombination cassette is then transferred into the conditional replication shuttle vector (e.g., pSV1.RecA). The recombination cassette, the RecA-like protein gene if present, and the gene for the marker protein, are linked together on the conditional replication shuttle vector such that when the PEU integrates into the particular nucleotide sequence, the RecA-like protein gene and the gene encoding the marker protein remain linked together, and neither the RecA-like protein gene nor the gene encoding the marker protein remain linked to the integrated PEU. The PEU itself preferably includes a gene encoding a marker protein which is constructed to remain linked to the integrated PEU.</PDAT></PTEXT></PARA>
<PARA ID="P-00116" LVL="0"><PTEXT><PDAT>In a preferred embodiment the conditional replication shuttle vector is a TSSV. In a one such embodiment the TSSV is pSV1.RecA having the ATCC no. 97968, which is modified to contain a PEU as described above.</PDAT></PTEXT></PARA>
<PARA ID="P-00117" LVL="0"><PTEXT><PDAT>The BBPAC is preferably contained in a recombination. deficient host cell. In such embodiments neither the BBPAC alone, nor the BBPAC in combination with the host cell, can independently support homologous recombination. In a particular embodiment of this tppe both the BBPAC and the host cell are RecA</PDAT><HIL><SP><PDAT>&minus;</PDAT></SP></HIL><PDAT>, and inducing the host cell to transiently support homologous recombination comprises inducing the transient expression of the RecA-like protein to support homologous recombination in the host cell. However, as any person skilled in the art would readily understand, alternative causes for recombination deficiency may be rectified by methods that are analogous to those taught by the present invention and/or readily apparent in view of such teachings. For example recombination deficiency may be due to a deficiency of an alternative recombination protein such as another Rec protein including recB, recC, recD, and recE &lsqb;Clark et al., </PDAT><HIL><ITALIC><PDAT>Critical Reviews in Microbiol</PDAT></ITALIC></HIL><PDAT>. 20:125-142 (1994)&rsqb; which may be manipulated in a manner that is analogous to that taught herein for RecA-like proteins.</PDAT></PTEXT></PARA>
<PARA ID="P-00118" LVL="0"><PTEXT><PDAT>In the case of a RecA host cell, inducing the host cell to transiently support homologous recombination comprises inducing the transient expression of a RecA-like protein in the host cell. Such induction may be performed by expressing a RecA-like protein contained by the recombination deficient host that is under the control of an inducible promoter.</PDAT></PTEXT></PARA>
<PARA ID="P-00119" LVL="0"><PTEXT><PDAT>Preferably inducing the transient expression of the RecA-like protein is performed with a conditional replication shuttle vector that encodes the RecA-like protein. Such conditional replication shuttle vectors can be constructed by inserting a PCR amplified RecA-like gene, when desired, into an appropriate conditional replication shuttle vector which either contains a specific marker protein gene e.g., a drug resistant gene, or can be subsequently modified to contain one. Conditional replication shuttle vectors can also include pBR322 in a polyA temperature-sensitive bacterial strain.</PDAT></PTEXT></PARA>
<PARA ID="P-00120" LVL="0"><PTEXT><PDAT>Inducing the transient expression of the RecA-like protein consists of transforming the host cell with the TSSV at a permissive temperature, and growing the host cell at a non-permissive temperature. The TSSV encodes a RecA-like protein that is expressed in the host cell and supports the homologous recombination between the recombination cassette and the particular nucleotide sequence contained in the BBPAC. The TSSV encoding the RecA-like protein is diluted out when the host cell is grown at the non-permissive temperature.</PDAT></PTEXT></PARA>
<PARA ID="P-00121" LVL="0"><PTEXT><PDAT>The RecA-like protein of a conditional replication shuttle vector can be controlled by either an inducible promoter or a constitutive promoter. In one particular embodiment the transient expression of the RecA-like protein is achieved by the transient induction of the inducible promoter in a host cell. In another embodiment, the constitutive promoter is the endogenous </PDAT><HIL><ITALIC><PDAT>E. coli </PDAT></ITALIC></HIL><PDAT>recA promoter.</PDAT></PTEXT></PARA>
<PARA ID="P-00122" LVL="0"><PTEXT><PDAT>According to the methods of the present invention a RecA</PDAT><HIL><SP><PDAT>&minus;</PDAT></SP></HIL><PDAT> host cell containing the BBPAC is transformed with the conditional replication shuttle vector. The BBPAC can also contain a marker gene which bestows resistance to a host cell against a corresponding toxic agent/drug such as an antibiotic or in a specific embodiment, chloramphenicol. The cells are grown under the conditions in which the conditional replication shuttle vector can replicate (e.g., when the conditional replication shuttle vector is a TSSV which replicates at 30&deg; but not at 43&deg;, the host cell is grown at 30&deg; C.) and the transformants can be selected via the specific drug resistant gene (or first marker protein gene) carried by conditional replication shuttle vector, and the marker protein gene carried by the BBPAC. Since the conditional replication shuttle vector also carries the RecA-like protein gene, homologous recombination can occur between the conditional replication shuttle vector and BBPAC to form co-integrates through the sequence homology at either the 5&prime; or the 3&prime; flanking regions of the recombination cassette. The co-integrates then can be selected by growing the cells on plates containing the drugs specific for the first and second drug resistance genes, at non-permissive conditions (e.g. for the TSSV above, at 43&deg; C.) so that the non-integrated, free conditional replication shuttle vectors are lost. This results in the selection for host cells carrying the integrated conditional replication shuttle vectors, (which co-integrate either into the BBPAC or into the host chromosome). Correct BBPAC co-integrates can be identified by PCR or more preferably with Southern blot analyses.</PDAT></PTEXT></PARA>
<PARA ID="P-00123" LVL="0"><PTEXT><PDAT>The co-integrates can then be re-streaked onto plates containing the second drug, (i.e., the drug which the gene initially carried by the BBPAC protects against) and grown under non-permissive conditions overnight. A fraction of the co-integrates undergo a second recombination event (defined as resolution), through sequence homology at either the 5&prime; or the 3&prime; flanking regions of the recombination cassette. The resolved independent origin based cloning vector automatically loses both the first drug resistant gene (i.e., the specific drug resistant gene contained by the conditional replication shuttle vector) and the RecA-like protein gene due to the linkage arrangement of the RecA-like protein gene, the drug resistant gene and the PEU on the conditional replication shuttle vector, described above. In addition, the excised conditional replication shuttle vector cannot replicate under the non-permissive conditions and is therefore diluted out.</PDAT></PTEXT></PARA>
<PARA ID="P-00124" LVL="0"><PTEXT><PDAT>The resolved BBPAC can be further selected for by growing the host cells (e.g., at 37&deg; C.) on plates containing the second drug and an agent that counterselects against cells containing the gene resistant to the first drug (e.g., a gene conferring tetracycline resistance may be counter-selected against with fusaric acid). The resolved BBPAC will be either the original BBPAC or the BBPAC containing the PEU.</PDAT></PTEXT></PARA>
<PARA ID="P-00125" LVL="0"><PTEXT><PDAT>One method to identify the correctly resolved BBPAC is to choose 5-10 colonies and prepare a miniprep DNA. The DNA can then be analyzed using Southern blots to detect the correct targeting events.</PDAT></PTEXT></PARA>
<PARA ID="P-00126" LVL="0"><PTEXT><PDAT>In a preferred embodiment the BPEU element also contains a marker such as an antibiotic resistance gene (e.g. ampicillin) that remains with the PEU upon integration into the BBPAC. This marker can be used to identify BBPACs that contain the PEU. In this case the co-integration and resolution steps of the targeted BBPAC modification can be simplified by adding a selection requirement for this additional antibiotic resistance. Such methodology can obviate the need to perform Southern blot analyses. This feature also permits the simultaneous modification of a pool of BBPACs.</PDAT></PTEXT></PARA>
<PARA ID="P-00127" LVL="0"><PTEXT><PDAT>The marker can be a marker gene that encodes a marker protein that confers a specific drug resistance to the host cell, as exemplified above, against drugs such as antibiotics, e.g., ampicillin, chloramphenicol, and tetracycline, a protein that confers a particular physical characteristic to the cells, such as a green fluorescent protein or a modified green fluorescent protein as described in U.S. Pat. No. 5,625,048, Issued Apr. 29, 1997 and WO 97/26333 Published Jul. 24, 1997 hereby incorporated by reference in their entireties, or an enzyme such as luciferase. Alternatively, it can be another marker protein including e.g., &bgr;-galactosidase.</PDAT></PTEXT></PARA>
<PARA ID="P-00128" LVL="0"><PTEXT><PDAT>In preferred embodiments the methods of homologous recombination are selective, and nonspecific nucleotide sequence rearrangements either do not occur, or are essentially undetectable by one or more conventional methods of analysis. One such method includes pulsed field gel mapping of the BBPAC containing a PEU and the unmodified BBPAC to determine whether any unexpected deletions, or insertions or rearrangement were generated during the modification procedure. In one particular embodiment, the same filter can be probed separately with a probe for the whole independent BBPAC, with a probe for the particular nucleotide sequence, or a probe for the PEU. A restriction enzyme digestion can reveal a finger print of the modified BBPAC indicating whether the fragments are preserved. Restriction enzyme digestions can be repeated with one or more additional restriction enzymes selected with respect to the restriction site map of the BBPAC</PDAT></PTEXT></PARA>
<PARA ID="P-00129" LVL="0"><PTEXT><PDAT>In an alternative method, the BBPAC can be assayed with both a probe specific for any region of the DNA contained by the recombination cassette predicted to be inserted into the independent origin based cloning vector (e.g., the PEU) and a probe specific for a region outside of the modification region (e.g., outside of the PEU).</PDAT></PTEXT></PARA>
<PARA ID="P-00130" LVL="0"><PTEXT><PDAT>A BBPAC of the present invention can be purified by gel filtration, e.g. a column filled with SEPHAROSE CL-4B yielded intact linear BAC DNA. The column can be pre-equilibrated in an appropriate buffer as described in U.S. patent application Ser. No. 08/880,966, filed Jun. 23, 1997 and hereby incorporated by reference in its entirety. The purified DNA can be directly visualized with ultraviolet light after ethidium bromide staining, for example. Columns such as the SEPHAROSE CL-4B column also can efficiently separate degraded DNA from the pure linear DNA.</PDAT></PTEXT></PARA>
<PARA ID="P-00131" LVL="0"><PTEXT><PDAT>The BBPAC of the present invention can be introduced into the desired host cells by methods known in the art, e.g., transfection, electroporatipn, microinjection, transduction, cell fusion, DEAE dextran, calcium phosphate precipitation, lipofection (lysosome fusion), use of a gene gun, or a DNA vector transporter (see, e.g., Wu et al., 1992</PDAT><HIL><ITALIC><PDAT>, J. Biol. Chem</PDAT></ITALIC></HIL><PDAT>. 267:963-967; Wu and Wu, 1988</PDAT><HIL><ITALIC><PDAT>, J. Biol. Chem</PDAT></ITALIC></HIL><PDAT>. 263:14621-14624; Hartmut et al., Canadian Patent Application No. 2,012,311, filed Mar. 15, 1990). Preferably the modified BBPACs are introduced by a psoralen-inactivated adenovirus as carrier as described by &lsqb;Baker et al., </PDAT><HIL><ITALIC><PDAT>NAR </PDAT></ITALIC></HIL><PDAT>25:1950-1956 (1997)&rsqb;. Essentially any cell line can be used since BBPACs replicate in mammalian cells and the SV40 promoter is active in the majority of mammalian cells.</PDAT></PTEXT></PARA>
<PARA ID="P-00132" LVL="0"><PTEXT><PDAT>The present invention also provides methods of performing randomized gene trapping. One such embodiment is based on the insertion a PEU (preferably a BPEU) into a BBPAC through the use of a transposon system. The PEU element is initially placed into a plasmid, preferably a conditional replication shuttle vector, that contains a mini-transposon. The BPEU is specifically located between the inverted repeat ends of the transposon. When a marker is included in the BPEU, the marker is also located in between the transposon ends.</PDAT></PTEXT></PARA>
<PARA ID="P-00133" LVL="0"><PTEXT><PDAT>A gene encoding transposase is located outside of the inverted repeat ends of the transposon on the shuttle vector. In a preferred embodiment, the gene encoding transposase is under the control of an inducible promoter. In this case, the inducible promoter is also outside of the inverted repeat ends of the transposon on the shuttle vector. In a preferred embodiment of this type the inducible promoter is the &bgr;-galactosidase (lac) promoter which can be induced by IPTG (isopropyl-&bgr;-D-thiogalactopyranoside) and is kept fully repressed in the absence of the inducer by the constitutive expression of lacI</PDAT><HIL><SP><PDAT>q </PDAT></SP></HIL><PDAT>by either the host cell (e.g., DH10B, which expresses lacI</PDAT><HIL><SP><PDAT>q </PDAT></SP></HIL><PDAT>constitutively at high levels) or the conditional replication shuttle vector. Of course other inducible promoters that can be used.</PDAT></PTEXT></PARA>
<PARA ID="P-00134" LVL="0"><PTEXT><PDAT>In one embodiment a bacterial host cell containing the BBPAC is transformed by a shuttle vector e.g., a TSSV such as pSV.TN10.RGT exemplified below, containing transposase under the control of an inducible promoter, and a PEU (preferably a BPEU having a marker) which is inserted in the TSSV in between the inverted ends of the transposon. A transformed host cell can be selected for having markers contained on the BBPAC, the shuttle vector and the PEU (contained by the shuttle vector). Treatment of the host cells with an inducer for the inducible promoter transiently induces the expression of the transposase, which in turn, induces the transposition of they PEU into the BBPAC and the bacterial host cell genome. Although the majority of the mini-transposons insert into the bacterial genome, this is unimportant. In one such embodiment the induction is controlled such that each BBPAC receives only a single transposon or no transposon at all.</PDAT></PTEXT></PARA>
<PARA ID="P-00135" LVL="0"><PTEXT><PDAT>Following the insertion of the transposon, the shuttle vector is eliminated from the bacterial host. In one embodiment the shuttle vector is a conditional replication shuttle vector and the host cells are grown under conditions in which the shuttle vector cannot grow, e.g., at a non-permissive temperature such as 43&deg; C., when the conditional replication shuttle vector is a TSSV which cannot replicate at 43&deg; C. The TSSV will not replicate and therefore be diluted out and lost. In this case, the markers on the BBPAC and the PEU preferably are also selected for.</PDAT></PTEXT></PARA>
<PARA ID="P-00136" LVL="0"><PTEXT><PDAT>In another embodiment, the host cells are grown under conditions in which cells containing the shuttle vector can be selected against (e.g., the shuttle vector can contain a tetracycline resistance gene, and the host cells can be grown in fusaric acid). In this example, the Tet resistance gene is placed on the shuttle vector such that it is physically outside of the transposon inverted repeats of the shuttle vector, and therefore, the Tet resistance gene is not transported by the transposon. Therefore the selection for the loss of tetracycline resistance is equivalent to the selection for loss of the shuttle vector. Again, the markers on the BBPAC and the PEU are preferably selected for during this step of the procedure.</PDAT></PTEXT></PARA>
<PARA ID="P-00137" LVL="0"><PTEXT><PDAT>Preferably, the shuttle vector is a conditional replication shuttle vector that contains a marker that can be counter-selected against (e.g., the Tet resistance gene) and the elimination of the shuttle vector includes both growing the host cells under conditions in which the conditional replication shuttle vector cannot replicate, and under conditions in which the host cells containing the shuttle vector can be selected against. In one such embodiment, these two discriminating features are performed in two separate steps, e.g., when the counterselecting agent is used, the host cell is be grown under conditions that allow the shuttle vector to replicate, (in the case of the TSSV exemplified above, at 37&deg; C.).</PDAT></PTEXT></PARA>
<PARA ID="P-00138" LVL="0"><PTEXT><PDAT>Once the shuttle vector is removed, all bacteria which contain the markers of the BBPAC and the PEU also must contain a minitransposon insertion, either in the bacterial chromosome or in the BBPAC. The supercoiled BBPAC DNA can be isolated from the host cells by conventional alkaline lysis. Since the BBPAC is the only circular plasmid in the bacteria the DNA prep only contains the circular BBPAC DNA. The circular BAC DNA can be electroporated into competent bacterial cells e.g., according to the protocol described by Sheng et al. &lsqb;</PDAT><HIL><ITALIC><PDAT>NAR </PDAT></ITALIC></HIL><PDAT>23, 1990-1996 (1995)&rsqb;, and the cells can then be are selected for the markers contained by the PEU and the BBPAC.</PDAT></PTEXT></PARA>
<PARA ID="P-00139" LVL="0"><PTEXT><PDAT>The greater the number of cells chosen, the more PEU integration sites within the BBPAC are obtained, and therefore, the more trappable eukaryotic genes obtained. In one embodiment the insertion site of the PEU element can be mapped by pulsed field gel electrophoresis and Southern blots. The BBPACs are then ready for placing into eukaryotic cells as described herein.</PDAT></PTEXT></PARA>
<PARA ID="P-00140" LVL="0"><PTEXT><PDAT>Transposon systems appropriate for use in the present invention include Tn3, and Tn10 &lsqb;Chatterjee et al., </PDAT><HIL><ITALIC><PDAT>Genet. Anal Biomol. Eng</PDAT></ITALIC></HIL><PDAT>., 13:33-42 (1996)&rsqb; hereby incorporated by reference in its entirety. The mini-Tn10 transposon with an inducible transposase for example, can insert a 10 kb nucleic acid sequence located between the inverted repeats into relatively random locations &lsqb;Chatterjee et al., </PDAT><HIL><ITALIC><PDAT>Genet. Anal. Biomol. Eng</PDAT></ITALIC></HIL><PDAT>., 13:3342 (1996); Chatterjee et al., </PDAT><HIL><ITALIC><PDAT>NAR, </PDAT></ITALIC></HIL><PDAT>25:2205-2212 (1997)&rsqb;.</PDAT></PTEXT></PARA>
<PARA ID="P-00141" LVL="0"><PTEXT><PDAT>Shuttle vectors that contain a nucleotide sequence that encode transposase under the control of a inducible promoter, a promoter Exon/intron unit (PEU) and a pair of inverted transposon ends are also part of the present invention. The PEU is positioned in between the pair of inverted transposon ends. The shuttle vector is preferably a condition replication shuttle vector and more preferably a temperature sensitive shuttle vector (TSSV). In a preferred embodiment the promoter is a bi-directional promoter making the PEU a BPEU. In another preferred embodiment the TSSV also contains a gene that confers tetracycline resistance and this is positioned outside of the pair of transposons. In a more preferred embodiment, the TSSV is pSV1.Tn10-RGT which can be readily constructed from pSV1.RecA having the ATCC no. 97968.</PDAT></PTEXT></PARA>
<PARA ID="P-00142" LVL="0"><PTEXT><PDAT>The present invention may be better understood by reference to the following non-limiting Example, which is provided as being exemplary of the invention. The following example is presented in order to more fully illustrate the preferred embodiments of the invention. It should in no way be construed, however, as limiting the broad scope of the invention.</PDAT></PTEXT></PARA>
<H LVL="1"><STEXT><PDAT>EXAMPLE</PDAT></STEXT></H>
<H LVL="1"><STEXT><PDAT>GENE TRAPPING IN BBPACs</PDAT></STEXT></H>
<H LVL="1"><STEXT><PDAT>Introduction</PDAT></STEXT></H>
<PARA ID="P-00143" LVL="0"><PTEXT><PDAT>Bacterial artificial chromosomes (BACs) and P-1 derived artificial chromosomes (PACs) are large genomic clones that propagate in </PDAT><HIL><ITALIC><PDAT>E. Coli </PDAT></ITALIC></HIL><PDAT>as circular plasmid &lsqb;Shizya et al., </PDAT><HIL><ITALIC><PDAT>PNAS </PDAT></ITALIC></HIL><PDAT>89, 8794-8797 (1992); Ioannou et al., </PDAT><HIL><ITALIC><PDAT>Nature Genetics</PDAT></ITALIC></HIL><PDAT>, 6:84-89 (1994)&rsqb;. BACs and PACs are ideal systems for use in exon trapping. First, BACs and PACs have a cloning capacity of 700 kb &lsqb;Zimmer and Verrinder Gibbins, </PDAT><HIL><ITALIC><PDAT>Genomics</PDAT></ITALIC></HIL><PDAT>, 42:217-226 (1997)&rsqb;, with most libraries having an average insert size of 150 kb. This means that a single BAC can hold most mammalian genes. Therefore, exon trapping performed with a BAC can result in the trapping of all of the exons of the gene including the polyA signal sequence. Thus, instead of exon trapping, the present invention allows gene trapping. Second, BACs are extremely stable, and therefore, chimeric genes are generally not formed, and inserts are rarely deleted. Such high stability ensures that the trapped gene is an endogenous gene, not an artifactural chimeric gene. Third, BACs and PACs exist as circular supercoiled bacterial plasmids, and therefore are extremely amenable to further manipulation. In addition, conventional bacterial plasmid DNA preparation and sequencing methods can be applied to BACs and PACs. Therefore, manipulating BACs and PACs is as simple as manipulating smaller plasmids. Fourth, unlike small plasmids, BACs are large enough to contain the necessary elements for DNA replication and nuclear retention in mammalian cells. When introduced into mammalian cells, BACs are maintained as stable episomal plasmids &lsqb;Baker and Cotten, </PDAT><HIL><ITALIC><PDAT>NAR </PDAT></ITALIC></HIL><PDAT>25, 1950-1956 (1997)&rsqb;. This property allows exon trapping to be performed in a variety of cell lines, as opposed to being restricted to COS cell lines, as currently required by conventional exon trapping systems. Two novel gene trapping systems are described below. The first system, termed &ldquo;targeted gene trapping&rdquo;, targets the promoter-5&prime; exon elements to a designated location in the BAC by homologous recombination. The second system, termed &ldquo;randomized gene trapping&rdquo;, employs the same promoter-5&prime; exon element, but the promoter-5&prime; exon element is randomly inserted into a BAC via a Tn 10 transposon system. The resulting collection of BACs are then used for gene trapping.</PDAT></PTEXT></PARA>
<PARA ID="P-00144" LVL="0"><PTEXT><PDAT>The following steps are involved in a gene trapping system,(Table 1). First, a promoter-5&prime; exon/intron unit is inserted into the BBPAC, e.g., a BAC, containing genomic DNA, either by targeted modification or transposon mediated integration. Then DNA is prepared from the modified BAC and transfected into the desired mammalian cell line. After culturing for a few days, RNA is isolated from these cell lines and oligo dT primed cDNAs are prepared. Then PCR amplification is performed with a 5&prime; vector-exon specific oligo and an oligo dT. The resulting cDNA products are suheloned into a suitable cloning vector. The clones are then sequenced to identify the trapped gene. The cDNAs can be hybridized back to the original BACs to confirm their origin.</PDAT></PTEXT></PARA>
<CWU>
<TABLE-US ID="TABLE-US-00001">
<TABLE-CALS>
<table frame="none" colsep="0" rowsep="0">
<tgroup align="left" colsep="0" rowsep="0" cols="1">
<colspec colname="1" colwidth="217pt" align="center"/>
<thead>
<row>
<entry namest="1" nameend="1" rowsep="1"><PTEXT><PDAT>TABLE 1</PDAT></PTEXT></entry>
</row>
<row>
<entry namest="1" nameend="1" align="center" rowsep="1"></entry>
</row>
</thead>
<tbody valign="top">
<row>
<entry><PTEXT><PDAT></PDAT>
<CWU>
<CHEM-US ID="CHEM-US-00001">
<CHEMCDX ID="CHEMCDX-00001" ALT="chemistry chemdraw file" FILE="US06485912-20021126-C00001.CDX"/>
<CHEMMOL ID="CHEMMOL-00001" ALT="chemistry mol file" FILE="US06485912-20021126-C00001.MOL"/>
<EMI ID="EMI-C00001" ALT="embedded image" HE="177.1308" WI="100.33065" FILE="US06485912-20021126-C00001.TIF"/>
</CHEM-US>
</CWU>
</PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT></PDAT>
<CWU>
<CHEM-US ID="CHEM-US-00002">
<CHEMCDX ID="CHEMCDX-00002" ALT="chemistry chemdraw file" FILE="US06485912-20021126-C00002.CDX"/>
<CHEMMOL ID="CHEMMOL-00002" ALT="chemistry mol file" FILE="US06485912-20021126-C00002.MOL"/>
<EMI ID="EMI-C00002" ALT="embedded image" HE="146.65455" WI="91.4571" FILE="US06485912-20021126-C00002.TIF"/>
</CHEM-US>
</CWU>
</PTEXT></entry>
</row>
<row>
<entry namest="1" nameend="1" align="center" rowsep="1"></entry>
</row>
</tbody>
</tgroup>
</table>
</TABLE-CALS>
</TABLE-US>
</CWU>
<CWU>
<TABLE-US ID="TABLE-US-00002">
<TABLE-CALS>
<table frame="none" colsep="0" rowsep="0">
<tgroup align="left" colsep="0" rowsep="0" cols="1">
<colspec colname="1" colwidth="217pt" align="center"/>
<thead>
<row>
<entry namest="1" nameend="1" rowsep="1"><PTEXT><PDAT>TABLE 2</PDAT></PTEXT></entry>
</row>
<row>
<entry namest="1" nameend="1" align="center" rowsep="1"></entry>
</row>
</thead>
<tbody valign="top">
<row>
<entry><PTEXT><PDAT></PDAT>
<CWU>
<CHEM-US ID="CHEM-US-00003">
<CHEMCDX ID="CHEMCDX-00003" ALT="chemistry chemdraw file" FILE="US06485912-20021126-C00003.CDX"/>
<CHEMMOL ID="CHEMMOL-00003" ALT="chemistry mol file" FILE="US06485912-20021126-C00003.MOL"/>
<EMI ID="EMI-C00003" ALT="embedded image" HE="224.90055" WI="207.38025" FILE="US06485912-20021126-C00003.TIF"/>
</CHEM-US>
</CWU>
</PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT></PDAT>
<CWU>
<CHEM-US ID="CHEM-US-00004">
<CHEMCDX ID="CHEMCDX-00004" ALT="chemistry chemdraw file" FILE="US06485912-20021126-C00004.CDX"/>
<CHEMMOL ID="CHEMMOL-00004" ALT="chemistry mol file" FILE="US06485912-20021126-C00004.MOL"/>
<EMI ID="EMI-C00004" ALT="embedded image" HE="238.33845" WI="205.22565" FILE="US06485912-20021126-C00004.TIF"/>
</CHEM-US>
</CWU>
</PTEXT></entry>
</row>
<row>
<entry namest="1" nameend="1" align="center" rowsep="1"></entry>
</row>
</tbody>
</tgroup>
</table>
</TABLE-CALS>
</TABLE-US>
</CWU>
<H LVL="1"><STEXT><PDAT>Procedures and Results</PDAT></STEXT></H>
<PARA ID="P-00145" LVL="1"><PTEXT><PDAT>I. The promoter-5&prime; Exon/intron Unit (PEU) and the Bidirectional Promoter-5&prime; Exon/intron unit (BPEU): Unlike the conventional gene trapping system, in which small genomic fragments are cloned into multiple cloning sites lying within an intron, the gene trapping system involves insertion of a unit containing a strong promoter such as viral promoters (e.g., CMV) or promoters for housekeeping genes, plus a 5&prime; exon (called a vector-derived exon), adjacent intron elements, and a bacterial antibiotic resistance gene, such as the Amp gene, into the BBPAC (FIG. </PDAT><HIL><BOLD><PDAT>1</PDAT></BOLD></HIL><PDAT>A). The promoter can be any promoter that stimulates strong and ubiquitous expression in most mammalian cell types, including the SV40 promoter, and the metallothionein-1 promoter. The 5&prime; vector-derived exon can be any initial exon of any eukaryotic gene. For example, the conventional 5&prime; exon/intron region used in the pSPL3 vector &lsqb;Buckler et al., </PDAT><HIL><ITALIC><PDAT>PNAS </PDAT></ITALIC></HIL><PDAT>88:4005-4009 (1991)&rsqb; can be used.</PDAT></PTEXT></PARA>
<PARA ID="P-00146" LVL="0"><PTEXT><PDAT>In this example the first exon is the beta-globin first exon, the second exon is a fusion of the second beta-globin exon and the HIV tat exon. These exons are then followed by HIV-tat intron. A 3&prime; polyA containing exon is specifically not included in the gene trapping system for the following reasons: first, the BBPAC needs to be modified only once to introduce the promoter-exon/intron unit (PEU) into the BBPAC; second, this design also allows trapping of the endogenous polyA signal sequence, and therefore all of the exons of the particular gene except the first one; third, since there are no 3&prime; splice acceptor and polyA signal sequences provided (as are provided in the conventional exon trapping system) there is no background due to splicing of the vector exons alone.</PDAT></PTEXT></PARA>
<PARA ID="P-00147" LVL="0"><PTEXT><PDAT>The gene trap system is designed to also trap the polyA signal sequence. Therefore, those genes that do not have their polyA signal sequence in a BAC will be missed by the gene trap method. This problem can be solved by using an overlapping set of BACs to do gene trapping. These overlapping sets of BACs essentially guarantee that a BAC exists in the contig that contains the exon with the polyA sequence for any given gene. Therefore, gene trapping using a BAC contig greatly increases the odds that all genes will be identified.</PDAT></PTEXT></PARA>
<PARA ID="P-00148" LVL="0"><PTEXT><PDAT>An improved version of the gene trapping system comprises the insertion of a unit containing a bidirectional promoter-exon/intron (BPEU). In addition, an antibiotic resistance gene can also be included (FIG. </PDAT><HIL><BOLD><PDAT>1</PDAT></BOLD></HIL><PDAT>B). Therefore a single insertion enables trapping of genes that lie in opposite orientations on both sides of the BPEU elements. Due to the higher efficiency of the gene trapping with BPEU, the subsequent steps of gene trapping is further exemplified with insertion of the BPEU elements. However, the same procedures can be followed with a single directional PEU.</PDAT></PTEXT></PARA>
<PARA ID="P-00149" LVL="1"><PTEXT><PDAT>II. Targeted gene trapping: Targeted gene trapping refers to the insertion of the BPEU into the designated site within the BBPAC using the targeted BBPAC modification technology disclosed herein, and in U.S. patent application Ser. No. 08/880,966, filed Jun. 23, 1997 incorporated herein in its entirety. The insertion site can be anywhere within the BBPAC, including the genomic insert or the vector sequence, solely depending on the homologous sequence used to target the BPEU element. The total homologous sequence used is optimally about 500 bp or greater. Since for a given BBPAC library, the vector sequence is identical and known, the universal shuttle vector is preferably designed to target the BPEU elements to the vector backbone (see </PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 2A</PDAT></FGREF><PDAT>, the genomic insert of the BBPAC is represented as the sequence between two NotI sites). Since the BPEU element also contains an antibiotic resistance gene (e.g. ampicillin), the co-integration and resolution steps of the targeted BBPAC modification can be simplified by adding a selection requirement for this additional antibiotic resistance. Such methodology can obviate the need to perform Southern blot analyses. This feature permits the simultaneous modification of a pool of BBPACs.</PDAT></PTEXT></PARA>
<PARA ID="P-00150" LVL="0"><PTEXT><PDAT>BBPACs containing the BPEUs targeted to the vector backbone can be transfected into eukaryotic cells allowing two genes in opposite transcription orientations to be trapped when the genes are in the proper orientation (see </PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 2B</PDAT></FGREF><PDAT>; the splicing machinery of the cell only traps genes having a 3&prime; splice site acceptor 5&prime; to the Poly A signal sequence). Therefore, when employing a BBPAC containing multiple genes, a single insertion of a BPEU most likely will miss some of the genes (see </PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 2B</PDAT></FGREF><PDAT>, e.g., Gene </PDAT><HIL><BOLD><PDAT>2</PDAT></BOLD></HIL><PDAT>). This problem can be solved using a dense overlapping of set BBPACs (i.e., a BBPAC contig). Performing targeted gene trapping on such a set of BBPAC&apos;s can result in obtaining essentially all of the genes in the region. Another aspect of this gene trap system is that since it provides the vector-driven first exon and only traps exons with a 3&prime; splice acceptor, it therefore skips the very first exon of a given gene (FIG. </PDAT><HIL><BOLD><PDAT>2</PDAT></BOLD></HIL><PDAT>B). Fortunately, the first exon of a gene seldom contains a coding sequence. This first exon has to be identified by another method, such as by screening cDNA libraries.</PDAT></PTEXT></PARA>
<PARA ID="P-00151" LVL="1"><PTEXT><PDAT>III. Randomized Gene Trapping: Randomized gene trapping involves the relatively random insertion of a PEU (preferably a BPEU) into a BAC mediated by transposon system (e.g. Tn10 or Tn3). The BPEU element and the bacterial resistant gene, e.g., the Amp gene, is carried by a plasmid that also contains a mini-transposon and a temperature sensitive origin of replication. The use of the Tn-10 system illustrates this mode of randomized gene trapping though there are many other suitable transposon systems. The gene trapping vector using the Tn-10 transposon is further illustrated in </PDAT><FGREF ID="DRAWINGS"><PDAT>FIGS. 3A and 3B</PDAT></FGREF><PDAT> using pSV. Tn10-RGT. The BPEU and the Amp gene are located between the inverted 70 bp of the transposon ends. The gene encoding transposase along with its inducible promoter, in this case a lac promoter, is located outside of the inverted repeats. The lac promoter is inducible by IPTG (isopropyl-&bgr;-D-thiogalactopyranoside) and therefore, in this system, so the expression of transposase is inducible by IPTG. The rest of the plasmid is composed of a temperature sensitive origin of replication and a tetracycline (Tet) resistance gene, being analogous to the TSSV pSV1.RecA exemplified above, minus the RecA gene. The mini-Tn10 transposon with an inducible transposase previously has been shown to insert a nucleic acid sequence between the inverted repeats (up to 10 kb) into relatively random locations in bacterially propagated large genomic clones &lsqb;Chatterjee and Sternberg, </PDAT><HIL><ITALIC><PDAT>Genet. Anal. Biomol. Eng</PDAT></ITALIC></HIL><PDAT>., 13:33-42 (1996); Chatterjee and Coren, </PDAT><HIL><ITALIC><PDAT>NAR </PDAT></ITALIC></HIL><PDAT>25, 2205-2212 (1997)&rsqb;.</PDAT></PTEXT></PARA>
<PARA ID="P-00152" LVL="0"><PTEXT><PDAT>The following procedure can be used to isolate a nested group of BACs and PACs carrying a single, and relatively randomly inserted BPEU element. In this example, the BBPAC is a BAC containing a fragment of eukaryotic genomic DNA and a chloramphenicol resistance gene. First, a bacterial host cell containing the BAC is transformed by the TSSV, pSV.TN10.RGT. The bacterial host cell is next selected for having resistance to chloramphenicol, and tetracycline. In this example the bacterial host cell is DH10B, which expresses lacI</PDAT><HIL><SP><PDAT>q </PDAT></SP></HIL><PDAT>constitutively at high levels. Therefore the transposase, which is under the control of the lac promoter, is not expressed. If the bacterial host does not express sufficient level of the lacI</PDAT><HIL><SP><PDAT>q</PDAT></SP></HIL><PDAT>, the lacI</PDAT><HIL><SP><PDAT>q </PDAT></SP></HIL><PDAT>gene can be cloned into the pSV.Tn10.RGT shuttle vector which then supplies the lacI</PDAT><HIL><SP><PDAT>q </PDAT></SP></HIL><PDAT>when transformed into bacteria. Treatment of the host cells with IPTG will transiently induce the expression of the transposase, which in turn, induces the transposition of the BPEU element and the Amp resistance gene into the BAC and the bacterial host cell genome. The majority of the mini-transposons insert into the bacterial genome.</PDAT></PTEXT></PARA>
<PARA ID="P-00153" LVL="0"><PTEXT><PDAT>The IPTG induction can be carefully controlled such that each BAC will receive only a single transposon or no transposon at all. After the transposon insertion, the pSV.Tn10-RGT plasmid is eliminated from the bacteria. Two methods for eliminating the pSV.Tn10-RGT TSSV which can be used separately, or in tandem are:</PDAT></PTEXT></PARA>
<PARA ID="P-00154" LVL="2"><PTEXT><PDAT>(1) the host bacterial cells can be grown at 43&deg; C. in LB with chloramphenicol and ampicillin. The TSSV will not replicate and therefore be diluted out and lost.</PDAT></PTEXT></PARA>
<PARA ID="P-00155" LVL="2"><PTEXT><PDAT>(2) the host bacterial cells can be grown at 37&deg; C., and then chloramphenicol, ampicillin and fusaric acid can be added to the media to select for loss of tetracycline resistance. Since the pSV.Tn10.RGT carries the Tet resistance gene and the Tet resistance gene is physically outside of the transposon inverted repeats of the TSSV, the Tet resistance gene is not transported by the transposon. Therefore the selection for the loss of tetracycline resistance is equivalent to the selection for loss of the pSV.Tn10.RGT plasmid.</PDAT></PTEXT></PARA>
<PARA ID="P-00156" LVL="0"><PTEXT><PDAT>Once the shuttle plasmid is lost, all bacteria which grow in chloramphenicol and ampicillin have a minitransposon insertion, either in the bacterial chromosome or in the BAC. To isolate those having a transposon insertion in the BAC, the supercoiled BAC DNA can be isolated from the host bacterial cells (and bacterial chromosomes) by conventional alkaline lysis. Since the BAC is the only circular plasmid in the bacteria (the TSSV has been eliminated as described above), the DNA prep only contains the circular BAC DNA (with perhaps a small amount of chromosomal DNA contaminant). The circular BAC DNA is next electroporated into competent DH10B bacterial cells according to the protocol described by Sheng et al. &lsqb;</PDAT><HIL><ITALIC><PDAT>NAR </PDAT></ITALIC></HIL><PDAT>23, 1990-1996 (1995)&rsqb;, and then DH10B cells are selected for chloramphenicol and ampicillin resistance. Those bacterial that grown on the chloramphenicol and ampicillin plates contain BACs with BPEU elements inserted at relatively random locations within the BAC (FIG. </PDAT><HIL><BOLD><PDAT>3</PDAT></BOLD></HIL><PDAT>B). The more clones picked, the more integration sites within the BAC one obtains, and the more genes one obtains in the subsequent gene trapping. The insertion site of the BPEU element can be optionally mapped by pulsed field gel electrophoresis and Southern blots. The BACs are then ready for gene trapping in eukaryotic cells as described above.</PDAT></PTEXT></PARA>
<PARA ID="P-00157" LVL="0"><PTEXT><PDAT>There are several advantages to the randomized gene trap (RGT) system over the target gene trap system. First, one round of modification by RGT of a single BAC can potentially trap all of the genes in the BAC whereas the targeted BAC modification can only trap up to two genes per BAC. Second, the density of BPEU insertion can be easily controlled by the RGT method. Since the transposons insert relatively randomly, by picking increasing number of colonies in the last step, one gets increasing coverage of the BAC with transposon insertions. Such stringency readily can be adjusted for gene rich and gene poor BACs with the RGT method . Third, the pSV1.Tn10-RGT plasmid can be used for BACS, PACs and P1.</PDAT></PTEXT></PARA>
<PARA ID="P-00158" LVL="1"><PTEXT><PDAT>IV. Isolation of maxiprep BBPAC DNA: Maxiprep DNA from BBPACs with BPEU insertions can be prepared by a number of methods including the conventional cesium gradient method, or with commercially available columns (e.g., Nucleobond, etc.) as described in U.S. patent application Ser. No. 08/880,966, filed Jun. 23, 1997. If a pool of modified BBPACs are to be used for gene trapping , the maxiprep DNA can be prepared from the culture containing the pool of bacteria.</PDAT></PTEXT></PARA>
<PARA ID="P-00159" LVL="1"><PTEXT><PDAT>V. Transfection of BBPAC DNA into mammalian cells: Maxiprep BBPAC DNA are transfected into appropriate mammalian cell lines using the method described by Baker and Cotten &lsqb;</PDAT><HIL><ITALIC><PDAT>NAR </PDAT></ITALIC></HIL><PDAT>25, 1950-1956 (1997)&rsqb;, which utilizes the psoralen-inactivated adenovirus as a carrier. This method proved to be more efficient for transfecting BAC DNA into mammalian cells, than conventional electroporation or lipofection, (which are alternative methods). The cell we used can be essentially any cell line, since BACs can replicate on their own in mammalian cells and the SV40 promoter is active in the majority of mammalian cells.</PDAT></PTEXT></PARA>
<PARA ID="P-00160" LVL="1"><PTEXT><PDAT>VI. RNA Isolation, cDNA synthesis, PCR amplification, Subcloning of PCR products and sequencing: After the transfection of the mammalian cells with the BACs, the subsequent steps required for completing the gene trapping procedure are similar to those for conventional exon trapping systems &lsqb;Buckler et al., </PDAT><HIL><ITALIC><PDAT>PNAS </PDAT></ITALIC></HIL><PDAT>88:4005-4009 (1991)&rsqb;. For example, five to ten days after transfection, RNA can be prepared from the transfected cells using a standard protocol. Then first strand cDNA is synthesized using an oligo dT primer flanked with 10-15 basepairs GC rich sequence, and reverse transcriptase. The first strand cDNA is amplified by PCR using an oligo dA primer and a primer for the HIV-tat exon. The PCR is performed at several conditions to optimize the &excl;amplification of the cDNA ranging from 500 bp to 3-4 kb. The amplified PCR products are then subcloned into the TA cloning vectors and the trapped gene sequence can be determined by conventional methods.</PDAT></PTEXT></PARA>
<PARA ID="P-00161" LVL="1"><PTEXT><PDAT>VII: Conversion of a BBPAC contig into a gene map: Many positional cloning projects and genome projects involve initially making an overlapping set of BBPACs, called a contig, and then identifying genes within the contig. Current methods of identification of genes within the contig include cDNA selection, exon trapping and sequencing. cDNA selection is laborious and dependent on the availability of the RNA source. Exon trapping, is efficient, but often only results in trapping small single exons, and can only work with one BBPAC at a time. Sequencing can potentially identify all of the genes in the BBPAC, but is expensive and relies on the existing cDNA database and search algorithms, which are far from complete. The gene trap strategy of the present invention can be directly applied to BBPAC contigs as a pool. A mini-gene trap cDNA library can be isolated and each gene can be quickly assigned to its physical location within the contig by hybridization to the BBPACs. Advantages of using the gene trap system of the present invention for the generation of a transcript map are: (1) Potentially all of the cDNAs can be isolated, (especially with the randomized gene trapping method). (2) The trapped genes contain multiple exons including the polyA signal sequence, as opposed to the individual exons contained in the vectors of the prior art methods. Thus the cDNAs of the present invention can be directly used for further biological experimentation. (3) Multiple BBPACs in the contig can be pooled to perform the gene trap at once, as opposed to the prior art methods which uses only one BBPAC at a time. (4) The gene trap system of the present invention is simpler and less expensive than direct sequencing. The gene trap system of the present invention not only is useful for making transcript maps in positional cloning projects, but also may be valuable for building gene maps from a BBPAC physical map for use in genome projects, such as the human genome project.</PDAT></PTEXT></PARA>
<PARA ID="P-00162" LVL="1"><PTEXT><PDAT>VIII: Gene trap cDNA library (or GT-cDNA library): Construction of a cDNA library frequently depends on the availability of the tissue from which the RNA is isolated. cDNA that are expressed in a tissue which has a limited number of cells (i.e. inner ear or hypothalamus), or expressed at a very specific developmental stage, or expressed at a very low level, could easily be missing in the existing cDNA libraries. Human cDNA libraries for example, are currently available for only a few organs and at only a few different developmental stages. This greatly limits the isolation of the coding sequence of rare human transcripts, which maybe particularly important in certain disease states. The present invention overcomes this shortcoming in the prior art by providing a method of constructing a cDNA library from a genomic DNA of any source, irrespective of the expression pattern and level of the genes in vivo. For example, a BAC library, such as the human BAC library, can be divided into pools of 100-200 BACs per pool. Each pool can undergo gene trapping to produce a pool-specific cDNA library. The procedure is repeated until the entire BAC library is converted into a gene-trapped cDNA library. If the stringency of gene trapping is relatively high, the gene trap cDNA library will represent an essentially complete set of genes from any genome.</PDAT></PTEXT></PARA>
<PARA ID="P-00163" LVL="1"><PTEXT><PDAT>IX: Constructing BBPACs from vectors containing PEUs.</PDAT></PTEXT></PARA>
<PARA ID="P-00164" LVL="0"><PTEXT><PDAT>BBPACs can also be constructed from vectors which already contain PEUs. Methods of constructing such BBPACs are well known in the art &lsqb;see, for example, Shizuya et al., </PDAT><HIL><ITALIC><PDAT>PNAs, USA</PDAT></ITALIC></HIL><PDAT>, 89:8794-8797 (1992); and Kim et al., </PDAT><HIL><ITALIC><PDAT>Genomics, </PDAT></ITALIC></HIL><PDAT>34:213-218 (1996)&rsqb;. Prior to the construction of the BBPACs, the PEUs can be placed into the vectors by a number of methods including those exemplified above.</PDAT></PTEXT></PARA>
<PARA ID="P-00165" LVL="0"><PTEXT><PDAT>The present invention is not to be limited in scope by the specific embodiments describe herein. Indeed, various modifications of the invention in addition to those described herein will become apparent to those skilled in the art from the foregoing description and the accompanying figures. Such modifications are intended to fall within the scope of the appended claims.</PDAT></PTEXT></PARA>
<PARA ID="P-00166" LVL="0"><PTEXT><PDAT>It is further to be understood that all base sizes, and all molecular weight or molecular mass values, given for nucleic acids are approximate, and are provided for description.</PDAT></PTEXT></PARA>
<PARA ID="P-00167" LVL="0"><PTEXT><PDAT>Various publications are cited herein, the disclosures of which are incorporated by reference in their entireties.</PDAT></PTEXT></PARA>
</BTEXT>
</DETDESC>
</SDODE>
<SDOCL>
<H LVL="1"><STEXT><PDAT>What is claimed is: </PDAT></STEXT></H>
<CL>
<CLM ID="CLM-00001">
<PARA ID="P-00168" LVL="0"><PTEXT><PDAT>1. A method of placing a eukaryotic promoter exon/intron unit (PEU) into a Bacterial or Bacteriophage-Derived Artificial Chromosome (BBPAC) that contains a trappable eukaryotic gene comprising:</PDAT></PTEXT></PARA>
<CLMSTEP LVL="2"><PTEXT><PDAT>(a) introducing a conditional replication shuttle vector into a host cell containing the BBPAC under conditions in which the conditional replication shuttle vector can replicate and transform the host cell, wherein: </PDAT></PTEXT></CLMSTEP>
<CLMSTEP LVL="3"><PTEXT><PDAT>(i) the BBPAC contains a trappable eukaryotic gene, BBPAC vector DNA, and a second marker gene; </PDAT></PTEXT></CLMSTEP>
<CLMSTEP LVL="3"><PTEXT><PDAT>(ii) the conditional replication shuttle vector contains a first marker gene which can be counter-selected against; a recombination cassette; and a gene encoding a protein that supports homologous recombination, wherein said protein remedies a deficiency of an endogenous recombination protein in said host cell; </PDAT></PTEXT></CLMSTEP>
<CLMSTEP LVL="4"><PTEXT><PDAT>wherein the recombination cassette comprises a PEU flanked on both its 5&prime; and 3&prime; ends by nucleotide sequences that are homologous to BBPAC vector DNA; wherein the recombination cassette, the gene encoding said protein and the first marker gene are linked together on the conditional replication shuttle vector such that when the PEU integrates into the BBPAC, the gene encoding&apos;said protein and the first marker gene remain linked together, but neither the gene encoding said protein nor the first marker gene remain linked to the integrated PEU; </PDAT></PTEXT></CLMSTEP>
<CLMSTEP LVL="3"><PTEXT><PDAT>(iii) the PEU comprises a third marker gene, a eukaryotic promoter, at least one 5&prime; vector-derived exon, and an intron or fragment thereof; wherein the 5&prime; vector-derived exon is adjacent to the intron or fragment thereof and is operatively downstream from the eukaryotic promoter; wherein when the trappable eukaryotic gene comprises an exon with a 3&prime; splice acceptor, the PEU can integrate into the BBPAC placing the exon of the trappable eukaryotic gene operatively downstream of the PEU; and </PDAT></PTEXT></CLMSTEP>
<CLMSTEP LVL="3"><PTEXT><PDAT>(iv) wherein neither the host cell nor the BBPAC independently or in conjunction can support homologous recombination, without the conditional replication shuttle vector; </PDAT></PTEXT></CLMSTEP>
<CLMSTEP LVL="2"><PTEXT><PDAT>(b) growing the host cell under conditions in which the conditional replication shuttle vector can replicate, the gene encoding said protein can be expressed, and in which a cell that contains the first and second marker genes is selected for; and wherein a first homologous recombination event occurs between the recombination cassette and the BBPAC to form a co-integrate; </PDAT></PTEXT></CLMSTEP>
<CLMSTEP LVL="2"><PTEXT><PDAT>(c) growing the cell selected for in step (b) under conditions in which the conditional replication shuttle vector cannot replicate and in which a cell that contains the first and second marker proteins is selected for, whereby a cell containing the co-integrate between the recombination cassette and the BBPAC is selected for; and </PDAT></PTEXT></CLMSTEP>
<CLMSTEP LVL="2"><PTEXT><PDAT>(d) growing the cell selected for in step (c) under conditions in which the conditional replication shuttle vector cannot replicate and in which a cell that contains the second marker gene is selected for; wherein a second homologous recombination event occurs between the conditional replication shuttle vector and the BBPAC; and wherein the PEU is placed into the BBPAC. </PDAT></PTEXT></CLMSTEP>
</CLM>
<CLM ID="CLM-00002">
<PARA ID="P-00169" LVL="0"><PTEXT><PDAT>2. The method of </PDAT><CLREF ID="CLM-00001"><PDAT>claim 1</PDAT></CLREF><PDAT> wherein the PEU does not contain an exon encoding a 3&prime; polyadenylation sequence.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00003">
<PARA ID="P-00170" LVL="0"><PTEXT><PDAT>3. A method of isolating a cell that contains a BBPAC having a eukaryotic promoter exon/intron unit (PEU) and a trappable eukaryotic gene comprising growing the cell selected for in step (d) of </PDAT><CLREF ID="CLM-00001"><PDAT>claim 1</PDAT></CLREF><PDAT> under conditions in which a cell that contains the second and third marker genes is selected for, while a cell that contains the first marker gene is selected against; wherein a cell containing a BBPAC having a eukaryotic promoter exon/intron unit (PEU) is isolated.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00004">
<PARA ID="P-00171" LVL="0"><PTEXT><PDAT>4. The method of </PDAT><CLREF ID="CLM-00003"><PDAT>claim 3</PDAT></CLREF><PDAT> wherein the first marker gene is a tetracycline resistance gene that can be counter-selected against by growing the cell in the presence of fusaric acid.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00005">
<PARA ID="P-00172" LVL="0"><PTEXT><PDAT>5. The method of </PDAT><CLREF ID="CLM-00001"><PDAT>claim 1</PDAT></CLREF><PDAT> wherein the PEU is a bi-directional eukaryotic promoter-exon/intron unit (BPEU).</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00006">
<PARA ID="P-00173" LVL="0"><PTEXT><PDAT>6. The method of </PDAT><CLREF ID="CLM-00001"><PDAT>claim 1</PDAT></CLREF><PDAT> wherein the conditional replication shuttle vector is a temperature sensitive shuttle vector (TSSV) having a temperature-sensitive origin of replication, wherein the TSSV replicates at a permissive temperature, but does not replicate at a non-permissive temperature.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00007">
<PARA ID="P-00174" LVL="0"><PTEXT><PDAT>7. The method of </PDAT><CLREF ID="CLM-00001"><PDAT>claim 1</PDAT></CLREF><PDAT> wherein the BBPAC is a BAC.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00008">
<PARA ID="P-00175" LVL="0"><PTEXT><PDAT>8. The method of </PDAT><CLREF ID="CLM-00001"><PDAT>claim 1</PDAT></CLREF><PDAT> wherein the PEU comprises two 5&prime; vector-derived exons and one intron.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00009">
<PARA ID="P-00176" LVL="0"><PTEXT><PDAT>9. The method of </PDAT><CLREF ID="CLM-00008"><PDAT>claim 8</PDAT></CLREF><PDAT> wherein the two 5&prime; vector-derived exons consist of the first exon of beta-globin and a fusion exon containing the second exon of beta-globin fused to the HIV-tat exon; the intron is the HIV-tat intron; and wherein the fusion exon is adjacent to the HIV-tat intron.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00010">
<PARA ID="P-00177" LVL="0"><PTEXT><PDAT>10. A method of transcribing a trappable eukaryotic gene contained in a BBPAC in a eukaryotic cell comprising:</PDAT></PTEXT></PARA>
<CLMSTEP LVL="2"><PTEXT><PDAT>(a) isolating the BBPAC containing the trappable eukaryotic gene operably downstream of the PEU from the isolated cell of </PDAT><CLREF ID="CLM-00003"><PDAT>claim 3</PDAT></CLREF><PDAT>; </PDAT></PTEXT></CLMSTEP>
<CLMSTEP LVL="2"><PTEXT><PDAT>(b) transfecting the isolated BBPAC into a eukaryotic cell; and </PDAT></PTEXT></CLMSTEP>
<CLMSTEP LVL="2"><PTEXT><PDAT>(c) culturing the eukaryotic cell; wherein when the PEU is operatively upstream to an exon of the trappable eukaryotic gene, the eukaryotic promoter of the PEU facilitates the transcription of the exon of the trappable eukarvotic gene into an mRNA. </PDAT></PTEXT></CLMSTEP>
</CLM>
<CLM ID="CLM-00011">
<PARA ID="P-00178" LVL="0"><PTEXT><PDAT>11. A method of determining the nucleotide sequence of a trappable eukaryotic gene contained in a BBPAC comprising:</PDAT></PTEXT></PARA>
<CLMSTEP LVL="2"><PTEXT><PDAT>(a) preparing a cognate cDNA of the mRNA of </PDAT><CLREF ID="CLM-00010"><PDAT>claim 10</PDAT></CLREF><PDAT> as a template; and </PDAT></PTEXT></CLMSTEP>
<CLMSTEP LVL="2"><PTEXT><PDAT>(b) determining the nucleotide sequence of the cognate cDNA; wherein the nucleotide sequence of the trappable eukaryotic gene contained in the BBPAC is determined. </PDAT></PTEXT></CLMSTEP>
</CLM>
<CLM ID="CLM-00012">
<PARA ID="P-00179" LVL="0"><PTEXT><PDAT>12. The method of </PDAT><CLREF ID="CLM-00011"><PDAT>claim 11</PDAT></CLREF><PDAT> wherein preparing the cognate cDNA is performed by PCR.</PDAT></PTEXT></PARA>
</CLM>
</CL>
</SDOCL>
<SDODR ID="DRAWINGS">
<EMI ID="EMI-D00001" ALT="embedded image" FILE="US06485912-20021126-D00001.TIF"/>
<EMI ID="EMI-D00002" ALT="embedded image" FILE="US06485912-20021126-D00002.TIF"/>
<EMI ID="EMI-D00003" ALT="embedded image" FILE="US06485912-20021126-D00003.TIF"/>
</SDODR>
</PATDOC>

<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE PATDOC SYSTEM "ST32-US-Grant-025xml.dtd" [
<!ENTITY US06485977-20021126-D00001.TIF SYSTEM "US06485977-20021126-D00001.TIF" NDATA TIF>
<!ENTITY US06485977-20021126-D00002.TIF SYSTEM "US06485977-20021126-D00002.TIF" NDATA TIF>
<!ENTITY US06485977-20021126-D00003.TIF SYSTEM "US06485977-20021126-D00003.TIF" NDATA TIF>
<!ENTITY US06485977-20021126-D00004.TIF SYSTEM "US06485977-20021126-D00004.TIF" NDATA TIF>
]>
<PATDOC DTD="2.5" STATUS="Build 20020918">
<SDOBI>
<B100>
<B110><DNUM><PDAT>06485977</PDAT></DNUM></B110>
<B130><PDAT>B1</PDAT></B130>
<B140><DATE><PDAT>20021126</PDAT></DATE></B140>
<B190><PDAT>US</PDAT></B190>
</B100>
<B200>
<B210><DNUM><PDAT>09660742</PDAT></DNUM></B210>
<B211US><PDAT>09</PDAT></B211US>
<B220><DATE><PDAT>20000913</PDAT></DATE></B220>
</B200>
<B400>
<B472>
<B474US><PDAT>72</PDAT></B474US>
</B472>
</B400>
<B500>
<B510>
<B511><PDAT>C12N 15867</PDAT></B511>
<B512><PDAT>C12N 1563</PDAT></B512>
<B512><PDAT>C12N 1564</PDAT></B512>
<B512><PDAT>C12N  510</PDAT></B512>
<B516><PDAT>7</PDAT></B516>
</B510>
<B520>
<B521><PDAT>435455</PDAT></B521>
<B522><PDAT>4353201</PDAT></B522>
<B522><PDAT>435456</PDAT></B522>
<B522><PDAT>435 691</PDAT></B522>
<B522><PDAT>435 697</PDAT></B522>
<B522><PDAT>435325</PDAT></B522>
<B522><PDAT>536 231</PDAT></B522>
<B522><PDAT>536 234</PDAT></B522>
<B522><PDAT>536 241</PDAT></B522>
</B520>
<B540><STEXT><PDAT>Recombinant constructs and techniques for delivering to eucaryotic cells bacterial proteins that are secreted via type III secretion systems</PDAT></STEXT></B540>
<B560>
<B561>
<PCIT>
<DOC><DNUM><PDAT>6221355</PDAT></DNUM>
<DATE><PDAT>20010400</PDAT></DATE>
<KIND><PDAT>B1</PDAT></KIND>
</DOC>
<PARTY-US>
<NAM><SNM><STEXT><PDAT>Dowdy</PDAT></STEXT></SNM></NAM>
</PARTY-US>
<PNC><PDAT>4241921</PDAT></PNC></PCIT><CITED-BY-EXAMINER/>
</B561>
<B562><NCIT><STEXT><PDAT>Fawell et al., &ldquo;Tat-Mediated Delivery of Heterologous Proteins Into Cells,&rdquo; </PDAT><HIL><ITALIC><PDAT>Proc. Natl. Acad. Sci. USA</PDAT></ITALIC></HIL><PDAT>, 91:664:668 (1994). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Alfano et al., &ldquo;The Type III (Hrp) Secrection Pathway of Plant Pathogenic Bacteria: Trafficking Harpins, Avr Proteins, and Death,&rdquo; </PDAT><HIL><ITALIC><PDAT>J. Bacteriol</PDAT></ITALIC></HIL><PDAT>., 179(18):5655-5662 (1997). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Rossier et al., &ldquo;The </PDAT><HIL><ITALIC><PDAT>Xanthomonas </PDAT></ITALIC></HIL><PDAT>Hrp Type III System Secretes Proteins From Plant and Mammalian Bacterial Pathogens,&rdquo; </PDAT><HIL><ITALIC><PDAT>Proc. Natl. Acad. Sci. USA </PDAT></ITALIC></HIL><PDAT>96:9368-9373 (1999). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Gal&aacute;n et al., &ldquo;Type III Secretion Machines: Bacterial Devices for Protein Delivery into Host Cells,&rdquo; </PDAT><HIL><ITALIC><PDAT>Science </PDAT></ITALIC></HIL><PDAT>284:1322-1328 (1999). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Phelan et al., &ldquo;Intercellular Delivery of Functional p53 by the Herpesvirus Protein VP22,&rdquo; </PDAT><HIL><ITALIC><PDAT>Nature Biotechnology </PDAT></ITALIC></HIL><PDAT>16:440-443 (1998). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Chen et al., &ldquo;Selective Killing of Transformed Cells by Cyclin/Cyclin-Dependent Kinase 2 Antagonists,&rdquo; </PDAT><HIL><ITALIC><PDAT>Proc. Natl. Acad. Sci. USA </PDAT></ITALIC></HIL><PDAT>96:4325-4329 (1999). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Alfano et al., &ldquo;The </PDAT><HIL><ITALIC><PDAT>Pseudomonas syringae </PDAT></ITALIC></HIL><PDAT>Hrp Pathogenicity Island Has a Tripartite Mosaic Structure Composed of a Cluster of Type III Secretion Genes Bounded by Exchangeable Effector and Conserved Effector Loci That Contribute to Parasitic Fitness and Pathogenicity in Plants,&rdquo; </PDAT><HIL><ITALIC><PDAT>PNAS </PDAT></ITALIC></HIL><PDAT>97:4856-4861 (2000). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Collmer et al., &ldquo;</PDAT><HIL><ITALIC><PDAT>Pseudomonas syringae </PDAT></ITALIC></HIL><PDAT>Hrp Type III Secretion System and Effector Proteins, &rdquo; </PDAT><HIL><ITALIC><PDAT>PNAS </PDAT></ITALIC></HIL><PDAT>97:8770-8777 (2000). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Schwarze et al., &ldquo;Protein Transduction: Unrestricted Delivery into all Cells&quest;&rdquo; </PDAT><HIL><ITALIC><PDAT>Trends In Cell Biology </PDAT></ITALIC></HIL><PDAT>10:290-295 (2000). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Schwarze et al., &ldquo;In Vivo Protein Transduction: Delivery of a Biologically Active Protein into the Mouse,&rdquo; </PDAT><HIL><ITALIC><PDAT>Science </PDAT></ITALIC></HIL><PDAT>285:1569-1572 (1999). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Anderson et al., &ldquo;Reciprocal Secretion of Proteins by the Bacterial Type III Machines of Plant and Animal Pathogens Suggests Universal Recognition of mRNA Targeting Signals,&rdquo; </PDAT><HIL><ITALIC><PDAT>PNAS </PDAT></ITALIC></HIL><PDAT>96:12839-12843 (1999).</PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
</B560>
<B570>
<B577><PDAT>11</PDAT></B577>
<B578US><PDAT>1</PDAT></B578US>
</B570>
<B580>
<B582><PDAT>4353201</PDAT></B582>
<B582><PDAT>435455</PDAT></B582>
<B582><PDAT>435456</PDAT></B582>
<B582><PDAT>435 691</PDAT></B582>
<B582><PDAT>435 697</PDAT></B582>
<B582><PDAT>435325</PDAT></B582>
<B582><PDAT>536 231</PDAT></B582>
<B582><PDAT>536 234</PDAT></B582>
<B582><PDAT>536 241</PDAT></B582>
</B580>
<B590><B595><PDAT>4</PDAT></B595><B596><PDAT>4</PDAT></B596></B590>
</B500>
<B600>
<B680US><DOC><DNUM><PDAT>60/153507</PDAT></DNUM><DATE><PDAT>19990913</PDAT></DATE><KIND><PDAT>00</PDAT></KIND></DOC></B680US>
</B600>
<B700>
<B720>
<B721>
<PARTY-US>
<NAM><FNM><PDAT>Alan</PDAT></FNM><SNM><STEXT><PDAT>Collmer</PDAT></STEXT></SNM></NAM>
<ADR>
<CITY><PDAT>Ithaca</PDAT></CITY>
<STATE><PDAT>NY</PDAT></STATE>
</ADR>
</PARTY-US>
</B721>
<B721>
<PARTY-US>
<NAM><FNM><PDAT>Steven V.</PDAT></FNM><SNM><STEXT><PDAT>Beer</PDAT></STEXT></SNM></NAM>
<ADR>
<CITY><PDAT>Ithaca</PDAT></CITY>
<STATE><PDAT>NY</PDAT></STATE>
</ADR>
</PARTY-US>
</B721>
</B720>
<B730>
<B731>
<PARTY-US>
<NAM><ONM><STEXT><PDAT>Cornell Research Foundation, Inc.</PDAT></STEXT></ONM></NAM>
<ADR><CITY><PDAT>Itchaca</PDAT></CITY><STATE><PDAT>NY</PDAT></STATE></ADR>
</PARTY-US>
</B731>
<B732US>
<PDAT>02</PDAT>
</B732US>
</B730>
<B740>
<B741>
<PARTY-US>
<NAM><ONM><STEXT><PDAT>Nixon Peabody LLP</PDAT></STEXT></ONM></NAM>
</PARTY-US>
</B741>
</B740>
<B745>
<B746>
<PARTY-US>
<NAM><FNM><PDAT>David</PDAT></FNM><SNM><STEXT><PDAT>Guzo</PDAT></STEXT></SNM></NAM>
</PARTY-US>
</B746>
<B748US><PDAT>1636</PDAT></B748US>
</B745>
</B700>
</SDOBI>
<SDOAB>
<BTEXT>
<PARA ID="P-00001" LVL="0"><PTEXT><PDAT>The present invention relates to a method for delivering effector proteins into a target cell. This method involves introducing into the target cell an effector protein fused to a protein transduction domain of a human immunodeficiency virus TAT protein or derivatives or functional analogs thereof. The present invention also relates to a fusion protein including an effector protein fused to a protein transduction domain of a human immunodeficiency virus TAT protein or derivatives or functional analogs thereof. Another aspect of the present invention relates to a DNA construct including a first DNA molecule encoding an effector protein and a second DNA molecule operatively associated with the first DNA molecule and encoding a protein transduction domain of a human immunodeficiency virus TAT protein or derivatives or functional analogs thereof and its use in a method for delivering effector proteins into a target cell.</PDAT></PTEXT></PARA>
</BTEXT>
</SDOAB>
<SDODE>
<RELAPP>
<BTEXT>
<PARA ID="P-00002" LVL="0"><PTEXT><PDAT>This application claims the benefit of U.S. Provisional Patent Application Ser. No. 60/153,507, filed Sep. 13, 1999.</PDAT></PTEXT></PARA>
</BTEXT>
</RELAPP>
<GOVINT>
<BTEXT>
<PARA ID="P-00003" LVL="0"><PTEXT><PDAT>This invention was made in part with support by the U.S. Government under Grant No. MCB-953034488 from the National Science Foundation. The U.S. Government may have certain rights in this invention.</PDAT></PTEXT></PARA>
</BTEXT>
</GOVINT>
<BRFSUM>
<BTEXT>
<H LVL="1"><STEXT><PDAT>BACKGROUND OF THE INVENTION</PDAT></STEXT></H>
<PARA ID="P-00004" LVL="0"><PTEXT><PDAT>The most common bacterial pathogens of plants colonize the apoplast, and from that location outside of the walls of living cells they incite a variety of diseases in most cultivated plants (Alfano et al., &ldquo;Bacterial Pathogens in Plants: Life Up Against the Wall,&rdquo; </PDAT><HIL><ITALIC><PDAT>Plant Cell </PDAT></ITALIC></HIL><PDAT>8:1683-1698 (1996)). The majority of these are Gram-negative bacteria in the genera Erwinia, Pseudomonas, Xanthomonas, and Ralstonia. Most are host specific and will elicit the hypersensitive response (&ldquo;HR&rdquo;) in nonhosts. The HR is a rapid, programmed death of plant cells in contact with the pathogen. Some of the defense responses associated with the HR are localized at the periphery of plant cells at the site of bacterial contact, but what actually stops bacterial growth is not known (Brown et al., &ldquo;hrp genes in </PDAT><HIL><ITALIC><PDAT>Xanthomonas campestris </PDAT></ITALIC></HIL><PDAT>pv. </PDAT><HIL><ITALIC><PDAT>vesicatoria </PDAT></ITALIC></HIL><PDAT>Determine Ability to Suppress Papilla Deposition in Pepper Mesophyll Cells,&rdquo; </PDAT><HIL><ITALIC><PDAT>MPMI </PDAT></ITALIC></HIL><PDAT>8:825-836 (1995); Young et al., &ldquo;Changes in the Plasma Membrane Distribution of Rice Phospholipase D During Resistant Interactions With </PDAT><HIL><ITALIC><PDAT>Xanthomonas oryzae </PDAT></ITALIC></HIL><PDAT>pv. </PDAT><HIL><ITALIC><PDAT>oryzae,&rdquo; Plant Cell </PDAT></ITALIC></HIL><PDAT>8:1079-1090 (1996); Bestwick et al., &ldquo;Localization of Hydrogen Peroxide Accumulation During the Hypersensitive Reaction of Lettuce Cells to </PDAT><HIL><ITALIC><PDAT>Pseudomonas syringae </PDAT></ITALIC></HIL><PDAT>pv. </PDAT><HIL><ITALIC><PDAT>phaseolicola,&rdquo; Plant Cell </PDAT></ITALIC></HIL><PDAT>9:209-221 (1997)). Pathogenesis in host plants, in contrast, involves prolonged bacterial multiplication, spread to surrounding tissues, and the eventual production of macroscopic symptoms characteristic of the disease. Although these bacteria are diverse in their taxonomy and pathology, they all possess hrp (&ldquo;hypersensitive response and pathogenicity&rdquo;) genes which direct their ability to elicit the HR in nonhosts or to be pathogenic (and parasitic) in hosts (Lindgren, &ldquo;The Role of hrp Genes During Plant-Bacterial Interactions,&rdquo; </PDAT><HIL><ITALIC><PDAT>Annu. Rev. Phytopathol. </PDAT></ITALIC></HIL><PDAT>35:129-152 (1997)). The hrp genes encode a type III protein secretion system that appears to be capable of delivering proteins, known as effector proteins, across the walls and plasma membranes of living plant cells. Such effector proteins are variously known as hypersensitive response elicitors, Avr (Avirulence) proteins, Hop (hypersensitive response and pathogenicity-dependent outer proteins), Vir (virulence) proteins, or Pth (pathogenicity) proteins, depending on the phenotype by which they were discovered (see, e.g., Alfano et al., &ldquo;The Type III (Hrp) Secretion Pathway of Plant Pathogenic Bacteria: Trafficking Harpins, Avr Proteins, and Death,&rdquo; </PDAT><HIL><ITALIC><PDAT>J. Bacteriol. </PDAT></ITALIC></HIL><PDAT>179:5655-5662 (1997), which is hereby incorporated by reference). The Avr proteins are so named because they can betray the parasite to the R gene-encoded surveillance system of plants, thereby triggering the HR (Vivian et al., &ldquo;Avirulence Genes in Plant-Pathogenic Bacteria: Signals or Weapons&quest;,&rdquo; </PDAT><HIL><ITALIC><PDAT>Microbiology </PDAT></ITALIC></HIL><PDAT>143:693-704 (1997); Leach et al., &ldquo;Bacterial Avirulence Genes,&rdquo; </PDAT><HIL><ITALIC><PDAT>Annul. Rev. Phytopathol. </PDAT></ITALIC></HIL><PDAT>34:153-179 (1996)). But Avr-like proteins also appear to be key to parasitism in compatible host plants, where the parasite proteins are undetected and the HR is not triggered. Thus, bacterial avirulence and pathogenicity are interrelated phenomena and explorations of HR elicitation are furthering our understanding of parasitic mechanisms.</PDAT></PTEXT></PARA>
<PARA ID="P-00005" LVL="0"><PTEXT><PDAT>A current model for plant-bacterium interaction and co-evolution based on Hrp delivery of Avr proteins into plant cells proposes that (i) Avr-like proteins are the primary effectors of parasitism, (ii) conserved Hrp systems are capable of delivering many, diverse Avr-like proteins into plant cells, and (iii) genetic changes in host populations that reduce the parasitic benefit of an effector protein or allow its recognition by the R-gene surveillance system will lead to a proliferation of complex arsenals of avr-like genes in co-evolving bacteria (Alfano et al., &ldquo;Bacterial Pathogens in Plants: Life Up Against the Wall,&rdquo; </PDAT><HIL><ITALIC><PDAT>Plant Cell, </PDAT></ITALIC></HIL><PDAT>8:1683-1698 (1996)). There are still many gaps in this model. For example, the physical transfer of Avr proteins into plant cells has never been observed, the virulence functions of Avr proteins are unknown, and it is likely that previous searches for Avr genes in various bacteria have yielded incomplete inventories of the genes in various bacteria and, thus, incomplete inventories of the genes encoding effector proteins.</PDAT></PTEXT></PARA>
<PARA ID="P-00006" LVL="0"><PTEXT><PDAT>Until recently, Avr proteins had not been reported outside of the cytoplasm of living </PDAT><HIL><ITALIC><PDAT>Pseudomonas syringae </PDAT></ITALIC></HIL><PDAT>and Xanthomonas spp. cells (Leach et al., &ldquo;Bacterial Avirulence Genes,&rdquo; </PDAT><HIL><ITALIC><PDAT>Annul. Rev. Phytopathol, </PDAT></ITALIC></HIL><PDAT>34:153-179 (1996); Puri et al., &ldquo;Expression of avrPphB, an Avirulence Gene from </PDAT><HIL><ITALIC><PDAT>Pseudomonas Syringae </PDAT></ITALIC></HIL><PDAT>pv. </PDAT><HIL><ITALIC><PDAT>phaseolicola, </PDAT></ITALIC></HIL><PDAT>and the Delivery of Signals Causing the Hypersensitive Reaction in Bean,&rdquo; </PDAT><HIL><ITALIC><PDAT>MPMI </PDAT></ITALIC></HIL><PDAT>10:247-256 (1997)), but it now appears that the Hrp systems of Erwinia spp. can secrete Avr proteins in culture. A homolog of the </PDAT><HIL><ITALIC><PDAT>Pseudomonas syringae </PDAT></ITALIC></HIL><PDAT>pv. </PDAT><HIL><ITALIC><PDAT>tomato </PDAT></ITALIC></HIL><PDAT>avrE gene has been found in </PDAT><HIL><ITALIC><PDAT>Erwinia amylovora </PDAT></ITALIC></HIL><PDAT>and designated dspA in strain CFBP1430 and dspE in strain Ea321 (Gaudriault et al., &ldquo;DspA, an Essential Pathogenicity Factor of </PDAT><HIL><ITALIC><PDAT>Erwinia amylovora </PDAT></ITALIC></HIL><PDAT>Showing Homology with AvrE of </PDAT><HIL><ITALIC><PDAT>Pseudomonas syringae, </PDAT></ITALIC></HIL><PDAT>is Secreted via the Hrp Secretion Pathway in a DspB-dependent Way,&rdquo; </PDAT><HIL><ITALIC><PDAT>Mol. Microbiol., </PDAT></ITALIC></HIL><PDAT>26:1057-1069 (1997); Bogdanove et al., &ldquo;Homology and Functional Similarity of a hrp-linked Pathogenicity Operon, dspEF, of </PDAT><HIL><ITALIC><PDAT>Erwinia amylovora </PDAT></ITALIC></HIL><PDAT>and the avrE locus of </PDAT><HIL><ITALIC><PDAT>Pseudomonas syringae </PDAT></ITALIC></HIL><PDAT>Pathovar Tomato,&rdquo; </PDAT><HIL><ITALIC><PDAT>Proc. Natl. Acad. Sci. USA, </PDAT></ITALIC></HIL><PDAT>95:1325-1330 (1998)). dsp genes are required for the pathogenicity of </PDAT><HIL><ITALIC><PDAT>Erwinia amylovora, </PDAT></ITALIC></HIL><PDAT>but not for HR elicitation. A protein of the expected size of DspA is secreted in a Hrp- and DspB-dependent manner by CFBP1430 (DspB is a potential chaperone) (Gaudriault et al., &ldquo;DspA, an Essential Pathogenicity Factor of </PDAT><HIL><ITALIC><PDAT>Erwinia amylovora </PDAT></ITALIC></HIL><PDAT>Showing Homology with AvrE of </PDAT><HIL><ITALIC><PDAT>Pseudomonas syringae, </PDAT></ITALIC></HIL><PDAT>is Secreted via the Hrp Secretion Pathway in a DspB-dependent Way,&rdquo; </PDAT><HIL><ITALIC><PDAT>Mol. Microbiol., </PDAT></ITALIC></HIL><PDAT>26:1057-1069 (1997)). Specific antibodies were used to demonstrate unambiguously that DspE is efficiently secreted in a Hrp-dependent manner by strain Ea321 (Bogdanove et al., &ldquo;</PDAT><HIL><ITALIC><PDAT>Erwinia amylovora </PDAT></ITALIC></HIL><PDAT>Secretes DspE, a Pathogenicity Factor and Functional AvrE Homolog, Through the Hrp (Type III Secretion) Pathway,&rdquo; </PDAT><HIL><ITALIC><PDAT>J. Bacteriol., </PDAT></ITALIC></HIL><PDAT>180(8):2244-2247 (1998)).</PDAT></PTEXT></PARA>
<PARA ID="P-00007" LVL="0"><PTEXT><PDAT>Furthermore, the </PDAT><HIL><ITALIC><PDAT>Erwinia chrysanthemi </PDAT></ITALIC></HIL><PDAT>Hrp system enables </PDAT><HIL><ITALIC><PDAT>E. coli </PDAT></ITALIC></HIL><PDAT>to secrete effector proteins of </PDAT><HIL><ITALIC><PDAT>P. syringae </PDAT></ITALIC></HIL><PDAT>and Yersinia spp. (Ham, et al., &ldquo;A Cloned </PDAT><HIL><ITALIC><PDAT>Erwinia chrysanthemi </PDAT></ITALIC></HIL><PDAT>Hrp (Type III Protein Secretion) System Functions in </PDAT><HIL><ITALIC><PDAT>Escherichia coli </PDAT></ITALIC></HIL><PDAT>to Deliver </PDAT><HIL><ITALIC><PDAT>Pseudomonas syringae </PDAT></ITALIC></HIL><PDAT>Avr Signals to Plant Cells and to Secrete Avr Proteins in Culture,&rdquo; </PDAT><HIL><ITALIC><PDAT>Proc. Natl. Acad. Sci. USA </PDAT></ITALIC></HIL><PDAT>95:10206-10211 (1998); Anderson et al., &ldquo;Reciprocal Secretion of Proteins by the Bacterial Type III Machines of Plant and Animal Pathogens Suggests Universal Recognition of mRNA Targeting Signals,&rdquo; </PDAT><HIL><ITALIC><PDAT>Proc. Natl. Acad. Sci. USA </PDAT></ITALIC></HIL><PDAT>96:12839-12843 (1999); Mudgett and Staskawicz, &ldquo;Characterization of the </PDAT><HIL><ITALIC><PDAT>Pseudomonas syringae </PDAT></ITALIC></HIL><PDAT>pv. </PDAT><HIL><ITALIC><PDAT>tomato </PDAT></ITALIC></HIL><PDAT>AvrRpt2 Protein: Demonstration of Secretion and Processing During Bacterial Pathogenesis,&rdquo; </PDAT><HIL><ITALIC><PDAT>Mol. Microbiol. </PDAT></ITALIC></HIL><PDAT>32:927-941 (1999)). Also, conditions have now been defined that permit detection of Hrp-dependent secretion of effector proteins by </PDAT><HIL><ITALIC><PDAT>P. syringae </PDAT></ITALIC></HIL><PDAT>and </PDAT><HIL><ITALIC><PDAT>X. campestris. </PDAT></ITALIC></HIL><PDAT>Rossier et al., &ldquo;The Xanthomonas Hrp Type III System Secretes Proteins from Plant and Mammalian Bacterial Pathogens,&rdquo; </PDAT><HIL><ITALIC><PDAT>Proc. Natl. Acad. Sci. USA </PDAT></ITALIC></HIL><PDAT>96:9368-9373 (1999); van Dijk et al., &ldquo;The Avr (Effector) Proteins HrmA (HopPsyA) and AvrPto are Secreted in Culture from </PDAT><HIL><ITALIC><PDAT>Pseudomonas syringae </PDAT></ITALIC></HIL><PDAT>Pathovars via the Hrp (Type III) Protein Secretion System in a Temperature and pH-Sensitive Manner,&rdquo; </PDAT><HIL><ITALIC><PDAT>J. Bacteriol. </PDAT></ITALIC></HIL><PDAT>181:4790-4797 (1999)).</PDAT></PTEXT></PARA>
<PARA ID="P-00008" LVL="0"><PTEXT><PDAT>The biochemical activities or parasite-promoting functions of effector proteins remain unclear, although several of those known make measurable contributions to virulence (Leach et al., &ldquo;Bacterial Avirulence Genes,&rdquo; </PDAT><HIL><ITALIC><PDAT>Annul. Rev. Phytopathol, </PDAT></ITALIC></HIL><PDAT>34:153-179 (1996)). Members of the AvrBs3 family in Xanthomonas spp. are targeted to the plant nucleus (Van den Ackerveken et al., &ldquo;Bacterial Avirulence Proteins as Triggers of Plant Defense Resistance,&rdquo; </PDAT><HIL><ITALIC><PDAT>Trends Microbiol, </PDAT></ITALIC></HIL><PDAT>(1997); Gabriel, &ldquo;Targeting of Protein Signals from Xanthomonas to the Plant Nucleus,&rdquo; </PDAT><HIL><ITALIC><PDAT>Trends Plant Sci., </PDAT></ITALIC></HIL><PDAT>2:204-206 (1997)), and some of these have been shown recently to redundantly encode watersoaking functions associated with circulence (Yang et al., &ldquo;Watersoaking Function(s) of XcmH1005 are Redundantly Encoded by Members of the Xanthomonas avr/pth Gene Family,&rdquo; </PDAT><HIL><ITALIC><PDAT>MPMI, </PDAT></ITALIC></HIL><PDAT>9:105-113 (1996)). AvrD (</PDAT><HIL><ITALIC><PDAT>Pseudomonas syringae </PDAT></ITALIC></HIL><PDAT>pv. </PDAT><HIL><ITALIC><PDAT>tomato</PDAT></ITALIC></HIL><PDAT>) directs the synthesis of syringolide elicitors of the HR (Leach et al., &ldquo;Bacterial Avirulence Genes,&rdquo; </PDAT><HIL><ITALIC><PDAT>Annul. Rev. Phytopathol, </PDAT></ITALIC></HIL><PDAT>34:153-179 (1996)); AvrBs2 (</PDAT><HIL><ITALIC><PDAT>Xanthomonas campestris </PDAT></ITALIC></HIL><PDAT>pv. </PDAT><HIL><ITALIC><PDAT>vesicatoria</PDAT></ITALIC></HIL><PDAT>) shows similarity to </PDAT><HIL><ITALIC><PDAT>A. tumefaciens </PDAT></ITALIC></HIL><PDAT>agrocinopine synthase (Swords et al., &ldquo;Spontaneous and Induced Mutations in a Single Open Reading Frame Alters Both Virulence and Avirulence in </PDAT><HIL><ITALIC><PDAT>Xanthomonas campestris </PDAT></ITALIC></HIL><PDAT>pv. </PDAT><HIL><ITALIC><PDAT>vesicatoria </PDAT></ITALIC></HIL><PDAT>avrBs2,&rdquo; </PDAT><HIL><ITALIC><PDAT>J. Bacteriol., </PDAT></ITALIC></HIL><PDAT>4661-4669 (1996)); and AvrRxv (</PDAT><HIL><ITALIC><PDAT>Xanthomonas campestris </PDAT></ITALIC></HIL><PDAT>pv. </PDAT><HIL><ITALIC><PDAT>vesicatoria</PDAT></ITALIC></HIL><PDAT>) is a homolog of AvrA (</PDAT><HIL><ITALIC><PDAT>Salmonella typhimurium</PDAT></ITALIC></HIL><PDAT>) and YopJ (Yersinia spp.), proteins which travel the type III pathway in animal pathogens and trigger apoptosis in macrophages (Hardt et al., &ldquo;A Secreted Salmonella Protein With Homology to an Avirulence Determinant of Plant Pathogenic Bacteria,&rdquo; </PDAT><HIL><ITALIC><PDAT>Proc. Natl. Acad. Sci. USA, </PDAT></ITALIC></HIL><PDAT>94:9887-9892 (1997); Monack et al., Yersinia Signals Macrophages to Undergo Apoptosis and YopJ is Necessary for this Cell Death,&rdquo; </PDAT><HIL><ITALIC><PDAT>Proc. Natl. Acad. Sci. USA, </PDAT></ITALIC></HIL><PDAT>94:10385-10390 (1997)). This last observation has led to the suggestion that avr-R gene interactions may occur also in animal pathogenesis (Galan, &ldquo;&lsquo;Avirulence Gene&rsquo; in Animal Pathogens&quest;,&rdquo; </PDAT><HIL><ITALIC><PDAT>Trends Microbiol., </PDAT></ITALIC></HIL><PDAT>6:3-6 (1998)).</PDAT></PTEXT></PARA>
<PARA ID="P-00009" LVL="0"><PTEXT><PDAT>The primary sequences of the </PDAT><HIL><ITALIC><PDAT>Pseudomonas syringae </PDAT></ITALIC></HIL><PDAT>Avr proteins reveal little about their potential function, but interestingly, when heterologously expressed in plants, three of them have produced necrosis in test plants lacking the cognate R gene (Gopalan et al., &ldquo;Expression of the </PDAT><HIL><ITALIC><PDAT>Pseudomonas syringae </PDAT></ITALIC></HIL><PDAT>Avirulence Protein AvrB in Plant Cells Alleviates its Dependence on the Hypersensitive Response and Pathogenicity (Hrp) Secretion System in Eliciting Genotype-specific Hypersensitive Cell Death,&rdquo; </PDAT><HIL><ITALIC><PDAT>Plant Cell, </PDAT></ITALIC></HIL><PDAT>8:1095-1105 (1996); Stevens et al., &ldquo;Sequence Variations in Alleles of the Avirulence Gene avrPphE.R2 from </PDAT><HIL><ITALIC><PDAT>Pseudomonas syringae </PDAT></ITALIC></HIL><PDAT>pv. </PDAT><HIL><ITALIC><PDAT>phaseolicola </PDAT></ITALIC></HIL><PDAT>Lead to Loss of Recognition of the AvrPphE Protein Within Bean Cells and Gain in Cultivar Specific Virulence,&rdquo; </PDAT><HIL><ITALIC><PDAT>Mol. Microbiol., </PDAT></ITALIC></HIL><PDAT>29(1):165-77 (1998); McNellis et al., &ldquo;Glucocorticoid-inducible Expression of a Bacterial Avirulence Gene in Transgenic Arabidopsis Induces Hypersensitive Cell Death,&rdquo; </PDAT><HIL><ITALIC><PDAT>Plant J., </PDAT></ITALIC></HIL><PDAT>14(2):247-57 (1998)). A key question is whether this results from interaction of abnormally high levels of the bacterial protein with plant virulence targets or with cross-reacting R-gene products. Further evidence suggesting that some avr genes in </PDAT><HIL><ITALIC><PDAT>Pseudomonas syringae </PDAT></ITALIC></HIL><PDAT>are beneficial to the bacteria in host plants is found in recent studies of avrD and avrPphE. Highly conserved, nonfunctional alleles of these genes have been retained in pathogens whose hosts would recognize the functional Avr product (Stevens et al., &ldquo;Sequence Variations in Alleles of the Avirulence Gene avrPphE.R2 from </PDAT><HIL><ITALIC><PDAT>Pseudomonas syringae </PDAT></ITALIC></HIL><PDAT>pv. </PDAT><HIL><ITALIC><PDAT>phaseolicola </PDAT></ITALIC></HIL><PDAT>Lead to Loss of Recognition of the AvrPphE Protein Within Bean Cells and Gain in Cultivar Specific Virulence,&rdquo; </PDAT><HIL><ITALIC><PDAT>Mol. Microbiol., </PDAT></ITALIC></HIL><PDAT>29(1):165-77 (1998); Keith et al., &ldquo;Comparison of avrD Alleles from </PDAT><HIL><ITALIC><PDAT>Pseudomonas syringae </PDAT></ITALIC></HIL><PDAT>pv. </PDAT><HIL><ITALIC><PDAT>glycinea,</PDAT></ITALIC></HIL><PDAT>&rdquo; </PDAT><HIL><ITALIC><PDAT>MPMI, </PDAT></ITALIC></HIL><PDAT>10:416-422 (1997)).</PDAT></PTEXT></PARA>
<PARA ID="P-00010" LVL="0"><PTEXT><PDAT>Avr-like genes may function heterologously to support pathogenesis as well as HR elicitation. The pathogenicity of an </PDAT><HIL><ITALIC><PDAT>Erwinia amylovora </PDAT></ITALIC></HIL><PDAT>dspE mutant can be restored (at least partially) by a plasmid carrying the </PDAT><HIL><ITALIC><PDAT>Pseudomonas syringae </PDAT></ITALIC></HIL><PDAT>avrE locus, suggesting that DspE and AvrE have similar functions (Bogdanove et al., &ldquo;Homology and Functional Similarity of a hrp-linked Pathogenicity Operon, dspEF, of </PDAT><HIL><ITALIC><PDAT>Erwinia amylovora </PDAT></ITALIC></HIL><PDAT>and the avrE locus of </PDAT><HIL><ITALIC><PDAT>Pseudomonas syringae </PDAT></ITALIC></HIL><PDAT>Pathovar Tomato,&rdquo; </PDAT><HIL><ITALIC><PDAT>Proc. Natl. Acad. Sci. USA, </PDAT></ITALIC></HIL><PDAT>95:1325-1330 (1998)). That dspE is essential for </PDAT><HIL><ITALIC><PDAT>Erwinia amylovora </PDAT></ITALIC></HIL><PDAT>pathogenicity, whereas avrE contributes only quantitatively to the virulence of </PDAT><HIL><ITALIC><PDAT>Pseudomonas syringae </PDAT></ITALIC></HIL><PDAT>pv tomato (Lorang et al., &ldquo;avrA and avrE in </PDAT><HIL><ITALIC><PDAT>Pseudomonas syringae </PDAT></ITALIC></HIL><PDAT>pv. </PDAT><HIL><ITALIC><PDAT>Tomato </PDAT></ITALIC></HIL><PDAT>PT23 Play a Role in Virulence on Tomato Plants,&rdquo; </PDAT><HIL><ITALIC><PDAT>MPMI, </PDAT></ITALIC></HIL><PDAT>7:508-515 (1994)), suggests that there is less redundancy in the </PDAT><HIL><ITALIC><PDAT>Erwinia amylovora </PDAT></ITALIC></HIL><PDAT>virulence system. This would be consistent with a more recent acquisition of the Hrp system by </PDAT><HIL><ITALIC><PDAT>Erwinia amylovora </PDAT></ITALIC></HIL><PDAT>and/or a slower coevolution with its perennial hosts (Bogdanove et al., &ldquo;Homology and Functional Similarity of a hrp-linked Pathogenicity Operon, dspEF, of </PDAT><HIL><ITALIC><PDAT>Erwinia amylovora </PDAT></ITALIC></HIL><PDAT>and the avrE locus of </PDAT><HIL><ITALIC><PDAT>Pseudomonas syringae </PDAT></ITALIC></HIL><PDAT>Pathovar Tomato,&rdquo; </PDAT><HIL><ITALIC><PDAT>Proc. Natl. Acad. Sci. USA, </PDAT></ITALIC></HIL><PDAT>95:1325-1330 (1998)). The heterologous function of </PDAT><HIL><ITALIC><PDAT>Pseudomonas syringae </PDAT></ITALIC></HIL><PDAT>avr genes in </PDAT><HIL><ITALIC><PDAT>Erwinia amylovora </PDAT></ITALIC></HIL><PDAT>and </PDAT><HIL><ITALIC><PDAT>Erwinia chrysanthemi </PDAT></ITALIC></HIL><PDAT>suggests that Hrp&plus; bacteria in the field may be able to &lsquo;sample&rsquo; a buffet of avr-like genes from diverse sources in their coevolution with changing plant populations. Many avr genes have been known to be potentially mobile, because of their presence on plasmids (Vivian et al., &ldquo;Avirulence Genes in Plant-Pathogenic Bacteria: Signals or Weapons&quest;,&rdquo; </PDAT><HIL><ITALIC><PDAT>Microbiology </PDAT></ITALIC></HIL><PDAT>143:693-704 (1997); Leach et al., &ldquo;Bacterial Avirulence Genes,&rdquo; </PDAT><HIL><ITALIC><PDAT>Annu. Rev. Phytopathol, </PDAT></ITALIC></HIL><PDAT>34:153-179 (1996)). Recent observations with </PDAT><HIL><ITALIC><PDAT>Pseudomonas syringae </PDAT></ITALIC></HIL><PDAT>highlight the apparent mobility of avr genes. Several </PDAT><HIL><ITALIC><PDAT>Pseudomonas syringae </PDAT></ITALIC></HIL><PDAT>avr genes are liked with transposable elements or phage sequences (Hanekamp et al., &ldquo;Avirulence Gene D of </PDAT><HIL><ITALIC><PDAT>Pseudomonas syringae </PDAT></ITALIC></HIL><PDAT>pv. </PDAT><HIL><ITALIC><PDAT>Tomato </PDAT></ITALIC></HIL><PDAT>May Have Undergone Horizontal Gene Transfer,&rdquo; </PDAT><HIL><ITALIC><PDAT>FEBS Lett., </PDAT></ITALIC></HIL><PDAT>415:40-44 (1997)), and the hrp clusters in different strains of </PDAT><HIL><ITALIC><PDAT>Pseudomonas syringae, </PDAT></ITALIC></HIL><PDAT>although conserved in themselves, are bordered by a hypervariable region enriched in avr genes and mobile DNA elements. Alfano et al., &ldquo;The </PDAT><HIL><ITALIC><PDAT>Pseudomonas syringae </PDAT></ITALIC></HIL><PDAT>Hrp Pathogenicity Island has a Tripartite Mosaic Structure Composed of a Cluster of Type III Secretion Genes Bounded by Exchangeable Effector and Conserved Effector Loci that Contribute to Parasitic Fitness and Pathogenicity in Plants,&rdquo; </PDAT><HIL><ITALIC><PDAT>Proc. Natl. Acad. Sci. USA </PDAT></ITALIC></HIL><PDAT>97:4856-4861 (2000).</PDAT></PTEXT></PARA>
<PARA ID="P-00011" LVL="0"><PTEXT><PDAT>Two classes of extracellular Hrp proteins have now been defined-harpins and pilins. Harpins are glycine-rich proteins that lack cysteine, are secreted in culture when the Hrp system is expressed, and possess heat-stable HR elicitor activity when infiltrated into the leaves of tobacco and several other plants (Alfano et al., &ldquo;Bacterial Pathogens in Plants: Life Up Against the Wall,&rdquo; </PDAT><HIL><ITALIC><PDAT>Plant Cell, </PDAT></ITALIC></HIL><PDAT>8:1683-1698 (1996)). Mutation of the prototypical hrpN harpin gene in </PDAT><HIL><ITALIC><PDAT>Erwinia amylovora </PDAT></ITALIC></HIL><PDAT>Ea321 strongly diminishes HR and pathogenicity phenotypes (Kim et al., &ldquo;HrpW of </PDAT><HIL><ITALIC><PDAT>Erwinia amylovora, </PDAT></ITALIC></HIL><PDAT>a New Harpin That is a Member of a Proposed Class of Pectate Lyases,&rdquo; </PDAT><HIL><ITALIC><PDAT>J. Bacteriol. </PDAT></ITALIC></HIL><PDAT>180(19):5203-5210 (1998)), but mutation of the hrpZ harpin gene in different </PDAT><HIL><ITALIC><PDAT>Pseudomonas syringae </PDAT></ITALIC></HIL><PDAT>strains has little or no effect on Hrp phenotypes (Alfano et al., &ldquo;Analysis of the Role of the </PDAT><HIL><ITALIC><PDAT>Pseudomonas syringae </PDAT></ITALIC></HIL><PDAT>pv. </PDAT><HIL><ITALIC><PDAT>syringae </PDAT></ITALIC></HIL><PDAT>HrpZ Harpin in Elicitation of the Hypersensitive Response in Tobacco Using Functionally Nonpolar Deletion Mutations, Truncated HrpZ Fragments, and hrmA Mutations,&rdquo; </PDAT><HIL><ITALIC><PDAT>Mol. Microbiol. </PDAT></ITALIC></HIL><PDAT>19:715-728 (1996); Charkowski et al.,. &ldquo;The </PDAT><HIL><ITALIC><PDAT>Pseudomonas syringae </PDAT></ITALIC></HIL><PDAT>pv. </PDAT><HIL><ITALIC><PDAT>tomato </PDAT></ITALIC></HIL><PDAT>HrpW Protein Has Domains Similar to Harpins and Pectate Lyases and Can Elicit the Plant Hypersensitive Response and Bind to Pectate,&rdquo; </PDAT><HIL><ITALIC><PDAT>J. Bacteriol. </PDAT></ITALIC></HIL><PDAT>180 (19):5211-5217 (1998)). The natural function of harpins or the basis for their ability to elicit an apparent programmed cell death when artificially introduced into the apoplast of plants is unknown. However, two lines of evidence point to a site of action in the plant cell wall. First, purified </PDAT><HIL><ITALIC><PDAT>Pseudomonas syringae </PDAT></ITALIC></HIL><PDAT>harpin binds to cell walls and has biological activity only with walled cells (Hoyos et al., &ldquo;The Interaction of Harpin</PDAT><HIL><SB><PDAT>Pss </PDAT></SB></HIL><PDAT>With Plant Cell Walls,&rdquo; </PDAT><HIL><ITALIC><PDAT>MPMI </PDAT></ITALIC></HIL><PDAT>9:608-616 (1996)). Second, HrpW, a second harpin discovered in both </PDAT><HIL><ITALIC><PDAT>Erwinia amylovora </PDAT></ITALIC></HIL><PDAT>and </PDAT><HIL><ITALIC><PDAT>Pseudomonas syringae, </PDAT></ITALIC></HIL><PDAT>has an N-terminal half that is harpin-like but a C-terminal half that is homologous to a newly-defined class of pectate lyases found in fungal and bacterial pathogens (Kim et al., &ldquo;HrpW of </PDAT><HIL><ITALIC><PDAT>Erwinia amylovora, </PDAT></ITALIC></HIL><PDAT>a New Harpin That is a Member of a Proposed Class of Pectate Lyases,&rdquo; </PDAT><HIL><ITALIC><PDAT>J. Bacteriol. </PDAT></ITALIC></HIL><PDAT>180(19):5203-5210 (1998); Charkowski et al., &ldquo;The </PDAT><HIL><ITALIC><PDAT>Pseudomonas syringae </PDAT></ITALIC></HIL><PDAT>pv. </PDAT><HIL><ITALIC><PDAT>tomato </PDAT></ITALIC></HIL><PDAT>HrpW Protein Has Domains Similar to Harpins and Pectate Lyases and Can Elicit the Plant Hypersensitive Response and Bind to Pectate,&rdquo; </PDAT><HIL><ITALIC><PDAT>J. Bacteriol. </PDAT></ITALIC></HIL><PDAT>180 (19):5211-5217 (1998)). Elicitor activity resides in the harpin domain, and the pectate lyase domain, although lacking enzymatic activity, binds specifically to pectate (Charkowski, A. et al., &ldquo;The </PDAT><HIL><ITALIC><PDAT>Pseudomonas syringae </PDAT></ITALIC></HIL><PDAT>pv. </PDAT><HIL><ITALIC><PDAT>tomato </PDAT></ITALIC></HIL><PDAT>HrpW Protein Has Domains Similar to Harpins and Pectate Lyases and Can Elicit the Plant Hypersensitive Response and Bind to Pectate,&rdquo; </PDAT><HIL><ITALIC><PDAT>J. Bacteriol. </PDAT></ITALIC></HIL><PDAT>180 (19):5211-5217 (1998)). The second class of extracellular Hrp proteins are represented by the </PDAT><HIL><ITALIC><PDAT>Pseudomonas syringae </PDAT></ITALIC></HIL><PDAT>HrpA pilin, which is a subunit of a Hrp-pilus that is 6-8 nm in diameter and is formed on bacteria in a Hrp-dependent manner (Roine et al., &ldquo;Hrp Pilus: An hrp-dependent Bacterial Surface Appendage Produced by </PDAT><HIL><ITALIC><PDAT>Pseudomonas syringae </PDAT></ITALIC></HIL><PDAT>pv. </PDAT><HIL><ITALIC><PDAT>tomato </PDAT></ITALIC></HIL><PDAT>DC3000, &rdquo; </PDAT><HIL><ITALIC><PDAT>Proc. Natl. Acad. Sci. USA </PDAT></ITALIC></HIL><PDAT>94:3459-3464 (1997)). The Hrp pilus is required for pathogenicity and elicitation of the HR, and a similar structure is important for T-DNA transfer in </PDAT><HIL><ITALIC><PDAT>Agrobacterium tumefaciens </PDAT></ITALIC></HIL><PDAT>(Fullner et al., &ldquo;Pilus Assembly by Agrobacterium T-DNA Transfer Genes,&rdquo; </PDAT><HIL><ITALIC><PDAT>Science, </PDAT></ITALIC></HIL><PDAT>237:1107-1109 (1996)). Whether these structures promote the transfer of bacterial macromolecules into plant cells by serving as conduits, guides, or attachment factors is not known.</PDAT></PTEXT></PARA>
<PARA ID="P-00012" LVL="0"><PTEXT><PDAT>Type III secretion systems are present in both animal and plant pathogenic bacteria, which indicates that they are capable of operating not only across bacterial genera but also across host kingdoms (Galan et al., &ldquo;Type III Secretion Machines: Bacterial Devices for Protein Delivery into Host Cells,&rdquo; </PDAT><HIL><ITALIC><PDAT>Science </PDAT></ITALIC></HIL><PDAT>284:1322-1328 (1999)). At present, the metabolic changes caused by effector proteins secreted by the type III protein secretion system of plant pathogenic bacteria are unknown. However, perturbations in pathways involved in innate immunity, programmed cell death, and the cell cycle are unlikely. Supporting this expectation is the finding that effectors of Salmonella, Shigella, and Yersinia spp. have activities such as altering F-actin stability, activation of caspase-1, tyrosine phosphatase activity, and inhibition of mitogen-activated protein kinases (Gal&aacute;n et al., &ldquo;Type III Secretion Machines: Ingenious Bacterial Devices for Protein Delivery into Host Cells,&rdquo; </PDAT><HIL><ITALIC><PDAT>Science </PDAT></ITALIC></HIL><PDAT>284:1322-1328 (1999); Orth et al., &ldquo;Inhibition of the Mitogen-Activated Protein Kinase Superfamily by a Yersinia Effector,&rdquo; </PDAT><HIL><ITALIC><PDAT>Science </PDAT></ITALIC></HIL><PDAT>285:1920-1923 (1999)). Many of the metabolic targets are likely to be universal among eucaryotes and, therefore, these phytopathogen effector proteins are likely to provide tools for altering the metabolism of yeast, nematodes, insects, and higher animals for various biotechnological purposes.</PDAT></PTEXT></PARA>
<PARA ID="P-00013" LVL="0"><PTEXT><PDAT>A limiting factor in the potential biotechnological use of these phytopathogen effector proteins is that the metabolic targets of the effector proteins are inside host cells and, therefore, the effector proteins must be either produced inside the target cells or delivered into them by some means. One such means is gene therapy techniques, however, this technology is relatively difficult to apply.</PDAT></PTEXT></PARA>
<PARA ID="P-00014" LVL="0"><PTEXT><PDAT>Thus, it would be beneficial to obtain a recombinant construct and delivery system which overcomes these and other deficiencies in the art.</PDAT></PTEXT></PARA>
<H LVL="1"><STEXT><PDAT>SUMMARY OF THE INVENTION</PDAT></STEXT></H>
<PARA ID="P-00015" LVL="0"><PTEXT><PDAT>One aspect of the present invention relates to a method for delivering effector proteins into a target cell. This method involves introducing into the target cell an effector protein fused to a protein transduction domain of a human immunodeficiency virus TAT protein or derivatives or functional analogs thereof.</PDAT></PTEXT></PARA>
<PARA ID="P-00016" LVL="0"><PTEXT><PDAT>Another aspect of the present invention relates to a DNA construct including a first DNA molecule encoding an effector protein and a second DNA molecule operatively associated with the first DNA molecule and encoding a protein transduction domain of a human immunodeficiency virus TAT protein or derivatives or functional analogs thereof.</PDAT></PTEXT></PARA>
<PARA ID="P-00017" LVL="0"><PTEXT><PDAT>The method of the present invention allows efficient delivery of effector proteins into cells, in particular, mammalian cells. This method also allows for delivery of effector proteins for use in pharmaceutical, insecticide, fungicide, herbicide, and other applications. In particular, the present invention will allow the delivery of effector proteins into patients in the form of protein therapy. Therapy with biologically active full-length proteins will allow access to the built-in evolutionary specificity of these proteins for their targets, thereby potentially avoiding the nonspecific effects sometimes seen with small-molecule therapies. Moreover, when used in conjunction with tissue-specific viral vectors, use of the present invention allows the targeted delivery of effector proteins to particular cells with the added benefit of secondary redistribution of the effector protein subsequent to the initial targeting. A precedent for this approach can be found in an experiment wherein the VP22 protein transduction domain was fused to the p53 tumor suppressor protein (Phelan et al., &ldquo;Intercellular Delivery of Functional p53 by the Herpesvirus Protein VP22,&rdquo; </PDAT><HIL><ITALIC><PDAT>Nat. Biotechnol. </PDAT></ITALIC></HIL><PDAT>16:440-443 (1998), which is hereby incorporated by reference).</PDAT></PTEXT></PARA>
</BTEXT>
</BRFSUM>
<DRWDESC>
<BTEXT>
<H LVL="1"><STEXT><PDAT>BRIEF DESCRIPTION OF THE DRAWINGS</PDAT></STEXT></H>
<PARA ID="P-00018" LVL="0"><PTEXT><FGREF ID="DRAWINGS"><PDAT>FIG. 1</PDAT></FGREF><PDAT> is a diagram showing the genetic organization of the hrp and dsp genes contained by cosmids pCPP430 and pCPP431. The letters designating the known or proposed functions correspond to the following: S, secretion; R, regulation; H, harpin; A, avirulence; D, disease; U, unknown.</PDAT></PTEXT></PARA>
<PARA ID="P-00019" LVL="0"><PTEXT><FGREF ID="DRAWINGS"><PDAT>FIG. 2</PDAT></FGREF><PDAT> is a diagram of the physical maps for cosmids pCPP2156 and pCPP2157, which contain the </PDAT><HIL><ITALIC><PDAT>Erwinia chrysanthemi </PDAT></ITALIC></HIL><PDAT>hrp region, and comparison of the hrp regions of </PDAT><HIL><ITALIC><PDAT>Erwinia chrysanthemi </PDAT></ITALIC></HIL><PDAT>and </PDAT><HIL><ITALIC><PDAT>Erwinia amylovora </PDAT></ITALIC></HIL><PDAT>(Bauer et al., &ldquo;</PDAT><HIL><ITALIC><PDAT>Erwinia chrysanthemi </PDAT></ITALIC></HIL><PDAT>harpin</PDAT><HIL><SB><PDAT>Ech</PDAT></SB></HIL><PDAT>: An Elicitor of the Hypersensitive Response that Contributes to Soft-rot Pathogenesis,&rdquo; </PDAT><HIL><ITALIC><PDAT>MPMI </PDAT></ITALIC></HIL><PDAT>8:484-491 (1995); Kim et al., &ldquo;The hrpC and hrpN Operons of </PDAT><HIL><ITALIC><PDAT>Erwinia chrysanthemi </PDAT></ITALIC></HIL><PDAT>EC 16 are Flanked by plcA and Homologs of Hemolysin/Adhesin Genes and Accompanying Activator/Transporter Genes,&rdquo; </PDAT><HIL><ITALIC><PDAT>MPMI </PDAT></ITALIC></HIL><PDAT>11(6):563-567 (1998); Bogdanove et al., &ldquo;</PDAT><HIL><ITALIC><PDAT>Erwinia amylovora </PDAT></ITALIC></HIL><PDAT>Secretes Harpin via a Type III of Pathway and Contains a Homolog of YopN of Yersinia spp.,&rdquo; </PDAT><HIL><ITALIC><PDAT>J. Bacteriol. </PDAT></ITALIC></HIL><PDAT>178:1720-1730 (1996); Wei et al., &ldquo;Harpin, Elicitor of the Hypersensitive Response Produced by the Plant Pathogen </PDAT><HIL><ITALIC><PDAT>Erwinia amylovora,&rdquo; Science, </PDAT></ITALIC></HIL><PDAT>257:85-88 (1992); Wei et al., &ldquo;HrpI of </PDAT><HIL><ITALIC><PDAT>Erwinia amylovora </PDAT></ITALIC></HIL><PDAT>Functions in Secretion of Harpin and is a Member of a New Protein Family,&rdquo; </PDAT><HIL><ITALIC><PDAT>J. Bacteriol., </PDAT></ITALIC></HIL><PDAT>175:7958-7967 (1993); Kim et al., &ldquo;The HrpA and HrpC Operons of </PDAT><HIL><ITALIC><PDAT>Erwinia amylovora </PDAT></ITALIC></HIL><PDAT>Encode Components of a Type III Pathway that Secrets Harpin,&rdquo; </PDAT><HIL><ITALIC><PDAT>J. Bacteriol. </PDAT></ITALIC></HIL><PDAT>179:1690-1697 (1997), which are hereby incorporated by reference). Arrow-shaped boxes denote putative transcriptional units. Shadowed areas denote hrp regions. Dashed boxes denote transcriptional units predicted on the basis of the homology and spacing of partially sequenced regions (shaded areas) in comparison with the corresponding </PDAT><HIL><ITALIC><PDAT>Erwinia amylovora </PDAT></ITALIC></HIL><PDAT>hrp genes. The filled triangle indicates the location of mini-Tn5Cm in pCPP2368.</PDAT></PTEXT></PARA>
<PARA ID="P-00020" LVL="0"><PTEXT><FGREF ID="DRAWINGS"><PDAT>FIG. 3</PDAT></FGREF><PDAT> is a map of plasmid pCPP 3125.</PDAT></PTEXT></PARA>
<PARA ID="P-00021" LVL="0"><PTEXT><FGREF ID="DRAWINGS"><PDAT>FIG. 4</PDAT></FGREF><PDAT> is a map of plasmid pCPP 3126.</PDAT></PTEXT></PARA>
</BTEXT>
</DRWDESC>
<DETDESC>
<BTEXT>
<H LVL="1"><STEXT><PDAT>DETAILED DESCRIPTION OF THE INVENTION</PDAT></STEXT></H>
<PARA ID="P-00022" LVL="0"><PTEXT><PDAT>One aspect of the present invention relates to a method for delivering effector proteins into a target cell. This method involves introducing into the target cell an effector protein fused to a protein transduction domain of a human immunodeficiency virus TAT protein or derivatives or functional analogs thereof.</PDAT></PTEXT></PARA>
<PARA ID="P-00023" LVL="0"><PTEXT><PDAT>Effector proteins are delivered into host cells via the type III protein secretion system. Thus, effector proteins for the present invention can be obtained with constructs utilizing a DNA molecule encoding a functional type III secretion system and a DNA molecule encoding a protein or polypeptide capable of being secreted by the type III secretion system, as disclosed in the U.S. patent application Ser. No. 09/350,852, filed Jul. 9, 1999, which is hereby incorporated by reference. These constructs can be used under conditions effective to transform host cells so that they express and secrete (i.e., into the host cell environment) an effector protein or polypeptide of interest, which is then isolated. Effective conditions include optimal growth temperatures and nutrient media which will enable maximum growth of the host cells and maximal expression of the protein or polypeptide of interest. Exemplary culture media include, without limitation, LM media and minimal media, both of which are known in the art. One of ordinary skill in the art can readily determine the optimal growth temperatures for particular strains of host cells and suitable nutrient media capable of optimizing host cell growth.</PDAT></PTEXT></PARA>
<PARA ID="P-00024" LVL="0"><PTEXT><PDAT>Suitable type III secretion systems include those obtained from the genus Erwinia, more preferably, the harpin secretion systems obtained from </PDAT><HIL><ITALIC><PDAT>Erwinia amylovora </PDAT></ITALIC></HIL><PDAT>or </PDAT><HIL><ITALIC><PDAT>Erwinia chrysanthemi, </PDAT></ITALIC></HIL><PDAT>and Pseudomonas, more preferably, the harpin secretion systems obtained from </PDAT><HIL><ITALIC><PDAT>Pseudomonas syringae. </PDAT></ITALIC></HIL><PDAT>For example, the harpin secretion system of </PDAT><HIL><ITALIC><PDAT>Erwinia amylovora </PDAT></ITALIC></HIL><PDAT>is present on cosmid pCPP430 (Beer et al., &ldquo;The hrp Gene Cluster of </PDAT><HIL><ITALIC><PDAT>Erwinia amylovora,</PDAT></ITALIC></HIL><PDAT>&rdquo; in </PDAT><HIL><ITALIC><PDAT>Advances in Molecular Genetics of plant</PDAT></ITALIC></HIL><PDAT>-</PDAT><HIL><ITALIC><PDAT>Microbe Interactions, </PDAT></ITALIC></HIL><PDAT>Proceedings of the 5th International Symposium on the Molecular Genetics of Plant-Microbe Interactions, Interlaken, Switzerland, September, 1990, pp. 53-60 (1991) which is hereby incorporated by reference) and the harpin secretion system of </PDAT><HIL><ITALIC><PDAT>Erwinia carotovora </PDAT></ITALIC></HIL><PDAT>is present in cosmid pCPP2156 (Ham et al., &ldquo;A Cloned </PDAT><HIL><ITALIC><PDAT>Erwinia chrysanthemi </PDAT></ITALIC></HIL><PDAT>Hrp (type III Protein Secretion) System Functions in </PDAT><HIL><ITALIC><PDAT>Escherichia coli </PDAT></ITALIC></HIL><PDAT>to Deliver </PDAT><HIL><ITALIC><PDAT>Pseudomonas syringae </PDAT></ITALIC></HIL><PDAT>Avr Signals to Plant Cells and to Secrete Avr Proteins in Culture,&rdquo; </PDAT><HIL><ITALIC><PDAT>Proc. Natl. Acad. Sci. USA, </PDAT></ITALIC></HIL><PDAT>95(17): 10206-11 (1998), which is hereby incorporated by reference). A diagram of cosmid pCPP430 is shown at </PDAT><FGREF ID="DRAWINGS"><PDAT>FIG. 1 and a</PDAT></FGREF><PDAT> diagram of cosmid pCPP2156 is shown at FIG. </PDAT><HIL><BOLD><PDAT>2</PDAT></BOLD></HIL><PDAT>.</PDAT></PTEXT></PARA>
<PARA ID="P-00025" LVL="0"><PTEXT><PDAT>Type III protein secretion systems are present in bacterial pathogens of both animals and plants, and are typified by the type III system of Yersinia spp. (Finlay et al., &ldquo;Common Themes in Microbial Pathogenicity Revisited,&rdquo; </PDAT><HIL><ITALIC><PDAT>Microbiol. Mol. Biol. Rev., </PDAT></ITALIC></HIL><PDAT>61:136-169 (1997); Cornelis et al., &ldquo;The Yersinia Yop Regulon: A Bacterial System for Subverting Eukaryotic Cells,&rdquo; </PDAT><HIL><ITALIC><PDAT>Mol. Microbiol., </PDAT></ITALIC></HIL><PDAT>23:861-867 (1997), which are hereby incorporated by reference). These animal pathogens are primarily extracellular parasites, and their Yops (Yersinia outer proteins) are secreted and translocated directly into host cells in a contact-dependent manner (Cornelis et al., &ldquo;The Yersinia Yop Regulon: A Bacterial System for Subverting Eukaryotic Cells,&rdquo; </PDAT><HIL><ITALIC><PDAT>Mol. Microbiol., </PDAT></ITALIC></HIL><PDAT>23:861-867 (1997), which is hereby incorporated by reference). A similar host-contact dependency may operate in most plant pathogenic bacteria. Nine of the hrp genes are universal components of type III secretion systems, and these have been renamed hrc (HR and conserved) and given the last-letter designation of their Yersinia homolog (with the exception of hrcV) (Bogdanove et al., &ldquo;Unified Nomenclature for Broadly Conserved hrp Genes of Phytopathogenic Bacteria,&rdquo; </PDAT><HIL><ITALIC><PDAT>Mol. Microbiol., </PDAT></ITALIC></HIL><PDAT>20:681-683 (1996), which is hereby incorporated by reference). The Hrc proteins enable protein movement across the bacterial inner and outer membranes independently of the general protein export (Sec) pathway (Charkowski et al., &ldquo;Altered Localization of HrpZ in </PDAT><HIL><ITALIC><PDAT>Pseudomonas syringae </PDAT></ITALIC></HIL><PDAT>pv. </PDAT><HIL><ITALIC><PDAT>syringae </PDAT></ITALIC></HIL><PDAT>hrp Mutants Suggests That Different Components of the Type III Secretion Pathway Control Protein Translocation Across the Inner and Outer Membranes of Gram-negative Bacteria,&rdquo; </PDAT><HIL><ITALIC><PDAT>J. Bacteriol., </PDAT></ITALIC></HIL><PDAT>179:3866-3874 (1997), which is hereby incorporated by reference). In contrast to the Hrc proteins, the Hrp proteins may be peripheral components of the Hrp secretion system and are more likely to perform type III secretion functions that are extracellular and specific to protein transfer across the plant cell wall and plasma membrane.</PDAT></PTEXT></PARA>
<PARA ID="P-00026" LVL="0"><PTEXT><PDAT>The effector protein or polypeptide must be compatible for secretion by the type III secretion system employed. By compatible, it is intended that the protein or polypeptide contain a secretion signal that can be recognized by the particular type III secretion system that is employed. The secretion signal enables the expressed protein or polypeptide to be recognized by the type III secretion system and transported via the expressed secretion system into the extracellular environment in which the recombinant host cells exist, i.e., culture medium.</PDAT></PTEXT></PARA>
<PARA ID="P-00027" LVL="0"><PTEXT><PDAT>Suitable secretion signals can be either an mRNA or a polypeptide fragment of a naturally-occurring protein secreted by the type III secretion system.</PDAT></PTEXT></PARA>
<PARA ID="P-00028" LVL="0"><PTEXT><PDAT>Compatible secretion signals can readily be determined for any particular type III secretion system that is to be employed. By identifying proteins that are normally secreted by the type III secretion system, it is possible to prepare deletion mutants missing various fragments of the full length protein that is normally secreted by the secretion system. Using labeled antibodies raised against epitopes of the various deletion fragments that are expressed (i.e., N-terminal epitopes, C-terminal epitopes, etc.), it is possible to identify deletion mutants that are secreted and those that are not secreted. Thus, protein domains necessary for secretion of the full length protein can be readily identified. Once the protein domains have been identified and sequenced, they can be utilized as secretion signals in fusion proteins of the present invention.</PDAT></PTEXT></PARA>
<PARA ID="P-00029" LVL="0"><PTEXT><PDAT>Typically, the secretion signal is an N-terminal domain of a protein that is normally secreted by the particular type III secretion system, for example, a 201 amino acid sequence from the N-terminal domain of the DspE protein of </PDAT><HIL><ITALIC><PDAT>Erwinia amylovora </PDAT></ITALIC></HIL><PDAT>(see, e.g., U.S. patent application Ser. No. 09/350,852, filed Jul. 9, 1999, which is hereby incorporated by reference). The 201 amino acid secretion signal of </PDAT><HIL><ITALIC><PDAT>Erwinia amylovora </PDAT></ITALIC></HIL><PDAT>DspE is compatible with the harpin secretion system of </PDAT><HIL><ITALIC><PDAT>Erwinia amylovora. </PDAT></ITALIC></HIL><PDAT>Other secretion signals that are compatible with various type III secretion systems have been described in the art and others are continually being identified.</PDAT></PTEXT></PARA>
<PARA ID="P-00030" LVL="0"><PTEXT><PDAT>Purified effector protein may be obtained by several methods. The protein or polypeptide is preferably produced in purified form (preferably at least about 80%, more preferably 90%, pure) by conventional techniques. Since the recombinant host cells express a type III secretion system, the protein or polypeptide is secreted into the growth medium of recombinant host cells. In such cases, to isolate the protein, the recombinant host cells are propagated, the growth medium is centrifuged to separate cellular components from supernatant containing the secreted protein or polypeptide, and the supernatant is removed. The supernatant is then subjected to sequential ammonium sulfate precipitation. The fraction containing the polypeptide or protein is subjected to gel filtration in an appropriately sized dextran or polyacrylamide column to separate the proteins. If necessary, the protein fraction may be further purified by HPLC.</PDAT></PTEXT></PARA>
<PARA ID="P-00031" LVL="0"><PTEXT><PDAT>Effector proteins carrying protein transduction domains may also be prepared independently of the type III secretion system by using current state-of-the-art techniques for preparing large amounts of purified proteins from recombinant </PDAT><HIL><ITALIC><PDAT>E. coli </PDAT></ITALIC></HIL><PDAT>cells. Such techniques employ strong, inducible promoters and peptide tags, such as His</PDAT><HIL><SB><PDAT>6</PDAT></SB></HIL><PDAT>, for one-step affinity purification of the recombinant protein from </PDAT><HIL><ITALIC><PDAT>E. coli </PDAT></ITALIC></HIL><PDAT>cell lysates (as described below in Example 1).</PDAT></PTEXT></PARA>
<PARA ID="P-00032" LVL="0"><PTEXT><PDAT>In one embodiment, the target cell is a eucaryote cell. The eucaryote cells include those in tissue culture, such as HeLa cells, or in whole animals, such as those delivered to mouse via intraperitoneal injection (Schwarze et al., &ldquo;Protein Transduction: Unrestricted Delivery into all Cells&quest;&rdquo; </PDAT><HIL><ITALIC><PDAT>Trends Cell Biol. </PDAT></ITALIC></HIL><PDAT>10:290-295 (2000), which is hereby incorporated by reference).</PDAT></PTEXT></PARA>
<PARA ID="P-00033" LVL="0"><PTEXT><PDAT>The effector protein may be produced by a bacterial plant pathogen, animal pathogen, or a rhizosphere bacteria, including, but not limited to enteropathogenic </PDAT><HIL><ITALIC><PDAT>Escherichia coli, Salmonella typhimurium, </PDAT></ITALIC></HIL><PDAT>Shigella spp., Yersinia spp., </PDAT><HIL><ITALIC><PDAT>Pseudomonas syringae, Xanthomonas campestris, Ralstonia solanacearum, Erwinia amylovora, Pseudomonas fluorescens, </PDAT></ITALIC></HIL><PDAT>and </PDAT><HIL><ITALIC><PDAT>Pseudomonas aeruginosa. </PDAT></ITALIC></HIL></PTEXT></PARA>
<PARA ID="P-00034" LVL="0"><PTEXT><PDAT>Suitable effector proteins include a hypersensitive response elicitor, an avirulence protein, a hypersensitive response and pathogenicity-dependent outer protein, a virulence protein, and a pathogenicity protein. Examples of effector proteins include HopPsyA AAF71481 (</PDAT><HIL><ITALIC><PDAT>P. syringae</PDAT></ITALIC></HIL><PDAT>), HopPtoA AF232006 (</PDAT><HIL><ITALIC><PDAT>P. syringae</PDAT></ITALIC></HIL><PDAT>), Tir BAA96815 (</PDAT><HIL><ITALIC><PDAT>E. coli</PDAT></ITALIC></HIL><PDAT>), ExoS AAG07228 (</PDAT><HIL><ITALIC><PDAT>P. aeruginosa</PDAT></ITALIC></HIL><PDAT>), ExoT AAG03434 (</PDAT><HIL><ITALIC><PDAT>P. aeruginosa</PDAT></ITALIC></HIL><PDAT>), ExoY AAG05579 (</PDAT><HIL><ITALIC><PDAT>P. aeruginosa</PDAT></ITALIC></HIL><PDAT>), SopE AAC02071 (</PDAT><HIL><ITALIC><PDAT>S. typhimurium</PDAT></ITALIC></HIL><PDAT>), SopB AAF21057 (SigA) (</PDAT><HIL><ITALIC><PDAT>S. typhimurium</PDAT></ITALIC></HIL><PDAT>), SipA CAA63302 (</PDAT><HIL><ITALIC><PDAT>S. typhimurium</PDAT></ITALIC></HIL><PDAT>), SptP AAC44349 (</PDAT><HIL><ITALIC><PDAT>S. typhimurium</PDAT></ITALIC></HIL><PDAT>), IpaB A34965 (Shigella spp.), IpaA AAA26525 (Shigella spp.), IpaD S15579 (Shigella spp.), YopE S14242 (Yersinia spp.), YopH AAC69768 (Yersinia spp.), YpkA AAC69765 (Yersinia spp.), YopJ AAC69766 (YopP) (Yersinia spp.), AvrPto AAA25728 (</PDAT><HIL><ITALIC><PDAT>P. syringae</PDAT></ITALIC></HIL><PDAT>), AvrBs2 AAD11434 (</PDAT><HIL><ITALIC><PDAT>X. campestris</PDAT></ITALIC></HIL><PDAT>), and AvrBs3 CAA34257 (</PDAT><HIL><ITALIC><PDAT>X. campestris</PDAT></ITALIC></HIL><PDAT>) (see, e.g., Gal&aacute;n et al., &ldquo;Type III Secretion Machines: Bacterial Devices for Protein Delivery into Host Cells,&rdquo; </PDAT><HIL><ITALIC><PDAT>Science </PDAT></ITALIC></HIL><PDAT>284:1322-1328 (1999), which is hereby incorporated by reference).</PDAT></PTEXT></PARA>
<PARA ID="P-00035" LVL="0"><PTEXT><PDAT>In one embodiment, the effector protein is heterologous (i.e., not normally present) to the target cell.</PDAT></PTEXT></PARA>
<PARA ID="P-00036" LVL="0"><PTEXT><PDAT>In the present invention, the effector protein is fused to a protein transduction domain (PTD) of a human immunodeficiency virus (HIV) trans-activating protein (TAT) protein or derivatives or functional analogs thereof to produce a fusion protein. The protein transduction domain of a human immunodeficiency virus TAT protein has the following amino acid sequence YGRKKRRQRRR (SEQ. ID. No. 1) (Schwarze et al., &ldquo;In Vivo Protein Transduction: Delivery of a Biologically Active Protein into the Mouse,&rdquo; </PDAT><HIL><ITALIC><PDAT>Science </PDAT></ITALIC></HIL><PDAT>285:1569-1572 (1999); Strauss, &ldquo;Introducing Proteins Into the Body&apos;s Cells,&rdquo; </PDAT><HIL><ITALIC><PDAT>Science </PDAT></ITALIC></HIL><PDAT>285:466-467 (1999), which are hereby incorporated by reference). Functional analogous protein transduction domains are also found in the herpes-simplex-virus-1 DNA-binding protein VP22 and the Drosophila Antennapedia (Antp) homeotic transcription factor (Joliot et al., &ldquo;Antennapedia Homeobox Peptide Regulates Neural Morphogenesis,&rdquo; </PDAT><HIL><ITALIC><PDAT>Proc. Natl. Acad. Sci. USA </PDAT></ITALIC></HIL><PDAT>88:1864-1868 (1991); Elliott, et al., &ldquo;Intercellular Trafficking and Protein Delivery by a Herpesvirus Structural Protein,&rdquo; </PDAT><HIL><ITALIC><PDAT>Cell </PDAT></ITALIC></HIL><PDAT>88:223-233 (1997), which are hereby incorporated by reference). A common factor in these protein transduction domains is the presence of the basic amino acids Arg and Lys. Research in several laboratories around the world is directed at identifying additional proteins with protein transduction domains and identifying variants of known protein transduction domains with improved protein transduction activity (Schwarze et al., &ldquo;Protein Transduction: Unrestricted Delivery Into All Cells&quest;,&rdquo; </PDAT><HIL><ITALIC><PDAT>Trends Cell Biol. </PDAT></ITALIC></HIL><PDAT>10:290-295 (2000), which is hereby incorporated by reference).</PDAT></PTEXT></PARA>
<PARA ID="P-00037" LVL="0"><PTEXT><PDAT>The fusion proteins of the present invention can be created by standard rDNA techniques. In particular, the effector protein may be linked to PTD from the human immunodeficiency virus TAT protein, whether a mRNA or a polypeptide fragment, by an in-frame gene fusion, which preferably results in linking the mRNA or polypeptide fragment to the N-terminal end of the effector protein. Such fusion proteins include a PTD from the HIV TAT protein linked to an effector protein, for example, by a peptide bond between the PTD from the HIV TAT protein and the effector protein. Fusion proteins can be prepared by ligating two or more DNA molecules together, one of which encodes the effector protein and the other of which encodes the PTD from the HIV TAT protein. The two DNA molecules must be ligated in a manner which allows their proper expressions. A number of efficient expression schemes for preparing fusion proteins have been developed and are well known in the art.</PDAT></PTEXT></PARA>
<PARA ID="P-00038" LVL="0"><PTEXT><PDAT>Methods for producing fusion proteins of the present invention are known in the art and are described in, for example, Schwarze et al., &ldquo;Protein Transduction: Unrestricted Delivery Into All Cells&quest;,&rdquo; </PDAT><HIL><ITALIC><PDAT>Trends in Cell Biology </PDAT></ITALIC></HIL><PDAT>10:290-295 (2000), which is hereby incorporated by reference.</PDAT></PTEXT></PARA>
<PARA ID="P-00039" LVL="0"><PTEXT><PDAT>In one embodiment, the effector protein fused to a protein transduction domain of a human immunodeficiency virus TAT protein or derivatives or functional analogs thereof is introduced into the largest cell by topical application.</PDAT></PTEXT></PARA>
<PARA ID="P-00040" LVL="0"><PTEXT><PDAT>In another embodiment, the effector protein fused to a protein transduction domain of a human immunodeficiency virus TAT protein or derivatives or functional analogs thereof is introduced by introducing into the target cell a DNA construct which includes a DNA molecule encoding an effector protein operatively associated with a DNA molecule encoding a protein transduction domain of a human immunodeficiency virus TAT protein or derivatives or functional analogs thereof under conditions effective to express the DNA molecule encoding an effector protein in the target cell. This embodiment allows the delivery of the effector protein fused to a protein transduction domain of a human immunodeficiency virus TAT protein to be targeted to particular cells, depending upon the expression system used to deliver the DNA construct. In addition, this embodiment allows secondary redistribution of the effector protein subsequent to the initial targeting.</PDAT></PTEXT></PARA>
<PARA ID="P-00041" LVL="0"><PTEXT><PDAT>Once the DNA construct is obtained, it can be incorporated in cells using conventional recombinant DNA technology. Generally, this involves inserting the DNA construct into an expression system to which the DNA construct is heterologous (i.e., not normally present). Expression systems of the present invention contain an expression vector into which is inserted one or more heterologous DNA constructs of the present invention. The heterologous DNA construct is inserted into the expression system or vector in proper sense orientation. The vector contains the necessary elements for the transcription of the DNA constructs of the present invention.</PDAT></PTEXT></PARA>
<PARA ID="P-00042" LVL="0"><PTEXT><PDAT>U.S. Pat. No. 4,237,224 to Cohen and Boyer, which is hereby incorporated by reference, describes the production of expression systems in the form of recombinant plasmids using restriction enzyme cleavage and ligation with DNA ligase. These recombinant plasmids are then introduced by means of transformation and transfection, and replicated in cultures including prokaryotic organisms and eukaryotic cells grown in tissue culture.</PDAT></PTEXT></PARA>
<PARA ID="P-00043" LVL="0"><PTEXT><PDAT>Recombinant or engineered genes may also be introduced into viruses, such as vaccinia virus. Recombinant viruses can be generated by transfection of plasmids into cells infected with virus.</PDAT></PTEXT></PARA>
<PARA ID="P-00044" LVL="0"><PTEXT><PDAT>Suitable vectors include, but are not limited to, the following viral vectors such as lambda vector system gt11, gt WES.tB, Charon 4, and plasmid vectors such as pBR322, pBR325, pACYC177, pACYC184, pUC8, pUC9, pUC18, pUC19, pLG339, pR290, pKC37, pKC101, SV 40, pBluescript II SK &plus;/&minus; or KS &plus;/&minus; (see &ldquo;Stratagene Cloning Systems&rdquo; Catalog (1993) from Stratagene, La Jolla, Calif., which is hereby incorporated by reference), pQE, pIH821, pGEX, pET series (see Studier et. al., &ldquo;Use of T7 RNA Polymerase to Direct Expression of Cloned Genes,&rdquo; </PDAT><HIL><ITALIC><PDAT>Gene Expression Technology, </PDAT></ITALIC></HIL><PDAT>vol. 185 (1990), which is hereby incorporated by reference), and any derivatives thereof. Suitable vectors are continually being developed and identified. Recombinant molecules can be introduced into cells via transformation, transduction, conjugation, mobilization, or electroporation. The DNA sequences are cloned into the vector using standard cloning procedures in the art, as described by Maniatis et al., </PDAT><HIL><ITALIC><PDAT>Molecular Cloning: A Laboratory Manual, </PDAT></ITALIC></HIL><PDAT>Cold Springs Laboratory, Cold Springs Harbor, N.Y. (1982), which is hereby incorporated by reference.</PDAT></PTEXT></PARA>
<PARA ID="P-00045" LVL="0"><PTEXT><PDAT>A variety of host-vector systems may be utilized to express the effector protein fused to the PTD of the HIV TAT protein. Primarily, the vector system must be compatible with the host cell used. Host-vector systems include, but are not limited to, the following: bacteria transformed with bacteriophage DNA, plasmid DNA, or cosmid DNA; microorganisms such as yeast containing yeast vectors; mammalian cell systems infected with virus (e.g., vaccinia virus, adenovirus, etc.); insect cell systems infected with virus (e.g., baculovirus); and plant cells infected by bacteria or transformed via particle bombardment (i.e., biolistics). The expression elements of these vectors vary in their strength and specificities. Depending upon the host-vector system utilized, any one of a number of suitable transcription elements can be used.</PDAT></PTEXT></PARA>
<PARA ID="P-00046" LVL="0"><PTEXT><PDAT>Different genetic signals and processing events control many levels of gene expression (e.g., DNA transcription and messenger RNA (mRNA) translation).</PDAT></PTEXT></PARA>
<PARA ID="P-00047" LVL="0"><PTEXT><PDAT>Transcription of DNA is dependent upon the presence of a promoter which is a DNA sequence that directs the binding of RNA polymerase and thereby promotes mRNA synthesis. The DNA sequences of eucaryotic promoters differ from those of procaryotic promoters. Furthermore, eucaryotic promoters and accompanying genetic signals may not be recognized in or may not function in a procaryotic system, and, further, procaryotic promoters are not recognized and do not function in eucaryotic cells.</PDAT></PTEXT></PARA>
<PARA ID="P-00048" LVL="0"><PTEXT><PDAT>Specific initiation signals are also required for efficient gene transcription and translation in procaryotic cells. These transcription and translation initiation signals may vary in &ldquo;strength&rdquo; as measured by the quantity of gene specific messenger RNA and protein synthesized, respectively. The DNA expression vector, which contains a promoter, may also contain any combination of various &ldquo;strong&rdquo; transcription and/or translation initiation signals. Efficient translation of mRNA in procaryotes requires a ribosome binding site called the Shine-Dalgarno (&ldquo;SD&rdquo;) sequence on the mRNA. This sequence is a short nucleotide sequence of mRNA that is located before the start codon, usually ATG, which encodes the amino-terminal methionine of the protein. The SD sequences are complementary to the 3&prime;-end of the 16S rRNA (ribosomal RNA) and probably promote binding of mRNA to ribosomes by duplexing with the rRNA to allow correct positioning of the ribosome. Thus, any SD-ATG combination that can be utilized by host cell ribosomes may be employed. Such combinations include, but are not limited to, SD-ATG combinations synthesized by recombinant techniques, the SD-ATG combination from the cro gene or the N gene of coliphage lambda, or from the </PDAT><HIL><ITALIC><PDAT>Escherichia coli </PDAT></ITALIC></HIL><PDAT>tryptophan E, D, C, B or A genes. For a review on maximizing gene expression, see Roberts and Lauer, </PDAT><HIL><ITALIC><PDAT>Methods in Enzymology, </PDAT></ITALIC></HIL><PDAT>68:473 (1979), which is hereby incorporated by reference.</PDAT></PTEXT></PARA>
<PARA ID="P-00049" LVL="0"><PTEXT><PDAT>Promoters vary in their &ldquo;strength&rdquo; (i.e. their ability to promote transcription). For the purposes of expressing a cloned DNA construct of the present invention, it is desirable to use strong promoters in order to obtain a high level of transcription and, hence, expression of the DNA construct. Depending upon the host cell system utilized, any one of a number of suitable promoters may be used. For instance, when cloning in </PDAT><HIL><ITALIC><PDAT>Escherichia coli, </PDAT></ITALIC></HIL><PDAT>its bacteriophages, or plasmids, promoters such as the T7 phage promoter, lac promoter, trp promoter, recA promoter, ribosomal RNA promoter, the PR and PL promoters of coliphage lambda and others, including but not limited, to lacUV5, ompF, bla, lpp, and the like, may be used to direct high levels of transcription of adjacent DNA segments. Additionally, a hybrid trp-lacUV5 (tac) promoter or other </PDAT><HIL><ITALIC><PDAT>Escherichia coli </PDAT></ITALIC></HIL><PDAT>promoters produced by recombinant DNA or other synthetic DNA techniques may be used to provide for transcription of the inserted construct.</PDAT></PTEXT></PARA>
<PARA ID="P-00050" LVL="0"><PTEXT><PDAT>Expression vectors may be chosen which inhibit the action of the promoter unless specifically induced. In certain operons, the addition of specific inducers is necessary for efficient transcription of the inserted DNA. For example, the lac operon is induced by the addition of lactose or IPTG (isopropylthio-beta-D-galactoside). A variety of other operons, such as trp, pro, etc., are under different controls.</PDAT></PTEXT></PARA>
<PARA ID="P-00051" LVL="0"><PTEXT><PDAT>The present invention also relates to a DNA construct including a first DNA molecule encoding an effector protein and a second DNA molecule operatively associated with the first DNA molecule and encoding a protein transduction domain of a human immunodeficiency virus TAT protein or derivatives or functional analogs thereof.</PDAT></PTEXT></PARA>
<PARA ID="P-00052" LVL="0"><PTEXT><PDAT>The present invention allows the delivery of effector proteins into patients in the form of protein therapy. Therapy with biologically active full-length proteins will allow access to the built-in evolutionary specificity of these proteins for their targets, thereby potentially avoiding the nonspecific effects sometimes seen with small molecule therapies.</PDAT></PTEXT></PARA>
<PARA ID="P-00053" LVL="0"><PTEXT><PDAT>Techniques for delivery of effector proteins into patients in the form of protein therapy are described in Schwartz et al., &ldquo;Protein Transduction: Unrestricted Delivery Into All Cells&quest;,&rdquo; </PDAT><HIL><ITALIC><PDAT>Trends in Cell Biology </PDAT></ITALIC></HIL><PDAT>10:290-295 (2000), which is hereby incorporated by reference. They can be administered orally, parenterally, subcutaneously, intravenously, intramuscularly, intraperitoneally, by intranasal instillation, by intracavitary or intravesical instillation, intraocularly, intraarterially, intralesionally, or by application to mucous membranes, such as, that of the nose, throat, and bronchial tubes. They may be administered alone or with pharmaceutically or physiologically acceptable carriers, excipients, or stabilizers, and can be in solid or liquid form such as, tablets, capsules, powders, solutions, suspensions, or emulsions.</PDAT></PTEXT></PARA>
<PARA ID="P-00054" LVL="0"><PTEXT><PDAT>The solid unit dosage forms can be of the conventional type. The solid form can be a capsule, such as an ordinary gelatin type containing the fusion protein of the present invention and a carrier, for example, lubricants and inert fillers such as, lactose, sucrose, or cornstarch. In another embodiment, these compounds are tableted with conventional tablet bases such as lactose, sucrose, or cornstarch in combination with binders like acacia, cornstarch, or gelatin, disintegrating agents such as, cornstarch, potato starch, or alginic acid, and a lubricant like stearic acid or magnesium stearate.</PDAT></PTEXT></PARA>
<PARA ID="P-00055" LVL="0"><PTEXT><PDAT>The fusion protein of the present invention may also be administered in injectable dosages by solution or suspension of these materials in a physiologically acceptable diluent with a pharmaceutical carrier. Such carriers include sterile liquids such as water and oils, with or without the addition of a surfactant and other pharmaceutically and physiologically acceptable carrier, including adjuvants, excipients or stabilizers. Illustrative oils are those of petroleum, animal, vegetable, or synthetic origin, for example, peanut oil, soybean oil, or mineral oil. In general, water, saline, aqueous dextrose and related sugar solution, and glycols such as, propylene glycol or polyethylene glycol, are preferred liquid carriers, particularly for injectable solutions.</PDAT></PTEXT></PARA>
<PARA ID="P-00056" LVL="0"><PTEXT><PDAT>For use as aerosols, the fusion protein of the present invention in solution or suspension may be packaged in a pressurized aerosol container together with suitable propellants, for example, hydrocarbon propellants like propane, butane, or isobutane with conventional adjuvants. The fusion proteins of the present invention also may be administered in a non-pressurized form such as in a nebulizer or atomizer.</PDAT></PTEXT></PARA>
<H LVL="1"><STEXT><PDAT>EXAMPLES</PDAT></STEXT></H>
<H LVL="1"><STEXT><PDAT>Example 1</PDAT></STEXT></H>
<PARA ID="P-00057" LVL="7"><PTEXT><PDAT>Construction of pCPP3122 (pDF4) (pET16B derivative): A Vector Containing a HIS6-tag and the TAT Protein Transduction Domain (PTD)</PDAT></PTEXT></PARA>
<PARA ID="P-00058" LVL="0"><PTEXT><PDAT>To create His6-TAT-effector protein fusions, pET16B (Novagen, Madison, Wis.) was digested with NdeI and NcoI to remove the existing HIS-tag and Factor Xa protease cleavage regions, giving the following sequence (SEQ. ID. No. 2):</PDAT></PTEXT></PARA>
<CWU>
<TABLE-US ID="TABLE-US-00001">
<TABLE-CALS>
<table frame="none" colsep="0" rowsep="0" pgwide="1" tabstyle="monospace">
<tgroup align="left" colsep="0" rowsep="0" cols="2">
<colspec colname="1" colwidth="294pt" align="left"/>
<colspec colname="2" colwidth="-301pt" align="left"/>
<tbody valign="top">
<row>
<entry><PTEXT><PDAT>&emsp;NcoI&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;NdeI</PDAT></PTEXT></entry>
<entry></entry>
</row>
<row>
<entry><PTEXT><HIL><ULINE><PDAT>CC</PDAT><HIL><BOLD><PDAT>ATG</PDAT></BOLD></HIL><PDAT>GG</PDAT></ULINE></HIL><PDAT>CCATCATCATCATCATCATCATCATCATCACAGCAGCGGCCATATCGAAGGTCGT</PDAT><HIL><ULINE><PDAT>CATATG</PDAT></ULINE></HIL></PTEXT></entry>
</row>
</tbody>
</tgroup>
</table>
</TABLE-CALS>
</TABLE-US>
</CWU>
<PARA ID="P-00059" LVL="7"><PTEXT><PDAT>The corresponding amino acid sequence is MGHHHHHHHHHHSSGHIEGRHM (SEQ. ID. No. 3) (HHHHHHHHHH is HIS-Tag).</PDAT></PTEXT></PARA>
<PARA ID="P-00060" LVL="0"><PTEXT><PDAT>This digested vector was gel purified on a 1% agarose gel to separate the vector backbone from the sequence illustrated above. The vector backbone fragment was eluted from the gel matrix using the Bio-Rad (Hercules, Calif.) prep-a-gene kit. This purified fragment was ligated to a fragment containing NcoI and NdeI sticky ends that was prepared as follows. To generate an oligonucleotide containing NcoI and NdeI and the nucleotide sequence (SEQ. ID. No. 4):</PDAT></PTEXT></PARA>
<CWU>
<TABLE-US ID="TABLE-US-00002">
<TABLE-CALS>
<table frame="none" colsep="0" rowsep="0" pgwide="1" tabstyle="monospace">
<tgroup align="left" colsep="0" rowsep="0" cols="2">
<colspec colname="1" colwidth="308pt" align="left"/>
<colspec colname="2" colwidth="-315pt" align="left"/>
<tbody valign="top">
<row>
<entry><PTEXT><PDAT>&emsp;NcoI&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;NdeI</PDAT></PTEXT></entry>
<entry></entry>
</row>
<row>
<entry><PTEXT><HIL><ULINE><PDAT>CC</PDAT></ULINE></HIL><HIL><ULINE><HIL><BOLD><PDAT>ATG</PDAT></BOLD></HIL></ULINE></HIL><HIL><ULINE><PDAT>G</PDAT></ULINE></HIL><PDAT>GCCATCACCATCACCATCACGGCTATGGCCGTAAAAAACGCCGTCAGCGCCGTCGCGGT</PDAT><HIL><ULINE><PDAT>CATATG</PDAT></ULINE></HIL></PTEXT></entry>
</row>
</tbody>
</tgroup>
</table>
</TABLE-CALS>
</TABLE-US>
</CWU>
<PARA ID="P-00061" LVL="7"><PTEXT><PDAT>with the corresponding amino acid sequence (SEQ. ID. No. 5):</PDAT></PTEXT></PARA>
<CWU>
<TABLE-US ID="TABLE-US-00003">
<TABLE-CALS>
<table frame="none" colsep="0" rowsep="0" tabstyle="monospace">
<tgroup align="left" colsep="0" rowsep="0" cols="2">
<colspec colname="offset" colwidth="56pt" align="left"/>
<colspec colname="1" colwidth="161pt" align="left"/>
<tbody valign="top">
<row>
<entry></entry>
<entry><PTEXT><PDAT>MG</PDAT><HIL><ULINE><PDAT>HHHHHH</PDAT></ULINE></HIL><PDAT>G</PDAT><HIL><ULINE><PDAT>YGRKKRRQRRR</PDAT></ULINE></HIL><PDAT>GHM</PDAT></PTEXT></entry>
</row>
<row>
<entry></entry>
<entry><PTEXT><PDAT>&emsp;&emsp;HIS-Tag&emsp;&emsp;PTD domain</PDAT></PTEXT></entry>
</row>
</tbody>
</tgroup>
</table>
</TABLE-CALS>
</TABLE-US>
</CWU>
<PARA ID="P-00062" LVL="7"><PTEXT><PDAT>four oligonucleotides were synthesized by IDT Inc. (Coralville, Iowa) with the sequences:</PDAT></PTEXT></PARA>
<CWU>
<TABLE-US ID="TABLE-US-00004">
<TABLE-CALS>
<table frame="none" colsep="0" rowsep="0" pgwide="1" tabstyle="monospace">
<tgroup align="left" colsep="0" rowsep="0" cols="2">
<colspec colname="1" colwidth="336pt" align="left"/>
<colspec colname="2" colwidth="-343pt" align="left"/>
<tbody valign="top">
<row>
<entry><PTEXT><PDAT>&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;NcoI&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;EaeI</PDAT></PTEXT></entry>
<entry></entry>
</row>
<row>
<entry><PTEXT><PDAT>pET16b-His6T GGATCA</PDAT><HIL><ULINE><PDAT>CCATGG</PDAT></ULINE></HIL><PDAT>GCCATCACCATCACCATCACGGCTA</PDAT><HIL><ULINE><PDAT>TGGCCG</PDAT></ULINE></HIL><PDAT>TAGTCG (SEQ. ID. No.6)</PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT> </PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;NcoI&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;EaeI</PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>pET16b-His6B CGACTA</PDAT><HIL><ULINE><PDAT>CGGCCA</PDAT></ULINE></HIL><PDAT>TAGCCGTGATGGTGATGGTGATGGC</PDAT><HIL><ULINE><PDAT>CCATGG</PDAT></ULINE></HIL><PDAT>TGATCC (SEQ. ID. No.7)</PDAT></PTEXT></entry>
</row>
</tbody>
</tgroup>
</table>
</TABLE-CALS>
</TABLE-US>
</CWU>
<CWU>
<TABLE-US ID="TABLE-US-00005">
<TABLE-CALS>
<table frame="none" colsep="0" rowsep="0" pgwide="1" tabstyle="monospace">
<tgroup align="left" colsep="0" rowsep="0" cols="2">
<colspec colname="1" colwidth="287pt" align="left"/>
<colspec colname="2" colwidth="-294pt" align="left"/>
<tbody valign="top">
<row>
<entry><PTEXT><PDAT>&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;EaeI&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;NdeI</PDAT></PTEXT></entry>
<entry></entry>
</row>
<row>
<entry><PTEXT><PDAT>pET16b-TatT CGGCTA</PDAT><HIL><ULINE><PDAT>TGGCCG</PDAT></ULINE></HIL><PDAT>TAAAAAACGCCGTCAGCGCCGTCGCGGT</PDAT><HIL><ULINE><PDAT>CATATG</PDAT></ULINE></HIL><PDAT>TTACTAGC (SEQ. ID. No.8)</PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT> </PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;EaeI&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;NdeI</PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>pET16b-TatB GCTAGTAA</PDAT><HIL><ULINE><PDAT>CATATG</PDAT></ULINE></HIL><PDAT>ACCGCGACGGCGCTGACGGCGTTTTTTA</PDAT><HIL><ULINE><PDAT>CGGCCA</PDAT></ULINE></HIL><PDAT>TAGCCG (SEQ. ID. No.9)</PDAT></PTEXT></entry>
</row>
</tbody>
</tgroup>
</table>
</TABLE-CALS>
</TABLE-US>
</CWU>
<PARA ID="P-00063" LVL="7"><PTEXT><PDAT>These 2 sets of oligonucleotides were annealed, digested with EaeI, and ligated together to create:</PDAT></PTEXT></PARA>
<CWU>
<TABLE-US ID="TABLE-US-00006">
<TABLE-CALS>
<table frame="none" colsep="0" rowsep="0" pgwide="1" tabstyle="monospace">
<tgroup align="left" colsep="0" rowsep="0" cols="2">
<colspec colname="1" colwidth="364pt" align="left"/>
<colspec colname="2" colwidth="-371pt" align="left"/>
<tbody valign="top">
<row>
<entry><PTEXT><PDAT>&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;NcoI&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;EaeI&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;NdeI</PDAT></PTEXT></entry>
<entry></entry>
</row>
<row>
<entry><PTEXT><PDAT>GGATCA</PDAT><HIL><ULINE><PDAT>CCATGG</PDAT></ULINE></HIL><PDAT>GCCATCACCATCACCATCACGGCTA</PDAT><HIL><ULINE><PDAT>TGGCCG</PDAT></ULINE></HIL><PDAT>TAAAAAACGCCGTCAGCGCCGTCGCGGT</PDAT><HIL><ULINE><PDAT>CATATG</PDAT></ULINE></HIL><PDAT>TTACTAGC</PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT> </PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>CCTAGT</PDAT><HIL><ULINE><PDAT>GGTACC</PDAT></ULINE></HIL><PDAT>CGGTAGTGGTAGTGGTAGTGCCGAT</PDAT><HIL><ULINE><PDAT>ACCGGC</PDAT></ULINE></HIL><PDAT>ATTTTTTGCGGCAGTCGCGGCAGCGCCA</PDAT><HIL><ULINE><PDAT>GTATAC</PDAT></ULINE></HIL><PDAT>AATGATCG</PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>(SEQ. ID. No.10)</PDAT></PTEXT></entry>
</row>
</tbody>
</tgroup>
</table>
</TABLE-CALS>
</TABLE-US>
</CWU>
<PARA ID="P-00064" LVL="7"><PTEXT><PDAT>The larger fragment was digested with NcoI and NdeI and was separated from the smaller fragments by passage through a G25 spin column (Pharmacia, Piscataway, N.J.). This final construct was ligated to the former pET16B vector backbone. After overnight ligation at 16&deg; C., half the ligation mix was transformed into </PDAT><HIL><ITALIC><PDAT>E. coli </PDAT></ITALIC></HIL><PDAT>DH5&agr; (SupE44 &Dgr;lacU169 (f80 lacZ&Dgr;M15) hsdR17 recA1 endA1 gyrA96 thi-1, available from Life Technologies, Grand Island, N.Y.) via heat-shock transformation. Colonies were selected on LB&plus;Amp plates.</PDAT></PTEXT></PARA>
<PARA ID="P-00065" LVL="0"><PTEXT><PDAT>Several individual colonies were cultured and the DNA was harvested and sequenced. A clone containing the desired sequence was obtained and frozen at 80&deg; C.</PDAT></PTEXT></PARA>
<PARA ID="P-00066" LVL="0"><PTEXT><PDAT>To create a better multiple cloning site and to obtain a transcription terminator, maintaining flexibility with an existing pFLAG-CTC cloning system, an NdeI-SSPI fragment was cloned from pFLAG-CTC (for construction of C-terminal fusion to FLAG peptide, Ap</PDAT><HIL><SP><PDAT>r</PDAT></SP></HIL><PDAT>, available from Kodak Scientific Imaging Systems, Rochester, N.Y.). This construct was verified via restriction enzyme digests.</PDAT></PTEXT></PARA>
<PARA ID="P-00067" LVL="0"><PTEXT><PDAT>A key advantage of pCPP3122 is that it facilitates rapid generation of fusion proteins from effector genes originally cloned in pFLAG-CTC. The latter vector is used to demonstrate that candidate effector proteins are secreted by the type III secretion system.</PDAT></PTEXT></PARA>
<H LVL="1"><STEXT><PDAT>Example 2</PDAT></STEXT></H>
<PARA ID="P-00068" LVL="7"><PTEXT><PDAT>Construction of pCPP3122 Derivatives Expressing Fusions Proteins Including Two Different Effector Proteins</PDAT></PTEXT></PARA>
<PARA ID="P-00069" LVL="0"><PTEXT><PDAT>hopPsyA encodes the HopPsyA (HrmA) protein of </PDAT><HIL><ITALIC><PDAT>Pseudomonas syringae </PDAT></ITALIC></HIL><PDAT>pv. </PDAT><HIL><ITALIC><PDAT>syringae </PDAT></ITALIC></HIL><PDAT>61, and has the following sequence (SEQ. ID. No. 11):</PDAT></PTEXT></PARA>
<PARA ID="P-00070" LVL="1"><PTEXT><PDAT>GTGAACCCTATCCATGCACGCTTCTCCAGCGTAGAAGCGCTCAGACATTCAAACGTTGATATTCAGGCAATCAAATCCGAGGGTCAGTTGGAAGTCAACGGCAAGCGTTACGAGATTCGTGCGGCCGCTGACGGCTCAATCGCGGTCCTCAGACCCGATCAACAGTCCAAAGCAGACAAGTTCTTCAAAGGCGCAGCGCATCTTATTGGCGGACAAAGCCAGCGTGCCCAAATAGCCCAGGTACTCAACGAGAAAGCGGCGGCAGTTCCACGCCTGGACAGAATGTTGGGCAGACGCTTCGATCTGGAGAAGGGCGGAAGTAGCGCTGTGGGCGCCGCAATCAAGGCTGCCGACAGCCGACTGACATCAAAACAGACATTTGCCAGCTTCCAGCAATGGGCTGAAAAAGCTGAGGCGCTCGGGCGATACCGAAATCGGTATCTACATGATCTACAAGAGGGACACGCCAGACACAACGCCTATGAATGCGGCAGAGTCAAGAACATTACCTGGAAACGCTACAGGCTCTCGATAACAAGAAAAACCTTATCATACGCCCCGCAGATCCATGATGATCGGGAAGAGGAAGAGCTTGATCTGGGCCGATACATCGCTGAAGACAGAAATGCCAGAACCGGCTTTTTTAGAATGGTTCCTAAAGACCAACGCGCACCTGAGACAAACTCGGGACGACTTACCATTGGTGTAGAACCTAAATATGGAGCGCAGTTGGCCCTCGCAATGGCAACCCTGATGGACAAGCACAAATCTGTGACACAAGGTAAAGTCGTCGGTCCGGCAAAATATGGCCAGCAAACTGACTCTGCCATTCTTTACATAAATGGTGATCTTGCAAAAGCAGTAAAACTGGGCGAAAAGCTGAAAAAGCTGAGCGGTATCCCTCCTGAAGGATTCGTCGAACATACACCGCTAAGCATGCAGTCGACGGGTCTCGGTCTTTCTTATGCCGAGTCGGTTGAAGGGCAGCCTTCCAGCCACGGACAGGCGAGAACACACGTTATCATGGATGCCTTGAAAGGCCAGGGCCCCATGGAGAACAGACTCAAAATGGCGCTGGCAGAAAGAGGCTATGACCCGGAAAATCCGGCGCTCAGGGCGCGAAACTGA (1128)</PDAT></PTEXT></PARA>
<PARA ID="P-00071" LVL="0"><PTEXT><PDAT>HopPsyA has an amino acid sequence (SEQ. ID. No. 12) as follows:</PDAT></PTEXT></PARA>
<PARA ID="P-00072" LVL="1"><PTEXT><PDAT>VNPIHARFSSVEALRHSNVDIQAIKSEGQLEVNGKRYEIRAAADGSIAVLRPDQQSKADKFFKGAAHLIGGQSQRAQIAQVLNEKAAAVPRLDRMLGRRFDLEKGGSSAVGAAIKAADSRLTSKQTFASFQQWAEKAEALGRYRNRYLHDLQEGHARHNAYECGRVKNITWKRYRLSITRKTLSYAPQIHDDREEEELDLGRYIAEDRNARTGFFRMVPKDQRAPETNSGRLTIGVEPKYGAQLALAMATLMDKHKSVTQGKVVGPAKYGQQTDSAILYINGDLAKAVKLGEKLKKLSGIPPEGFVEHTPLSMQSTGLGLSYAESVEGQPSSHGQARTHVIMDALKGQGPMENRLKMALAERGYDPENPALRARN (375)</PDAT></PTEXT></PARA>
<PARA ID="P-00073" LVL="7"><PTEXT><PDAT>HopPsyA was cloned into pCPP3122 via an NdeI-SSPI fragment from pFLAG-CTC::HopPsyA (pCPP2352) to create pCPP3125 (FIG. </PDAT><HIL><BOLD><PDAT>3</PDAT></BOLD></HIL><PDAT>).</PDAT></PTEXT></PARA>
<PARA ID="P-00074" LVL="0"><PTEXT><PDAT>HopPtoA encodes the HopPtoA protein of </PDAT><HIL><ITALIC><PDAT>Pseudomonas syringae </PDAT></ITALIC></HIL><PDAT>pv. </PDAT><HIL><ITALIC><PDAT>tomato </PDAT></ITALIC></HIL><PDAT>DC300 CEL, and has the following sequence (SEQ. ID. No. 13):</PDAT></PTEXT></PARA>
<PARA ID="P-00075" LVL="1"><PTEXT><PDAT>ATGCACATCAACCGACGCGTCCAACAACCGCCTGTGACTGCGACGGATAGCTTTCGGACAGCGTCCGACGCGTCTCTTGCCTCCAGCTCTGTGCGATCTGTCAGCTCCGATCAGCAACGCGAGATAAATGCGATTGCCGATTACCTGACAGATCATGTGTTCGCTGCGCATAAACTGCCGCCGGCCGATTCGGCTGATGGCCAAGCTGCAGTTGACGTACACAATGCGCAGATCACTGCGCTGATCGAGACGCGCGCCAGCCGCCTGCACTTCGAAGGGGAAACCCCGGCAACCATCGCCGACACCTTCGCCAAGGCGGAAAAGCTCGACCGATTGGCGACGACTACATCAGGCGCGTTGCGGGCGACGCCCTTTGCCATGGCCTCGTTGCTTCAGTACATGCAGCCTGCGATCAACAAGGGCGATTGGCTGCCGGCTCCGCTCAAACCGCTGACCCCGCTCATTTCCGGAGCGCTGTCGGGCGCCATGGACCAGGTGGGCACCAAGATGATGGACCGCGCGACGGGTGATCTGCATTACCTGAGCGCCTCGCCGGACAGGCTCCACGATGCGATGGCCGCTTCGGTGAAGCGCCACTCGCCAAGCCTTGCTCGACAGGTTCTGGACACGGGGGTTGCGGTTCAGACGTACTCGGCGCGCAACGCCGTACGTACCGTATTGGCTCCGGCACTGGCGTCCAGACCCGCCGTGCAGGGTGCTGTGGACCTTGGTGTATCGATGGCGGGTGGTCTGGCTGCCAACGCAGGCTTTGGCAACCGCCTGCTCAGTGTGCAGTCGCGTGATCACCAGCGTGGCGGTGCATTAGTGCTCGGTTTGAAGGATAAAGAGCCCAAGGCTCAACTGAGCGAAGAAAACGACTGGCTCGAGGCTTATAAAGCAATCAAATCGGCCAGCTACTCGGGTGCGGCGCTCAACGCTGGCAAGCGGATGGCCGGTCTGCCACTGGATATGGCGACCGACGCAATGGGTGCGGTAAGAAGCCTGGTGTCAGCGTCCAGCCTGACCCAAAACGGTCTGGCCCTGGCGGGTGGCTTTGCAGGGGTAGGCAAGTTGCAGGAGATGGCGACGAAAAATATCACCGACCCGGCGACCAAGGCCGCGGTCAGTCAGTTGACCAACCTGGCAGGTTCGGCAGCCGTTTTCGCAGGCTGGACCACGGCCGCGCTGACAACCGATCCCGCGGTGAAAAAAGCCGAGTCGTTCATACAGGACACGGTGAAATCGACTGCATCCAGTACCACAGGCTACGTAGCCGACCAGACCGTCAAACTGGCGAAGACCGTCAAAGACATGGGCGGGGAGGCGATCACCCATACCGGCGCCAGCTTGCGCAATACGGTCAATAACCTGCGTCAACGCCCGGCTCGTGAAGCTGATATAGAAGAGGGGGGCACGGCGGCTTCTCCAAGTGAAATACCGTTTCGGCCTATGCGGTCGTAA (1461)</PDAT></PTEXT></PARA>
<PARA ID="P-00076" LVL="0"><PTEXT><PDAT>HopPtoA has an amino acid sequence (SEQ. ID. No. 14) as follows:</PDAT></PTEXT></PARA>
<PARA ID="P-00077" LVL="1"><PTEXT><PDAT>MHINRRVQQPPVTATDSFRTASDASLASSSVRSVSSDQQREINAIADYLTDHVFAAHKLPPADSADGQAAVDVHNAQITALIETRASRLHFEGETPATIADTFAKAEKLDRLATTTSGALRATPFAMASLLQYMQPAINKGDWLPAPLKPLTPLISGALSGAMDQVGTKMMDRATGDLHYLSASPDRLHDAMAASVKRHSPSLARQVLDTGVAVQTYSARNAVRTVLAPALASRPAVQGAVDLGVSMAGGLAANAGFGNRLLSVQSRDHQRGGALVLGLKDKEPKAQLSEENDWLEAYKAIKSASYSGAALNAGKRMAGLPLDMATDAMGAVRSLVSASSLTQNGLALAGGFAGVGKLQEMATKNITDPATKAAVSQLTNLAGSAAVFAGWTTAALTTDPAVKKAESFIQDTVKSTASSTTGYVADQTVKLAKTVKDMGGEAITHTGASLRNTVNNLRQRPAREADIEEGGTAASPSEIPFRPMRS (486)</PDAT></PTEXT></PARA>
<PARA ID="P-00078" LVL="0"><PTEXT><PDAT>HopPtoA was cloned into pCPP3122 via an NdeI-SalI fragment from pFLAG-CTC::HopPtoA to create pCPP3126 (FIG. </PDAT><HIL><BOLD><PDAT>4</PDAT></BOLD></HIL><PDAT>).</PDAT></PTEXT></PARA>
<PARA ID="P-00079" LVL="0"><PTEXT><PDAT>Although the invention has been described in detail for the purpose of illustration, it is understood that such detail is solely for that purpose, and variations can be made therein by those skilled in the art without departing from the spirit and scope of the invention which is defined by the following claims.</PDAT></PTEXT></PARA>
<CWU>
<SEQLST-US ID="SEQLST-1">
<SEQ-LST-NEW>
<S100>
<S160>
<PDAT>14</PDAT>
</S160>
</S100>
<S200>
<S210>
<PDAT>1</PDAT>
</S210>
<S211>
<PDAT>11</PDAT>
</S211>
<S212>
<PDAT>PRT</PDAT>
</S212>
<S213>
<PDAT>Homo sapiens</PDAT>
</S213>
</S200>
<S400>
<PDAT> 1
Tyr Gly Arg Lys Lys Arg Arg Gln Arg Arg Arg
  1               5                  10
</PDAT>
</S400>
<S200>
<S210>
<PDAT>2</PDAT>
</S210>
<S211>
<PDAT>68</PDAT>
</S211>
<S212>
<PDAT>DNA</PDAT>
</S212>
<S213>
<PDAT>Artificial Sequence</PDAT>
</S213>
<S220>
<S223><STEXT><PDAT>Description of Artificial Sequence
      Oligonucleotide</PDAT></STEXT></S223>
</S220>
</S200>
<S400>
<PDAT> 2
ccatgggcca tcatcatcat catcatcatc atcatcacag cagcggccat atcgaaggtc     60
gtcatatg                                                              68
</PDAT>
</S400>
<S200>
<S210>
<PDAT>3</PDAT>
</S210>
<S211>
<PDAT>22</PDAT>
</S211>
<S212>
<PDAT>PRT</PDAT>
</S212>
<S213>
<PDAT>Artificial Sequence</PDAT>
</S213>
<S220>
<S223><STEXT><PDAT>Description of Artificial Sequence
      Polypeptide</PDAT></STEXT></S223>
</S220>
</S200>
<S400>
<PDAT> 3
Met Gly His His His His His His His His His His Ser Ser Gly His
  1               5                  10                  15
Ile Glu Gly Arg His Met
             20
</PDAT>
</S400>
<S200>
<S210>
<PDAT>4</PDAT>
</S210>
<S211>
<PDAT>71</PDAT>
</S211>
<S212>
<PDAT>DNA</PDAT>
</S212>
<S213>
<PDAT>Artificial Sequence</PDAT>
</S213>
<S220>
<S223><STEXT><PDAT>Description of Artificial Sequence
      Oligonucleotide</PDAT></STEXT></S223>
</S220>
</S200>
<S400>
<PDAT> 4
ccatgggcca tcaccatcac catcacggct atggccgtaa aaaacgccgt cagcgccgtc     60
gcggtcatat g                                                          71
</PDAT>
</S400>
<S200>
<S210>
<PDAT>5</PDAT>
</S210>
<S211>
<PDAT>23</PDAT>
</S211>
<S212>
<PDAT>PRT</PDAT>
</S212>
<S213>
<PDAT>Artificial Sequence</PDAT>
</S213>
<S220>
<S223><STEXT><PDAT>Description of Artificial Sequence
      Polypeptide</PDAT></STEXT></S223>
</S220>
</S200>
<S400>
<PDAT> 5
Met Gly His His His His His His Gly Tyr Gly Arg Lys Lys Arg Arg
  1               5                  10                  15
Gln Arg Arg Arg Gly His Met
             20
</PDAT>
</S400>
<S200>
<S210>
<PDAT>6</PDAT>
</S210>
<S211>
<PDAT>49</PDAT>
</S211>
<S212>
<PDAT>DNA</PDAT>
</S212>
<S213>
<PDAT>Artificial Sequence</PDAT>
</S213>
<S220>
<S223><STEXT><PDAT>Description of Artificial Sequence
      Oligonucleotide</PDAT></STEXT></S223>
</S220>
</S200>
<S400>
<PDAT> 6
ggatcaccat gggccatcac catcaccatc acggctatgg ccgtagtcg                 49
</PDAT>
</S400>
<S200>
<S210>
<PDAT>7</PDAT>
</S210>
<S211>
<PDAT>49</PDAT>
</S211>
<S212>
<PDAT>DNA</PDAT>
</S212>
<S213>
<PDAT>Artificial Sequence</PDAT>
</S213>
<S220>
<S223><STEXT><PDAT>Description of Artificial Sequence
      Oligonucleotide</PDAT></STEXT></S223>
</S220>
</S200>
<S400>
<PDAT> 7
cgactacggc catagccgtg atggtgatgg tgatggccca tggtgatcc                 49
</PDAT>
</S400>
<S200>
<S210>
<PDAT>8</PDAT>
</S210>
<S211>
<PDAT>54</PDAT>
</S211>
<S212>
<PDAT>DNA</PDAT>
</S212>
<S213>
<PDAT>Artificial Sequence</PDAT>
</S213>
<S220>
<S223><STEXT><PDAT>Description of Artificial Sequence
      Oligonucleotide</PDAT></STEXT></S223>
</S220>
</S200>
<S400>
<PDAT> 8
cggctatggc cgtaaaaaac gccgtcagcg ccgtcgcggt catatgttac tagc           54
</PDAT>
</S400>
<S200>
<S210>
<PDAT>9</PDAT>
</S210>
<S211>
<PDAT>54</PDAT>
</S211>
<S212>
<PDAT>DNA</PDAT>
</S212>
<S213>
<PDAT>Artificial Sequence</PDAT>
</S213>
<S220>
<S223><STEXT><PDAT>Description of Artificial Sequence
      Oligonucleotide</PDAT></STEXT></S223>
</S220>
</S200>
<S400>
<PDAT> 9
gctagtaaca tatgaccgcg acggcgctga cggcgttttt tacggccata gccg           54
</PDAT>
</S400>
<S200>
<S210>
<PDAT>10</PDAT>
</S210>
<S211>
<PDAT>170</PDAT>
</S211>
<S212>
<PDAT>DNA</PDAT>
</S212>
<S213>
<PDAT>Artificial Sequence</PDAT>
</S213>
<S220>
<S223><STEXT><PDAT>Description of Artificial Sequence
      Oligonucleotide</PDAT></STEXT></S223>
</S220>
</S200>
<S400>
<PDAT> 10
ggatcaccat gggccatcac catcaccatc acggctatgg ccgtaaaaaa cgccgtcagc     60
gccgtcgcgg tcatatgtta ctagccctag tggtacccgg tagtggtagt ggtagtgccg    120
ataccggcat tttttgcggc agtcgcggca gcgccagtat acaatgatcg               170
</PDAT>
</S400>
<S200>
<S210>
<PDAT>11</PDAT>
</S210>
<S211>
<PDAT>1128</PDAT>
</S211>
<S212>
<PDAT>DNA</PDAT>
</S212>
<S213>
<PDAT>Pseudomonas syringae</PDAT>
</S213>
</S200>
<S400>
<PDAT> 11
gtgaacccta tccatgcacg cttctccagc gtagaagcgc tcagacattc aaacgttgat     60
attcaggcaa tcaaatccga gggtcagttg gaagtcaacg gcaagcgtta cgagattcgt    120
gcggccgctg acggctcaat cgcggtcctc agacccgatc aacagtccaa agcagacaag    180
ttcttcaaag gcgcagcgca tcttattggc ggacaaagcc agcgtgccca aatagcccag    240
gtactcaacg agaaagcggc ggcagttcca cgcctggaca gaatgttggg cagacgcttc    300
gatctggaga agggcggaag tagcgctgtg ggcgccgcaa tcaaggctgc cgacagccga    360
ctgacatcaa aacagacatt tgccagcttc cagcaatggg ctgaaaaagc tgaggcgctc    420
gggcgatacc gaaatcggta tctacatgat ctacaagagg gacacgccag acacaacgcc    480
tatgaatgcg gcagagtcaa gaacattacc tggaaacgct acaggctctc gataacaaga    540
aaaaccttat catacgcccc gcagatccat gatgatcggg aagaggaaga gcttgatctg    600
ggccgataca tcgctgaaga cagaaatgcc agaaccggct tttttagaat ggttcctaaa    660
gaccaacgcg cacctgagac aaactcggga cgacttacca ttggtgtaga acctaaatat    720
ggagcgcagt tggccctcgc aatggcaacc ctgatggaca agcacaaatc tgtgacacaa    780
ggtaaagtcg tcggtccggc aaaatatggc cagcaaactg actctgccat tctttacata    840
aatggtgatc ttgcaaaagc agtaaaactg ggcgaaaagc tgaaaaagct gagcggtatc    900
cctcctgaag gattcgtcga acatacaccg ctaagcatgc agtcgacggg tctcggtctt    960
tcttatgccg agtcggttga agggcagcct tccagccacg gacaggcgag aacacacgtt   1020
atcatggatg ccttgaaagg ccagggcccc atggagaaca gactcaaaat ggcgctggca   1080
gaaagaggct atgacccgga aaatccggcg ctcagggcgc gaaactga                1128
</PDAT>
</S400>
<S200>
<S210>
<PDAT>12</PDAT>
</S210>
<S211>
<PDAT>375</PDAT>
</S211>
<S212>
<PDAT>PRT</PDAT>
</S212>
<S213>
<PDAT>Pseudomonas syringae</PDAT>
</S213>
</S200>
<S400>
<PDAT> 12
Val Asn Pro Ile His Ala Arg Phe Ser Ser Val Glu Ala Leu Arg His
  1               5                  10                  15
Ser Asn Val Asp Ile Gln Ala Ile Lys Ser Glu Gly Gln Leu Glu Val
             20                  25                  30
Asn Gly Lys Arg Tyr Glu Ile Arg Ala Ala Ala Asp Gly Ser Ile Ala
         35                  40                  45
Val Leu Arg Pro Asp Gln Gln Ser Lys Ala Asp Lys Phe Phe Lys Gly
     50                  55                  60
Ala Ala His Leu Ile Gly Gly Gln Ser Gln Arg Ala Gln Ile Ala Gln
 65                  70                  75                  80
Val Leu Asn Glu Lys Ala Ala Ala Val Pro Arg Leu Asp Arg Met Leu
                 85                  90                  95
Gly Arg Arg Phe Asp Leu Glu Lys Gly Gly Ser Ser Ala Val Gly Ala
            100                 105                 110
Ala Ile Lys Ala Ala Asp Ser Arg Leu Thr Ser Lys Gln Thr Phe Ala
        115                 120                 125
Ser Phe Gln Gln Trp Ala Glu Lys Ala Glu Ala Leu Gly Arg Tyr Arg
    130                 135                 140
Asn Arg Tyr Leu His Asp Leu Gln Glu Gly His Ala Arg His Asn Ala
145                 150                 155                 160
Tyr Glu Cys Gly Arg Val Lys Asn Ile Thr Trp Lys Arg Tyr Arg Leu
                165                 170                 175
Ser Ile Thr Arg Lys Thr Leu Ser Tyr Ala Pro Gln Ile His Asp Asp
            180                 185                 190
Arg Glu Glu Glu Glu Leu Asp Leu Gly Arg Tyr Ile Ala Glu Asp Arg
        195                 200                 205
Asn Ala Arg Thr Gly Phe Phe Arg Met Val Pro Lys Asp Gln Arg Ala
    210                 215                 220
Pro Glu Thr Asn Ser Gly Arg Leu Thr Ile Gly Val Glu Pro Lys Tyr
225                 230                 235                 240
Gly Ala Gln Leu Ala Leu Ala Met Ala Thr Leu Met Asp Lys His Lys
                245                 250                 255
Ser Val Thr Gln Gly Lys Val Val Gly Pro Ala Lys Tyr Gly Gln Gln
            260                 265                 270
Thr Asp Ser Ala Ile Leu Tyr Ile Asn Gly Asp Leu Ala Lys Ala Val
        275                 280                 285
Lys Leu Gly Glu Lys Leu Lys Lys Leu Ser Gly Ile Pro Pro Glu Gly
    290                 295                 300
Phe Val Glu His Thr Pro Leu Ser Met Gln Ser Thr Gly Leu Gly Leu
305                 310                 315                 320
Ser Tyr Ala Glu Ser Val Glu Gly Gln Pro Ser Ser His Gly Gln Ala
                325                 330                 335
Arg Thr His Val Ile Met Asp Ala Leu Lys Gly Gln Gly Pro Met Glu
            340                 345                 350
Asn Arg Leu Lys Met Ala Leu Ala Glu Arg Gly Tyr Asp Pro Glu Asn
        355                 360                 365
Pro Ala Leu Arg Ala Arg Asn
    370                 375
</PDAT>
</S400>
<S200>
<S210>
<PDAT>13</PDAT>
</S210>
<S211>
<PDAT>1461</PDAT>
</S211>
<S212>
<PDAT>DNA</PDAT>
</S212>
<S213>
<PDAT>Pseudomonas syringae</PDAT>
</S213>
</S200>
<S400>
<PDAT> 13
atgcacatca accgacgcgt ccaacaaccg cctgtgactg cgacggatag ctttcggaca     60
gcgtccgacg cgtctcttgc ctccagctct gtgcgatctg tcagctccga tcagcaacgc    120
gagataaatg cgattgccga ttacctgaca gatcatgtgt tcgctgcgca taaactgccg    180
ccggccgatt cggctgatgg ccaagctgca gttgacgtac acaatgcgca gatcactgcg    240
ctgatcgaga cgcgcgccag ccgcctgcac ttcgaagggg aaaccccggc aaccatcgcc    300
gacaccttcg ccaaggcgga aaagctcgac cgattggcga cgactacatc aggcgcgttg    360
cgggcgacgc cctttgccat ggcctcgttg cttcagtaca tgcagcctgc gatcaacaag    420
ggcgattggc tgccggctcc gctcaaaccg ctgaccccgc tcatttccgg agcgctgtcg    480
ggcgccatgg accaggtggg caccaagatg atggaccgcg cgacgggtga tctgcattac    540
ctgagcgcct cgccggacag gctccacgat gcgatggccg cttcggtgaa gcgccactcg    600
ccaagccttg ctcgacaggt tctggacacg ggggttgcgg ttcagacgta ctcggcgcgc    660
aacgccgtac gtaccgtatt ggctccggca ctggcgtcca gacccgccgt gcagggtgct    720
gtggaccttg gtgtatcgat ggcgggtggt ctggctgcca acgcaggctt tggcaaccgc    780
ctgctcagtg tgcagtcgcg tgatcaccag cgtggcggtg cattagtgct cggtttgaag    840
gataaagagc ccaaggctca actgagcgaa gaaaacgact ggctcgaggc ttataaagca    900
atcaaatcgg ccagctactc gggtgcggcg ctcaacgctg gcaagcggat ggccggtctg    960
ccactggata tggcgaccga cgcaatgggt gcggtaagaa gcctggtgtc agcgtccagc   1020
ctgacccaaa acggtctggc cctggcgggt ggctttgcag gggtaggcaa gttgcaggag   1080
atggcgacga aaaatatcac cgacccggcg accaaggccg cggtcagtca gttgaccaac   1140
ctggcaggtt cggcagccgt tttcgcaggc tggaccacgg ccgcgctgac aaccgatccc   1200
gcggtgaaaa aagccgagtc gttcatacag gacacggtga aatcgactgc atccagtacc   1260
acaggctacg tagccgacca gaccgtcaaa ctggcgaaga ccgtcaaaga catgggcggg   1320
gaggcgatca cccataccgg cgccagcttg cgcaatacgg tcaataacct gcgtcaacgc   1380
ccggctcgtg aagctgatat agaagagggg ggcacggcgg cttctccaag tgaaataccg   1440
tttcggccta tgcggtcgta a                                             1461
</PDAT>
</S400>
<S200>
<S210>
<PDAT>14</PDAT>
</S210>
<S211>
<PDAT>486</PDAT>
</S211>
<S212>
<PDAT>PRT</PDAT>
</S212>
<S213>
<PDAT>Pseudomonas syringae</PDAT>
</S213>
</S200>
<S400>
<PDAT> 14
Met His Ile Asn Arg Arg Val Gln Gln Pro Pro Val Thr Ala Thr Asp
  1               5                  10                  15
Ser Phe Arg Thr Ala Ser Asp Ala Ser Leu Ala Ser Ser Ser Val Arg
             20                  25                  30
Ser Val Ser Ser Asp Gln Gln Arg Glu Ile Asn Ala Ile Ala Asp Tyr
         35                  40                  45
Leu Thr Asp His Val Phe Ala Ala His Lys Leu Pro Pro Ala Asp Ser
     50                  55                  60
Ala Asp Gly Gln Ala Ala Val Asp Val His Asn Ala Gln Ile Thr Ala
 65                  70                  75                  80
Leu Ile Glu Thr Arg Ala Ser Arg Leu His Phe Glu Gly Glu Thr Pro
                 85                  90                  95
Ala Thr Ile Ala Asp Thr Phe Ala Lys Ala Glu Lys Leu Asp Arg Leu
            100                 105                 110
Ala Thr Thr Thr Ser Gly Ala Leu Arg Ala Thr Pro Phe Ala Met Ala
        115                 120                 125
Ser Leu Leu Gln Tyr Met Gln Pro Ala Ile Asn Lys Gly Asp Trp Leu
    130                 135                 140
Pro Ala Pro Leu Lys Pro Leu Thr Pro Leu Ile Ser Gly Ala Leu Ser
145                 150                 155                 160
Gly Ala Met Asp Gln Val Gly Thr Lys Met Met Asp Arg Ala Thr Gly
                165                 170                 175
Asp Leu His Tyr Leu Ser Ala Ser Pro Asp Arg Leu His Asp Ala Met
            180                 185                 190
Ala Ala Ser Val Lys Arg His Ser Pro Ser Leu Ala Arg Gln Val Leu
        195                 200                 205
Asp Thr Gly Val Ala Val Gln Thr Tyr Ser Ala Arg Asn Ala Val Arg
    210                 215                 220
Thr Val Leu Ala Pro Ala Leu Ala Ser Arg Pro Ala Val Gln Gly Ala
225                 230                 235                 240
Val Asp Leu Gly Val Ser Met Ala Gly Gly Leu Ala Ala Asn Ala Gly
                245                 250                 255
Phe Gly Asn Arg Leu Leu Ser Val Gln Ser Arg Asp His Gln Arg Gly
            260                 265                 270
Gly Ala Leu Val Leu Gly Leu Lys Asp Lys Glu Pro Lys Ala Gln Leu
        275                 280                 285
Ser Glu Glu Asn Asp Trp Leu Glu Ala Tyr Lys Ala Ile Lys Ser Ala
    290                 295                 300
Ser Tyr Ser Gly Ala Ala Leu Asn Ala Gly Lys Arg Met Ala Gly Leu
305                 310                 315                 320
Pro Leu Asp Met Ala Thr Asp Ala Met Gly Ala Val Arg Ser Leu Val
                325                 330                 335
Ser Ala Ser Ser Leu Thr Gln Asn Gly Leu Ala Leu Ala Gly Gly Phe
            340                 345                 350
Ala Gly Val Gly Lys Leu Gln Glu Met Ala Thr Lys Asn Ile Thr Asp
        355                 360                 365
Pro Ala Thr Lys Ala Ala Val Ser Gln Leu Thr Asn Leu Ala Gly Ser
    370                 375                 380
Ala Ala Val Phe Ala Gly Trp Thr Thr Ala Ala Leu Thr Thr Asp Pro
385                 390                 395                 400
Ala Val Lys Lys Ala Glu Ser Phe Ile Gln Asp Thr Val Lys Ser Thr
                405                 410                 415
Ala Ser Ser Thr Thr Gly Tyr Val Ala Asp Gln Thr Val Lys Leu Ala
            420                 425                 430
Lys Thr Val Lys Asp Met Gly Gly Glu Ala Ile Thr His Thr Gly Ala
        435                 440                 445
Ser Leu Arg Asn Thr Val Asn Asn Leu Arg Gln Arg Pro Ala Arg Glu
    450                 455                 460
Ala Asp Ile Glu Glu Gly Gly Thr Ala Ala Ser Pro Ser Glu Ile Pro
465                 470                 475                 480
Phe Arg Pro Met Arg Ser
                485
</PDAT>
</S400>
</SEQ-LST-NEW>
</SEQLST-US>
</CWU>
</BTEXT>
</DETDESC>
</SDODE>
<SDOCL>
<H LVL="1"><STEXT><PDAT>What is claimed is: </PDAT></STEXT></H>
<CL>
<CLM ID="CLM-00001">
<PARA ID="P-00080" LVL="0"><PTEXT><PDAT>1. A method for delivering effector proteins into a target cell comprising:</PDAT></PTEXT></PARA>
<CLMSTEP LVL="2"><PTEXT><PDAT>introducing into the target cell an effector protein fused to a protein transduction domain of a human immunodeficiency virus TAT protein or derivatives or functional analogs thereof, wherein the effector protein is a protein secreted and/or delivered into eucaryotic cells by a type III secretion system. </PDAT></PTEXT></CLMSTEP>
</CLM>
<CLM ID="CLM-00002">
<PARA ID="P-00081" LVL="0"><PTEXT><PDAT>2. A method according to </PDAT><CLREF ID="CLM-00001"><PDAT>claim 1</PDAT></CLREF><PDAT>, wherein the target cell is a eucaryotic cell.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00003">
<PARA ID="P-00082" LVL="0"><PTEXT><PDAT>3. A method according to </PDAT><CLREF ID="CLM-00001"><PDAT>claim 1</PDAT></CLREF><PDAT>, wherein the effector protein is produced by a bacterial plant pathogen, animal pathogen, or a rhizosphere bacteria.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00004">
<PARA ID="P-00083" LVL="0"><PTEXT><PDAT>4. A method according to </PDAT><CLREF ID="CLM-00001"><PDAT>claim 1</PDAT></CLREF><PDAT>, wherein the effector protein is selected from the group consisting of a hypersensitive response elicitor, an avirulence protein, a hypersensitive response and pathogenicity-dependent outer protein, a virulence protein, and a pathogenicity protein.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00005">
<PARA ID="P-00084" LVL="0"><PTEXT><PDAT>5. A method according to </PDAT><CLREF ID="CLM-00001"><PDAT>claim 1</PDAT></CLREF><PDAT>, wherein the effector protein is heterologous to the target cell.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00006">
<PARA ID="P-00085" LVL="0"><PTEXT><PDAT>6. A method according to </PDAT><CLREF ID="CLM-00001"><PDAT>claim 1</PDAT></CLREF><PDAT>, wherein said introducing comprises:</PDAT></PTEXT></PARA>
<CLMSTEP LVL="2"><PTEXT><PDAT>introducing into the target cell a DNA construct comprising a DNA molecule encoding an effector protein operatively associated with a DNA molecule encoding a protein transduction domain of a human immunodeficiency virus TAT protein or derivatives or functional analogs thereof under conditions effective to express the DNA molecule encoding an effector protein in the target cell. </PDAT></PTEXT></CLMSTEP>
</CLM>
<CLM ID="CLM-00007">
<PARA ID="P-00086" LVL="0"><PTEXT><PDAT>7. A DNA construct comprising:</PDAT></PTEXT></PARA>
<CLMSTEP LVL="2"><PTEXT><PDAT>a first DNA molecule encoding an effector protein, wherein the effector protein is a protein secreted and/or delivered into eucaryotic cells by a type III secretion system and </PDAT></PTEXT></CLMSTEP>
<CLMSTEP LVL="2"><PTEXT><PDAT>a second DNA molecule operatively associated with the first DNA molecule and encoding a protein transduction domain of a human immunodeficiency virus TAT protein or derivatives or functional analogs thereof. </PDAT></PTEXT></CLMSTEP>
</CLM>
<CLM ID="CLM-00008">
<PARA ID="P-00087" LVL="0"><PTEXT><PDAT>8. A DNA construct according to </PDAT><CLREF ID="CLM-00007"><PDAT>claim 7</PDAT></CLREF><PDAT>, wherein the effector protein is produced by a bacterial plant pathogen, animal pathogen, or a rhizosphere bacteria.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00009">
<PARA ID="P-00088" LVL="0"><PTEXT><PDAT>9. A DNA construct according to </PDAT><CLREF ID="CLM-00007"><PDAT>claim 7</PDAT></CLREF><PDAT>, wherein the effector protein is selected from the group consisting of a hypersensitive response elicitor, an avirulence protein, a hypersensitive response and pathogenicity-dependent outer protein, a virulence protein, and a pathogenicity protein.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00010">
<PARA ID="P-00089" LVL="0"><PTEXT><PDAT>10. A DNA construct according to </PDAT><CLREF ID="CLM-00007"><PDAT>claim 7</PDAT></CLREF><PDAT>, wherein the gene encoding an effector protein is heterologous to the target cell.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00011">
<PARA ID="P-00090" LVL="0"><PTEXT><PDAT>11. An isolated target cell transformed with the DNA construct according to </PDAT><CLREF ID="CLM-00007"><PDAT>claim 7</PDAT></CLREF><PDAT>.</PDAT></PTEXT></PARA>
</CLM>
</CL>
</SDOCL>
<SDODR ID="DRAWINGS">
<EMI ID="EMI-D00001" ALT="embedded image" FILE="US06485977-20021126-D00001.TIF"/>
<EMI ID="EMI-D00002" ALT="embedded image" FILE="US06485977-20021126-D00002.TIF"/>
<EMI ID="EMI-D00003" ALT="embedded image" FILE="US06485977-20021126-D00003.TIF"/>
<EMI ID="EMI-D00004" ALT="embedded image" FILE="US06485977-20021126-D00004.TIF"/>
</SDODR>
</PATDOC>

<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE PATDOC SYSTEM "ST32-US-Grant-025xml.dtd" [
<!ENTITY US06486279-20021126-C00001.CDX SYSTEM "US06486279-20021126-C00001.CDX" NDATA CDX>
<!ENTITY US06486279-20021126-C00001.MOL SYSTEM "US06486279-20021126-C00001.MOL" NDATA MOL>
<!ENTITY US06486279-20021126-C00001.TIF SYSTEM "US06486279-20021126-C00001.TIF" NDATA TIF>
<!ENTITY US06486279-20021126-C00002.CDX SYSTEM "US06486279-20021126-C00002.CDX" NDATA CDX>
<!ENTITY US06486279-20021126-C00002.MOL SYSTEM "US06486279-20021126-C00002.MOL" NDATA MOL>
<!ENTITY US06486279-20021126-C00002.TIF SYSTEM "US06486279-20021126-C00002.TIF" NDATA TIF>
<!ENTITY US06486279-20021126-C00003.CDX SYSTEM "US06486279-20021126-C00003.CDX" NDATA CDX>
<!ENTITY US06486279-20021126-C00003.MOL SYSTEM "US06486279-20021126-C00003.MOL" NDATA MOL>
<!ENTITY US06486279-20021126-C00003.TIF SYSTEM "US06486279-20021126-C00003.TIF" NDATA TIF>
<!ENTITY US06486279-20021126-C00004.CDX SYSTEM "US06486279-20021126-C00004.CDX" NDATA CDX>
<!ENTITY US06486279-20021126-C00004.MOL SYSTEM "US06486279-20021126-C00004.MOL" NDATA MOL>
<!ENTITY US06486279-20021126-C00004.TIF SYSTEM "US06486279-20021126-C00004.TIF" NDATA TIF>
<!ENTITY US06486279-20021126-C00005.CDX SYSTEM "US06486279-20021126-C00005.CDX" NDATA CDX>
<!ENTITY US06486279-20021126-C00005.MOL SYSTEM "US06486279-20021126-C00005.MOL" NDATA MOL>
<!ENTITY US06486279-20021126-C00005.TIF SYSTEM "US06486279-20021126-C00005.TIF" NDATA TIF>
<!ENTITY US06486279-20021126-C00006.CDX SYSTEM "US06486279-20021126-C00006.CDX" NDATA CDX>
<!ENTITY US06486279-20021126-C00006.MOL SYSTEM "US06486279-20021126-C00006.MOL" NDATA MOL>
<!ENTITY US06486279-20021126-C00006.TIF SYSTEM "US06486279-20021126-C00006.TIF" NDATA TIF>
<!ENTITY US06486279-20021126-C00007.CDX SYSTEM "US06486279-20021126-C00007.CDX" NDATA CDX>
<!ENTITY US06486279-20021126-C00007.MOL SYSTEM "US06486279-20021126-C00007.MOL" NDATA MOL>
<!ENTITY US06486279-20021126-C00007.TIF SYSTEM "US06486279-20021126-C00007.TIF" NDATA TIF>
<!ENTITY US06486279-20021126-C00008.CDX SYSTEM "US06486279-20021126-C00008.CDX" NDATA CDX>
<!ENTITY US06486279-20021126-C00008.MOL SYSTEM "US06486279-20021126-C00008.MOL" NDATA MOL>
<!ENTITY US06486279-20021126-C00008.TIF SYSTEM "US06486279-20021126-C00008.TIF" NDATA TIF>
<!ENTITY US06486279-20021126-C00009.CDX SYSTEM "US06486279-20021126-C00009.CDX" NDATA CDX>
<!ENTITY US06486279-20021126-C00009.MOL SYSTEM "US06486279-20021126-C00009.MOL" NDATA MOL>
<!ENTITY US06486279-20021126-C00009.TIF SYSTEM "US06486279-20021126-C00009.TIF" NDATA TIF>
<!ENTITY US06486279-20021126-C00010.CDX SYSTEM "US06486279-20021126-C00010.CDX" NDATA CDX>
<!ENTITY US06486279-20021126-C00010.MOL SYSTEM "US06486279-20021126-C00010.MOL" NDATA MOL>
<!ENTITY US06486279-20021126-C00010.TIF SYSTEM "US06486279-20021126-C00010.TIF" NDATA TIF>
<!ENTITY US06486279-20021126-C00011.CDX SYSTEM "US06486279-20021126-C00011.CDX" NDATA CDX>
<!ENTITY US06486279-20021126-C00011.MOL SYSTEM "US06486279-20021126-C00011.MOL" NDATA MOL>
<!ENTITY US06486279-20021126-C00011.TIF SYSTEM "US06486279-20021126-C00011.TIF" NDATA TIF>
<!ENTITY US06486279-20021126-C00012.CDX SYSTEM "US06486279-20021126-C00012.CDX" NDATA CDX>
<!ENTITY US06486279-20021126-C00012.MOL SYSTEM "US06486279-20021126-C00012.MOL" NDATA MOL>
<!ENTITY US06486279-20021126-C00012.TIF SYSTEM "US06486279-20021126-C00012.TIF" NDATA TIF>
<!ENTITY US06486279-20021126-C00013.CDX SYSTEM "US06486279-20021126-C00013.CDX" NDATA CDX>
<!ENTITY US06486279-20021126-C00013.MOL SYSTEM "US06486279-20021126-C00013.MOL" NDATA MOL>
<!ENTITY US06486279-20021126-C00013.TIF SYSTEM "US06486279-20021126-C00013.TIF" NDATA TIF>
<!ENTITY US06486279-20021126-C00014.CDX SYSTEM "US06486279-20021126-C00014.CDX" NDATA CDX>
<!ENTITY US06486279-20021126-C00014.MOL SYSTEM "US06486279-20021126-C00014.MOL" NDATA MOL>
<!ENTITY US06486279-20021126-C00014.TIF SYSTEM "US06486279-20021126-C00014.TIF" NDATA TIF>
<!ENTITY US06486279-20021126-C00015.CDX SYSTEM "US06486279-20021126-C00015.CDX" NDATA CDX>
<!ENTITY US06486279-20021126-C00015.MOL SYSTEM "US06486279-20021126-C00015.MOL" NDATA MOL>
<!ENTITY US06486279-20021126-C00015.TIF SYSTEM "US06486279-20021126-C00015.TIF" NDATA TIF>
<!ENTITY US06486279-20021126-C00016.CDX SYSTEM "US06486279-20021126-C00016.CDX" NDATA CDX>
<!ENTITY US06486279-20021126-C00016.MOL SYSTEM "US06486279-20021126-C00016.MOL" NDATA MOL>
<!ENTITY US06486279-20021126-C00016.TIF SYSTEM "US06486279-20021126-C00016.TIF" NDATA TIF>
<!ENTITY US06486279-20021126-C00017.CDX SYSTEM "US06486279-20021126-C00017.CDX" NDATA CDX>
<!ENTITY US06486279-20021126-C00017.MOL SYSTEM "US06486279-20021126-C00017.MOL" NDATA MOL>
<!ENTITY US06486279-20021126-C00017.TIF SYSTEM "US06486279-20021126-C00017.TIF" NDATA TIF>
<!ENTITY US06486279-20021126-C00018.CDX SYSTEM "US06486279-20021126-C00018.CDX" NDATA CDX>
<!ENTITY US06486279-20021126-C00018.MOL SYSTEM "US06486279-20021126-C00018.MOL" NDATA MOL>
<!ENTITY US06486279-20021126-C00018.TIF SYSTEM "US06486279-20021126-C00018.TIF" NDATA TIF>
<!ENTITY US06486279-20021126-C00019.CDX SYSTEM "US06486279-20021126-C00019.CDX" NDATA CDX>
<!ENTITY US06486279-20021126-C00019.MOL SYSTEM "US06486279-20021126-C00019.MOL" NDATA MOL>
<!ENTITY US06486279-20021126-C00019.TIF SYSTEM "US06486279-20021126-C00019.TIF" NDATA TIF>
<!ENTITY US06486279-20021126-C00020.CDX SYSTEM "US06486279-20021126-C00020.CDX" NDATA CDX>
<!ENTITY US06486279-20021126-C00020.MOL SYSTEM "US06486279-20021126-C00020.MOL" NDATA MOL>
<!ENTITY US06486279-20021126-C00020.TIF SYSTEM "US06486279-20021126-C00020.TIF" NDATA TIF>
<!ENTITY US06486279-20021126-C00021.CDX SYSTEM "US06486279-20021126-C00021.CDX" NDATA CDX>
<!ENTITY US06486279-20021126-C00021.MOL SYSTEM "US06486279-20021126-C00021.MOL" NDATA MOL>
<!ENTITY US06486279-20021126-C00021.TIF SYSTEM "US06486279-20021126-C00021.TIF" NDATA TIF>
<!ENTITY US06486279-20021126-C00022.CDX SYSTEM "US06486279-20021126-C00022.CDX" NDATA CDX>
<!ENTITY US06486279-20021126-C00022.MOL SYSTEM "US06486279-20021126-C00022.MOL" NDATA MOL>
<!ENTITY US06486279-20021126-C00022.TIF SYSTEM "US06486279-20021126-C00022.TIF" NDATA TIF>
]>
<PATDOC DTD="2.5" STATUS="Build 20020918">
<SDOBI>
<B100>
<B110><DNUM><PDAT>06486279</PDAT></DNUM></B110>
<B130><PDAT>B2</PDAT></B130>
<B140><DATE><PDAT>20021126</PDAT></DATE></B140>
<B190><PDAT>US</PDAT></B190>
</B100>
<B200>
<B210><DNUM><PDAT>09882776</PDAT></DNUM></B210>
<B211US><PDAT>09</PDAT></B211US>
<B220><DATE><PDAT>20010614</PDAT></DATE></B220>
</B200>
<B500>
<B510>
<B511><PDAT>C08G 6106</PDAT></B511>
<B516><PDAT>7</PDAT></B516>
</B510>
<B520>
<B521><PDAT>526171</PDAT></B521>
<B522><PDAT>526 92</PDAT></B522>
<B522><PDAT>526135</PDAT></B522>
<B522><PDAT>526145</PDAT></B522>
<B522><PDAT>526146</PDAT></B522>
<B522><PDAT>526259</PDAT></B522>
<B522><PDAT>526268</PDAT></B522>
<B522><PDAT>526281</PDAT></B522>
<B522><PDAT>526283</PDAT></B522>
<B522><PDAT>526308</PDAT></B522>
<B522><PDAT>526309</PDAT></B522>
<B522><PDAT>526335</PDAT></B522>
<B522><PDAT>526336</PDAT></B522>
<B522><PDAT>525269</PDAT></B522>
<B522><PDAT>525289</PDAT></B522>
<B522><PDAT>525290</PDAT></B522>
<B522><PDAT>525297</PDAT></B522>
<B522><PDAT>26433113</PDAT></B522>
<B522><PDAT>26433115</PDAT></B522>
</B520>
<B540><STEXT><PDAT>Acid activation of ruthenium metathesis catalysts and living ROMP metathesis polymerization in water</PDAT></STEXT></B540>
<B560>
<B561>
<PCIT>
<DOC><DNUM><PDAT>5312940</PDAT></DNUM>
<DATE><PDAT>19940500</PDAT></DATE>
<KIND><PDAT>A</PDAT></KIND>
</DOC>
<PARTY-US>
<NAM><SNM><STEXT><PDAT>Grubbs et al.</PDAT></STEXT></SNM></NAM>
</PARTY-US>
<PNC><PDAT>556136</PDAT></PNC></PCIT><CITED-BY-OTHER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>5710298</PDAT></DNUM>
<DATE><PDAT>19980100</PDAT></DATE>
<KIND><PDAT>A</PDAT></KIND>
</DOC>
<PARTY-US>
<NAM><SNM><STEXT><PDAT>Grubbs et al.</PDAT></STEXT></SNM></NAM>
</PARTY-US>
<PNC><PDAT>556 22</PDAT></PNC></PCIT><CITED-BY-OTHER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>5831108</PDAT></DNUM>
<DATE><PDAT>19981100</PDAT></DATE>
<KIND><PDAT>A</PDAT></KIND>
</DOC>
<PARTY-US>
<NAM><SNM><STEXT><PDAT>Grubbs et al.</PDAT></STEXT></SNM></NAM>
</PARTY-US>
<PNC><PDAT>556 21</PDAT></PNC></PCIT><CITED-BY-OTHER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>6020443</PDAT></DNUM>
<DATE><PDAT>20000200</PDAT></DATE>
<KIND><PDAT>A</PDAT></KIND>
</DOC>
<PARTY-US>
<NAM><SNM><STEXT><PDAT>Woodson et al.</PDAT></STEXT></SNM></NAM>
</PARTY-US>
<PNC><PDAT>556135</PDAT></PNC></PCIT><CITED-BY-OTHER/>
</B561>
<B561>
<PCIT>
<DOC><DNUM><PDAT>6284852</PDAT></DNUM>
<DATE><PDAT>20010900</PDAT></DATE>
<KIND><PDAT>B1</PDAT></KIND>
</DOC>
<PARTY-US>
<NAM><SNM><STEXT><PDAT>Lynn et al.</PDAT></STEXT></SNM></NAM>
</PARTY-US>
<PNC><PDAT>526171</PDAT></PNC></PCIT><CITED-BY-EXAMINER/>
</B561>
<B562><NCIT><STEXT><PDAT>Lynn, David M., et al., &ldquo;Living Ring-Opening Metathesis Polymerization in Aqueous Media Catalyzed by Well-Defined Ruthenium Carbene Complexes&rdquo;, J. Am. Chem. Soc., vol. 118, pp. 784-790 (1996). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Lynn, David M., et al., &ldquo;Living Ring-Opening Metathesis Polymerization in Water via Activation of Water-Soluble Ruthenium Alkylidenes&rdquo;, Arnold and Mabel Beckman Laboratory of Chemical Synthesis, Division of Chemistry and Chemical Engineering, California Institute of Technology, Pasadena, CA 91125, Polymer Preprints, vol. 39, pp. 278-279 (1998). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Mohr, Bernhard, et al., &ldquo;Synthesis of Water-Soluble, Aliphatic Phosphines and Their Application to Well-Defined Ruthenium Olefin Metathesis Catalysts&rdquo;, Organometallics, vol. 15, No. 20, pp. 4317-4325 (1996). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Bazan, Guillermo C., et al., &ldquo;Living Ring-Opening Metathesis Polymerization of 2,3-Difunctionalized 7-Oxanorbornenes and 7-Oxanorbornadienes by Mo(CHCMe</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>R)(N-2,6-C</PDAT><HIL><SB><PDAT>6</PDAT></SB></HIL><PDAT>H</PDAT><HIL><SB><PDAT>3</PDAT></SB></HIL><PDAT>-i-Pr</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>)(O-t-Bu)</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>and Mo(CHCMe</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>R)(N-2,6-C</PDAT><HIL><SB><PDAT>6</PDAT></SB></HIL><PDAT>H</PDAT><HIL><SB><PDAT>3</PDAT></SB></HIL><PDAT>-i-Pr</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>)(O-CMe</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>CF</PDAT><HIL><SB><PDAT>3</PDAT></SB></HIL><PDAT>)</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>&rdquo;, J. Am. Chem. Soc., vol. 113, pp. 6899-6907 (1991). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Bazan, G.C., et al., &ldquo;Living Ring-Opening Metathesis Polymerization of 2,3-Difunctionalized Norbornadienes by Mo(CH-t-Bu)(N-2,6-C</PDAT><HIL><SB><PDAT>6</PDAT></SB></HIL><PDAT>H</PDAT><HIL><SB><PDAT>3</PDAT></SB></HIL><PDAT>-i-Pr</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>)(O-t-Bu)</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>&rdquo;, J. Am. Chem. Soc., vol. 112, pp. 8378-8387 (1990). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Nishikawa, Tomotaka, et al., &ldquo;Evidence for Living Radical Polymerization of Methyl Methacrylate with Ruthenium Complex: Effects of Protic and Radical Compounds and Reinitiation from the Recovered Polymers&rdquo;, Macromolecules, vol. 30, No. 8, pp. 2244-2248 (1997). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Tallarico, John A., et al., &ldquo;Ring-Opening Metathesis. A Ruthenium Catalyst Caught in the Act&rdquo;, J. Am. Chem. Soc., vol. 119, pp. 7157-7158 (1997). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Manning, David D., et al., &ldquo;Neoglycopolymer Inhibitors of the Selectins&rdquo;, Tetrahedron, vol. 53, No. 35, pp. 11937-11952 (1997). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Novak, B.M., et al., &ldquo;The Development of Well-Defined Catalysts for Ring-Opening Olefin Metathesis Polymerizations (ROMP)&rdquo;, Advances in Polymer Science, vol. 102, pp. 47-72 &copy; Springer-Verlag Berlin Heidelberg 1992. </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Schrock, Richard R., et al., &ldquo;Synthesis of. Molybdenum Imido Alkylidene Complexes and Some Reactions Involving Acyclic Olefins&rdquo;, J. Am. Chem. Soc., vol. 112, pp. 3875-3886 (1990). </PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
<B562><NCIT><STEXT><PDAT>Lynn, David M., et al., &ldquo;Living Ring-Opening Metathesis Polymerization in Water&rdquo;, J. Am. Chem. Soc., vol. 120, pp. 1627-1628 (1998).</PDAT></STEXT></NCIT><CITED-BY-OTHER/></B562>
</B560>
<B570>
<B577><PDAT>22</PDAT></B577>
<B578US><PDAT>1</PDAT></B578US>
</B570>
<B580>
<B582><PDAT>526171</PDAT></B582>
<B582><PDAT>526281</PDAT></B582>
<B582><PDAT>526283</PDAT></B582>
<B582><PDAT>526308</PDAT></B582>
<B582><PDAT>526309</PDAT></B582>
<B582><PDAT>526 92</PDAT></B582>
<B582><PDAT>526135</PDAT></B582>
<B582><PDAT>526145</PDAT></B582>
<B582><PDAT>526146</PDAT></B582>
<B582><PDAT>526259</PDAT></B582>
<B582><PDAT>526268</PDAT></B582>
<B582><PDAT>526335</PDAT></B582>
<B582><PDAT>526336</PDAT></B582>
<B582><PDAT>525269</PDAT></B582>
<B582><PDAT>525289</PDAT></B582>
<B582><PDAT>525290</PDAT></B582>
<B582><PDAT>525297</PDAT></B582>
<B582><PDAT>26433113</PDAT></B582>
<B582><PDAT>26433115</PDAT></B582>
</B580>
<B590><B595><PDAT>0</PDAT></B595><B596><PDAT>0</PDAT></B596></B590>
</B500>
<B600>
<B620><PARENT-US><CDOC><DOC><DNUM><PDAT>09/882776</PDAT></DNUM></DOC></CDOC><PDOC><DOC><DNUM><PDAT>09/183025</PDAT></DNUM><DATE><PDAT>19981029</PDAT></DATE><CTRY><PDAT>US</PDAT></CTRY><KIND><PDAT>00</PDAT></KIND></DOC></PDOC><PSTA><PDAT>01</PDAT></PSTA><PPUB><DOC><DNUM><PDAT>6284852</PDAT></DNUM><CTRY><PDAT>US</PDAT></CTRY><KIND><PDAT>A </PDAT></KIND></DOC></PPUB></PARENT-US></B620>
<B680US><DOC><DNUM><PDAT>60/064405</PDAT></DNUM><DATE><PDAT>19971030</PDAT></DATE><KIND><PDAT>00</PDAT></KIND></DOC></B680US>
<B690US>
<DOC>
<DNUM><PDAT>20020055598</PDAT></DNUM>
<DATE><PDAT>20020509</PDAT></DATE>
<CTRY><PDAT>US</PDAT></CTRY>
<KIND><PDAT>A1</PDAT></KIND>
</DOC>
</B690US></B600>
<B700>
<B720>
<B721>
<PARTY-US>
<NAM><FNM><PDAT>David M.</PDAT></FNM><SNM><STEXT><PDAT>Lynn</PDAT></STEXT></SNM></NAM>
<ADR>
<CITY><PDAT>Pasadena</PDAT></CITY>
<STATE><PDAT>CA</PDAT></STATE>
</ADR>
</PARTY-US>
</B721>
<B721>
<PARTY-US>
<NAM><FNM><PDAT>Eric L.</PDAT></FNM><SNM><STEXT><PDAT>Dias</PDAT></STEXT></SNM></NAM>
<ADR>
<CITY><PDAT>Chapel Hill</PDAT></CITY>
<STATE><PDAT>NC</PDAT></STATE>
</ADR>
</PARTY-US>
</B721>
<B721>
<PARTY-US>
<NAM><FNM><PDAT>Robert H.</PDAT></FNM><SNM><STEXT><PDAT>Grubbs</PDAT></STEXT></SNM></NAM>
<ADR>
<CITY><PDAT>South Pasadena</PDAT></CITY>
<STATE><PDAT>CA</PDAT></STATE>
</ADR>
</PARTY-US>
</B721>
<B721>
<PARTY-US>
<NAM><FNM><PDAT>Bernard</PDAT></FNM><SNM><STEXT><PDAT>Mohr</PDAT></STEXT></SNM></NAM>
<ADR>
<CITY><PDAT>Heidelberg</PDAT></CITY>
<CTRY><PDAT>DE</PDAT></CTRY>
</ADR>
</PARTY-US>
</B721>
</B720>
<B730>
<B731>
<PARTY-US>
<NAM><ONM><STEXT><PDAT>California Institute of Technology</PDAT></STEXT></ONM></NAM>
<ADR><CITY><PDAT>Pasadena</PDAT></CITY><STATE><PDAT>CA</PDAT></STATE></ADR>
</PARTY-US>
</B731>
<B732US>
<PDAT>02</PDAT>
</B732US>
</B730>
<B740>
<B741>
<PARTY-US>
<NAM><ONM><STEXT><PDAT>Pillsbury Winthrop LLP</PDAT></STEXT></ONM></NAM>
</PARTY-US>
</B741>
</B740>
<B745>
<B746>
<PARTY-US>
<NAM><FNM><PDAT>Fred</PDAT></FNM><SNM><STEXT><PDAT>Teskin</PDAT></STEXT></SNM></NAM>
</PARTY-US>
</B746>
<B748US><PDAT>1713</PDAT></B748US>
</B745>
</B700>
</SDOBI>
<SDOAB>
<BTEXT>
<PARA ID="P-00001" LVL="0"><PTEXT><PDAT>Activation of ruthenium based catalyst compounds with acid to improve reaction rates and yields of olefin metathesis reactions, including ROMP, RCM, ADMET and cross-methasis reactions is disclosed. The ruthenium catalyst compounds are ruthenium carbene complexes of the general formula A</PDAT><HIL><SB><PDAT>x</PDAT></SB></HIL><PDAT>L</PDAT><HIL><SB><PDAT>y</PDAT></SB></HIL><PDAT>X</PDAT><HIL><SB><PDAT>z</PDAT></SB></HIL><PDAT>Ru&boxH;CHR&prime; where x&equals;0, 1 or 2, y&equals;0, 1 or 2, and z&equals;1 or 2 and where R&prime; is hydrogen or a substituted or unsubstituted alkyl or aryl, L is any neutral electron donor, X is any anionic ligand, and A is a ligand having a covalent structure connecting a neutral electron donor and an anionic ligand. The use of acid with these catalysts allows for reactions with a wide range of olefins in a variety of solvents, including acid-initiated RIM processes and living ROMP reactions of water-soluble monomers in water.</PDAT></PTEXT></PARA>
</BTEXT>
</SDOAB>
<SDODE>
<RELAPP>
<BTEXT>
<PARA ID="P-00002" LVL="0"><PTEXT><PDAT>The present application is a divisional of U.S. application Ser. No. 09/183,025 (now issued U.S. Pat. No. 6,284,852) filed Oct. 29, 1998, which is entitled ACID ACTIVATION OF RUTHENIUM METATHESIS CATALYSTS AND LIVING ROMP METATHESIS POLYMERIZATION by inventors David M. Lynn, Eric L. Dias, Robert H. Grubbs, and Bernhard Mohr, the contents of which are herein incorporated by reference.</PDAT></PTEXT></PARA>
<PARA ID="P-00003" LVL="0"><PTEXT><PDAT>This application claims the benefit of U.S. Provisional Application No. 60/064,405, filed Oct. 30, 1997, which is incorporated herein by reference.</PDAT></PTEXT></PARA>
</BTEXT>
</RELAPP>
<GOVINT>
<BTEXT>
<PARA ID="P-00004" LVL="0"><PTEXT><PDAT>The U.S. Government has certain rights in this invention pursuant to Grant No. CH 9509745 awarded by the National Science Foundation and Grant No. GM 31332 awarded by the National Institutes of Health.</PDAT></PTEXT></PARA>
</BTEXT>
</GOVINT>
<BRFSUM>
<BTEXT>
<H LVL="1"><STEXT><PDAT>BACKGROUND OF THE INVENTION</PDAT></STEXT></H>
<PARA ID="P-00005" LVL="0"><PTEXT><PDAT>1. Field of the Invention</PDAT></PTEXT></PARA>
<PARA ID="P-00006" LVL="0"><PTEXT><PDAT>The invention relates to highly active and stable ruthenium metal carbene complex compounds and their use as catalysts for olefin metathesis reactions.</PDAT></PTEXT></PARA>
<PARA ID="P-00007" LVL="0"><PTEXT><PDAT>2. Description of the Related Art</PDAT></PTEXT></PARA>
<PARA ID="P-00008" LVL="0"><PTEXT><PDAT>The formation of carbon-carbon bonds via olefin metathesis is of considerable interest and commercial utility, and considerable research efforts have been undertaken to develop olefin metathesis catalysts and systems. Group VIII transition metal catalysts have proven to be particularly useful for catalyzing olefin metathesis reactions, such as ring-opening metathesis polymerization (ROMP), ring-closing metathesis polymerization (RCM), acyclic diene metathesis (ADMFT), and cross metathesis reactions. Both classical and well-defined olefin metathesis catalysts based on ruthenium have been shown to exhibit good tolerance to a variety of functional groups, as has been reported by, e.g., Grubbs, R. H. J. M. S.-Pure Appl. Chem. 1994, A31(11), 1829-1833; Aqueous Organometallic Chemistry and Catalysis. Horvath, I. T., Joo, F. Eds; Kluwer Academic Publishers: Boston, 1995; Novak, B. M.; Grubbs, R. H. J. Am. Chem. Soc. 1988, 110, 7542-7543; Novak, B. M.; Grubbs, R. H. J. Am. Chem. Soc. 1988, 110, 960-96; Nguyen, S. T.; Johnson, L. K.; Grubbs, R. H. J. Am. Chem. Soc. 1992, 114, 3974-3975 and Schwab, P.; Grubbs, R. H.; Ziller, J. W. J. Am. Chem. Soc. 1996, 118, 100, each of which is incorporated herein by reference. In particular, as reported by Lynn, D. M.; Kanaoka, S.; Grubbs, R. H. J. Am. Chem. Soc. 1996, 118, 784 and by Mohr, B.; Lynn, D. M.; Grubbs, R. H. Organometallics 1996, 15, 4317-4325, both of which are incorporated herein by reference, the robust nature of the ruthenium-carbon bonds in these complexes has enabled olefin metathesis reactions to be carried out in protic media. However, slow reaction rates and low yields have limited the application of these catalysts for a variety of olefin monomers and reaction conditions.</PDAT></PTEXT></PARA>
<PARA ID="P-00009" LVL="0"><PTEXT><PDAT>As an example, there is a need for homogeneous polymerization systems that are living in water and that will polymerize water-soluble monomers. In living polymerization systems, polymerization occurs without chain transfer or chain termination, giving greater control over polydispersity of the resultant polymers. Such polymerization systems are highly desirable as they would allow the controlled synthesis of water-soluble polymers and would enable precise control over the composition of block copolymers for use, for example, in biomedical applications. However, such polymerization systems represent a formidable challenge. For example, the addition of water to traditional living anionic or cationic systems results in rapid termination. The advent of late transition metal catalysts tolerant of numerous polar and protic functionalities has recently enabled living ring-opening metathesis polymerizations (ROMP), free-radical polymerizations, and isocyanide polymerizations in aqueous environments, as reported by Lynn, D. M.; Kanaoka, S.; Grubbs, R. H. J. Am. Chem. Soc. 1996, 118, 784; Manning, D. D.; Strong, L. E.; Hu, X.; Beck, P.; Kiessling, L. L. Tetrahedron, 1997, 53, 11937-11952; Manning, D. D.; Hu, X.; Beck, P.; Kiessling, L. L. J.Am. Chem. Soc. 1997, 119, 3161-3162; Nishikawa, T; Ando, T; Kamigaito, M; Sawamoto, M. Macromolecules 1997, 30, 2244-2248; Deming, T. J.; Novak, B. M. Polym. Prepr. (Am. Chem. Soc., Div. Polym. Chem.) 1991, 32, 455-456; and Deming, T. J.; Novak, B. M. Macromolecules, 1991, 24, 326-328, each of which is incorporated herein by reference. Although these examples represent significant advances toward entirely aqueous systems, the catalysts themselves are insoluble in water and the polymerization reactions basically occur in &ldquo;wet&rdquo; organic phases.</PDAT></PTEXT></PARA>
<PARA ID="P-00010" LVL="0"><PTEXT><PDAT>Aqueous ring-opening metathesis polymerization of strained, cyclic olefins initiated by Group VIII salts and coordination complexes is well-documented. Although these complexes serve as robust polymerization catalysts in water, the polymerizations are not living and inefficient initiation steps produce erratic results (typically less than 1% of metal centers are converted to catalytically-active species) and results in poor control over polymer molecular weight.</PDAT></PTEXT></PARA>
<PARA ID="P-00011" LVL="0"><PTEXT><PDAT>We recently reported the synthesis of well-defined, water soluble ruthenium alkylidenes which serve as excellent initiators for olefin metathesis reactions in water, methanol, and aqueous emulsions. See Mohr, B.; Lynn, D. M.; Grubbs, R. H. Organometallics, 1996, 15, 4317-4325, incorporated herein by reference. Further investigation of these complexes, however, revealed that potential applications could be limited by relatively fast termination reactions. Similar ruthenium alkylidene complexes are disclosed in U.S. Pat. Nos. 5,312,940 and 5,342,909 and U.S. application Ser. No. 08/693,789, filed Jul. 31, 1996 (now U.S. Pat. No. 5,831,100), and Ser. No. 08/708,057, filed Aug. 30, 1996 (now U.S. Pat. No. 5,710,290), each of which is incorporated herein by reference.</PDAT></PTEXT></PARA>
<PARA ID="P-00012" LVL="0"><PTEXT><PDAT>For these reasons, there is a need for well-defined olefin metathesis catalysts and systems with improved efficiencies that provide for increased reaction rates, increased product yields, and that allow for metathesis of a wider range of olefins in a broader range of solvents than previously possible.</PDAT></PTEXT></PARA>
<H LVL="1"><STEXT><PDAT>SUMMARY OF THE INVENTION</PDAT></STEXT></H>
<PARA ID="P-00013" LVL="0"><PTEXT><PDAT>The present invention meets the above and other needs and is directed to the use of acid to activate and enhance ruthenium-based metathesis catalysts for olefin metathesis, including ring-opening metathesis polymerization (ROMP) of strained and unstrained cyclic olefins, and ring-closing metathesis (RCM), acyclic diene metathesis (ADMET), and cross metathesis reactions of acyclic olefins.</PDAT></PTEXT></PARA>
<PARA ID="P-00014" LVL="0"><PTEXT><PDAT>In one embodiment of the invention, the ruthenium catalyst compounds are ruthenium carbene complexes of the general formula A</PDAT><HIL><SB><PDAT>x</PDAT></SB></HIL><PDAT>L</PDAT><HIL><SB><PDAT>y</PDAT></SB></HIL><PDAT>X</PDAT><HIL><SB><PDAT>z</PDAT></SB></HIL><PDAT>Ru&boxH;CHR&prime; where x&equals;0, 1 or 2, y&equals;0, 1 or 2, and z&equals;1 or 2, and where R&prime; is hydrogen or a substituted or unsubstituted alkyl or aryl, L is any neutral electron donor, X is any anionic ligand, and A is a ligand. having a covalent structure connecting a neutral electron donor and an anionic ligand. In other embodiments of the invention, the ruthenium catalyst compounds have the general formulas:</PDAT></PTEXT></PARA>
<PARA ID="P-00015" LVL="0"><PTEXT><F><PTEXT><PDAT>A</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>LRu&boxH;CHR&prime;, ALXRu&boxH;CHR&prime; and L</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>X</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>Ru&boxH;CHR&prime;.</PDAT></PTEXT></F></PTEXT></PARA>
<PARA ID="P-00016" LVL="0"><PTEXT><PDAT>These ruthenium catalysts contain acid-labile ligands and the addition of inorganic or organic acids to olefin metathesis reactions employing these catalysts results in substantially enhanced activities relative to systems in which acid is not present. Substantial rate increases in the presence of acid have been observed for olefin metathesis reactions in aqueous, protic and organic solvents in methods according to the present invention.</PDAT></PTEXT></PARA>
<PARA ID="P-00017" LVL="0"><PTEXT><PDAT>In another aspect of the invention, acid is used to activate ruthenium alkylidene complexes that are otherwise unreactive with olefins. This aspect of the invention allows for greater control in reaction injection molding (RIM) processes, as the catalyst and monomer can be stored together, either in solution or in neat monomer, and then acid is added to initiate polymerization. Similar processes can be applied to photoinitiated-ROMP (PROMP) systems and to photomasking applications using photoacid generators (photoacid generators are compounds that are not themselves acids, but which break down into acids and other products upon exposure to light energy).</PDAT></PTEXT></PARA>
<PARA ID="P-00018" LVL="0"><PTEXT><PDAT>The invention is further directed to living polymerization reactions taking place in aqueous solutions in the absence of any surfactants or organic cosolvents. In another embodiment of the invention, water-soluble ruthenium alkylidene complexes initiate living ROMP of water-soluble monomers in the presence of acid.</PDAT></PTEXT></PARA>
<H LVL="1"><STEXT><PDAT>DETAILED DESCRIPTION OF THE INVENTION</PDAT></STEXT></H>
<PARA ID="P-00019" LVL="0"><PTEXT><PDAT>In general, transition metal alkylidenes are deactivated or destroyed in polar, protic species. The ruthenium alkylidenes of the present invention are not only stable in the presence of polar or protic functional groups or solvents, but the catalytic activities of these alkylidenes are enhanced by the deliberate addition of specific amounts of acid not present as a substrate or solvent. A number of ruthenium alkylidenes of the present invention are otherwise inactive absent the addition of acid to the reaction mixture. Such acidic conditions would destroy alkylidenes based on earlier transition metals.</PDAT></PTEXT></PARA>
<PARA ID="P-00020" LVL="0"><PTEXT><PDAT>Ruthenium alkylidenes of the present invention include alkylidenes of the general formula A</PDAT><HIL><SB><PDAT>x</PDAT></SB></HIL><PDAT>L</PDAT><HIL><SB><PDAT>y</PDAT></SB></HIL><PDAT>X</PDAT><HIL><SB><PDAT>z</PDAT></SB></HIL><PDAT>Ru&boxH;CHR&prime; where x&equals;0, 1 or 2, y&equals;0, 1 or 2, and z&equals;1 or 2, and where R&prime; is hydrogen or a substituted or unsubstituted alkyl or aryl, L is any neutral electron donor, X is any anionic ligand, and A is a ligand having a covalent structure connecting a neutral electron donor and an anionic ligand. These alkylidenes have enhanced catalytic activities in the presence of acid for a variety of olefin metathesis reactions, including but not limited to ROMP, RCM, ADMET and cross-metathesis and dimerization reactions. Preferred ruthenium alkylidenes are of the general formulas A</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>LRu&boxH;CHR&prime;, ALXRu&boxH;CHR&prime; and L</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>X</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>Ru&boxH;CHR&prime;.</PDAT></PTEXT></PARA>
<PARA ID="P-00021" LVL="0"><PTEXT><PDAT>Olefin monomers that can be reacted according to the processes of the present invention include acyclic olefins, cyclic olefins, both strained and unstrained, dienes and unsaturated polymers. These olefins can be functionalized as well, and can include functional groups either as substituents of the olefins or incorporated into the carbon chain of the olefin. These functional groups can be, for example, alcohol, thiol, ketone, aldehyde, ester, disulfide, carbonate, imine, carboxyl, amine, amide, nitro acid, carboxylic acid. isocyanate, carbodiimide, ether, halogen, quaternary amine, carbohydrate, phosphate, sulfate or sulfonate groups.</PDAT></PTEXT></PARA>
<PARA ID="P-00022" LVL="0"><PTEXT><PDAT>Both organic and inorganic acids are useful in enhancing catalytic activity of our catalysts, the preferred acids being HI, HCl, HBr, H</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>SO</PDAT><HIL><SB><PDAT>4</PDAT></SB></HIL><PDAT>, H</PDAT><HIL><SB><PDAT>3</PDAT></SB></HIL><PDAT>O</PDAT><HIL><SP><PDAT>&plus;</PDAT></SP></HIL><PDAT>, HNO</PDAT><HIL><SB><PDAT>3</PDAT></SB></HIL><PDAT>, H</PDAT><HIL><SB><PDAT>3</PDAT></SB></HIL><PDAT>PO</PDAT><HIL><SB><PDAT>4</PDAT></SB></HIL><PDAT>, CH</PDAT><HIL><SB><PDAT>3</PDAT></SB></HIL><PDAT>CO</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>H and tosic acid, most preferably HCl. Acids may be added to the catalysts either before or during the reaction with olefin, with longer catalyst life generally observed when the catalyst is introduced to an acidic solution of olefin monomer. The acid or the catalyst can be dissolved in a variety of suitable solvents, including protic, aqueous or organic solvents or mixtures thereof. Preferred solvents include aromatic or halogenated aromatic solvents, aliphatic or halogenated organic solvents, alcoholic solvents, water or mixtures thereof. Of the aromatic solvents, the most preferred is benzene. Dichloromethane is most preferred of the halogenated aliphatic solvents; methanol is most preferred of the alcoholic solvents. Alternatively, the acid or the catalyst or both can be dissolved into neat olefin monomer.</PDAT></PTEXT></PARA>
<PARA ID="P-00023" LVL="0"><PTEXT><PDAT>In addition to the above acids, an alternative embodiment of the invention, photoacid generators that are converted to acids upon exposure to light energy may be used to activate or enhance the reaction. For example, UV curing of dicyclopentadiene (DCPD) to yield poly(DCPD) by photoinitiated-ROMP (PROMP) is readily accomplished as photoacid generators may be stored with both monomer and catalyst until metathesis is initiated through irradiation.</PDAT></PTEXT></PARA>
<PARA ID="P-00024" LVL="0"><PTEXT><PDAT>The preferred substituents of catalysts of the present invention are as follows. The neutral electron donor L is preferably a phosphine of the formula PR</PDAT><HIL><SP><PDAT>3</PDAT></SP></HIL><PDAT>R</PDAT><HIL><SP><PDAT>4</PDAT></SP></HIL><PDAT>R</PDAT><HIL><SP><PDAT>5 </PDAT></SP></HIL><PDAT>where R</PDAT><HIL><SP><PDAT>3 </PDAT></SP></HIL><PDAT>can be a secondary alkyl or cycloalkyl, and R</PDAT><HIL><SP><PDAT>4 </PDAT></SP></HIL><PDAT>and R</PDAT><HIL><SP><PDAT>5 </PDAT></SP></HIL><PDAT>can be an aryl, C</PDAT><HIL><SB><PDAT>1</PDAT></SB></HIL><PDAT>-C</PDAT><HIL><SB><PDAT>10 </PDAT></SB></HIL><PDAT>primary alkyl, secondary alkyl, or cycloalkyl, each independent of the other. More preferably, L is either P(cyclohexyl)</PDAT><HIL><SB><PDAT>3</PDAT></SB></HIL><PDAT>, P(cyclopentyl)</PDAT><HIL><SB><PDAT>3</PDAT></SB></HIL><PDAT>, P(isopropyl)</PDAT><HIL><SB><PDAT>3</PDAT></SB></HIL><PDAT>, or P(phenyl)</PDAT><HIL><SB><PDAT>3</PDAT></SB></HIL><PDAT>. The anionic ligand X is preferably hydrogen, or a halogen, or a unsubstituted or substitued moiety where the moiety is a C</PDAT><HIL><SB><PDAT>1</PDAT></SB></HIL><PDAT>-C</PDAT><HIL><SB><PDAT>20 </PDAT></SB></HIL><PDAT>alkyl, aryl, C</PDAT><HIL><SB><PDAT>1</PDAT></SB></HIL><PDAT>-C</PDAT><HIL><SB><PDAT>20 </PDAT></SB></HIL><PDAT>alkoxide, aryloxide, C</PDAT><HIL><SB><PDAT>3</PDAT></SB></HIL><PDAT>-C</PDAT><HIL><SB><PDAT>20 </PDAT></SB></HIL><PDAT>alkyldiketonate, aryldiketonate, C</PDAT><HIL><SB><PDAT>1</PDAT></SB></HIL><PDAT>-C</PDAT><HIL><SB><PDAT>20 </PDAT></SB></HIL><PDAT>carboxylate, arylsulfonate, C</PDAT><HIL><SB><PDAT>1</PDAT></SB></HIL><PDAT>-C</PDAT><HIL><SB><PDAT>20 </PDAT></SB></HIL><PDAT>alkylsulfonate, C</PDAT><HIL><SB><PDAT>1</PDAT></SB></HIL><PDAT>-C</PDAT><HIL><SB><PDAT>20 </PDAT></SB></HIL><PDAT>alkylthio, C</PDAT><HIL><SB><PDAT>1</PDAT></SB></HIL><PDAT>-C</PDAT><HIL><SB><PDAT>20 </PDAT></SB></HIL><PDAT>alkylsulfonyl, or C</PDAT><HIL><SB><PDAT>1</PDAT></SB></HIL><PDAT>-C</PDAT><HIL><SB><PDAT>20 </PDAT></SB></HIL><PDAT>alkylsulfinyl. In the case of substituted moiety, the substitution is C</PDAT><HIL><SB><PDAT>1</PDAT></SB></HIL><PDAT>-C</PDAT><HIL><SB><PDAT>5 </PDAT></SB></HIL><PDAT>alkyl, halogen, C</PDAT><HIL><SB><PDAT>1</PDAT></SB></HIL><PDAT>-C</PDAT><HIL><SB><PDAT>5 </PDAT></SB></HIL><PDAT>alkoxy, unmodified phenyl, halogen substituted phenyl, C</PDAT><HIL><SB><PDAT>1</PDAT></SB></HIL><PDAT>-C</PDAT><HIL><SB><PDAT>5 </PDAT></SB></HIL><PDAT>alkyl substituted phenyl, or C</PDAT><HIL><SB><PDAT>1</PDAT></SB></HIL><PDAT>-C</PDAT><HIL><SB><PDAT>5 </PDAT></SB></HIL><PDAT>alkoxy substituted phenyl.</PDAT></PTEXT></PARA>
<PARA ID="P-00025" LVL="0"><PTEXT><PDAT>A first preferred embodiment of the catalyst has the formula: </PDAT>
<CWU>
<CHEM-US ID="CHEM-US-00001">
<CHEMCDX ID="CHEMCDX-00001" ALT="chemistry chemdraw file" FILE="US06486279-20021126-C00001.CDX"/>
<CHEMMOL ID="CHEMMOL-00001" ALT="chemistry mol file" FILE="US06486279-20021126-C00001.MOL"/>
<EMI ID="EMI-C00001" ALT="embedded image" HE="87.85665" WI="91.4571" FILE="US06486279-20021126-C00001.TIF"/>
</CHEM-US>
</CWU>
</PTEXT></PARA>
<PARA ID="P-00026" LVL="7"><PTEXT><PDAT>where each R is an aryl or alkyl, substituted or unsubstituted, and is preferably either a C</PDAT><HIL><SB><PDAT>1</PDAT></SB></HIL><PDAT>-C</PDAT><HIL><SB><PDAT>20 </PDAT></SB></HIL><PDAT>alkyl, an aryl, a substituted C</PDAT><HIL><SB><PDAT>1</PDAT></SB></HIL><PDAT>-C</PDAT><HIL><SB><PDAT>20 </PDAT></SB></HIL><PDAT>alkyl (substituted with an aryl, halide, hydroxy, C</PDAT><HIL><SB><PDAT>1</PDAT></SB></HIL><PDAT>-C</PDAT><HIL><SB><PDAT>20 </PDAT></SB></HIL><PDAT>alkoxy, or C</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>-C</PDAT><HIL><SB><PDAT>20 </PDAT></SB></HIL><PDAT>alkoxycarbonyl) or a substituted aryl (substituted with a C</PDAT><HIL><SB><PDAT>1</PDAT></SB></HIL><PDAT>-C</PDAT><HIL><SB><PDAT>20 </PDAT></SB></HIL><PDAT>alkyl, aryl, hydroxyl, C</PDAT><HIL><SB><PDAT>1</PDAT></SB></HIL><PDAT>-C</PDAT><HIL><SB><PDAT>5 </PDAT></SB></HIL><PDAT>alkoxy, amino, nitro, halide or methoxy). In the most preferred form, R is methyl or t-butyl, PR</PDAT><HIL><SB><PDAT>3 </PDAT></SB></HIL><PDAT>is P(cyclohexyl)</PDAT><HIL><SB><PDAT>3 </PDAT></SB></HIL><PDAT>and R&prime; is phenyl.</PDAT></PTEXT></PARA>
<PARA ID="P-00027" LVL="0"><PTEXT><PDAT>A second preferred embodiment of the catalyst has the formula: </PDAT>
<CWU>
<CHEM-US ID="CHEM-US-00002">
<CHEMCDX ID="CHEMCDX-00002" ALT="chemistry chemdraw file" FILE="US06486279-20021126-C00002.CDX"/>
<CHEMMOL ID="CHEMMOL-00002" ALT="chemistry mol file" FILE="US06486279-20021126-C00002.MOL"/>
<EMI ID="EMI-C00002" ALT="embedded image" HE="46.80585" WI="90.01125" FILE="US06486279-20021126-C00002.TIF"/>
</CHEM-US>
</CWU>
</PTEXT></PARA>
<PARA ID="P-00028" LVL="7"><PTEXT><PDAT>where R&Prime; is hydrogen, alkyl, halo, nitro or alkoxy, X is Cl, Br, I, CH</PDAT><HIL><SB><PDAT>3</PDAT></SB></HIL><PDAT>CO</PDAT><HIL><SB><PDAT>2 </PDAT></SB></HIL><PDAT>or CF</PDAT><HIL><SB><PDAT>3</PDAT></SB></HIL><PDAT>CO</PDAT><HIL><SB><PDAT>2 </PDAT></SB></HIL><PDAT>and each R is a substituted or unsubstituted alkyl or aryl, preferably either a C</PDAT><HIL><SB><PDAT>1</PDAT></SB></HIL><PDAT>-C</PDAT><HIL><SB><PDAT>20 </PDAT></SB></HIL><PDAT>alkyl, an aryl, a substituted C</PDAT><HIL><SB><PDAT>1</PDAT></SB></HIL><PDAT>-C</PDAT><HIL><SB><PDAT>20 </PDAT></SB></HIL><PDAT>alkyl (substituted with an aryl, halide, hydroxy, C</PDAT><HIL><SB><PDAT>1</PDAT></SB></HIL><PDAT>-C</PDAT><HIL><SB><PDAT>20 </PDAT></SB></HIL><PDAT>alkoxy, or C</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>-C</PDAT><HIL><SB><PDAT>20 </PDAT></SB></HIL><PDAT>alkoxycarbonyl) or a substituted aryl (substituted with a C</PDAT><HIL><SB><PDAT>1</PDAT></SB></HIL><PDAT>-C</PDAT><HIL><SB><PDAT>20 </PDAT></SB></HIL><PDAT>alkyl, aryl, hydroxyl, C</PDAT><HIL><SB><PDAT>1</PDAT></SB></HIL><PDAT>-C</PDAT><HIL><SB><PDAT>5 </PDAT></SB></HIL><PDAT>alkoxy, amino, nitro, halide or methoxy). In the most preferred form, R&prime; is phenyl, R&Prime; is nitro, PR</PDAT><HIL><SB><PDAT>3 </PDAT></SB></HIL><PDAT>is P(cyclohexyl)</PDAT><HIL><SB><PDAT>3</PDAT></SB></HIL><PDAT>, X is Cl and R is aryl or aryl substituted with 2,6-diisopropyl groups.</PDAT></PTEXT></PARA>
<PARA ID="P-00029" LVL="0"><PTEXT><PDAT>A third preferred embodiment of the catalyst has the formula: </PDAT>
<CWU>
<CHEM-US ID="CHEM-US-00003">
<CHEMCDX ID="CHEMCDX-00003" ALT="chemistry chemdraw file" FILE="US06486279-20021126-C00003.CDX"/>
<CHEMMOL ID="CHEMMOL-00003" ALT="chemistry mol file" FILE="US06486279-20021126-C00003.MOL"/>
<EMI ID="EMI-C00003" ALT="embedded image" HE="44.1693" WI="46.80585" FILE="US06486279-20021126-C00003.TIF"/>
</CHEM-US>
</CWU>
</PTEXT></PARA>
<PARA ID="P-00030" LVL="7"><PTEXT><PDAT>where PR</PDAT><HIL><SB><PDAT>3 </PDAT></SB></HIL><PDAT>is either P(cyclohexyl)</PDAT><HIL><SB><PDAT>3</PDAT></SB></HIL><PDAT>, P(cyclopentyl)</PDAT><HIL><SB><PDAT>3</PDAT></SB></HIL><PDAT>, P(isopropyl)</PDAT><HIL><SB><PDAT>3</PDAT></SB></HIL><PDAT>, or P(phenyl)</PDAT><HIL><SB><PDAT>3 </PDAT></SB></HIL><PDAT>and X is Cl, Br, I, CH</PDAT><HIL><SB><PDAT>3</PDAT></SB></HIL><PDAT>CO</PDAT><HIL><SB><PDAT>2 </PDAT></SB></HIL><PDAT>or CF</PDAT><HIL><SB><PDAT>3</PDAT></SB></HIL><PDAT>CO</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>.</PDAT></PTEXT></PARA>
<PARA ID="P-00031" LVL="0"><PTEXT><PDAT>A fourth preferred embodiment of the catalyst has the formula: </PDAT>
<CWU>
<CHEM-US ID="CHEM-US-00004">
<CHEMCDX ID="CHEMCDX-00004" ALT="chemistry chemdraw file" FILE="US06486279-20021126-C00004.CDX"/>
<CHEMMOL ID="CHEMMOL-00004" ALT="chemistry mol file" FILE="US06486279-20021126-C00004.MOL"/>
<EMI ID="EMI-C00004" ALT="embedded image" HE="44.1693" WI="46.80585" FILE="US06486279-20021126-C00004.TIF"/>
</CHEM-US>
</CWU>
</PTEXT></PARA>
<PARA ID="P-00032" LVL="7"><PTEXT><PDAT>where Cy is cyclohexyl, X is Cl, Br, I, CH</PDAT><HIL><SB><PDAT>3</PDAT></SB></HIL><PDAT>CO</PDAT><HIL><SB><PDAT>2 </PDAT></SB></HIL><PDAT>or CF</PDAT><HIL><SB><PDAT>3</PDAT></SB></HIL><PDAT>CO</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>, and R is one of the following: </PDAT>
<CWU>
<CHEM-US ID="CHEM-US-00005">
<CHEMCDX ID="CHEMCDX-00005" ALT="chemistry chemdraw file" FILE="US06486279-20021126-C00005.CDX"/>
<CHEMMOL ID="CHEMMOL-00005" ALT="chemistry mol file" FILE="US06486279-20021126-C00005.MOL"/>
<EMI ID="EMI-C00005" ALT="embedded image" HE="45.36" WI="159.6105" FILE="US06486279-20021126-C00005.TIF"/>
</CHEM-US>
</CWU>
</PTEXT></PARA>
<PARA ID="P-00033" LVL="0"><PTEXT><PDAT>Preferred forms of this fourth embodiment have the following formulas: </PDAT>
<CWU>
<CHEM-US ID="CHEM-US-00006">
<CHEMCDX ID="CHEMCDX-00006" ALT="chemistry chemdraw file" FILE="US06486279-20021126-C00006.CDX"/>
<CHEMMOL ID="CHEMMOL-00006" ALT="chemistry mol file" FILE="US06486279-20021126-C00006.MOL"/>
<EMI ID="EMI-C00006" ALT="embedded image" HE="311.31135" WI="122.89725" FILE="US06486279-20021126-C00006.TIF"/>
</CHEM-US>
</CWU>
</PTEXT></PARA>
<PARA ID="P-00034" LVL="0"><PTEXT><PDAT>The catalysts of this fourth embodiment are highly effective when used in either aqueous or alcoholic solvents.</PDAT></PTEXT></PARA>
<PARA ID="P-00035" LVL="0"><PTEXT><PDAT>The ruthenium alkylidene compounds of the present invention may be synthesized using diazo compounds, by neutral electron donor ligand exchange, by cross metathesis, using acetylene, using cumulated olefins, and in a one-pot method using diazo compounds and neutral electron donors according to methods described in U.S. Pat. Nos. 5,312,940 and 5,342,909 and U.S. application Ser. No. 08/693,789, filed Jul. 31, 1996, and Ser. No. 08/708,057, filed Aug. 30, 1996 (issued U.S. Pat. Nos. 5,831,108 and 5,710,298, respectively) and in Chang, S., Jones, L., II, Wang, C., Henling, L. M., and Grubbs, R. H., Organometallics, 1998, 17, 3460-3465, Schwab, P., Grubbs, R. H., Ziller, J. W., J. Am. Chem. Soc. 1996, 118, 100-110, and Mohr, B., Lynn, D. M., and Grubbs, R. H., Organometallics, 1996, 15, 4317-4325, each of which is incorporated herein by reference in its entirety, and to methods further described herein.</PDAT></PTEXT></PARA>
</BTEXT>
</BRFSUM>
<DETDESC>
<BTEXT>
<PARA ID="P-00036" LVL="0"><PTEXT><PDAT>The following non-limiting examples further illustrate the present invention:</PDAT></PTEXT></PARA>
<H LVL="1"><STEXT><PDAT>EXAMPLE 1</PDAT></STEXT></H>
<PARA ID="P-00037" LVL="7"><PTEXT><PDAT>Synthesis of Ruthenium Alkylidenes</PDAT></PTEXT></PARA>
<PARA ID="P-00038" LVL="0"><PTEXT><PDAT>General Considerations. All manipulations and reactions involving ruthenium alkylidenes were performed in a nitrogen-filled drybox or by using standard Schlenk techniques under an atmosphere of argon.</PDAT></PTEXT></PARA>
<PARA ID="P-00039" LVL="7"><PTEXT><PDAT>Synthesis of RuCl</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>(&boxH;CH&mdash;CH&boxH;CPh</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>)(PPh</PDAT><HIL><SB><PDAT>3</PDAT></SB></HIL><PDAT>)</PDAT><HIL><SB><PDAT>2 </PDAT></SB></HIL></PTEXT></PARA>
<PARA ID="P-00040" LVL="0"><PTEXT><PDAT>Inside a dry box a solution of RuCl</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>(PPh</PDAT><HIL><SB><PDAT>3</PDAT></SB></HIL><PDAT>)</PDAT><HIL><SB><PDAT>4 </PDAT></SB></HIL><PDAT>(6.0 g, 4.91 mmol) in a Schenk flask was reacted with 3,3-diphenylcyclopropene (954 mg, 1.0 eq) in a 1:1 mixture of CH</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>Cl</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>/C</PDAT><HIL><SB><PDAT>6</PDAT></SB></HIL><PDAT>H</PDAT><HIL><SB><PDAT>6</PDAT></SB></HIL><PDAT>. The flask was capped with a stopper, removed from the box, attached to a reflux condenser under argon and heated at 53&deg; C. for 11 h. After allowing the solution to cool to room temperature, all the solvent was removed in vacuo to give a dark yellow-brown solid. Benzene (10 ml) was added to the solid and subsequent swirling of the mixture broke the solid into a fine powder. Pentane (80 ml) was then slowly added to the mixture via cannula while stirring vigorously. The mixture was stirred at room temperature for 1 h and allowed to settle before the supernatant was removed via cannula filtration. This washing procedure was repeated two more times to ensure complete removal of all phosphine by-products. The resulting solid was then dried overnight to afford 4.28 g (98%) of RuCl</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>(&boxH;CH&mdash;CH&boxH;CPh</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>)(PPh</PDAT><HIL><SB><PDAT>3</PDAT></SB></HIL><PDAT>)</PDAT><HIL><SB><PDAT>2 </PDAT></SB></HIL><PDAT>as a yellow powder with a slight green tint.</PDAT></PTEXT></PARA>
<PARA ID="P-00041" LVL="7"><PTEXT><PDAT>Synthesis of RuCl</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>(&boxH;CHPh)(PR</PDAT><HIL><SB><PDAT>3</PDAT></SB></HIL><PDAT>)</PDAT><HIL><SB><PDAT>2 </PDAT></SB></HIL><PDAT>Complexes</PDAT></PTEXT></PARA>
<PARA ID="P-00042" LVL="0"><PTEXT><PDAT>RuCl</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>(&boxH;CHPh)(PPh</PDAT><HIL><SB><PDAT>3</PDAT></SB></HIL><PDAT>)</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>. A solution of RuCl</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>(PPh</PDAT><HIL><SB><PDAT>3</PDAT></SB></HIL><PDAT>)</PDAT><HIL><SB><PDAT>3 </PDAT></SB></HIL><PDAT>(2.37 g, 2.47 mmol) in CH</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>Cl</PDAT><HIL><SB><PDAT>2 </PDAT></SB></HIL><PDAT>(20 mL) was treated at &minus;78&deg; C. with a &minus;50&deg; C solution of phenyldiazomethane (584 mg, 4.94 mmol, 2.0 equiv) in CH</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>Cl</PDAT><HIL><SB><PDAT>2 </PDAT></SB></HIL><PDAT>or pentane (3 mL). A spontaneous color change from orange-brown to brown-green and vigorous bubbling was observed. After the cooling bath was removed, the solution was stirred for 5 min and the solution was then concentrated to &tilde;3 mL. Upon addition of pentane (20 mL), a green solid was precipitated which was separated from the brown mother-liquid via cannula filtration, dissolved in CH</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>Cl</PDAT><HIL><SB><PDAT>2 </PDAT></SB></HIL><PDAT>(3 mL). and reprecipitated with pentane. This procedure was repeated until the mother-liquid was nearly colorless. The remaining gray-green microcrystalline solid was dried under vacuum for several hours. Yield&equals;1.67 g (89%).</PDAT></PTEXT></PARA>
<PARA ID="P-00043" LVL="0"><PTEXT><PDAT>One-Pot Synthesis of RuCl</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>(&boxH;CHPh)(PCy</PDAT><HIL><SB><PDAT>3</PDAT></SB></HIL><PDAT>)</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>. A solution of RuCl</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>(PPh</PDAT><HIL><SB><PDAT>3</PDAT></SB></HIL><PDAT>)</PDAT><HIL><SB><PDAT>3 </PDAT></SB></HIL><PDAT>(4.0 g, 4.17 mmol) in CH</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>Cl</PDAT><HIL><SB><PDAT>2 </PDAT></SB></HIL><PDAT>(40 mL) was treated at &minus;78&deg; C. with a &minus;50&deg; C. solution of phenyldiazomethane (986 mg. 8.35 mmol, 2.0 equiv) in pentane (10 mL). Upon addition: of the diazo compound, an instantaneous color change from orange-brown to green-brown and vigorous bubbling was observed. After the reaction mixture was stirred at &minus;70&deg; C. to &minus;60&deg; C. for 5-10 min, an ice-cold solution of tricyclohexylphosphine (2.57 g. 9.19 mmol, 2.2 equiv) in CH</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>Cl</PDAT><HIL><SB><PDAT>2 </PDAT></SB></HIL><PDAT>was added via syringe. Accompanied by a color change from brown-green to red. The solution was allowed to warm to room temperature and stirred for 30 min. The solution was filtered, concentrated to half of the volume, and filtrated. Methanol (100 mL) was added to precipitate a purple microcrystalline solid, which was filtered off, washed several times with acetone and methanol (10-mL portions), and dried under vacuum for several hours. Yield&equals;3.40 g (99%).</PDAT></PTEXT></PARA>
<PARA ID="P-00044" LVL="0"><PTEXT><PDAT>One-pot Synthesis of RuCl</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>(&boxH;CHPh)(PCp</PDAT><HIL><SB><PDAT>3</PDAT></SB></HIL><PDAT>)</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>.</PDAT></PTEXT></PARA>
<PARA ID="P-00045" LVL="0"><PTEXT><PDAT>RuCl</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>(&boxH;CHPh)(PCp</PDAT><HIL><SB><PDAT>3</PDAT></SB></HIL><PDAT>)</PDAT><HIL><SB><PDAT>2 </PDAT></SB></HIL><PDAT>is obtained was obtained by methods analogous to those used for the one-pot synthesis of RuCl</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>(&boxH;CHPh)(PCy</PDAT><HIL><SB><PDAT>3</PDAT></SB></HIL><PDAT>)</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>, as a purple microcrystalline solid, using RuCl</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>(PPh</PDAT><HIL><SB><PDAT>3</PDAT></SB></HIL><PDAT>)</PDAT><HIL><SB><PDAT>3 </PDAT></SB></HIL><PDAT>(4.00 g, 4.17 mmol), phenyldiazomethane (986 mg, 8.35 mmol, 2.0 eq.), and tricyclopentyl-phosphine (2.19 g, 9.18 mmol, 2.2 eq.). Due to the better solubility of the compound, methanol was used for the washings. Yield 2.83 g (92%). </PDAT><HIL><SP><PDAT>1</PDAT></SP></HIL><PDAT>H NMR (CD</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>Cl</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>): &dgr;20.20 (s, Ru&boxH;CH),</PDAT><HIL><SP><PDAT>31</PDAT></SP></HIL><PDAT>P NMR (CD</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>Cl</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>): &dgr;29.96 (s, PCp</PDAT><HIL><SB><PDAT>3</PDAT></SB></HIL><PDAT>). Anal. Calcd. for C</PDAT><HIL><SB><PDAT>37</PDAT></SB></HIL><PDAT>H</PDAT><HIL><SB><PDAT>40</PDAT></SB></HIL><PDAT>Cl</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>P</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>Ru: C, 60.15; H, 8.19. Found: C, 60.39; H, 8.21.</PDAT></PTEXT></PARA>
<PARA ID="P-00046" LVL="7"><PTEXT><PDAT>Synthesis of (PCy</PDAT><HIL><SB><PDAT>3</PDAT></SB></HIL><PDAT>)(R-acac)</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>(CHPh) </PDAT>
<CWU>
<CHEM-US ID="CHEM-US-00007">
<CHEMCDX ID="CHEMCDX-00007" ALT="chemistry chemdraw file" FILE="US06486279-20021126-C00007.CDX"/>
<CHEMMOL ID="CHEMMOL-00007" ALT="chemistry mol file" FILE="US06486279-20021126-C00007.MOL"/>
<EMI ID="EMI-C00007" ALT="embedded image" HE="157.2291" WI="216.027" FILE="US06486279-20021126-C00007.TIF"/>
</CHEM-US>
</CWU>
</PTEXT></PARA>
<PARA ID="P-00047" LVL="0"><PTEXT><PDAT>Inside the dry box, 200 mg (0.243 mmol) of RuCl</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>(&boxH;CHR)(PCy</PDAT><HIL><SB><PDAT>3</PDAT></SB></HIL><PDAT>)</PDAT><HIL><SB><PDAT>2 </PDAT></SB></HIL><PDAT>prepared as above were weighed into a Schlenk flask and dissolved in approximately 120 ml of C</PDAT><HIL><SB><PDAT>6</PDAT></SB></HIL><PDAT>H</PDAT><HIL><SB><PDAT>6 </PDAT></SB></HIL><PDAT>and 150 mg of Tl(acetyl acetonate) (0.494 mmol, 2.03 eq) were added. The flask was capped with a rubber septum, removed from the dry box, and stirred for 1-2 hrs under argon on a Schlenk line, during which time the solution turned green. The solvent was removed in vacuo, and the solids were washed with hexanes (3&times;5 ml) to extract the product and PCy</PDAT><HIL><SB><PDAT>3</PDAT></SB></HIL><PDAT>. The filtrate was collected via cannula filtration in another Schlenk flask, and the solvent was removed in vacuo.</PDAT></PTEXT></PARA>
<PARA ID="P-00048" LVL="0"><PTEXT><PDAT>Inside the dry box, the product mixture was dissolved in benzene, and 100 mg of CuCl (1.01 mmol, 4 eq) were added. The suspension was placed back on the Schlenk line and stirred for 2 hrs, and the solvent was removed in vacuo. The product was extracted from the CuCl.PCy</PDAT><HIL><SB><PDAT>3 </PDAT></SB></HIL><PDAT>polymer with cold hexanes (3&times;5 ml). The filtrate was collected via cannula filtration, and the solvent removed in vacuo, leaving a green powder. </PDAT><HIL><SP><PDAT>1</PDAT></SP></HIL><PDAT>H NMR (C</PDAT><HIL><SB><PDAT>6</PDAT></SB></HIL><PDAT>D</PDAT><HIL><SB><PDAT>6</PDAT></SB></HIL><PDAT>): &dgr;19.35 (d, 1 H, RU&boxH;CH, </PDAT><HIL><SP><PDAT>3</PDAT></SP></HIL><PDAT>J</PDAT><HIL><SB><PDAT>HP</PDAT></SB></HIL><PDAT>&equals;12 Hz), 8.59 (d, 2 H, H</PDAT><HIL><SB><PDAT>ortho</PDAT></SB></HIL><PDAT>, </PDAT><HIL><SP><PDAT>3</PDAT></SP></HIL><PDAT>J</PDAT><HIL><SB><PDAT>HH</PDAT></SB></HIL><PDAT>&equals;8.0 Hz), 7.47 (t, 1, H, H</PDAT><HIL><SB><PDAT>para</PDAT></SB></HIL><PDAT>,</PDAT><HIL><SP><PDAT>3</PDAT></SP></HIL><PDAT>J</PDAT><HIL><SB><PDAT>HH</PDAT></SB></HIL><PDAT>&equals;7.3 Hz), 7.37 (app t, 2 H, H</PDAT><HIL><SB><PDAT>meta</PDAT></SB></HIL><PDAT>, </PDAT><HIL><SP><PDAT>3</PDAT></SP></HIL><PDAT>J</PDAT><HIL><SB><PDAT>HH</PDAT></SB></HIL><PDAT>&equals;8.0, 7.3 Hz), 5.58 (s, 1 H), 4.76 (s, 1 H), 2.18 (s, 3 H), 2.12 (s, 3 H), 1.80 (s, 3 H), 1.67 (s, 3 H), 1.20-2.00 (m, 33 H), </PDAT><HIL><SP><PDAT>31</PDAT></SP></HIL><PDAT>P(</PDAT><HIL><SP><PDAT>1</PDAT></SP></HIL><PDAT>H) NMR: &dgr;38.86 (s).</PDAT></PTEXT></PARA>
<PARA ID="P-00049" LVL="7"><PTEXT><PDAT>Synthesis of (PCy</PDAT><HIL><SB><PDAT>3</PDAT></SB></HIL><PDAT>)(t-Bu</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>acac)</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>Ru(CHPh) </PDAT>
<CWU>
<CHEM-US ID="CHEM-US-00008">
<CHEMCDX ID="CHEMCDX-00008" ALT="chemistry chemdraw file" FILE="US06486279-20021126-C00008.CDX"/>
<CHEMMOL ID="CHEMMOL-00008" ALT="chemistry mol file" FILE="US06486279-20021126-C00008.MOL"/>
<EMI ID="EMI-C00008" ALT="embedded image" HE="196.5789" WI="216.027" FILE="US06486279-20021126-C00008.TIF"/>
</CHEM-US>
</CWU>
</PTEXT></PARA>
<PARA ID="P-00050" LVL="0"><PTEXT><PDAT>Inside the dry box, 100 mg (0.12 mmol) of RuCl</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>(&boxH;CHPh)(PCy</PDAT><HIL><SB><PDAT>3</PDAT></SB></HIL><PDAT>)</PDAT><HIL><SB><PDAT>2 </PDAT></SB></HIL><PDAT>prepared as above were weighed into a Schlenk flask and dissolved in approximately 10 ml of C</PDAT><HIL><SB><PDAT>6</PDAT></SB></HIL><PDAT>H</PDAT><HIL><SB><PDAT>6 </PDAT></SB></HIL><PDAT>and 94 mg of Tl (t-Bu</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>-acetyl acetonate) (0.24 mmol, 2 eq) were added. The flask was capped with a rubber septum, removed from the dry box, and stirred for 2 days under argon on a Schlenk line, during which time the solution turned green. The solvent was removed in vacuo, and the solids were washed with hexanes (3&times;5 ml) to extract the product and PCy</PDAT><HIL><SB><PDAT>3</PDAT></SB></HIL><PDAT>. The filtrate was collected via cannula filtration in another Schlenk flask, and the solvent was removed in vacuo.</PDAT></PTEXT></PARA>
<PARA ID="P-00051" LVL="0"><PTEXT><PDAT>Inside the dry box, the product mixture was dissolved in benzene, and 100 mg of CuCl (1.01 mmol, 8 eq) were added. The suspension was placed back on the Schlenk line and stirred for 2 hrs, and the solvent was removed in vacuo. The product was extracted from the CuCl.PCy</PDAT><HIL><SB><PDAT>3 </PDAT></SB></HIL><PDAT>polymer with cold hexanes (3&times;5 ml). The filtrate was collected via cannula filtration, and the solvent removed in vacuo, leaving a light green powder. </PDAT><HIL><SP><PDAT>1</PDAT></SP></HIL><PDAT>H NMR: &dgr;19.04 (d, 1 H, Ru&boxH;CH, </PDAT><HIL><SP><PDAT>3</PDAT></SP></HIL><PDAT>J</PDAT><HIL><SB><PDAT>HP</PDAT></SB></HIL><PDAT>&equals;12 Hz), 8.28 (d, 2 H, H</PDAT><HIL><SB><PDAT>ortho</PDAT></SB></HIL><PDAT>, </PDAT><HIL><SP><PDAT>3</PDAT></SP></HIL><PDAT>J</PDAT><HIL><SB><PDAT>HH</PDAT></SB></HIL><PDAT>&equals;8.0 Hz), 7.56 (T, 1 H, H</PDAT><HIL><SB><PDAT>para</PDAT></SB></HIL><PDAT>, </PDAT><HIL><SP><PDAT>3</PDAT></SP></HIL><PDAT>J</PDAT><HIL><SB><PDAT>HH</PDAT></SB></HIL><PDAT>&equals;8.0 Hz), 7.31 (t, 2 H, H</PDAT><HIL><SB><PDAT>meta</PDAT></SB></HIL><PDAT>, </PDAT><HIL><SP><PDAT>3</PDAT></SP></HIL><PDAT>J</PDAT><HIL><SB><PDAT>HH</PDAT></SB></HIL><PDAT>&equals;8.0 Hz), 5.75 (s, 1 H), 5.11 (s, 1 H), 1.15 (app s, 18 H), 1.10 (s, 9 H), 0.82 (s, 9 h), 1.10-2.10 (m, 33 H), 31P&lcub;1H&rcub; NMR: &dgr;37.90 (s).</PDAT></PTEXT></PARA>
<PARA ID="P-00052" LVL="7"><PTEXT><PDAT>Synthesis of Schiff-base-Substituted Ru Complexes</PDAT></PTEXT></PARA>
<PARA ID="P-00053" LVL="0"><PTEXT><PDAT>Schiff-base substituted Ru complexes were prepared by first condensing salicylaldehydes with aliphatic or aromatic amine derivatives. The resulting ligands were converted to thallium salts and then substitution reactions were performed with RuCl</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>(&boxH;CHPh)(Cy</PDAT><HIL><SB><PDAT>3</PDAT></SB></HIL><PDAT>)</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>. Successful Schiff-base ligands were prepared according to the procedures described below using the following pairs salicylaldehydes and amine derivatives: salicylaldehyde and 2,6-diisopropylaniline, 5-nitrosalicylaldehyde and 2,6-diisopropylaniline, 5-nitrosalicylaldehyde and 2,6-dimethyl-4-methoxyaniline, 5-nitrosalicylaldehyde and 4-bromo-2,6-dimethylaniline, 5-nitrosalicylaldehyde and 4-amino-3,5-dichlorobenzotrifluoride, 3-methyl-5-nitrosalicylaldehyde and 2,6-diisopropylaniline, and 5-nitrosalicylaldehyde and 2,6-diisopropyl-4-nitroaniline.</PDAT></PTEXT></PARA>
<PARA ID="P-00054" LVL="0"><PTEXT><PDAT>General Procedure for the Preparation of Schiff-base Ligands. The condensation of salicylaldehydes with aliphatic or aromatic amine derivatives was carried out with stirring in ethyl alcohol at 80&deg; C. for 2 h. Upon cooling to 0&deg; C., a yellow solid precipitated from the reaction mixture. The solid was filtered, washed with cold ethyl alcohol, and then dried in vacuo to afford the desired salicylaldimine ligand in excellent yields.</PDAT></PTEXT></PARA>
<PARA ID="P-00055" LVL="0"><PTEXT><PDAT>General Procedure for the Preparation of Thallium Salts. To a solution of Schiff bases in benzene or THF (10 mL) was added dropwise a solution of thalium ethoxide in benzene or THF (5 mL) at room temperature. Immediately after the addition, a pale yellow solid formed and the reaction mixture was stirred for 2 h at room temperature. Filtration of the solid under a nitrogen or argon atmosphere gave the thallium salts in quantitative yields. The salts were immediately used in the next step without further purification.</PDAT></PTEXT></PARA>
<PARA ID="P-00056" LVL="0"><PTEXT><PDAT>General Procedure for Preparation of Schiff-base-Substituted Ru Complexes. To a solution of RuCl</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>(&boxH;CHPh)(Cy</PDAT><HIL><SB><PDAT>3</PDAT></SB></HIL><PDAT>)</PDAT><HIL><SB><PDAT>2 </PDAT></SB></HIL><PDAT>prepared as above in THF (5 ml) was added a solution of thallium salt prepared as above in THF (5 ml). The reaction mixture was stirred at room temperature for 3 h. After evaporation of the solvent, the residue was dissolved in a minimal amount of benzene and cooled to 0&deg; C. The thallium chloride (byproduct of the reaction) was removed via filtration. The desired complex was then washed with cold benzene (10 ml&times;3), and the filtrate was evaporated. The solid residue was recrystallized from pentane (&minus;70&deg; C.) to give the Schiff-base-substituted Ru complexes in moderate to good yields as brown solids.</PDAT></PTEXT></PARA>
<PARA ID="P-00057" LVL="7"><PTEXT><PDAT>Synthesis of RuCl</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>(&boxH;CHPh)&lsqb;Cy</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>PCH</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>CH</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>N(CH</PDAT><HIL><SB><PDAT>3</PDAT></SB></HIL><PDAT>)</PDAT><HIL><SB><PDAT>3</PDAT></SB></HIL><HIL><SP><PDAT>&plus;</PDAT></SP></HIL><PDAT>Cl&rsqb;</PDAT><HIL><SB><PDAT>2 </PDAT></SB></HIL></PTEXT></PARA>
<PARA ID="P-00058" LVL="0"><PTEXT><PDAT>RuCl</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>(&boxH;CHPh)&lsqb;Cy</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>PCH</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>CH</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>N(CH</PDAT><HIL><SB><PDAT>3</PDAT></SB></HIL><PDAT>)</PDAT><HIL><SB><PDAT>3</PDAT></SB></HIL><HIL><SP><PDAT>&plus;</PDAT></SP></HIL><PDAT>Cl&rsqb;</PDAT><HIL><SB><PDAT>2 </PDAT></SB></HIL><PDAT>was prepared by placing dicyclohexylphosphine (19.7 g, 0.99 mol) in THF (100 mL) into a Schlenk flask equipped with a stirbar, capped with a rubber septum, and purging with argon. The solution was cooled to 0&deg; C., and BH</PDAT><HIL><SB><PDAT>3</PDAT></SB></HIL><PDAT>.THF (100 mL of a 1.0 M solution in THF, 0.1 mol, 1.01 equiv) was slowly added via cannula. The colorless solution was stirred for 2 h at 0&deg; C. and then allowed to warm to room temperature. Evaporation of the solvent resulted in a crystalline white solid, Cy</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>PH(BH</PDAT><HIL><SB><PDAT>3</PDAT></SB></HIL><PDAT>), which was recrystallized from pentane. (Yield: 18.9 g (90%) as white needles).</PDAT></PTEXT></PARA>
<PARA ID="P-00059" LVL="0"><PTEXT><PDAT>The Cy</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>PH(BH</PDAT><HIL><SB><PDAT>3</PDAT></SB></HIL><PDAT>) (4 g, 18.90 mmol) was dissolved in THF (100 mL) and was placed into a Schlenk flask and purged with argon. The solution was cooled to &minus;78&deg; C., and n-butyllithium (12.4 mL of a 1.6 M solution in hexane, 19.80 mmol, 1.05 equiv) was added dropwise via syringe over a period of 10 min. The colorless reaction mixture was stirred for 2 h while slowly warming to room temperature. Upon cooling of the solution to &minus;78&deg; C., 2-chloro-N,N-dimethylaminoethane (2.44 g, 22.70 mmol, 1.20 equiv) in THF (50 mL) was slowly added via syringe. The reaction mixture was kept for 2 h at &minus;78&deg; C. and then stirred at room temperature overnight. Evaporation of the solvent gave a white solid which was subjected to column chromatography (silica gel/methanol, R</PDAT><HIL><SB><PDAT>1</PDAT></SB></HIL><PDAT>&equals;0.25) to yield 3.48 g (65%) of Cy</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>P(BH</PDAT><HIL><SB><PDAT>3</PDAT></SB></HIL><PDAT>)CH</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>CH</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>N(CH</PDAT><HIL><SB><PDAT>3</PDAT></SB></HIL><PDAT>)</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>, as a white solid.</PDAT></PTEXT></PARA>
<PARA ID="P-00060" LVL="0"><PTEXT><PDAT>1.50 g (5.30 mmol) of Cy</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>P(BH</PDAT><HIL><SB><PDAT>3</PDAT></SB></HIL><PDAT>)CH</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>CH</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>N(CH</PDAT><HIL><SB><PDAT>3</PDAT></SB></HIL><PDAT>)</PDAT><HIL><SB><PDAT>2 </PDAT></SB></HIL><PDAT>was dissolved in ether (60 mL) followed by addition of methyl iodide (1.88 g, 13.24 mmol, 2.5 equiv). The reaction mixture was stirred for 4 h at room temperature, during which a white solid precipitated. The precipitate was collected by filtration, washed with ether and dried in vacuo to yield 2.17 g (97%) of Cy</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>P(BH</PDAT><HIL><SB><PDAT>3</PDAT></SB></HIL><PDAT>)CH</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>CH</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>N(CH</PDAT><HIL><SB><PDAT>3</PDAT></SB></HIL><PDAT>)</PDAT><HIL><SB><PDAT>3</PDAT></SB></HIL><HIL><SP><PDAT>&plus;</PDAT></SP></HIL><PDAT>I</PDAT><HIL><SP><PDAT>&minus;</PDAT></SP></HIL><PDAT>, as a white solid.</PDAT></PTEXT></PARA>
<PARA ID="P-00061" LVL="0"><PTEXT><PDAT>The Cy</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>P(BH</PDAT><HIL><SB><PDAT>3</PDAT></SB></HIL><PDAT>)CH</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>CH</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>N(CH</PDAT><HIL><SB><PDAT>3</PDAT></SB></HIL><PDAT>)</PDAT><HIL><SB><PDAT>3</PDAT></SB></HIL><HIL><SP><PDAT>&plus;</PDAT></SP></HIL><PDAT>I</PDAT><HIL><SP><PDAT>&minus;</PDAT></SP></HIL><PDAT>, (1.50 g, 3.53 mmol) was then dissolved in morpholine (30 mL), placed into a Schlenk flask and purged with argon. The reaction mixture was stirred for 2 h at 110&deg; C. and then cooled to room temperature. Evaporation of the solvent gave a gummy white residue which was dissolved in a small mount of methanol (3 nL) and reprecipitated by addition of cold THF (25 mL). The supernatant was removed via cannula filtration, and the precipitate was washed with a small amount of THF (5 m) and dried in vacuo to yield 1.05 g (72%) of Cy</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>PCH</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>CH</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>N(CH</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>)</PDAT><HIL><SB><PDAT>3</PDAT></SB></HIL><HIL><SP><PDAT>&plus;</PDAT></SP></HIL><PDAT>I</PDAT><HIL><SP><PDAT>&minus;</PDAT></SP></HIL><PDAT> as a white crystalline solid.</PDAT></PTEXT></PARA>
<PARA ID="P-00062" LVL="0"><PTEXT><PDAT>RuCl</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>(&boxH;CHPh)(PPh</PDAT><HIL><SB><PDAT>3</PDAT></SB></HIL><PDAT>)</PDAT><HIL><SB><PDAT>2 </PDAT></SB></HIL><PDAT>(1.20 g, 1.53 mmol) prepared as above was then placed in a Schlenk flask equipped with a stirbar, capped with a rubber septum, and purged with argon. CH</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>Cl</PDAT><HIL><SB><PDAT>2 </PDAT></SB></HIL><PDAT>(15.0 ml) was added, and the dark green solution was cooled to &minus;78&deg; C. Cy</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>PCH</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>CH</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>N(CH</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>)</PDAT><HIL><SB><PDAT>3</PDAT></SB></HIL><HIL><SP><PDAT>&plus;</PDAT></SP></HIL><PDAT>I</PDAT><HIL><SP><PDAT>&minus;</PDAT></SP></HIL><PDAT> (1.0 g., 3.13 mmol, 2.05 equiv) was dissolved in methanol (10 mL) under argon, cooled to 78&deg; C., and slowly added to the Schlenk flask via syringe. The reaction mixture was stirred at &minus;78&deg; C. for 30 min while a color change to dark red was observed. Stirring was continued for 30 min as the reaction warmed to room temperature. Removal of the solvent in vacuo yielded a dark purple solid. The solid material was dissolved in CH</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>C</PDAT><HIL><BOLD><PDAT>1</PDAT></BOLD></HIL><HIL><SB><PDAT>2 </PDAT></SB></HIL><PDAT>(10 mL) and stirred, and pentane (100 mL) was added to precipitate a purple solid. The brownish red supernatant was removed and discarded via cannula filtration, and this procedure was repeated until the supernatant became colorless. By this stage, the solid product was insoluble in CH</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>Cl</PDAT><HIL><SB><PDAT>2 </PDAT></SB></HIL><PDAT>and was further treated with heat CH</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>Cl</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>, until the washings became colorless. The product was dissolved in methanol (15 mL) and cannula filtered from an insoluble dark purple material, and solvent was removed in vacuo to yield the desired product RuCl</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>(&boxH;CHPh)&lsqb;Cy</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>PCH</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>CH</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>N(CH</PDAT><HIL><SB><PDAT>3</PDAT></SB></HIL><PDAT>)</PDAT><HIL><SB><PDAT>3</PDAT></SB></HIL><HIL><SP><PDAT>&plus;</PDAT></SP></HIL><PDAT>Cl&rsqb;</PDAT><HIL><SB><PDAT>2 </PDAT></SB></HIL><PDAT>as a purple solid (0.680 g, 67.4%). Although the &lsqb;M</PDAT><HIL><SP><PDAT>&plus;</PDAT></SP></HIL><PDAT>&rsqb; peak was not observed in the FAB mass spectrum, the observed isotopic abundance for corresponding &lsqb;M&plus;H&mdash;Cl</PDAT><HIL><SP><PDAT>31</PDAT></SP></HIL><PDAT>&rsqb; peaks identically matched the predicted isotope pattern for the &lsqb;M&plus;H&mdash;Cl</PDAT><HIL><SP><PDAT>&minus;</PDAT></SP></HIL><PDAT>&rsqb; fragment of RuCl</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>(&boxH;CHPh)&lsqb;Cy</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>PCH</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>CH</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>N(CH</PDAT><HIL><SB><PDAT>3</PDAT></SB></HIL><PDAT>)</PDAT><HIL><SB><PDAT>3</PDAT></SB></HIL><HIL><SP><PDAT>&plus;</PDAT></SP></HIL><PDAT>Cl&rsqb;</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>.</PDAT></PTEXT></PARA>
<PARA ID="P-00063" LVL="7"><PTEXT><PDAT>Synthesis of RuCl</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>(&boxH;CHPh)&lsqb;Cy</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>P(N,N-dimethyllpiperidinium chloride)&rsqb;</PDAT><HIL><SB><PDAT>2 </PDAT></SB></HIL></PTEXT></PARA>
<PARA ID="P-00064" LVL="0"><PTEXT><PDAT>RuCl</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>(&boxH;CHPh)&lsqb;Cy</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>P(N,N-dimethylpiperidinium chloride)&rsqb;</PDAT><HIL><SB><PDAT>2 </PDAT></SB></HIL><PDAT>was prepared as follows. Lithiation of Cy</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>PH(BH)</PDAT><HIL><SB><PDAT>3 </PDAT></SB></HIL><PDAT>with n-butylithium (10.0 mL of a 1.6 M solution in hexane, 16.0 mmol. 1.06 equiv) was performed as described above. Upon cooling of the solution to &minus;78&deg; C., 6 (2.0 g. 7.42 mmol. 0.5 equiv) in THF (50 mL) was slowly added via syringe. The reaction mixture was maintained at &minus;78 &deg; C. for 2 h and then stirred at 60&deg; C. for 6 h. Upon evaporation of the solvent ether (50 mL) and saturated aqueous sodium bicarbonate solution (50 mL) were added. The organic phase was separated and the aqueous phase extracted with ether (2&times;100 mL). Evaporation of the combined organic layers gave a white solid which was subjected to column chromatography (silica gel/methanol, R</PDAT><HIL><SB><PDAT>1</PDAT></SB></HIL><PDAT>&equals;0.22) to yield 1.25 g (54%) of a white solid. This solid was then methylated with methyl iodide, analogous to method described above for the methylation of Cy</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>PCH</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>CH</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>N(CH</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>)</PDAT><HIL><SB><PDAT>3</PDAT></SB></HIL><HIL><SP><PDAT>&plus;</PDAT></SP></HIL><PDAT>I</PDAT><HIL><SP><PDAT>&minus;</PDAT></SP></HIL><PDAT> to yield Cy</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>P(BH</PDAT><HIL><SB><PDAT>3</PDAT></SB></HIL><PDAT>)(N,N-dimethylpiperidinium iodide) as a white solid (98%), which was then converted with morpholine to yield Cy</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>P(N,N-dimethylpiperidinium iodide) as a white solid (73%), again by a method analogous to that described above for the conversion of Cy</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>PCH</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>CH</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>N(CH</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>)</PDAT><HIL><SB><PDAT>3</PDAT></SB></HIL><HIL><SP><PDAT>&plus;</PDAT></SP></HIL><PDAT>I</PDAT><HIL><SP><PDAT>31 </PDAT></SP></HIL><PDAT> to Cy</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>PCH</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>CH</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>N(CH</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>)</PDAT><HIL><SB><PDAT>3</PDAT></SB></HIL><HIL><SP><PDAT>&plus;</PDAT></SP></HIL><PDAT>I</PDAT><HIL><SP><PDAT>&minus;</PDAT></SP></HIL><PDAT>.</PDAT></PTEXT></PARA>
<PARA ID="P-00065" LVL="0"><PTEXT><PDAT>RuCl</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>(PPh</PDAT><HIL><SB><PDAT>3</PDAT></SB></HIL><PDAT>)</PDAT><HIL><SB><PDAT>3 </PDAT></SB></HIL><PDAT>(1.38 g, 1.44 mmol) prepared as above was placed in a Schlenk flask and purged with argon. CH</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>Cl</PDAT><HIL><SB><PDAT>2 </PDAT></SB></HIL><PDAT>(15.0 mL) was added, and the dark red solution was cooled to &minus;78&deg; C. Phenyldiazomethane (0.340 g, 2.88 mmol, 2.0 equiv) was quickly weighed under air, dissolved in pentane (1.0 mL), cooled to &minus;78&deg; C., and added to the Schlenk flask via pipet under an argon purge. Upon addition of the diazo compound, an instantaneous color change from dark red to dark green was observed. The reaction was stirred for 5 min. and a solution of Cy</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>P(N,N-dimethylpiperidinium iodide) (1.10 g, 3.18 mmol, 2.2 equiv) in methanol (10 mL) was added via syringe. The solution became dark-red, and stirring was continued for 30 min as the reaction warmed to room temperature. Solvent was removed in vacuo and dried overnight to yield a burgundy solid. The solid material was dissolved in CH</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>Cl</PDAT><HIL><SB><PDAT>2 </PDAT></SB></HIL><PDAT>(15 mL) and stirred, and pentane (100 mL) was added to precipitate a burgundy solid. Pentane should be added quickly, as 19 slowly decomposes in CH</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>Cl</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>. The dark red supernatant was removed and discarded via cannula filtration, and the product was reprecipitated until the supernatant was colorless. The solid was dissolved in CH</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>Cl</PDAT><HIL><SB><PDAT>2 </PDAT></SB></HIL><PDAT>(10 mL), precipitated by addition of the THF (150 mL) and cannula filtered. This process continued until the supernatant was colorless. The product was dissolved in methanol (10 mL) and cannula filtered from insoluble material, and solvent was removed in vacuo to yield the desired RuCl</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>(&boxH;CHPh)&lsqb;Cy</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>P(N,N-dimethylpiperidinium chloride)&rsqb;</PDAT><HIL><SB><PDAT>2 </PDAT></SB></HIL><PDAT>product as a burgundy solid.</PDAT></PTEXT></PARA>
<H LVL="1"><STEXT><PDAT>EXAMPLE 2</PDAT></STEXT></H>
<PARA ID="P-00066" LVL="7"><PTEXT><PDAT>Synthesis of Olefin Monomers</PDAT></PTEXT></PARA>
<H LVL="1"><STEXT><PDAT>Synthesis of exo-N-(N&prime;,N&prime;,N&prime;-trimethylammonio)ethyl-bicyclo&lsqb;2.2.1&rsqb;hept-5-ene-2,3-dicarboximide chloride</PDAT></STEXT></H>
<PARA ID="P-00067" LVL="0"><PTEXT><PDAT>Exo-bicyclo&lsqb;2.2.1&rsqb;hept-5-ene-2,3-dicarboxylic anhydride (2.03 g, 12.37 mmol) and N,N-dimethylethylenediamine (1.09 g, 12.37 mmol) were dissolved in CH</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>Cl</PDAT><HIL><SB><PDAT>2 </PDAT></SB></HIL><PDAT>(30 mL) and heated at 90&deg; C. for 8 hours in a heavy-walled sealed tube. Upon cooling to room temperature, this solution was washed with brine (3&times;), the organic layer was dried over sodium sulfate, and the solvent was removed in vacuo. This white crystalline product was dissolved in THF (20 mL) and subsequently treated with 5 equivalents of methyl iodide at room temperature. The resulting white precipitate was filtered, washed liberally with THF, and dried under vacuum to yield the title compound as an iodide salt. Iodide/chloride ion exchange as previously described</PDAT><HIL><SP><PDAT>3 </PDAT></SP></HIL><PDAT>afforded 3 as a white flaky solid (34% yield based on anhydride starting material). </PDAT><HIL><SP><PDAT>1</PDAT></SP></HIL><PDAT>H NMR &dgr;(CD</PDAT><HIL><SB><PDAT>3</PDAT></SB></HIL><PDAT>OD): 6.38 (s, 2H), 4.0 (t, J&equals;7.05 Hz, 2H), 3.54 (t, J&equals;7.2 Hz, 2H), 3.25 (s, 2H), 3.22 (s, 9H), 2.90 (s, 2H), 1.37 (dd, J&equals;9.9 Hz, J&equals;9.9 Hz, 2H). </PDAT><HIL><SB><PDAT>13</PDAT></SB></HIL><PDAT>C NMR &dgr; (CD</PDAT><HIL><SB><PDAT>3</PDAT></SB></HIL><PDAT>OD): 177.53, 137.26, 61.86, 52.29, 47.54, 44.73, 42.07, 31.60.</PDAT></PTEXT></PARA>
<H LVL="1"><STEXT><PDAT>Synthesis of exo-N-(N&prime;,N&prime;,N&prime;-trimethylammonio)ethyl-bicyclo-7-oxabicyclo&lsqb;2.2.1&rsqb;hept-5-ene-2,3-dicarboximide chloride</PDAT></STEXT></H>
<PARA ID="P-00068" LVL="0"><PTEXT><PDAT>In a three-necked round bottom flask under an atmosphere of nitrogen, exo-7-oxabicyclo&lsqb;2.2.1&rsqb;hept-5-ene-2,3-dicarboxylic anhydride (4.0 g, 24.07 mmol) and N,N-dimethylethylenediamine (3.17 g, 35.98 mmol) were dissolved in toluene (40 mL). Magnesium sulfate (8.0 g) was added to this solution and the reaction was heated at 60&deg; C. for 23 hours. Upon cooling to room temperature, the reaction mixture was filtered and washed with water (4&times;). The organic layer was dried over sodium sulfate and the solvent was removed in vacuo. This white crystalline product was dissolved in THF (15 mL) and subsequently treated with 2.1 equivalents of methyl iodide at room temperature. The resulting white precipitate was filtered, washed liberally with THF, and dried under vacuum to yield the title compound as an iodide salt. Iodide/chloride exchange as previously described</PDAT><HIL><SP><PDAT>3 </PDAT></SP></HIL><PDAT>afforded 4 as a white flaky solid (14% yield based on anhydride starting material). </PDAT><HIL><SP><PDAT>1</PDAT></SP></HIL><PDAT>H NMR &dgr; (CD</PDAT><HIL><SB><PDAT>3</PDAT></SB></HIL><PDAT>OD): 6.56 (s, 2H), 5.19 (s, 2H), 3.94 (t, J&equals;6.0 Hz, 2H), 3.58 (t, J&equals;6.44 Hz, 2H), 3.18 (s, 9H), 3.00 (s, 2H). 13C NMR &dgr; (CD</PDAT><HIL><SB><PDAT>3</PDAT></SB></HIL><PDAT>OD): 176.58, 136.34, 81.03, 62.28, 52.59, 52.50, 32.49.</PDAT></PTEXT></PARA>
<H LVL="1"><STEXT><PDAT>EXAMPLE 3</PDAT></STEXT></H>
<PARA ID="P-00069" LVL="7"><PTEXT><PDAT>Acid Activation of ROMP of DCPD</PDAT></PTEXT></PARA>
<PARA ID="P-00070" LVL="0"><PTEXT><PDAT>Ruthenium catalysts 1-5 prepared as in Example 1 show enhanced activities for the ROMP of high- and low-strained cyclic olefins, the RCM and ADMET of multiply-unsaturated substrates, and the acyclic cross metathesis of linear olefins in the presence of acids. </PDAT>
<CWU>
<CHEM-US ID="CHEM-US-00009">
<CHEMCDX ID="CHEMCDX-00009" ALT="chemistry chemdraw file" FILE="US06486279-20021126-C00009.CDX"/>
<CHEMMOL ID="CHEMMOL-00009" ALT="chemistry mol file" FILE="US06486279-20021126-C00009.MOL"/>
<EMI ID="EMI-C00009" ALT="embedded image" HE="550.86885" WI="165.6207" FILE="US06486279-20021126-C00009.TIF"/>
</CHEM-US>
</CWU>
</PTEXT></PARA>
<PARA ID="P-00071" LVL="7"><PTEXT><PDAT>Typical polymerization reactions were conducted in the following manner. In a nitrogen-filled drybox, monomer was added to a NMR tube or a vial equipped with a teflon-coated stirbar and capped with a rubber septum. The ruthenium alkylidene catalysts were added to a second vial and the vial was capped with a rubber septum. Outside the drybox, water or methanol was added to each vial via syringe, and the polymerization was initiated by transferring the catalyst solution to the vial containing the monomer.</PDAT></PTEXT></PARA>
<PARA ID="P-00072" LVL="0"><PTEXT><PDAT>The addition of acid to ruthenium catalysts 1-5 results in faster catalyst turnover and increased yields for reactions with olefins that are otherwise slow, incomplete, or not reactive. This enhanced activity is observed in both protic solvents such as water or methanol (with complexes 3-5) and organic solvents (with complexes 1-4) with either stoichiometric or nonstoichiometric equivalents of strong or weak organic and inorganic acids. Acids may be added to the catalysts either before or during the reaction with olefin, with longer catalyst life observed when the catalyst is introduced to an acidic solution of olefin monomer. This allows the metathesis of a wider range of olefins in a broader range of solvents than previously possible.</PDAT></PTEXT></PARA>
<PARA ID="P-00073" LVL="0"><PTEXT><PDAT>Comparative results of ROMP reactions using complexes 3 and 4 with different monomers, in neat monomer or methanol, and in the presence and absence of HCl are tabulated in Table 1 below.</PDAT></PTEXT></PARA>
<CWU>
<TABLE-US ID="TABLE-US-00001">
<TABLE-CALS>
<table frame="none" colsep="0" rowsep="0">
<tgroup align="left" colsep="0" rowsep="0" cols="7">
<colspec colname="1" colwidth="42pt" align="center"/>
<colspec colname="2" colwidth="35pt" align="center"/>
<colspec colname="3" colwidth="28pt" align="center"/>
<colspec colname="4" colwidth="28pt" align="center"/>
<colspec colname="5" colwidth="28pt" align="center"/>
<colspec colname="6" colwidth="28pt" align="center"/>
<colspec colname="7" colwidth="28pt" align="center"/>
<thead>
<row>
<entry namest="1" nameend="7" rowsep="1"><PTEXT><PDAT>TABLE 1</PDAT></PTEXT></entry>
</row>
<row>
<entry namest="1" nameend="7" align="center" rowsep="1"></entry>
</row>
<row>
<entry></entry>
<entry></entry>
<entry><PTEXT><PDAT>Acid</PDAT></PTEXT></entry>
<entry></entry>
<entry></entry>
<entry></entry>
<entry><PTEXT><PDAT>Yield</PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>Complex</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>Monomer</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>(HCl)</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>Solvent</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>Temp</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>Time</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>(%)</PDAT></PTEXT></entry>
</row>
<row>
<entry namest="1" nameend="7" align="center" rowsep="1"></entry>
</row>
</thead>
<tbody valign="top">
<row>
<entry><PTEXT><PDAT></PDAT></PTEXT></entry>
</row>
</tbody>
</tgroup>
<tgroup align="left" colsep="0" rowsep="0" cols="7">
<colspec colname="1" colwidth="42pt" align="center"/>
<colspec colname="2" colwidth="35pt" align="center"/>
<colspec colname="3" colwidth="28pt" align="center"/>
<colspec colname="4" colwidth="28pt" align="center"/>
<colspec colname="5" colwidth="28pt" align="center"/>
<colspec colname="6" colwidth="28pt" align="center"/>
<colspec colname="7" colwidth="28pt" align="char" char="."/>
<tbody valign="top">
<row>
<entry><PTEXT><PDAT>  3</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>DCPD</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>no</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>none</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>RT</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>days</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>0</PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>3</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>DCPD</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>yes</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>none</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>RT</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>&lt;1 min</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>100</PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>3</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>10</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>no</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>MeOH</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>RT</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>days</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>0</PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>3</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>10</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>yes</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>MeOH</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>RT</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>15 min</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>100</PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>4</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>DCPD</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>no</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>none</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>RT</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>days</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>0</PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>4</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>DCPD</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>yes</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>none</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>RT</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>&lt;1 min</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>100</PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>4</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>10</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>no</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>MeOH</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>RT</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>12 h&emsp;</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>100</PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>4</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>10</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>yes</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>MeOH</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>RT</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>15 min</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>100</PDAT></PTEXT></entry>
</row>
<row>
<entry namest="1" nameend="7" align="center" rowsep="1"></entry>
</row>
<row>
<entry namest="1" nameend="7" align="left"><PTEXT><FOO ID="FOO-00001"><PTEXT><PDAT>DCPD &equals; dicyclopentadiene; </PDAT></PTEXT></FOO></PTEXT></entry>
</row>
<row>
<entry namest="1" nameend="7" align="left"><PTEXT><FOO ID="FOO-00002"><PTEXT><PDAT></PDAT>
<CWU>
<CHEM-US ID="CHEM-US-00010">
<CHEMCDX ID="CHEMCDX-00010" ALT="chemistry chemdraw file" FILE="US06486279-20021126-C00010.CDX"/>
<CHEMMOL ID="CHEMMOL-00010" ALT="chemistry mol file" FILE="US06486279-20021126-C00010.MOL"/>
<EMI ID="EMI-C00010" ALT="embedded image" HE="37.1952" WI="123.3792" FILE="US06486279-20021126-C00010.TIF"/>
</CHEM-US>
</CWU>
<PDAT> </PDAT></PTEXT></FOO></PTEXT></entry>
</row>
</tbody>
</tgroup>
</table>
</TABLE-CALS>
</TABLE-US>
</CWU>
<PARA ID="P-00074" LVL="7"><PTEXT><PDAT>As seen from Table 1, complex 3 does not react at all with olefins in the absence of acid, and complex 4 reacts extremely slowly in the absence of acid. Upon addition of acid, reactions occur to 100% yield within minutes. Thus, complexes 3 and 4 can be stored in solution in the presence of olefin without reaction, and acid can be added as des red to initiate catalysis in a RIM-type process with strained, cyclic olefins such as dicyclopentadiene (DCPD). Additionally, UV curing of DCPD to yield poly(DCPD) by photoinitiated-ROMP (PROMP) is readily accomplished as photoacid generators may be stored with both monomer and catalyst until metathesis is initiated through irradiation.</PDAT></PTEXT></PARA>
<H LVL="1"><STEXT><PDAT>EXAMPLE 4</PDAT></STEXT></H>
<PARA ID="P-00075" LVL="7"><PTEXT><PDAT>Acid Activation in RIM Processes</PDAT></PTEXT></PARA>
<PARA ID="P-00076" LVL="0"><PTEXT><PDAT>Catalysts 1 and 2 of Example 3 are efficient catalysts for the bulk polymerization of both endo- and exo-dicyclopentadiene (DCPD), yielding a hard, highly-crosslinked material. </PDAT>
<CWU>
<CHEM-US ID="CHEM-US-00011">
<CHEMCDX ID="CHEMCDX-00011" ALT="chemistry chemdraw file" FILE="US06486279-20021126-C00011.CDX"/>
<CHEMMOL ID="CHEMMOL-00011" ALT="chemistry mol file" FILE="US06486279-20021126-C00011.MOL"/>
<EMI ID="EMI-C00011" ALT="embedded image" HE="178.0947" WI="154.59255" FILE="US06486279-20021126-C00011.TIF"/>
</CHEM-US>
</CWU>
</PTEXT></PARA>
<PARA ID="P-00077" LVL="7"><PTEXT><PDAT>These catalysts are active enough, however, that polymerization ensues shortly after monomer and catalysts are mixed. On industrial scales, this can result in complete polymerization prior to injection of the reaction mixture into a mold. Catalysts 3 and 4 of Example 3, however, are unreactive toward DCPD in the absence, and can be stored indefinitely as a solution in DCPD monomer without appreciable decomposition of the catalyst or polymerization of the monomer: </PDAT>
<CWU>
<CHEM-US ID="CHEM-US-00012">
<CHEMCDX ID="CHEMCDX-00012" ALT="chemistry chemdraw file" FILE="US06486279-20021126-C00012.CDX"/>
<CHEMMOL ID="CHEMMOL-00012" ALT="chemistry mol file" FILE="US06486279-20021126-C00012.MOL"/>
<EMI ID="EMI-C00012" ALT="embedded image" HE="213.61725" WI="158.4198" FILE="US06486279-20021126-C00012.TIF"/>
</CHEM-US>
</CWU>
</PTEXT></PARA>
<PARA ID="P-00078" LVL="7"><PTEXT><PDAT>Upon addition of a strong inorganic acid or organic acid (particularly HCl) either as a gas, solid, or in a solution of water or organic solvent, these catalysts are activated, and polymerization ensues immediately. </PDAT>
<CWU>
<CHEM-US ID="CHEM-US-00013">
<CHEMCDX ID="CHEMCDX-00013" ALT="chemistry chemdraw file" FILE="US06486279-20021126-C00013.CDX"/>
<CHEMMOL ID="CHEMMOL-00013" ALT="chemistry mol file" FILE="US06486279-20021126-C00013.MOL"/>
<EMI ID="EMI-C00013" ALT="embedded image" HE="109.2042" WI="184.81365" FILE="US06486279-20021126-C00013.TIF"/>
</CHEM-US>
</CWU>
</PTEXT></PARA>
<PARA ID="P-00079" LVL="7"><PTEXT><PDAT>Thus, catalysts 3 and 4 can be stored with monomer, and be used in reaction-injection molding (RIM) processes through combination with another stream of monomer containing acid: </PDAT>
<CWU>
<CHEM-US ID="CHEM-US-00014">
<CHEMCDX ID="CHEMCDX-00014" ALT="chemistry chemdraw file" FILE="US06486279-20021126-C00014.CDX"/>
<CHEMMOL ID="CHEMMOL-00014" ALT="chemistry mol file" FILE="US06486279-20021126-C00014.MOL"/>
<EMI ID="EMI-C00014" ALT="embedded image" HE="128.6523" WI="196.83405" FILE="US06486279-20021126-C00014.TIF"/>
</CHEM-US>
</CWU>
</PTEXT></PARA>
<PARA ID="P-00080" LVL="0"><PTEXT><PDAT>In addition, solutions of 3 or 4, monomer, and a photoacid generator can be stored together and used in photomasking applications through UV curing techniques.</PDAT></PTEXT></PARA>
<H LVL="1"><STEXT><PDAT>EXAMPLE 5</PDAT></STEXT></H>
<PARA ID="P-00081" LVL="7"><PTEXT><PDAT>Acid Activation of ROMP of Norbornenes</PDAT></PTEXT></PARA>
<PARA ID="P-00082" LVL="0"><PTEXT><PDAT>Acids can be used effectively to initiate the ROMP of other monomers with these catalysts in solution as well. For example, while solutions of functionalized norbornene and 7-oxanorbornenes do not polymerize in the presence of catalysts 3 of Example 3, polymerization rapidly ensues upon addition of from 0.3 or more equivalents of acid. Such monomers will polymerize using catalysts 4 of Example 3, although initiation is very poor(&lt;5%), even at elevated temperatures. In the presence of acid, however, these catalysts fully initiate, and reactions proceed to completion: </PDAT>
<CWU>
<CHEM-US ID="CHEM-US-00015">
<CHEMCDX ID="CHEMCDX-00015" ALT="chemistry chemdraw file" FILE="US06486279-20021126-C00015.CDX"/>
<CHEMMOL ID="CHEMMOL-00015" ALT="chemistry mol file" FILE="US06486279-20021126-C00015.MOL"/>
<EMI ID="EMI-C00015" ALT="embedded image" HE="208.11735" WI="216.027" FILE="US06486279-20021126-C00015.TIF"/>
</CHEM-US>
</CWU>
</PTEXT></PARA>
<PARA ID="P-00083" LVL="7"><PTEXT><PDAT>The results of the above reactions using catalysts 3 or 4 to polymerize monomer 10 in the presence or absence of HCl and with methanol as a solvent are shown in Table 2 below.</PDAT></PTEXT></PARA>
<CWU>
<TABLE-US ID="TABLE-US-00002">
<TABLE-CALS>
<table frame="none" colsep="0" rowsep="0">
<tgroup align="left" colsep="0" rowsep="0" cols="7">
<colspec colname="1" colwidth="35pt" align="center"/>
<colspec colname="2" colwidth="35pt" align="center"/>
<colspec colname="3" colwidth="28pt" align="center"/>
<colspec colname="4" colwidth="28pt" align="center"/>
<colspec colname="5" colwidth="28pt" align="center"/>
<colspec colname="6" colwidth="35pt" align="center"/>
<colspec colname="7" colwidth="28pt" align="center"/>
<thead>
<row>
<entry namest="1" nameend="7" rowsep="1"><PTEXT><PDAT>TABLE 2</PDAT></PTEXT></entry>
</row>
<row>
<entry namest="1" nameend="7" align="center" rowsep="1"></entry>
</row>
<row>
<entry></entry>
<entry></entry>
<entry><PTEXT><PDAT>Acid</PDAT></PTEXT></entry>
<entry></entry>
<entry></entry>
<entry></entry>
<entry><PTEXT><PDAT>Yield</PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>Complex</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>Monomer</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>(HCl)</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>Solvent</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>Temp</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>Time</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>(%)</PDAT></PTEXT></entry>
</row>
<row>
<entry namest="1" nameend="7" align="center" rowsep="1"></entry>
</row>
</thead>
<tbody valign="top">
<row>
<entry><PTEXT><PDAT>3</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>10</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>no</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>MeOH</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>RT</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>days</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>&emsp;0</PDAT></PTEXT></entry>
</row>
</tbody>
</tgroup>
<tgroup align="left" colsep="0" rowsep="0" cols="8">
<colspec colname="1" colwidth="35pt" align="center"/>
<colspec colname="2" colwidth="35pt" align="center"/>
<colspec colname="3" colwidth="28pt" align="center"/>
<colspec colname="4" colwidth="28pt" align="center"/>
<colspec colname="5" colwidth="28pt" align="center"/>
<colspec colname="6" colwidth="14pt" align="right"/>
<colspec colname="7" colwidth="21pt" align="left"/>
<colspec colname="8" colwidth="28pt" align="center"/>
<tbody valign="top">
<row>
<entry><PTEXT><PDAT>3</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>10</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>yes</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>MeOH</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>RT</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>15</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>min</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>100</PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>4</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>10</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>no</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>MeOH</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>RT</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>12</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>h</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>100</PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>4</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>10</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>yes</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>MeOH</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>RT</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>15</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>min</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>100</PDAT></PTEXT></entry>
</row>
<row>
<entry namest="1" nameend="8" align="center" rowsep="1"></entry>
</row>
</tbody>
</tgroup>
</table>
</TABLE-CALS>
</TABLE-US>
</CWU>
<PARA ID="P-00084" LVL="7"><PTEXT><PDAT>Again, complex 3 does not react at all with the olefin in the absence of acid, and complex 4 reacts extremely slowly in the absence of acid. Upon addition of acid, reactions occur to 100% yield within minutes.</PDAT></PTEXT></PARA>
<PARA ID="P-00085" LVL="0"><PTEXT><PDAT>In addition, water-soluble catalyst 5 of Example 3 will also polymerize water-soluble norbornene and 7-oxanorbornenes monomers in water and methanol, but the catalyst typically dies at low conversion. Addition of up to one equivalent of HO or DO to these reactions results in complete conversion of monomer and the rate of polymerization is doubled.</PDAT></PTEXT></PARA>
<H LVL="1"><STEXT><PDAT>EXAMPLE 6</PDAT></STEXT></H>
<PARA ID="P-00086" LVL="7"><PTEXT><PDAT>Acid Activation for Living ROMP in Water</PDAT></PTEXT></PARA>
<PARA ID="P-00087" LVL="0"><PTEXT><PDAT>In this example, activation in water with a strong Bronsted acid of alkylidene complexes RuCl</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>(&boxH;CHPh)&lsqb;Cy</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>P(N,N-dimethylpiperidinium chloride)&rsqb;</PDAT><HIL><SB><PDAT>2 </PDAT></SB></HIL><PDAT>(complex 6 below) and RuCl</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>(&boxH;CHPh)&lsqb;Cy</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>PCH</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>CH</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>N(CH</PDAT><HIL><SB><PDAT>3</PDAT></SB></HIL><PDAT>)</PDAT><HIL><SB><PDAT>3</PDAT></SB></HIL><HIL><SP><PDAT>&plus;</PDAT></SP></HIL><PDAT>Cl&rsqb;</PDAT><HIL><SB><PDAT>2 </PDAT></SB></HIL><PDAT>(complex 7 below) (prepared as in Example 1) results in the quantitative conversion of functionalized monomers. In the presence of a Br&oslash;nsted acid, complexes 6 and 7 quickly and quantitatively initiate the living polymerization </PDAT>
<CWU>
<CHEM-US ID="CHEM-US-00016">
<CHEMCDX ID="CHEMCDX-00016" ALT="chemistry chemdraw file" FILE="US06486279-20021126-C00016.CDX"/>
<CHEMMOL ID="CHEMMOL-00016" ALT="chemistry mol file" FILE="US06486279-20021126-C00016.MOL"/>
<EMI ID="EMI-C00016" ALT="embedded image" HE="318.28545" WI="171.14895" FILE="US06486279-20021126-C00016.TIF"/>
</CHEM-US>
</CWU>
</PTEXT></PARA>
<PARA ID="P-00088" LVL="7"><PTEXT><PDAT>of water-soluble monomers in the absence of surfactant or organic solvents.</PDAT></PTEXT></PARA>
<PARA ID="P-00089" LVL="0"><PTEXT><PDAT>This result is a significant improvement over aqueous ROMP systems using &ldquo;classical&rdquo; aqueous ROMP catalysts. The propagating species in these reactions is stable, and the synthesis of water-soluble block copolymers was achieved via sequential monomer addition. Notably, the polymerizations are not living in the absence of acid. The effect of the acid in these systems appears to be twofold&mdash;in addition to eliminating hydroxide ions, which would cause catalyst decomposition; catalyst activity is also enhanced by protonation of phosphine ligands. Remarkably, the acids do not react with the ruthenium alkylidene bond.</PDAT></PTEXT></PARA>
<PARA ID="P-00090" LVL="0"><PTEXT><PDAT>Although alkylidenes 6 and 7 initiate the ROMP of functionalized norbornenes and 7-oxanorbornenes in aqueous solution quickly and completely (in the absence of acid), the propagating species in these reactions often decompose before polymerization is complete. For example, in the ROMP of water-soluble monomers exo-N-(N&prime;,N&prime;,N&prime;-trimethylammonio)ethyl-bicyclo&lsqb;2.2.1&rsqb;hept-5-ene-2,3-dicarboximide chloride (monomer 13) and exo-N-(N&prime;,N&prime;,N&prime;-trimethylammonio)ethyl-bicyclo-7-oxabicyclo&lsqb;2.2.1&rsqb;hept-5-ene-2,3-dicarboximide chloride (monomer 14) (prepared as in Example 2 above) initiated by alkylidene 6, conversions ranging from 45-80% are usually observed (Equation 1). Although these water-soluble complexes are similar to ruthenium alkylidenes which are very stable toward polar and protic functional groups in organic solvents, they appear to be susceptible to termination reactions when dissolved in water or methanol. </PDAT>
<CWU>
<CHEM-US ID="CHEM-US-00017">
<CHEMCDX ID="CHEMCDX-00017" ALT="chemistry chemdraw file" FILE="US06486279-20021126-C00017.CDX"/>
<CHEMMOL ID="CHEMMOL-00017" ALT="chemistry mol file" FILE="US06486279-20021126-C00017.MOL"/>
<EMI ID="EMI-C00017" ALT="embedded image" HE="213.8724" WI="216.027" FILE="US06486279-20021126-C00017.TIF"/>
</CHEM-US>
</CWU>
</PTEXT></PARA>
<PARA ID="P-00091" LVL="7"><PTEXT><PDAT>The results of the above reactions with catalysts 6 and 7, in the presence and absence of HCl is set forth in Table 3 below.</PDAT></PTEXT></PARA>
<CWU>
<TABLE-US ID="TABLE-US-00003">
<TABLE-CALS>
<table frame="none" colsep="0" rowsep="0">
<tgroup align="left" colsep="0" rowsep="0" cols="7">
<colspec colname="1" colwidth="35pt" align="center"/>
<colspec colname="2" colwidth="35pt" align="center"/>
<colspec colname="3" colwidth="28pt" align="center"/>
<colspec colname="4" colwidth="28pt" align="center"/>
<colspec colname="5" colwidth="28pt" align="center"/>
<colspec colname="6" colwidth="35pt" align="center"/>
<colspec colname="7" colwidth="28pt" align="center"/>
<thead>
<row>
<entry namest="1" nameend="7" rowsep="1"><PTEXT><PDAT>TABLE 3</PDAT></PTEXT></entry>
</row>
<row>
<entry namest="1" nameend="7" align="center" rowsep="1"></entry>
</row>
<row>
<entry></entry>
<entry></entry>
<entry><PTEXT><PDAT>Acid</PDAT></PTEXT></entry>
<entry></entry>
<entry></entry>
<entry></entry>
<entry><PTEXT><PDAT>Yield</PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>Complex</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>Monomer</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>(HCl)</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>Solvent</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>Temp</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>Time</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>(%)</PDAT></PTEXT></entry>
</row>
<row>
<entry namest="1" nameend="7" align="center" rowsep="1"></entry>
</row>
</thead>
<tbody valign="top">
<row>
<entry><PTEXT><PDAT></PDAT></PTEXT></entry>
</row>
</tbody>
</tgroup>
<tgroup align="left" colsep="0" rowsep="0" cols="8">
<colspec colname="1" colwidth="35pt" align="center"/>
<colspec colname="2" colwidth="35pt" align="center"/>
<colspec colname="3" colwidth="28pt" align="center"/>
<colspec colname="4" colwidth="28pt" align="center"/>
<colspec colname="5" colwidth="28pt" align="center"/>
<colspec colname="6" colwidth="14pt" align="right"/>
<colspec colname="7" colwidth="21pt" align="left"/>
<colspec colname="8" colwidth="28pt" align="char" char="."/>
<tbody valign="top">
<row>
<entry><PTEXT><PDAT>6 and 7</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>13</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>no</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>H</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>O</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>45</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>2</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>h</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>45</PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>6 and 7</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>13</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>yes</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>H</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>O</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>45</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>15</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>min</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>100</PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>6 and 7</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>14</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>no</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>H</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>O</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>45</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>2</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>h</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>80</PDAT></PTEXT></entry>
</row>
<row>
<entry><PTEXT><PDAT>6 and 7</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>14</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>yes</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>H</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>O</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>45</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>15</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>m</PDAT></PTEXT></entry>
<entry><PTEXT><PDAT>100</PDAT></PTEXT></entry>
</row>
<row>
<entry namest="1" nameend="8" align="center" rowsep="1"></entry>
</row>
</tbody>
</tgroup>
</table>
</TABLE-CALS>
</TABLE-US>
</CWU>
<PARA ID="P-00092" LVL="7"><PTEXT><PDAT>These results show that reaction times and yields are dramatically increased upon addition of acid to the reaction system.</PDAT></PTEXT></PARA>
<H LVL="1"><STEXT><PDAT>EXAMPLE 7</PDAT></STEXT></H>
<PARA ID="P-00093" LVL="7"><PTEXT><PDAT>Acid Generation of New Monophosphine Alkylidene in Living ROMP System</PDAT></PTEXT></PARA>
<PARA ID="P-00094" LVL="0"><PTEXT><PDAT>Consistent with data obtained for earlier &ldquo;classical&rdquo; aqueous ROMP systems, we determined that the presence of hydroxide ions in aqueous solutions of catalysts 6 and 7 of Example 8 resulted in rapid decomposition of the catalysts. In order to eliminate hydroxide ions that might result from the autoprotolysis of water or the basic nature of the phosphines employed, Br&oslash;nsted acids were added to aqueous polymerization mixtures of monomers 13 and 14, catalysts 6 and 7, and water. Although reactions performed in mildly acidic solutions of DCl/D</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>O yielded no dramatic improvements, the monomers could be completely polymerized in cases where 0.3-1.0 equivalent of DCl (relative to alkylidene) was added. The presence of acid also had a profound effect on the reaction rate: the polymerizations were at least twice as fast as those to which no acid was added. More interestingly, a propagating alkylidene species was clearly observed by 1H NMR following complete consumption of monomer and addition of more monomer to the reaction mixture resulted in further quantitative polymerization.</PDAT></PTEXT></PARA>
<PARA ID="P-00095" LVL="0"><PTEXT><PDAT>To further investigate this effect, the reaction of DCl with 6 was studied in the absence of olefin. Upon addition of 0.3 equivalents of DCl to a D</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>O solution of 6, the acid cleanly protonated 0.3 equivalents of phosphine to yield a phosphonium salt and 0.3 equivalents of a new alkylidene species, instead of protonating the ruthenium-carbon double bond (Equation 2). The remarkable stability of the alkylidene bond in the presence of this very strong acid highlights the tolerance of ruthenium-based metathesis catalysts of the present invention toward protic functionalities. </PDAT>
<CWU>
<CHEM-US ID="CHEM-US-00018">
<CHEMCDX ID="CHEMCDX-00018" ALT="chemistry chemdraw file" FILE="US06486279-20021126-C00018.CDX"/>
<CHEMMOL ID="CHEMMOL-00018" ALT="chemistry mol file" FILE="US06486279-20021126-C00018.MOL"/>
<EMI ID="EMI-C00018" ALT="embedded image" HE="226.1196" WI="408.77865" FILE="US06486279-20021126-C00018.TIF"/>
</CHEM-US>
</CWU>
</PTEXT></PARA>
<PARA ID="P-00096" LVL="0"><PTEXT><PDAT>The new alkylidene generated upon addition of acid has been identified by </PDAT><HIL><SP><PDAT>1</PDAT></SP></HIL><PDAT>H and </PDAT><HIL><SP><PDAT>31</PDAT></SP></HIL><PDAT>P NMR spectroscopy as a monophosphine derivative of 6 such as that shown in Equation 2. In aqueous reactions employing up to one equivalent of acid, the monophosphine species is remarkably stable, presumably stabilized through coordination of water. Addition of excess phosphine to the reaction mixture up to 1.5 hours after addition of acid reverses the equilibrium, reforming 6 with less than 5% detectable decomposition. Protonation of phosphine in this manner is not stoichiometric. For instance, the addition 1.0 equivalent of DO yielded an equilibrium mixture of monophosphine and bisphosphine alkylidene species in a ratio of 1:2. The alkylidenes decomposed more rapidly under these conditions in the absence of monomer.</PDAT></PTEXT></PARA>
<PARA ID="P-00097" LVL="0"><PTEXT><PDAT>As anticipated, we found that monomers 13 and 14 could be completely polymerized when up to 1.0 equivalent of DO was added to the reaction mixture. Additionally, the presence of acid also had a profound effect on the reaction rate: the polymerizations were up to ten times faster than those to which no acid had been added. More significantly, two propagating alkylidene species were observed by </PDAT><HIL><SP><PDAT>1</PDAT></SP></HIL><PDAT>H NMR spectroscopy following complete consumption of monomer, and the addition of more monomer to the reaction mixture resulted in further quantitative polymerization. The direct observation of propagating species is important, as it allows the extent of chain termination, a key factor in defining a living system, to be easily and directly addressed throughout the course of the reaction.</PDAT></PTEXT></PARA>
<PARA ID="P-00098" LVL="0"><PTEXT><PDAT>The alkylidenes observed in the above reactions, corresponding to both bisphosphine and monophosphine propagating species, are significantly more stable than the respective initiating species outlined above. In fact, at ambient temperature, the propagating species in these reactions can be observed for well over one month.</PDAT></PTEXT></PARA>
<PARA ID="P-00099" LVL="0"><PTEXT><PDAT>In addition to the relatively low concentration of the monophosphine species dictated by the equilibrium in Equation 2, stability toward bimolecular decomposition is presumably imparted via the relative steric bulk of the propagating alkylidene. The </PDAT><HIL><SP><PDAT>1</PDAT></SP></HIL><PDAT>H NMR resonances for the two propagating alkylidenes coalesce at higher temperatures, indicating rapid equilibration via phosphine scrambling.</PDAT></PTEXT></PARA>
<PARA ID="P-00100" LVL="0"><PTEXT><PDAT>To probe the living nature of the aqueous polymerizations conducted in the presence of acid, an NMR-scale polymerization of monomer 13 was conducted employing DCl (1.0 equivalent relative to alkylidene), and the relative amount of propagating species was quantified via integration of the alkylidene protons against the aromatic protons of the polymer endgroups. After 15 minutes at 45&deg; C., the reaction was &gt;95% complete and the relative integration of the alkylidene protons of the two propagating species (coalesced as a broad singlet at 19.2 ppm) did not decrease either during the reaction or after all monomer had been consumed. In fact, the propagating species remained intact for an additional 15 minutes in the absence of monomer before slowly decomposing.</PDAT></PTEXT></PARA>
<PARA ID="P-00101" LVL="0"><PTEXT><PDAT>A block copolymerization of monomers 13 and 14 was carried out, via sequential monomer addition, to demonstrate the robust nature of the propagating species in these reactions. After complete polymerization of monomer 13, the reaction was allowed to sit for 5 minutes before 20 equivalents of monomer 14 were injected. Monomer 14 was rapidly and completely consumed, and the concentration of the propagating species remained constant both during and after the polymerization of the second block.</PDAT></PTEXT></PARA>
<PARA ID="P-00102" LVL="0"><PTEXT><PDAT>Within the limits of NMR sensitivity, the direct observation and quantification of the propagating alkylidenes in the above experiments demonstrates the absence of chain termination in these reactions. The fact that the alkylidene resonance does not disappear over a time period twice as long as the time scale of the reaction indicates that these systems are indeed living. Gel permeation chromatography (GPC) analysis of these polymers yields a symmetric, monomodal peak with a polydispersity index (PDI) of 1.2-1.5.</PDAT></PTEXT></PARA>
<PARA ID="P-00103" LVL="0"><PTEXT><PDAT>The equilibrium represented in Equation 2 provides a straightforward explanation for the rate enhancements, and thus the living nature, of the polymerizations described above. For alkylidene complexes of the present invention of the type (PR</PDAT><HIL><SB><PDAT>3</PDAT></SB></HIL><PDAT>)</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>Cl</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>Ru&boxH;CHR, olefin metathesis has been shown to proceed through a mechanism in which a phosphine dissociates from the metal center. Rates of olefin metathesis in organic systems have been increased by the addition of phosphine scavengers, favoring the equilibrium for olefin coordination and phosphine dissociation, although the catalyst rapidly decomposes under these conditions. In aqueous systems employing complexes 6 and 7, protons act as phosphine scavengers, increasing the rate of olefin metathesis without concomitant acceleration of catalyst decomposition. The differences in the rates of propagation and termination under acidic conditions allows for rapid, quantitative conversion of monomer in a living manner.</PDAT></PTEXT></PARA>
<H LVL="1"><STEXT><PDAT>EXAMPLE 8</PDAT></STEXT></H>
<PARA ID="P-00104" LVL="7"><PTEXT><PDAT>ROMP of Unstrained Cylic Olefins and Metathesis of Acyclic Olefins</PDAT></PTEXT></PARA>
<PARA ID="P-00105" LVL="0"><PTEXT><PDAT>In contrast to the &ldquo;classical&rdquo; ruthenium metathesis catalysts mentioned above, which react only with highly-strained olefins, alkylidenes 6 and 7 of Example 6 also promote the ROMP of less-strained monomers such as 1,5-cyclooctadiene, and are active in the metathesis of acyclic olefins in protic solvents. For example, 6 will dimerize 1-hexene in methanol to give 5-decene in 20% yield (Equation 3). In these systems, separation of catalyst from product is facilitated through addition of water to the reaction mixture. Olefins collected from the resulting two-phase system contain very low levels of detectable ruthenium. </PDAT>
<CWU>
<CHEM-US ID="CHEM-US-00019">
<CHEMCDX ID="CHEMCDX-00019" ALT="chemistry chemdraw file" FILE="US06486279-20021126-C00019.CDX"/>
<CHEMMOL ID="CHEMMOL-00019" ALT="chemistry mol file" FILE="US06486279-20021126-C00019.MOL"/>
<EMI ID="EMI-C00019" ALT="embedded image" HE="88.82055" WI="216.027" FILE="US06486279-20021126-C00019.TIF"/>
</CHEM-US>
</CWU>
</PTEXT></PARA>
<PARA ID="P-00106" LVL="0"><PTEXT><PDAT>Although the invention has been described in some respects with reference to the above embodiments, many variations and modifications will be apparent to those skilled in the art. It is therefore the intention that the following summary not be given a restrictive interpretation, but rather should be viewed to encompass such variations and modifications that may be routinely derived from the inventive subject matter disclosed.</PDAT></PTEXT></PARA>
</BTEXT>
</DETDESC>
</SDODE>
<SDOCL>
<H LVL="1"><STEXT><PDAT>What is claimed is: </PDAT></STEXT></H>
<CL>
<CLM ID="CLM-00001">
<PARA ID="P-00107" LVL="0"><PTEXT><PDAT>1. A process for performing reaction injection molding, comprising:</PDAT></PTEXT></PARA>
<CLMSTEP LVL="2"><PTEXT><PDAT>contacting a ruthenium carbene catalyst of the formula A</PDAT><HIL><SB><PDAT>x</PDAT></SB></HIL><PDAT>L</PDAT><HIL><SB><PDAT>y</PDAT></SB></HIL><PDAT>X</PDAT><HIL><SB><PDAT>z</PDAT></SB></HIL><PDAT>Ru&boxH;CHR&prime; with an olefin monomer or unsaturated polymer to form a first mixture; </PDAT></PTEXT></CLMSTEP>
<CLMSTEP LVL="2"><PTEXT><PDAT>contacting an olefin monomer or unsaturated polymer with an inorganic or organic acid to form a second mixture; and </PDAT></PTEXT></CLMSTEP>
<CLMSTEP LVL="2"><PTEXT><PDAT>contacting the first mixture with the second mixture; wherein </PDAT></PTEXT></CLMSTEP>
<CLMSTEP LVL="3"><PTEXT><PDAT>x&equals;0, 1, or 2; </PDAT></PTEXT></CLMSTEP>
<CLMSTEP LVL="3"><PTEXT><PDAT>y&equals;0, 1,or 2; and </PDAT></PTEXT></CLMSTEP>
<CLMSTEP LVL="3"><PTEXT><PDAT>z&equals;1 or 2; and </PDAT></PTEXT></CLMSTEP>
<CLMSTEP LVL="3"><PTEXT><PDAT>&emsp;wherein </PDAT></PTEXT></CLMSTEP>
<CLMSTEP LVL="4"><PTEXT><PDAT>R&prime; is selected from the group consisting of hydrogen, alkyl, substituted alkyl, aryl and substituted aryl; </PDAT></PTEXT></CLMSTEP>
<CLMSTEP LVL="4"><PTEXT><PDAT>L is any neutral electron donor; </PDAT></PTEXT></CLMSTEP>
<CLMSTEP LVL="4"><PTEXT><PDAT>X is any anionic ligand; and </PDAT></PTEXT></CLMSTEP>
<CLMSTEP LVL="4"><PTEXT><PDAT>A is a ligand having a covalent structure connecting a neutral electron donor and an anionic ligand. </PDAT></PTEXT></CLMSTEP>
</CLM>
<CLM ID="CLM-00002">
<PARA ID="P-00108" LVL="0"><PTEXT><PDAT>2. The process of </PDAT><CLREF ID="CLM-00001"><PDAT>claim 1</PDAT></CLREF><PDAT> wherein the acid is selected from the group consisting of HI, HCl, HBr, H</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>SO</PDAT><HIL><SB><PDAT>4</PDAT></SB></HIL><PDAT>, H</PDAT><HIL><SB><PDAT>3</PDAT></SB></HIL><PDAT>O</PDAT><HIL><SP><PDAT>&plus;</PDAT></SP></HIL><PDAT>, HNO</PDAT><HIL><SB><PDAT>3</PDAT></SB></HIL><PDAT>, H</PDAT><HIL><SB><PDAT>3</PDAT></SB></HIL><PDAT>PO</PDAT><HIL><SB><PDAT>4</PDAT></SB></HIL><PDAT>, CH</PDAT><HIL><SB><PDAT>3</PDAT></SB></HIL><PDAT>CO</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>H, and tosic acid.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00003">
<PARA ID="P-00109" LVL="0"><PTEXT><PDAT>3. The process of </PDAT><CLREF ID="CLM-00001"><PDAT>claim 1</PDAT></CLREF><PDAT> wherein the acid is HCl.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00004">
<PARA ID="P-00110" LVL="0"><PTEXT><PDAT>4. The process of </PDAT><CLREF ID="CLM-00001"><PDAT>claim 1</PDAT></CLREF><PDAT> wherein the olefin monomer is selected from the group consisting of acyclic olefins, strained or unstrained cyclic olefins, and dienes, and wherein the olefin monomer is functionalized or unfunctionalized.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00005">
<PARA ID="P-00111" LVL="0"><PTEXT><PDAT>5. The process of </PDAT><CLREF ID="CLM-00004"><PDAT>claim 4</PDAT></CLREF><PDAT> wherein the olefin monomer is functionalized with a group selected from the group consisting of alcohol, thiol, ketone, aldehyde, ester, disulfide, carbonate, imine, carboxyl, amine, amide, nitro acid, carboxylic acid, isocyanate, carbodiimide, ether, halogen, quaternary amine, carbohydrate, phosphate, sulfate and sulfonate.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00006">
<PARA ID="P-00112" LVL="0"><PTEXT><PDAT>6. The process of </PDAT><CLREF ID="CLM-00001"><PDAT>claim 1</PDAT></CLREF><PDAT> wherein said acid is generated by irradiating a photoacid generator.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00007">
<PARA ID="P-00113" LVL="0"><PTEXT><PDAT>7. The process of </PDAT><CLREF ID="CLM-00001"><PDAT>claim 1</PDAT></CLREF><PDAT> wherein L is a phosphine of the formula PR</PDAT><HIL><SP><PDAT>3</PDAT></SP></HIL><PDAT>R</PDAT><HIL><SP><PDAT>4</PDAT></SP></HIL><PDAT>R</PDAT><HIL><SP><PDAT>5</PDAT></SP></HIL><PDAT>, wherein R</PDAT><HIL><SP><PDAT>3 </PDAT></SP></HIL><PDAT>is selected from the group consisting of secondary alkyl, and cycloalkyl, and R</PDAT><HIL><SP><PDAT>4 </PDAT></SP></HIL><PDAT>and R</PDAT><HIL><SP><PDAT>5 </PDAT></SP></HIL><PDAT>are independently selected from the group consisting of aryl, C</PDAT><HIL><SB><PDAT>1</PDAT></SB></HIL><PDAT>-C</PDAT><HIL><SB><PDAT>10 </PDAT></SB></HIL><PDAT>primary alkyl, secondary alkyl, and cycloalkyl; and</PDAT></PTEXT></PARA>
<CLMSTEP LVL="2"><PTEXT><PDAT>X is selected from the group consisting of hydrogen, halogen, and substituted or unsubstituted C</PDAT><HIL><SB><PDAT>1</PDAT></SB></HIL><PDAT>-C</PDAT><HIL><SB><PDAT>20 </PDAT></SB></HIL><PDAT>alkyl, aryl, C</PDAT><HIL><SB><PDAT>1</PDAT></SB></HIL><PDAT>-C</PDAT><HIL><SB><PDAT>20 </PDAT></SB></HIL><PDAT>alkoxide, aryloxide, C</PDAT><HIL><SB><PDAT>3</PDAT></SB></HIL><PDAT>-C</PDAT><HIL><SB><PDAT>20 </PDAT></SB></HIL><PDAT>alkyldiketonate, aryldiketonate, C</PDAT><HIL><SB><PDAT>1</PDAT></SB></HIL><PDAT>-C</PDAT><HIL><SB><PDAT>20 </PDAT></SB></HIL><PDAT>carboxylate, arylsulfonate, C</PDAT><HIL><SB><PDAT>1</PDAT></SB></HIL><PDAT>-C</PDAT><HIL><SB><PDAT>20 </PDAT></SB></HIL><PDAT>alkylsulfonate, C</PDAT><HIL><SB><PDAT>1</PDAT></SB></HIL><PDAT>-C</PDAT><HIL><SB><PDAT>20 </PDAT></SB></HIL><PDAT>alkylthio, C</PDAT><HIL><SB><PDAT>1</PDAT></SB></HIL><PDAT>-C</PDAT><HIL><SB><PDAT>20 </PDAT></SB></HIL><PDAT>alkylsulfonyl, and C</PDAT><HIL><SB><PDAT>1</PDAT></SB></HIL><PDAT>-C</PDAT><HIL><SB><PDAT>20 </PDAT></SB></HIL><PDAT>alkylsulfinyl, wherein the substituents are selected from the group consisting of C</PDAT><HIL><SB><PDAT>1</PDAT></SB></HIL><PDAT>-C</PDAT><HIL><SB><PDAT>5 </PDAT></SB></HIL><PDAT>alkyl, halogen, C</PDAT><HIL><SB><PDAT>1</PDAT></SB></HIL><PDAT>-C</PDAT><HIL><SB><PDAT>5 </PDAT></SB></HIL><PDAT>alkoxy, phenyl, halogen substituted phenyl, C</PDAT><HIL><SB><PDAT>1</PDAT></SB></HIL><PDAT>-C</PDAT><HIL><SB><PDAT>5 </PDAT></SB></HIL><PDAT>alkyl substituted phenyl, and C</PDAT><HIL><SB><PDAT>1</PDAT></SB></HIL><PDAT>-C</PDAT><HIL><SB><PDAT>5 </PDAT></SB></HIL><PDAT>alkoxy substituted phenyl. </PDAT></PTEXT></CLMSTEP>
</CLM>
<CLM ID="CLM-00008">
<PARA ID="P-00114" LVL="0"><PTEXT><PDAT>8. The process of </PDAT><CLREF ID="CLM-00001"><PDAT>claim 1</PDAT></CLREF><PDAT> wherein the reaction injection molding process occurs in the absence of a solvent.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00009">
<PARA ID="P-00115" LVL="0"><PTEXT><PDAT>9. The process of </PDAT><CLREF ID="CLM-00001"><PDAT>claim 1</PDAT></CLREF><PDAT> wherein said ruthenium carbene complex is of the formula A</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>LRu&boxH;CHR&prime;.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00010">
<PARA ID="P-00116" LVL="0"><PTEXT><PDAT>10. The process of </PDAT><CLREF ID="CLM-00009"><PDAT>claim 9</PDAT></CLREF><PDAT> wherein L is a phosphine of the formula PR</PDAT><HIL><SP><PDAT>3</PDAT></SP></HIL><PDAT>R</PDAT><HIL><SP><PDAT>4</PDAT></SP></HIL><PDAT>R</PDAT><HIL><SP><PDAT>5</PDAT></SP></HIL><PDAT>, wherein R</PDAT><HIL><SP><PDAT>3 </PDAT></SP></HIL><PDAT>is selected from the group consisting of secondary alkyl, and cycloalkyl, and R</PDAT><HIL><SP><PDAT>4 </PDAT></SP></HIL><PDAT>and R</PDAT><HIL><SP><PDAT>5 </PDAT></SP></HIL><PDAT>are independently selected from the group consisting of aryl, C</PDAT><HIL><SB><PDAT>1</PDAT></SB></HIL><PDAT>-C</PDAT><HIL><SB><PDAT>10 </PDAT></SB></HIL><PDAT>primary alkyl, secondary alkyl, and cycloalkyl; and X is selected from the group consisting of hydrogen, halogen, and substituted or unsubstituted C</PDAT><HIL><SB><PDAT>1</PDAT></SB></HIL><PDAT>-C</PDAT><HIL><SB><PDAT>20 </PDAT></SB></HIL><PDAT>alkyl, aryl, C</PDAT><HIL><SB><PDAT>1</PDAT></SB></HIL><PDAT>-C</PDAT><HIL><SB><PDAT>20 </PDAT></SB></HIL><PDAT>alkoxide, aryloxide, C</PDAT><HIL><SB><PDAT>3</PDAT></SB></HIL><PDAT>-C</PDAT><HIL><SB><PDAT>20 </PDAT></SB></HIL><PDAT>alkyldiketonate, aryldiketonate, C</PDAT><HIL><SB><PDAT>1</PDAT></SB></HIL><PDAT>-C</PDAT><HIL><SB><PDAT>20 </PDAT></SB></HIL><PDAT>carboxylate, arylsulfonate, C</PDAT><HIL><SB><PDAT>1</PDAT></SB></HIL><PDAT>-C</PDAT><HIL><SB><PDAT>20 </PDAT></SB></HIL><PDAT>alkylsulfonate, C</PDAT><HIL><SB><PDAT>1</PDAT></SB></HIL><PDAT>-C</PDAT><HIL><SB><PDAT>20 </PDAT></SB></HIL><PDAT>alkylthio, C</PDAT><HIL><SB><PDAT>1</PDAT></SB></HIL><PDAT>-C</PDAT><HIL><SB><PDAT>20 </PDAT></SB></HIL><PDAT>alkylsulfonyl, and C</PDAT><HIL><SB><PDAT>1</PDAT></SB></HIL><PDAT>-C</PDAT><HIL><SB><PDAT>20 </PDAT></SB></HIL><PDAT>alkylsulfinyl, wherein the substituents are selected from the group consisting of C</PDAT><HIL><SB><PDAT>1</PDAT></SB></HIL><PDAT>-C</PDAT><HIL><SB><PDAT>5 </PDAT></SB></HIL><PDAT>alkyl, halogen, C</PDAT><HIL><SB><PDAT>1</PDAT></SB></HIL><PDAT>-C</PDAT><HIL><SB><PDAT>5 </PDAT></SB></HIL><PDAT>alkoxy, phenyl, halogen substituted phenyl, C</PDAT><HIL><SB><PDAT>1</PDAT></SB></HIL><PDAT>-C</PDAT><HIL><SB><PDAT>5 </PDAT></SB></HIL><PDAT>alkyl substituted phenyl, and C</PDAT><HIL><SB><PDAT>1</PDAT></SB></HIL><PDAT>-C</PDAT><HIL><SB><PDAT>5 </PDAT></SB></HIL><PDAT>alkoxy substituted phenyl.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00011">
<PARA ID="P-00117" LVL="0"><PTEXT><PDAT>11. The process of </PDAT><CLREF ID="CLM-00009"><PDAT>claim 9</PDAT></CLREF><PDAT> wherein L is selected from the group consisting of &mdash;P(cyclohexyl)</PDAT><HIL><SB><PDAT>3</PDAT></SB></HIL><PDAT>, &mdash;P(cyclopentyl)</PDAT><HIL><SB><PDAT>3</PDAT></SB></HIL><PDAT>, &mdash;P(isopropyl)</PDAT><HIL><SB><PDAT>3 </PDAT></SB></HIL><PDAT>and &mdash;P(phenyl)</PDAT><HIL><SB><PDAT>3</PDAT></SB></HIL><PDAT>.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00012">
<PARA ID="P-00118" LVL="0"><PTEXT><PDAT>12. The process of </PDAT><CLREF ID="CLM-00009"><PDAT>claim 9</PDAT></CLREF><PDAT> wherein said ruthenium carbene complex is of the formula: </PDAT>
<CWU>
<CHEM-US ID="CHEM-US-00020">
<CHEMCDX ID="CHEMCDX-00020" ALT="chemistry chemdraw file" FILE="US06486279-20021126-C00020.CDX"/>
<CHEMMOL ID="CHEMMOL-00020" ALT="chemistry mol file" FILE="US06486279-20021126-C00020.MOL"/>
<EMI ID="EMI-C00020" ALT="embedded image" HE="82.58355" WI="91.93905" FILE="US06486279-20021126-C00020.TIF"/>
</CHEM-US>
</CWU>
</PTEXT></PARA>
<PARA ID="P-00119" LVL="7"><PTEXT><PDAT>wherein each R and R&prime; are independently selected from the group consisting of alkyl, substituted alkyl, aryl or substituted aryl.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00013">
<PARA ID="P-00120" LVL="0"><PTEXT><PDAT>13. The process of </PDAT><CLREF ID="CLM-00012"><PDAT>claim 12</PDAT></CLREF><PDAT> wherein each R and R&prime; are independently selected from the group consisting of</PDAT></PTEXT></PARA>
<CLMSTEP LVL="2"><PTEXT><PDAT>(a) C</PDAT><HIL><SB><PDAT>1</PDAT></SB></HIL><PDAT>-C</PDAT><HIL><SB><PDAT>20 </PDAT></SB></HIL><PDAT>alkyl; </PDAT></PTEXT></CLMSTEP>
<CLMSTEP LVL="2"><PTEXT><PDAT>(b) aryl; </PDAT></PTEXT></CLMSTEP>
<CLMSTEP LVL="2"><PTEXT><PDAT>(c) C</PDAT><HIL><SB><PDAT>1</PDAT></SB></HIL><PDAT>-C</PDAT><HIL><SB><PDAT>20 </PDAT></SB></HIL><PDAT>alkyl substituted with one or more groups selected from the group consisting of aryl, halide, hydroxy, C</PDAT><HIL><SB><PDAT>1</PDAT></SB></HIL><PDAT>-C</PDAT><HIL><SB><PDAT>20 </PDAT></SB></HIL><PDAT>alkoxy, and C</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>-C</PDAT><HIL><SB><PDAT>20 </PDAT></SB></HIL><PDAT>alkoxycarbonyl; and </PDAT></PTEXT></CLMSTEP>
<CLMSTEP LVL="2"><PTEXT><PDAT>(d) aryl substituted with one or more groups selected from the group consisting of C</PDAT><HIL><SB><PDAT>1</PDAT></SB></HIL><PDAT>-C</PDAT><HIL><SB><PDAT>20 </PDAT></SB></HIL><PDAT>alkyl, aryl, hydroxyl, C</PDAT><HIL><SB><PDAT>1</PDAT></SB></HIL><PDAT>-C</PDAT><HIL><SB><PDAT>5 </PDAT></SB></HIL><PDAT>alkoxy, amino, nitro, halide and methoxy. </PDAT></PTEXT></CLMSTEP>
</CLM>
<CLM ID="CLM-00014">
<PARA ID="P-00121" LVL="0"><PTEXT><PDAT>14. The process of </PDAT><CLREF ID="CLM-00012"><PDAT>claim 12</PDAT></CLREF><PDAT> wherein:</PDAT></PTEXT></PARA>
<CLMSTEP LVL="2"><PTEXT><PDAT>R is methyl or t-butyl; </PDAT></PTEXT></CLMSTEP>
<CLMSTEP LVL="2"><PTEXT><PDAT>PR</PDAT><HIL><SB><PDAT>3 </PDAT></SB></HIL><PDAT>is P(cyclohexyl)</PDAT><HIL><SB><PDAT>3</PDAT></SB></HIL><PDAT>; and </PDAT></PTEXT></CLMSTEP>
<CLMSTEP LVL="2"><PTEXT><PDAT>R&prime; is phenyl. </PDAT></PTEXT></CLMSTEP>
</CLM>
<CLM ID="CLM-00015">
<PARA ID="P-00122" LVL="0"><PTEXT><PDAT>15. The process of </PDAT><CLREF ID="CLM-00001"><PDAT>claim 1</PDAT></CLREF><PDAT> wherein said ruthenium complex is of the formula:</PDAT></PTEXT></PARA>
<PARA ID="P-00123" LVL="0"><PTEXT><F><PTEXT><PDAT>ALXRu&boxH;CHR&prime;. </PDAT></PTEXT></F></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00016">
<PARA ID="P-00124" LVL="0"><PTEXT><PDAT>16. The process of </PDAT><CLREF ID="CLM-00015"><PDAT>claim 15</PDAT></CLREF><PDAT> wherein L is a phosphine of the formula PR</PDAT><HIL><SP><PDAT>3</PDAT></SP></HIL><PDAT>R</PDAT><HIL><SP><PDAT>4</PDAT></SP></HIL><PDAT>R</PDAT><HIL><SP><PDAT>5</PDAT></SP></HIL><PDAT>, wherein R</PDAT><HIL><SP><PDAT>3 </PDAT></SP></HIL><PDAT>is selected from the group consisting of secondary alkyl, and cycloalkyl, and R</PDAT><HIL><SP><PDAT>4 </PDAT></SP></HIL><PDAT>and R</PDAT><HIL><SP><PDAT>5 </PDAT></SP></HIL><PDAT>are independently selected from the group consisting of aryl, C</PDAT><HIL><SB><PDAT>1</PDAT></SB></HIL><PDAT>-C</PDAT><HIL><SB><PDAT>10 </PDAT></SB></HIL><PDAT>primary alkyl, secondary alkyl, and cycloalkyl.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00017">
<PARA ID="P-00125" LVL="0"><PTEXT><PDAT>17. The process of </PDAT><CLREF ID="CLM-00015"><PDAT>claim 15</PDAT></CLREF><PDAT> wherein L is selected from the group consisting of &mdash;P(cyclohexyl)</PDAT><HIL><SB><PDAT>3</PDAT></SB></HIL><PDAT>, &mdash;P(cyclopentyl)</PDAT><HIL><SB><PDAT>3</PDAT></SB></HIL><PDAT>, &mdash;P(isopropyl)</PDAT><HIL><SB><PDAT>3 </PDAT></SB></HIL><PDAT>and &mdash;P(phenyl)</PDAT><HIL><SB><PDAT>3</PDAT></SB></HIL><PDAT>.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00018">
<PARA ID="P-00126" LVL="0"><PTEXT><PDAT>18. The process of </PDAT><CLREF ID="CLM-00015"><PDAT>claim 15</PDAT></CLREF><PDAT> wherein X is selected from the group consisting of hydrogen, halogen, and substituted or unsubstituted C</PDAT><HIL><SB><PDAT>1</PDAT></SB></HIL><PDAT>-C</PDAT><HIL><SB><PDAT>20 </PDAT></SB></HIL><PDAT>alkyl, aryl, C</PDAT><HIL><SB><PDAT>1</PDAT></SB></HIL><PDAT>-C</PDAT><HIL><SB><PDAT>20 </PDAT></SB></HIL><PDAT>alkoxide, aryloxide, C</PDAT><HIL><SB><PDAT>3</PDAT></SB></HIL><PDAT>-C</PDAT><HIL><SB><PDAT>20 </PDAT></SB></HIL><PDAT>alkyldiketonate, aryldiketonate, C</PDAT><HIL><SB><PDAT>1</PDAT></SB></HIL><PDAT>-C</PDAT><HIL><SB><PDAT>20 </PDAT></SB></HIL><PDAT>carboxylate, arylsulfonate, C</PDAT><HIL><SB><PDAT>1</PDAT></SB></HIL><PDAT>-C</PDAT><HIL><SB><PDAT>20 </PDAT></SB></HIL><PDAT>alkylsulfonate, C</PDAT><HIL><SB><PDAT>1</PDAT></SB></HIL><PDAT>-C</PDAT><HIL><SB><PDAT>20 </PDAT></SB></HIL><PDAT>alkylthio, C</PDAT><HIL><SB><PDAT>1</PDAT></SB></HIL><PDAT>-C</PDAT><HIL><SB><PDAT>20 </PDAT></SB></HIL><PDAT>alkylsulfonyl, and C</PDAT><HIL><SB><PDAT>1</PDAT></SB></HIL><PDAT>-C</PDAT><HIL><SB><PDAT>20 </PDAT></SB></HIL><PDAT>alkylsulfinyl, wherein the substituents are selected from the group consisting of C</PDAT><HIL><SB><PDAT>1</PDAT></SB></HIL><PDAT>-C</PDAT><HIL><SB><PDAT>5 </PDAT></SB></HIL><PDAT>alkyl, halogen, C</PDAT><HIL><SB><PDAT>1</PDAT></SB></HIL><PDAT>-C</PDAT><HIL><SB><PDAT>5 </PDAT></SB></HIL><PDAT>alkoxy, phenyl, halogen substituted phenyl, C</PDAT><HIL><SB><PDAT>1</PDAT></SB></HIL><PDAT>-C</PDAT><HIL><SB><PDAT>5 </PDAT></SB></HIL><PDAT>alkyl substituted phenyl, and C</PDAT><HIL><SB><PDAT>1</PDAT></SB></HIL><PDAT>-C</PDAT><HIL><SB><PDAT>5 </PDAT></SB></HIL><PDAT>alkoxy substituted phenyl.</PDAT></PTEXT></PARA>
</CLM>
<CLM ID="CLM-00019">
<PARA ID="P-00127" LVL="0"><PTEXT><PDAT>19. The process of </PDAT><CLREF ID="CLM-00015"><PDAT>claim 15</PDAT></CLREF><PDAT> wherein said ruthenium carbene complex is of the formula </PDAT>
<CWU>
<CHEM-US ID="CHEM-US-00021">
<CHEMCDX ID="CHEMCDX-00021" ALT="chemistry chemdraw file" FILE="US06486279-20021126-C00021.CDX"/>
<CHEMMOL ID="CHEMMOL-00021" ALT="chemistry mol file" FILE="US06486279-20021126-C00021.MOL"/>
<EMI ID="EMI-C00021" ALT="embedded image" HE="46.80585" WI="90.23805" FILE="US06486279-20021126-C00021.TIF"/>
</CHEM-US>
</CWU>
</PTEXT></PARA>
<PARA ID="P-00128" LVL="7"><PTEXT><PDAT>wherein</PDAT></PTEXT></PARA>
<CLMSTEP LVL="2"><PTEXT><PDAT>each R and R&prime; are independently selected from the group consisting of alkyl, substituted alkyl, aryl and substituted aryl; </PDAT></PTEXT></CLMSTEP>
<CLMSTEP LVL="2"><PTEXT><PDAT>R&Prime; is selected from the group consisting of hydrogen, halo, nitro, and alkoxy; and </PDAT></PTEXT></CLMSTEP>
<CLMSTEP LVL="2"><PTEXT><PDAT>X is selected from the group consisting of Cl, Br, I, CH</PDAT><HIL><SB><PDAT>3</PDAT></SB></HIL><PDAT>CO</PDAT><HIL><SB><PDAT>2 </PDAT></SB></HIL><PDAT>and CF</PDAT><HIL><SB><PDAT>3</PDAT></SB></HIL><PDAT>CO</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>. </PDAT></PTEXT></CLMSTEP>
</CLM>
<CLM ID="CLM-00020">
<PARA ID="P-00129" LVL="0"><PTEXT><PDAT>20. The process of </PDAT><CLREF ID="CLM-00019"><PDAT>claim 19</PDAT></CLREF><PDAT> wherein each R and R&prime; are independently selected from the group consisting of</PDAT></PTEXT></PARA>
<CLMSTEP LVL="2"><PTEXT><PDAT>(a) C</PDAT><HIL><SB><PDAT>1</PDAT></SB></HIL><PDAT>-C</PDAT><HIL><SB><PDAT>20 </PDAT></SB></HIL><PDAT>alkyl; </PDAT></PTEXT></CLMSTEP>
<CLMSTEP LVL="2"><PTEXT><PDAT>(b) aryl; </PDAT></PTEXT></CLMSTEP>
<CLMSTEP LVL="2"><PTEXT><PDAT>(c) C</PDAT><HIL><SB><PDAT>1</PDAT></SB></HIL><PDAT>-C</PDAT><HIL><SB><PDAT>20 </PDAT></SB></HIL><PDAT>alkyl substituted with one or more groups selected from the group consisting of aryl, halide, hydroxy, C</PDAT><HIL><SB><PDAT>1</PDAT></SB></HIL><PDAT>-C</PDAT><HIL><SB><PDAT>20 </PDAT></SB></HIL><PDAT>alkoxy, and C</PDAT><HIL><SB><PDAT>2</PDAT></SB></HIL><PDAT>-C</PDAT><HIL><SB><PDAT>20 </PDAT></SB></HIL><PDAT>alkoxycarbonyl; and </PDAT></PTEXT></CLMSTEP>
<CLMSTEP LVL="2"><PTEXT><PDAT>(d) aryl substituted with one or more groups selected from the group consisting of C</PDAT><HIL><SB><PDAT>1</PDAT></SB></HIL><PDAT>-C</PDAT><HIL><SB><PDAT>20 </PDAT></SB></HIL><PDAT>alkyl, aryl, hydroxyl, C</PDAT><HIL><SB><PDAT>1</PDAT></SB></HIL><PDAT>-C</PDAT><HIL><SB><PDAT>5 </PDAT></SB></HIL><PDAT>alkoxy, amino, nitro, halide and methoxy. </PDAT></PTEXT></CLMSTEP>
</CLM>
<CLM ID="CLM-00021">
<PARA ID="P-00130" LVL="0"><PTEXT><PDAT>21. The process of </PDAT><CLREF ID="CLM-00019"><PDAT>claim 19</PDAT></CLREF><PDAT> wherein</PDAT></PTEXT></PARA>
<CLMSTEP LVL="2"><PTEXT><PDAT>R&prime; is phenyl; </PDAT></PTEXT></CLMSTEP>
<CLMSTEP LVL="2"><PTEXT><PDAT>R&Prime; is nitro; </PDAT></PTEXT></CLMSTEP>
<CLMSTEP LVL="2"><PTEXT><PDAT>PR</PDAT><HIL><SB><PDAT>3 </PDAT></SB></HIL><PDAT>is P(cyclohexyl)</PDAT><HIL><SB><PDAT>3</PDAT></SB></HIL><PDAT>; </PDAT></PTEXT></CLMSTEP>
<CLMSTEP LVL="2"><PTEXT><PDAT>X is Cl; and </PDAT></PTEXT></CLMSTEP>
<CLMSTEP LVL="2"><PTEXT><PDAT>R is unsubstituted aryl or aryl substituted with a 2,6-diisopropyl group. </PDAT></PTEXT></CLMSTEP>
</CLM>
<CLM ID="CLM-00022">
<PARA ID="P-00131" LVL="0"><PTEXT><PDAT>22. A process for performing reaction injection molding, comprising:</PDAT></PTEXT></PARA>
<CLMSTEP LVL="2"><PTEXT><PDAT>contacting a ruthenium carbene catalyst of the formula </PDAT>
<CWU>
<CHEM-US ID="CHEM-US-00022">
<CHEMCDX ID="CHEMCDX-00022" ALT="chemistry chemdraw file" FILE="US06486279-20021126-C00022.CDX"/>
<CHEMMOL ID="CHEMMOL-00022" ALT="chemistry mol file" FILE="US06486279-20021126-C00022.MOL"/>
<EMI ID="EMI-C00022" ALT="embedded image" HE="80.4006" WI="206.41635" FILE="US06486279-20021126-C00022.TIF"/>
</CHEM-US>
</CWU>
</PTEXT></CLMSTEP>
<CLMSTEP LVL="2"><PTEXT><PDAT>with substituted or unsubstituted DCPD to form a first solution; </PDAT></PTEXT></CLMSTEP>
<CLMSTEP LVL="2"><PTEXT><PDAT>contacting substituted or unsubstituted DCPD with HCl to form a second solution; and </PDAT></PTEXT></CLMSTEP>
<CLMSTEP LVL="2"><PTEXT><PDAT>contacting the first solution with the second solution; wherein </PDAT></PTEXT></CLMSTEP>
<CLMSTEP LVL="3"><PTEXT><PDAT>R&prime; is phenyl; </PDAT></PTEXT></CLMSTEP>
<CLMSTEP LVL="3"><PTEXT><PDAT>R&Prime; is nitro; </PDAT></PTEXT></CLMSTEP>
<CLMSTEP LVL="3"><PTEXT><PDAT>PR</PDAT><HIL><SB><PDAT>3 </PDAT></SB></HIL><PDAT>is P(cyclohexyl)</PDAT><HIL><SB><PDAT>3</PDAT></SB></HIL><PDAT>; </PDAT></PTEXT></CLMSTEP>
<CLMSTEP LVL="3"><PTEXT><PDAT>X is Cl; and </PDAT></PTEXT></CLMSTEP>
<CLMSTEP LVL="3"><PTEXT><PDAT>R is unsubstituted aryl or aryl substituted with a 2,6-diisopropyl group.</PDAT></PTEXT></CLMSTEP>
</CLM>
</CL>
</SDOCL>
</PATDOC>

